<SEC-DOCUMENT>0001213900-21-026450.txt : 20210514
<SEC-HEADER>0001213900-21-026450.hdr.sgml : 20210514
<ACCEPTANCE-DATETIME>20210514163604
ACCESSION NUMBER:		0001213900-21-026450
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210514
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avalon GloboCare Corp.
		CENTRAL INDEX KEY:			0001630212
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				471685128
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38728
		FILM NUMBER:		21925296

	BUSINESS ADDRESS:	
		STREET 1:		4400 ROUTE 9
		STREET 2:		SUITE 3100
		CITY:			FREEHOLD
		STATE:			NJ
		ZIP:			07728
		BUSINESS PHONE:		(646) 762-4517

	MAIL ADDRESS:	
		STREET 1:		4400 ROUTE 9
		STREET 2:		SUITE 3100
		CITY:			FREEHOLD
		STATE:			NJ
		ZIP:			07728

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalon Globocare Corp.
		DATE OF NAME CHANGE:	20161018

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLOBAL TECHNOLOGIES CORP
		DATE OF NAME CHANGE:	20150108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0321_avalonglobo.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Mark One)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;<B>&nbsp;QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the quarterly period
ended March 31, 2021</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#9744;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the transition period
from __________ to __________</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>COMMISSION FILE NUMBER:
001-38728</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B><U>AVALON
GLOBOCARE CORP.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><B>Delaware</B></TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
  <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 49%"><FONT STYLE="text-decoration: none"><B>47-1685128</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: center">(State of incorporation)</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>4400 Route 9 South,
Suite 3100, Freehold, New Jersey 07728 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive
offices) (zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(732) 780-4400 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone
number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes&nbsp;&#9746; No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&sect; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). Yes&nbsp;</FONT>&#9746;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an
emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes&nbsp;&#9744; No&nbsp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of Each Class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001 par
    value per share</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AVCO</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Stock Market
    LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">State the number of shares outstanding of each
of the issuer&rsquo;s classes of common equity, as of the latest practicable date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 49%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
    May 14, 2021</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, $0.0001 par value per share</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,423,564
    shares</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AVALON GLOBOCARE CORP.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>March 31, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top"><TD STYLE="padding-bottom: 1.5pt; width: 10%">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; width: 80%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    No.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="text-align: center"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART I. - FINANCIAL INFORMATION</B></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: justify"><A HREF="#a_002">Financial Statements</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; text-align: justify"><A HREF="#a_003">Condensed Consolidated Balance Sheets as of March 31, 2021 (Unaudited) and December 31, 2020</A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; text-align: justify"><A HREF="#a_004">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months
    Ended March 31, 2021 and 2020</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; text-align: justify"><A HREF="#a_005">Unaudited Condensed Consolidated Statement of Changes in Equity for the Three Months Ended March
    31, 2021 and 2020</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; text-align: justify"><A HREF="#a_006">Unaudited Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2021
    and 2020</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">5</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; text-align: justify"><A HREF="#a_007">Notes to Unaudited Condensed Consolidated Financial Statements</A></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: justify"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion
    and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: justify"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative
    Disclosures About Market Risk</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4</FONT>.</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: justify"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="3"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A HREF="#a_011">PART II - OTHER INFORMATION</A></B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unregistered Sales of Equity Securities and Use of
    Proceeds</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defaults upon Senior Securities</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This&nbsp;report
contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates&rdquo;
and similar expressions or variations of such words are intended to identify forward-looking statements, but are not deemed to represent
an all-inclusive means of identifying forward-looking statements as denoted in this report. Additionally, statements concerning future
matters are forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Although&nbsp;forward-looking
statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently
known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes
may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could
cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the headings
&ldquo;Risks Factors&rdquo; and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
in our annual report on Form 10-K, in &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
in this Form 10-Q and information contained in other reports that we file with the SEC. You are urged not to place undue reliance on
these forward-looking statements, which speak only as of the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We&nbsp;file
reports with the SEC. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements, and other information
regarding issuers that file electronically with the SEC, including us. You can also read and copy any materials we file with the SEC
at the SEC&rsquo;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. You can obtain additional information about the operation
of the Public Reference Room by calling the SEC at 1-800-SEC-0330.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We&nbsp;undertake
no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the
date of this report, except as required by law. Readers are urged to carefully review and consider the various disclosures made throughout
the entirety of this quarterly report, which are designed to advise interested parties of the risks and factors that may affect our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
otherwise indicated, references in this report to &ldquo;we,&rdquo; &ldquo;us&rdquo;, &ldquo;Avalon&rdquo; or the &ldquo;Company&rdquo;
refer to Avalon GloboCare Corp. and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>PART 1 - FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="a_002"></A>Item 1. Financial Statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_003"></A>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED
CONSOLIDATED BALANCE SHEETS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>March
    31,</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>December
    31,</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>2021</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>2020</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>(Unaudited)</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">ASSETS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8.5pt">CURRENT ASSETS:</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Cash</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">1,692,540</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">726,577</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Rent
    receivable</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">23,471</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">35,395</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Deferred
    financing costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">152,438</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">222,141</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">295,731</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">302,224</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Current Assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">2,164,180</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">1,286,337</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">NON-CURRENT ASSETS:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Rent
    receivable - noncurrent portion</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">109,174</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">111,840</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Security
    deposit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">19,662</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Deferred
    leasing costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">133,359</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">144,197</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Operating
    lease right-of-use assets, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">241,729</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">137,333</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Property
    and equipment, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">439,962</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">479,115</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Investment
    in real estate, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">7,644,950</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">7,685,686</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Equity
    method investment</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">532,199</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">521,758</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Non-current Assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">9,121,035</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">9,079,929</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Assets</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">11,285,215</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">10,366,266</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">LIABILITIES AND EQUITY</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">CURRENT LIABILITIES:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accrued
    professional fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">1,445,225</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">1,212,822</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accrued
    research and development fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">432,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">513,533</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accrued
    payroll liability and directors' compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">165,846</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">154,292</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accrued
    liabilities and other payables</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">344,453</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">367,411</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accrued
    liabilities and other payables - related parties</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">313,105</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">267,956</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Operating
    lease obligation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">132,657</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">76,379</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Note
    payable - related party</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">390,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Current Liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">3,223,786</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">2,592,393</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">NON-CURRENT LIABILITIES:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Operating
    lease obligation - noncurrent portion</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">109,337</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">66,954</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Note
    payable - related party</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">390,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Loan
    payable - related party</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">3,305,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">3,200,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Non-current Liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">3,414,586</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">3,656,954</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">6,638,372</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">6,249,347</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Commitments
    and Contingencies</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">EQUITY:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Preferred stock, $0.0001
    par value; 10,000,000 shares authorized;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">no shares issued and outstanding
    at March 31, 2021 and December 31, 2020</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Common stock, $0.0001 par
    value; 490,000,000 shares authorized;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">84,943,564 shares issued
    and 84,423,564 shares outstanding at March 31, 2021;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">82,795,297 shares issued
    and 82,275,297 shares outstanding at December 31, 2020</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">8,494</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">8,279</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Additional
    paid-in capital</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">49,755,996</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">46,856,447</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Less:
    common stock held in treasury, at cost;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">520,000 shares at March
    31, 2021 and December 31, 2020</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(522,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(522,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accumulated
    deficit</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(44,408,493</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(42,041,375</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Statutory
    reserve</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">6,578</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">6,578</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Accumulated
    other comprehensive loss - foreign currency translation adjustment</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(193,232</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">(190,510</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Avalon GloboCare Corp. stockholders' equity</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">4,646,843</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">4,116,919</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Non-controlling
    interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">4,646,843</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">4,116,919</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">Total
    Liabilities and Equity</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">11,285,215</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">10,366,266</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8.5pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to the condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_004"></A>AVALON
GLOBOCARE CORP. AND SUBSIDIARIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="7" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
    the Three Months Ended<BR>
    March 31,</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2021</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2020</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">

    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">REVENUES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; width: 76%; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real property
    rental</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">289,774</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">296,956</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COSTS AND EXPENSES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real
    property operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">216,894</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">254,501</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">GROSS PROFIT</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Real
    property operating income</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">72,880</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,455</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">OTHER OPERATING EXPENSES:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Professional fees</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,381,178</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,553,698</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Compensation and related
    benefits</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">562,006</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,128,468</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development
    expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">213,188</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,402</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    general and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">220,096</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">307,079</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Other Operating Expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,376,468</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,264,647</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">LOSS FROM OPERATIONS</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,303,588</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,222,192</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">OTHER INCOME (EXPENSE)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense - related
    party</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(45,149</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(42,169</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from equity method
    investment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,514</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(9,084</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">133</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,664</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Other Expense, net</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(63,530</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(48,589</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">LOSS BEFORE INCOME TAXES</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,367,118</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,270,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">INCOME TAXES</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET LOSS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,367,118</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,270,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">LESS: NET LOSS ATTRIBUTABLE
    TO NON-CONTROLLING INTEREST</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET LOSS ATTRIBUTABLE
    TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,367,118</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,270,781</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPREHENSIVE LOSS:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET LOSS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,367,118</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,270,781</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">OTHER COMPREHENSIVE LOSS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unrealized
    foreign currency translation loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,722</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(22,066</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPREHENSIVE LOSS</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,369,840</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,292,847</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">LESS:
    COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 4pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">COMPREHENSIVE
    LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,369,840</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,292,847</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON
    GLOBOCARE CORP. COMMON SHAREHOLDERS:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 4pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.03</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.04</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-bottom: 4pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">83,413,154</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">76,712,054</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to the condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For the Three Months Ended March 31, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="38" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Avalon
    GloboCare Corp. Stockholders' Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Preferred
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Common
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Treasury
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Accumulated</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Additional</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Other</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Non-</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Paid-in</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Accumulated</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Statutory</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Comprehensive</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>controlling</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Capital</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Deficit</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Reserve</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Loss</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Interest</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    January 1, 2021</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">82,795,297</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,279</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">46,856,447</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(520,000</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,500</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(42,041,375</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,578</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(190,510</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,116,919</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale
    of common stock, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,848,267</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">185</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,337,074</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">2,337,259</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock <BR>
    for services (Note 8)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">300,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">30</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">359,970</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">360,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">202,505</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">202,505</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency<BR>
    translation adjustment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,722</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,722</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss for the three<BR>
    months ended March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,367,118</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(2,367,118</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-bottom: 4pt; padding-left: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    March 31, 2021</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">84,943,564</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,494</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">49,755,996</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(520,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,500</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(44,408,493</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,578</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(193,232</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,646,843</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See accompanying notes to the condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_005"></A>AVALON GLOBOCARE CORP. AND SUBSIDIARIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For the Three Months Ended March 31, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; text-align: center; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="38" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Avalon
    GloboCare Corp. Stockholders' Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Preferred
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Common
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Treasury
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Accumulated</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Additional</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Number</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Other</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Non-</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Paid-in</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Accumulated</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Statutory</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Comprehensive</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>controlling</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Total</B></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Capital</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Deficit</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Reserve</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Loss</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Interest</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt; width: 22%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    January 1, 2020</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">76,730,802</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,673</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">34,593,006</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(520,000</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,500</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(29,361,937</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,578</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(257,747</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 8pt">-</FONT></FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="width: 5%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">4,465,073</FONT></TD><TD STYLE="width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Sale
    of common stock, net</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">980,358</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">98</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,539,153</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">1,539,251</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock for services</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">222,577</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">22</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">213,278</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">213,300</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">785,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">785,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Foreign
    currency translation adjustment</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(22,066</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(22,066</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss for the three months ended March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,270,781</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(3,270,781</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-bottom: 0pt; padding-left: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance,
    March 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">77,933,737</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">7,793</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">37,130,787</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(520,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(522,500</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(32,632,718</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">6,578</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">(279,813</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">3,710,127</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to
the condensed consolidated financial statements.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A NAME="a_006"></A>AVALON GLOBOCARE CORP. AND SUBSIDIARIES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp; <FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Unaudited)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><B>For the Three Months Ended<BR>
 March 31,</B></TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,367,118</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,270,781</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Bad debt provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,698</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,875</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">76,535</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Amortization of straight-line rent receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,988</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Amortization of right-of-use asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,531</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Stock-based compensation and service expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">573,982</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,189,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Loss on equity method investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,514</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,084</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Loss on fixed assets disposal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,648</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accounts receivable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,932</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Rent receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,647</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,733</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Deferred leasing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,364</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40,803</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(96,669</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Accrued liabilities and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">163,442</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(38,817</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accrued liabilities and other payables - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,218</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Operating lease obligation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(33,326</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">NET CASH USED IN OPERATING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,515,525</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,998,796</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Additional investment in equity method investment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30,844</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">NET CASH USED IN INVESTING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30,844</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds received from loan payable - related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds received from equity offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,481,405</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,623,584</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Disbursements for equity offering costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(74,442</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(48,707</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,512,212</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,874,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 5.4pt">EFFECT OF EXCHANGE RATE ON CASH</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,701</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">NET INCREASE (DECREASE) IN CASH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">965,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(129,620</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 5.4pt">CASH&nbsp;&nbsp;- beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">726,577</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">764,891</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt">CASH - end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,692,540</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">635,271</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5.4pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">NON-CASH INVESTING AND FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Common stock issued for future services</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">57,207</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Common stock issued for accrued liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">261,032</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See accompanying notes to the condensed consolidated financial statements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A>AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 1 &ndash;&nbsp;<U>ORGANIZATION
AND NATURE OF OPERATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon GloboCare Corp. (the &ldquo;Company&rdquo;
or &ldquo;AVCO&rdquo;) is a Delaware corporation. The Company was incorporated under the laws of the State of Delaware on July 28, 2014.
On October 19, 2016, the Company entered into and closed a Share Exchange Agreement with the shareholders of Avalon Healthcare System,
Inc., a Delaware corporation (&ldquo;AHS&rdquo;), each of which were accredited investors (&ldquo;AHS Shareholders&rdquo;) pursuant to
which we acquired 100% of the outstanding securities of AHS in exchange for 50,000,000 shares of the Company&rsquo;s common stock (the
&ldquo;AHS Acquisition&rdquo;). AHS was incorporated on May 18, 2015 under the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For accounting purposes, AHS was the surviving
entity. The transaction was accounted for as a recapitalization of AHS pursuant to which AHS was treated as the accounting acquirer,
surviving and continuing entity although the Company is the legal acquirer. The Company did not recognize goodwill or any intangible
assets in connection with this transaction. Accordingly, the Company&rsquo;s historical financial statements are those of AHS and its
wholly-owned subsidiary, Avalon (Shanghai) Healthcare Technology Co., Ltd. (&ldquo;Avalon Shanghai&rdquo;) immediately following the
consummation of this reverse merger transaction. AHS owns 100% of the capital stock of Avalon Shanghai, which is a wholly foreign-owned
enterprise organized under the laws of the People&rsquo;s Republic of China (&ldquo;PRC&rdquo;). Avalon Shanghai was incorporated on
April 29, 2016 and is engaged in medical related consulting services for customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&trade;), and regenerative therapeutics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 23, 2017, the Company incorporated
Avalon (BVI) Ltd., a British Virgin Island company. There was no activity for the subsidiary since its incorporation through March 31,
2021. Avalon (BVI) Ltd. is dormant and is in process of being dissolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&ldquo;Avalon RT 9&rdquo;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&rsquo;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Currently, Avalon RT 9&rsquo;s business consists
of the ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2021, the occupancy rate of
the building is 89.4%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, the Company formed Genexosome
Technologies Inc. (&ldquo;Genexosome&rdquo;) in Nevada. Genexosome was engaged in developing proprietary diagnostic and therapeutic products
using exosomes. Genexosome owns 100% of the capital stock of Beijing Jieteng (Genexosome) Biotech Co., Ltd., a corporation incorporated
in the People&rsquo;s Republic of China on August 7, 2015 (&ldquo;Beijing Genexosome&rdquo;), and the Company holds 60% of Genexosome
and Dr. Yu Zhou holds 40% of Genexosome. The Company had not been able to realize the financial projections provided by Dr. Zhou at the
time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero. Dr. Zhou was terminated
as Co-CEO of Genexosome on August 14, 2019. Since the fourth quarter of 2019, the non-controlling interest keeps inactive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc., a Nevada corporation, which will focus on accelerating commercial activities related to cellular
therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T
and others. The subsidiary is designed to integrate and optimize our global scientific and clinical resources to further advance the
use of cellular therapies to treat certain cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2019, the Company formed a wholly
owned subsidiary, International Exosome Association LLC, a Delaware company. There was no activity for the subsidiary since its incorporation
through March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 1 &ndash;&nbsp;<U>ORGANIZATION
AND NATURE OF OPERATIONS (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the Company&rsquo;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2021 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 25%; padding-right: 0pt; padding-left: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of Subsidiary</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 16%; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Place
    and date of Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: top; width: 2%; padding-right: 0pt; padding-left: 0pt; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 13%; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of Ownership</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 40%; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Activities</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon Healthcare System, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;AHS&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 18, 2015</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&ldquo;USA&rdquo;)</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (BVI) Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Avalon BVI&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">British Virgin Island</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 23, 2017</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dormant,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">is in process of being dissolved</P></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon RT 9 Properties LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Avalon RT 9&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New Jersey</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 7, 2017</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owns
    and operates an income-producing real property and holds and manages the corporate headquarters</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (Shanghai) Healthcare Technology Co.,
    Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Avalon Shanghai&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 29, 2016</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AHS</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in China</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Genexosome Technologies Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Genexosome&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 31, 2017</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dormant
    </FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beijing Jieteng (Genexosome) Biotech Co.,
    Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Beijing Genexosome&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 7, 2015</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by Genexosome</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    development services for hospitals and other customers and sells developed items to hospitals and other customers in China</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avactis Biosciences Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Avactis&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 18, 2018</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrate
    and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with
    stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Exosome Association LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&ldquo;Exosome&rdquo;)</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 13, 2019</P></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</FONT></TD>
    <TD STYLE="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    standardization related to exosome industry</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>NOTE 2 &ndash;&nbsp;<U>BASIS OF PRESENTATION
AND GOING CONCERN CONDITION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These&nbsp;interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission and do not include all information and footnotes
necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United
States (&ldquo;U.S. GAAP&rdquo;). The Company&rsquo;s condensed consolidated financial statements include the accounts of the Company
and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain&nbsp;information and footnote disclosures
normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
These condensed consolidated financial statements should be read in conjunction with the Company&rsquo;s audited consolidated financial
statements and notes thereto included in the Company&rsquo;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2020 filed
with the Securities and Exchange Commission on March 30, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 2 &ndash;&nbsp;<U>BASIS OF PRESENTATION
AND GOING CONCERN CONDITION (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&trade;), and regenerative therapeutics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company owns commercial real
estate that houses its headquarters in Freehold, New Jersey and provides outsourced, customized international healthcare services to
the rapidly changing health care industry primarily focused in the People&rsquo;s Republic of China. The Company did not generate any
revenue from medical related consulting services segment during the three months ended March 31, 2021. These condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the
realization of assets and the satisfaction of liabilities in the normal course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying condensed consolidated
financial statements, the Company had working capital deficit of $1,059,606 as of March 31, 2021 and has incurred recurring net loss
and generated negative cash flow from operating activities of $2,367,118 and $1,515,525 for the three months ended March 31, 2021, respectively.
The Company has a limited operating history and its continued growth is dependent upon the continuation of providing medical consulting
services to its only few clients who are related parties and generating rental revenue from its income-producing real estate property
in New Jersey; hence generating revenues, and obtaining additional financing to fund future obligations and pay liabilities arising from
normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve
months from the release date of this report. These matters raise substantial doubt about the Company&rsquo;s ability to continue as a
going concern. The ability of the Company to continue as a going concern is dependent on the Company&rsquo;s ability to raise additional
capital, implement its business plan, and generate significant revenues. There are no assurances that the Company will be successful
in its efforts to generate significant revenues, maintain sufficient cash balance or report profitable operations or to continue as a
going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However, there is no assurance
these plans will be realized and that any additional financings will be available to the Company on satisfactory terms and conditions,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of an uncontrollable event such
as the COVID-19 pandemic had negatively impact on the Company&rsquo;s operations. Some tenants have delayed on rent payment. Our general
development operations have continued during the COVID-19 pandemic and we have not had significant disruption. However, we are uncertain
if the COVID-19 pandemic will impact future operations at our laboratory, or our ability to collaborate with other laboratories and universities.
In addition, we are unsure if the COVID-19 pandemic will impact future clinical trials. Given the dynamic nature of these circumstances,
the duration of business disruption and reduced traffic, the related financial effect cannot be reasonably estimated at this time but
is expected to adversely impact the Company&rsquo;s business for the rest of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 3 &ndash;&nbsp;<U>SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The preparation of the
condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant
estimates during the three months ended March 31, 2021 and 2020 include the useful life of property and equipment and investment in real
estate, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances,
and valuation of stock-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 &ndash;&nbsp;<U>SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Fair Value of Financial Instruments and
Fair Value Measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company adopted
the guidance of Accounting Standards Codification (&ldquo;ASC&rdquo;) 820 for fair value measurements which clarifies the definition
of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring
fair value as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;&#8239;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Level
                                            1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities
                                            available at the measurement date.</FONT></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT><TD STYLE="text-align: justify">Level
                                            2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets,
                                            quoted prices for identical or similar assets and liabilities in markets that are not active,
                                            inputs other than quoted prices that are observable, and inputs derived from or corroborated
                                            by observable market data. </TD></TR></TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT><TD STYLE="text-align: justify">Level
                                            3-Inputs are unobservable inputs which reflect the reporting entity&rsquo;s own assumptions
                                            on what assumptions the market participants would use in pricing the asset or liability based
                                            on the best available information. </TD></TR></TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The carrying amounts
reported in the condensed consolidated balance sheets for cash, rent receivable, accrued liabilities and other payables, accrued liabilities
and other payables &ndash; related parties, operating lease obligation, and note payable, approximate their fair market value as of March
31, 2021 and December 31, 2020 based on the short-term maturity of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &ldquo;Financial Instruments&rdquo;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021 and December 31, 2020, the
Company&rsquo;s cash balances by geographic area were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><B>Country:</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March 31, <BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December 31,<BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,527,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">90.2</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">559,711</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">77.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">China</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">165,283</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">166,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23.0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total cash</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,692,540</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">726,577</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2021 and December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Credit Risk and Uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company&rsquo;s cash is maintained
with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately
$76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered. At March 31, 2021, cash balances held in the PRC
are RMB 1,083,049 (approximately $165,000), of which, RMB 556,726 (approximately $85,000) was not covered by such limited insurance.
The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a portion of its cash in
bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages
this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit
quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2021, the Company&rsquo;s cash balances in United
States bank accounts had approximately $986,000 in excess of the federally-insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 &ndash;&nbsp;<U>SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Credit Risk and Uncertainties (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, a portion of the Company&rsquo;s operations
are carried out in PRC. Accordingly, the Company&rsquo;s business, financial condition and results of operations may be influenced by
the political, economic and legal environment in the PRC, and by the general state of the PRC&rsquo;s economy. The Company&rsquo;s operations
in PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company&rsquo;s
results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion and remittance abroad, and rates and methods of taxation, among other things.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company&rsquo;s sales
are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however,
concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also
performs ongoing credit evaluations of its customers to help further reduce credit risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Investment in Unconsolidated
Company &ndash; Epicon Biosciences Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The
Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events
or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than
temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down
would be recorded to estimated fair value. See Note 5 for discussion of equity method investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue Recognition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company recognizes
revenue under Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 606, Revenue from Contracts with Customers (&ldquo;ASC 606&rdquo;).
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or
services. The following five steps are applied to achieve that core principle:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract
    with the customer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance
    obligations in the contract</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction
    price</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction
    price to the performance obligations in the contract</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue
    when the company satisfies a performance obligation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In order to identify
the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify
each promised goods or service that is distinct. A performance obligation meets ASC 606&rsquo;s definition of a &ldquo;distinct&rdquo;
goods or service (or bundle of goods or services) if both of the following criteria are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit
    from the goods or service either on its own or together with other resources that are readily available to the customer (i.e., the
    goods or service is capable of being distinct).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&rsquo;s promise
    to transfer the goods or service to the customer is separately identifiable from other promises in the contract (i.e., the promise
    to transfer the goods or service is distinct within the context of the contract).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If a goods or service
is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or services is identified
that is distinct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 &ndash;&nbsp;<U>SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue Recognition (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company&rsquo;s
revenues are derived from providing medial related consulting services for its&rsquo; related parties. Revenues related to its service
offerings are recognized as the services are performed. Any payments received in advance of the performance of services are recorded
as&nbsp;deferred revenue&nbsp;until such time as the services are performed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined that the ASC 606 does
not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not offer promotional payments,
customer coupons, rebates or other cash redemption offers to its customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Per Share Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &ldquo;Earnings per Share,&rdquo;
requires presentation of both basic and diluted earnings per share (&ldquo;EPS&rdquo;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the three months ended March 31, 2021 and 2020, potentially dilutive
common shares consist of the common shares issuable upon the exercise of common stock options (using the treasury stock method). Common
stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period
in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding
as they would have had an anti-dilutive impact.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Three Months Ended<BR>
March&nbsp;31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Stock options</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">7,580,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">6,800,000</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Potentially dilutive securities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,580,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,800,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 3 &ndash;&nbsp;<U>SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Segment Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses &ldquo;the management approach&rdquo;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&rsquo;s
chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company&rsquo;s
reportable segments. The Company&rsquo;s chief operating decision maker is the Chief Executive Officer (&ldquo;CEO&rdquo;) and president
of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously had three reportable business
segments: real property operating segment, medical related consulting services segment, and development services and sales of developed
products segment. Due to the winding down of the development services and sales of developed products segment in 2020, the Company no
longer has any material revenues or expenses in this&nbsp;segment. As a result, commencing from the first quarter of 2021, the Company&rsquo;s
chief operating decision maker no longer reviews development services and sales of developed products operating results and the Company
no longer reports in three&nbsp;segments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the Company operates through two business segments: real property operating segment and medical related consulting services segment.
These reportable segments offer different types of services and products, have different types of revenue, and are managed separately
as each requires different operating strategies and management expertise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Reclassification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified
to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position,
results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, <I>Financial
Instruments - Credit Losses (&ldquo;Topic 326&rdquo;). </I>The ASU introduces a new accounting model, the Current Expected Credit Losses
model (&ldquo;CECL&rdquo;), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The
CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial
asset is originated or acquired. ASU 2016-13 is effective for annual period beginning after December 15, 2022, including interim reporting
periods within those annual reporting periods. The Company expects that the adoption will not have a material impact on the Company&rsquo;s
consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<I>Simplifying the Accounting for Income Taxes</I>, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim
and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019 &ndash; 12 did not have
a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its consolidated financial condition, results of operations, cash flows or disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>NOTE 4 &ndash;&nbsp;<U>PREPAID EXPENSES
AND OTHER CURRENT ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">At March 31, 2021 and December 31, 2020,
prepaid expenses and other current assets consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March 31,<BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December&nbsp;31, <BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0pt">Prepaid NASDAQ listing fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">63,417</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid directors and officers liability insurance premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">62,038</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,929</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Recoverable VAT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,934</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,446</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Deferred leasing costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,422</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,220</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Prepaid research and development fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,305</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,610</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,251</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,380</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">295,731</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">302,224</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 5 &ndash; <U>EQUITY
METHOD INVESTMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
equity method investment amounted to $532,199 and $521,758, respectively. The investment represents the Company&rsquo;s subsidiary, Avalon
Shanghai&rsquo;s interest in Epicon Biotech Co., Ltd. (&ldquo;Epicon&rdquo;). Epicon was incorporated on August 14, 2018 in PRC. Avalon
Shanghai and the other unrelated company, Jiangsu Unicorn Biological Technology Co., Ltd. (&ldquo;Unicorn&rdquo;), accounted for 40%
and 60% of the total ownership, respectively. Epicon is focused on cell preparation, third party testing, biological sample repository
for commercial and scientific research purposes and the clinical transformation of scientific achievements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company treats the equity investment in the
consolidated financial statements under the equity method. Under the equity method, the investment is initially recorded at cost, adjusted
for any excess of the Company&rsquo;s share of the incorporated-date fair values of the investee&rsquo;s identifiable net assets over
the cost of the investment (if any). Thereafter, the investment is adjusted for the post incorporation change in the Company&rsquo;s
share of the investee&rsquo;s net assets and any impairment loss relating to the investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, the Company&rsquo;s share of Epicon&rsquo;s net loss was $18,514 and $9,084, respectively, which was included in loss from equity
method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended March 31, 2021, activity
recorded for the Company&rsquo;s&nbsp;equity method investment&nbsp;in Epicon is summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt; text-indent: 0pt">Equity investment carrying amount at January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">521,758</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Payment made for equity method investment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Epicon's net loss attributable to the Company</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,514</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Foreign currency fluctuation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,889</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Equity investment carrying amount at March 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">532,199</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 5 &ndash; <U>EQUITY
METHOD INVESTMENT (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The tables below present
the summarized financial information, as provided to the Company by the investee, for the unconsolidated company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March&nbsp;31, <BR>
2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December&nbsp;31, <BR>
2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0pt">Current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,071</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">13,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Noncurrent assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,390</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,351</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Noncurrent liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,604</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,798</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>For the Three Months <BR>
Ended March&nbsp;31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">Net revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">$</TD>
    <TD STYLE="text-align: right">-</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">-</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0pt">Loss from operation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">46,286</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22,711</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,711</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 6 &ndash;&nbsp;<U>ACCRUED
LIABILITIES AND OTHER PAYABLES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">At March 31, 2021 and
December 31, 2020, accrued liabilities and other payables consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March&nbsp;31,<BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December&nbsp;31,<BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued professional fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,445,225</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,212,822</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued research and development fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">432,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">513,533</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued payroll liability and directors&rsquo; compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">165,846</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,292</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued tenants&rsquo; improvement reimbursement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,900</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,900</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Tenants&rsquo; security deposit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,533</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,634</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,374</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Deferred rental income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">110,360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">105,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,388,024</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,248,058</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>NOTE 7 &ndash;&nbsp;<U>RELATED PARTY TRANSACTIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Accrued Liabilities and Other Payables &ndash;
Related Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired Beijing Genexosome for a
cash payment of $450,000. As of March 31, 2021 and December 31, 2020, the unpaid acquisition consideration of $100,000, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been included in accrued liabilities
and other payables &ndash; related parties on the accompanying condensed consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&rsquo;s largest shareholder and chairman of the Board
of Directors, amounted to $213,105 and $167,956, respectively, and have been included in accrued liabilities and other payables &ndash;
related parties on the accompanying condensed consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowings from Related Party</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Promissory Note</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On March 18, 2019, the
Company issued Wenzhao Lu, the Company&rsquo;s largest shareholder and Chairman of the Board of Directors, a Promissory Note in the principal
amount of $1,000,000 (&ldquo;Promissory Note&rdquo;) in consideration of cash in the amount of $1,000,000. The Promissory Note accrues
interest at the rate of 5% per annum and matures March 19, 2022. The Company repaid principal of $410,000 and $200,000 in the third quarter
of 2019 and second quarter of 2020, respectively. As of both March 31, 2021 and December 31, 2020, the outstanding principal balance
was $390,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>NOTE 7 &ndash;&nbsp;<U>RELATED PARTY TRANSACTIONS (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowings from Related Party (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Line of Credit</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &ldquo;Line of Credit Agreement&rdquo;) providing the Company with a $20 million line of credit (the
&ldquo;Line of Credit&rdquo;) from Wenzhao Lu (the &ldquo;Lender&rdquo;), the largest shareholder and Chairman of the Board of Directors
of the Company. The Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital
and operating expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into
equity of the Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable
three years from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related
party Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to
maturity, without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default
occurs, the Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021
and December 31, 2020, $3,305,249 and $3,200,000 was outstanding under the Line of Credit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, the interest expense related to above borrowings amounted to $45,149 and $42,169, respectively, and has been included in interest
expense &ndash; related party on the accompanying condensed consolidated statements of operations and comprehensive loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As of March 31, 2021
and December 31, 2020, the related accrued and unpaid interest for above borrowings was $213,105 and $167,956, respectively, and has
been included in accrued liabilities and other payables &ndash; related parties on the accompanying condensed consolidated balance sheets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Office Space from
Related Party</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Beijing Genexosome uses
office space of a related party, free of rent, which is considered immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 8 &ndash;&nbsp;<U>EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>2020 Incentive Stock
Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company held its
annual meeting on August 4, 2020. During its annual meeting, the Company approved 2020 Incentive Stock Plan and reserved 5,000,000 shares
of common stock for issuance thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Common Shares Sold
for Cash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 13, 2019, the Company entered into
an Open Market Sale Agreement<SUP>SM </SUP>(the &ldquo;Sales Agreement&rdquo;) with Jefferies LLC, as sales agent (&ldquo;Jefferies&rdquo;),
pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock. During the three
months ended March 31, 2021, Jefferies sold an aggregate of 1,848,267 shares of common stock at an average price of $1.34 per share to
investors. The Company recorded net proceeds of $2,337,259, net of commission and other offering costs of $144,146.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Common Shares Issued
for Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the Company issued a total of 300,000 shares of its common stock for services rendered. These shares were valued at $360,000, the fair
market values on the grant dates using the reported closing share prices on the dates of grant and the Company recorded stock-based compensation
expense of $98,968 for the three months ended March 31, 2021 and reduced accrued liabilities of $261,032.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 8 &ndash;&nbsp;<U>EQUITY
(continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the shares of
the Company&rsquo;s common stock issuable upon exercise of options outstanding at March 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="14" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Options Outstanding</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Options Exercisable</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Range of<BR>
    Exercise <BR>
    Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number<BR>
    Outstanding at<BR>
    March 31, <BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted Average<BR>
    Remaining<BR>
    Contractual Life<BR>
    (Years)</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted<BR>
    Average<BR>
    Exercise<BR>
    Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number<BR>
    Exercisable at<BR>
    March 31,<BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted<BR>
    Average<BR>
    Exercise <BR>
    Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">5.86</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">0.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 &ndash; 1.93</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,810,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.37</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,366,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00 &ndash; 2.80</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,740,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,740,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3.01</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">30,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.76</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 &ndash; 4.76</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,580,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">4.46</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.45</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,136,666</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.47</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Stock option activities
for the three months ended March 31, 2021 were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of<BR>
    Options</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted<BR>
    Average<BR>
    Exercise Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: 0pt; padding-left: 0pt">Outstanding at January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7,140,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">440,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Terminated / Exercised / Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Outstanding at March 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,580,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.45</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt">Options exercisable at March 31, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,136,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Options expected to vest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of both stock options
outstanding and stock options exercisable at March 31, 2021 was $1,161,700.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of options granted during the
three months ended March 31, 2021 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 128.42%, risk-free rate of 0.36%, annual dividend yield of 0% and expected life of 5.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2021 was $419,020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The fair values of options
granted during the three months ended March 31, 2020 were estimated at the date of grant using the Black-Scholes option-pricing model
with the following assumptions: volatility of 137.42% - 139.58%, risk-free rate of 1.39% - 1.67%, annual dividend yield of 0% and expected
life of 5.00 &ndash; 10.00 years. The aggregate fair value of the options granted during the three months ended March 31, 2020 was $2,422,225.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, stock-based compensation expense associated with stock options granted amounted to $202,505 and $785,350, respectively, of which,
$139,507 and $674,998 was recorded as compensation and related benefits, $43,443 and $103,818 was recorded as professional fees, and
$19,555 and $6,534 was recorded as research and development expenses, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 8 &ndash;&nbsp;<U>EQUITY
(continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the status of the Company&rsquo;s
nonvested stock options granted as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of<BR>
    Options</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Weighted<BR>
    Average<BR>
    Exercise<BR>
    Price</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 0pt">Nonvested at January 1, 2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">218,334</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.18</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">440,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">Vested</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(215,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1.15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt">Nonvested at March 31, 2021</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">443,334</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1.14</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 9 -&nbsp;<U>STATUTORY
RESERVE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon Shanghai and Beijing Genexosome operate
in the PRC, are required to reserve 10% of their net profit after income tax, as determined in accordance with the PRC accounting rules
and regulations. Appropriation to the statutory reserve by the Company is based on profit arrived at under PRC accounting standards for
business enterprises for each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit arrived at must be set off against
any accumulated losses sustained by the Company in prior years, before allocation is made to the statutory reserve. Appropriation to
the statutory reserve must be made before distribution of dividends to shareholders. The appropriation is required until the statutory
reserve reaches 50% of the registered capital. This statutory reserve is not distributable in the form of cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai and Beijing Genexosome during the three months ended March 31,
2021 and 2020 as they incurred net losses in these periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 10 &ndash; <U>RESTRICTED
NET ASSETS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company&rsquo;s operations are
conducted through its PRC subsidiaries, which can only pay dividends out of their retained earnings determined in accordance with the
accounting standards and regulations in the PRC and after they have met the PRC requirements for appropriation to statutory reserve.
In addition, a portion of the Company&rsquo;s businesses and assets are denominated in RMB, which is not freely convertible into foreign
currencies. All foreign exchange transactions take place either through the People&rsquo;s Bank of China or other banks authorized to
buy and sell foreign currencies at the exchange rates quoted by the People&rsquo;s Bank of China. Approval of foreign currency payments
by the People&rsquo;s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers&rsquo;
invoices, shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities
may restrict the ability of the Company&rsquo;s PRC subsidiaries to transfer their net assets to the Parent Company through loans, advances
or cash dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule I of Article 5-04 of Regulation S-X
requires the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries
exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of this test, restricted
net assets of consolidated subsidiaries shall mean that amount of the registrant&rsquo;s proportionate share of net assets of its consolidated
subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent
company in the form of loans, advances or cash dividends without the consent of a third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s PRC subsidiaries&rsquo; net
assets as of March 31, 2021 and December 31, 2020 did not exceed 25% of the Company&rsquo;s consolidated net assets. Accordingly, the
Parent Company&rsquo;s condensed consolidated financial statements have not been required in accordance with Rule 5-04 and Rule 12-04
of SEC Regulation S-X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 11 -&nbsp;<U>CONCENTRATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Customers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information as
to each customer that accounted for 10% or more of the Company&rsquo;s revenues for the three months ended March 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Three Months Ended<BR>
March&nbsp;31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-left: 0pt; text-align: left"><B>Customer</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; padding-left: 0pt">A</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;30</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">B</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">C</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Less than 10%</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One customer, whose outstanding receivable accounted
for 10% or more of the Company&rsquo;s total outstanding accounts receivable, accounts receivable &ndash; related party, and rent receivable
at March 31, 2021, accounted for 70.3% of the Company&rsquo;s total outstanding accounts receivable, accounts receivable &ndash; related
party, and rent receivable at March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 11 &ndash;&nbsp;<U>CONCENTRATIONS (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Customers  (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Two customers, whose
outstanding receivable accounted for 10% or more of the Company&rsquo;s total outstanding accounts receivable, accounts receivable &ndash;
related party, and rent receivable at December 31, 2020, accounted for 78.3% of the Company&rsquo;s total outstanding accounts receivable,
accounts receivable &ndash; related party, and rent receivable at December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Suppliers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No supplier accounted for 10% or more of the
Company&rsquo;s purchase during the three months ended March 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One supplier, whose outstanding payable accounted
for 10% or more of the Company&rsquo;s total outstanding accounts payable at March 31, 2021, accounted for 90.2% of the Company&rsquo;s
total outstanding accounts payable at March 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One supplier, whose outstanding payable accounted
for 10% or more of the Company&rsquo;s total outstanding accounts payable at December 31, 2020, accounted for 93.6% of the Company&rsquo;s
total outstanding accounts payable at December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 12 &ndash;&nbsp;<U>SEGMENT
INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2020, the
Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting
services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals
and other customers segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the winding down of the development services
and sales of developed products segment in 2020, the Company no longer has any material revenues or expenses in this&nbsp;segment. As
a result, commencing from the first quarter of 2021, the Company&rsquo;s chief operating decision maker no longer reviews development
services and sales of developed products operating results. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021, the
Company operated in two reportable business segments - (1) the real property operating segment, and (2) the medical related consulting
services segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s reportable segments are strategic
business units that offer different services and products. They are managed separately based on the fundamental differences in their
operations. Information with respect to these reportable business segments for the three months ended March 31, 2021 and 2020 was as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 12 &ndash;&nbsp;<U>SEGMENT INFORMATION
(continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Three&nbsp; Months&nbsp;Ended<BR>
March&nbsp;31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Revenues</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left; padding-left: 10pt">Real property operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">289,774</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">296,956</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Costs and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">216,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">254,501</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">72,880</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,455</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Other operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Real property operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101,423</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,816</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Medical related consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161,553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">155,235</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Development services and sales of developed products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,999</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,113,492</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,962,597</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt">&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,376,468</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,264,647</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">&nbsp;&nbsp;Corporate/Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(45,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,169</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt">&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(45,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(42,169</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Other income (expense)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;&nbsp;Real property operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(935</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;&nbsp;Medical related consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,486</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,487</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">&nbsp;&nbsp;Development services and sales of developed products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">&nbsp;&nbsp;Corporate/Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt">&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,381</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,420</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Total other expense, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(63,530</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(48,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Real property operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,296</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Medical related consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,039</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,722</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Development services and sales of developed products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,158,640</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,004,766</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 20pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,367,118</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,270,781</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><B>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31,<BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March&nbsp;31, <BR>
2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December&nbsp;31, <BR>
2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">Real property operations</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,655,918</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,697,473</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Medical related consulting services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,561</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,459</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Development services and sales of developed products</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,869</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">Corporate/Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">220,433</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,084,912</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,164,801</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 12 &ndash;&nbsp;<U>SEGMENT INFORMATION
(continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><B>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31, <BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>March 31,<BR>
    2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>December&nbsp;31,<BR>
    2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,718,174</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">7,764,947</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">China</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">366,738</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">399,854</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,084,912</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,164,801</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 13 &ndash;&nbsp;<U>COMMITMENTS
AND CONTINGENCIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to
ordinary routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is
not subject to, any material legal proceedings, except as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 25, 2017, Genexosome entered into and closed
a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which
Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount
of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement
with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems,
held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the
assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr.
Zhou 400 shares of common stock of Genexosome. Further, the Company had not been able to realize the financial projections provided by
Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero on September
30, 2019. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&rsquo;s Hospital (&ldquo;Research Institute&rdquo;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome
including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation of Ohio Uniform Trade Secrets
Act. Research Institute is seeking monetary damages, injunctive relief, exemplary damages, injunctive relief and other equitable relief.
The Company intends to vigorously defend against this action and pursue all available legal remedies. The civil case against Avalon is
stayed pending resolution of the criminal proceedings against Dr. Zhou and Li Chen, and while there can be no assurances, the Company
believes it has substantial legal and factual defenses to the Research Institute&rsquo;s claims and the likelihood of any findings of
liability for the Company cannot be assessed at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Operating Leases Commitment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company is a party
to leases for office space. Rent expense under all operating leases amounted to approximately $39,000 for both the three months ended
March 31, 2021 and 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information related to
leases for the&nbsp;three months ended March 31, 2021 and 2020 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Three Month Ended<BR>
March 31,</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2020</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt">Cash paid for amounts included in the measurement of lease liabilities:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left; padding-left: 10pt">Operating cash flows paid for operating lease</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">29,590</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligation:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Operating lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">133,201</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">185,401</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the lease term
and discount rate for the Company&rsquo;s operating lease as of March 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Operating&nbsp;Lease</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 0pt">Weighted average remaining lease term (in years)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">Weighted average discount rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.88</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 13 &ndash;&nbsp;<U>COMMITMENTS
AND CONTINCENGIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Operating Leases Commitment (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><B>For the Twelve-month Period Ending March
    31:</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Operating&nbsp;Lease</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt">2022</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">140,817</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">111,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0pt; padding-left: 0pt">2024 and thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Total lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">252,164</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Amount of lease payments representing interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total present value of operating lease liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">241,994</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">132,657</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Long-term portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">109,337</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 0pt; padding-left: 0pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">241,994</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Investment Commitment&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2018, Avalon Shanghai entered into
a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (&ldquo;Unicorn&rdquo;), pursuant to which a company named
Epicon Biotech Co., Ltd. (&ldquo;Epicon&rdquo;) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai.
Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000
(approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon,
and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused
on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical
transformation of scientific achievements. As of March 31, 2021, Avalon Shanghai has contributed RMB 4,700,000 (approximately $0.7 million)
that was included in equity method investment on the accompanying condensed consolidated balance sheets. The Company intends to use its
present working capital together with borrowings from related party and equity raises to fund the project cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Joint Venture &ndash; AVAR BioTherapeutics
(China) Co. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2018, Avactis Biosciences, Inc.
(&ldquo;Avactis&rdquo;), a wholly-owned subsidiary of the Company, and Arbele Limited (&ldquo;Arbele&rdquo;) agreed to the establishment
of AVAR BioTherapeutics (China) Co. Ltd. (&ldquo;AVAR&rdquo;), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture
Agreement (the &ldquo;AVAR Agreement&rdquo;), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of
the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular
immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be
contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis&rsquo; cash reserves.
Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting
AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal
cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed
upon Avactis and AVAR and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AVALON GLOBOCARE CORP. AND SUBSIDIARIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Unaudited)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 13 &ndash;&nbsp;<U>COMMITMENTS
AND CONTINGENCIES (continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Joint Venture &ndash; AVAR BioTherapeutics
(China) Co. Ltd. (continued)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Avactis is responsible for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Contributing registered capital of RMB 5,000,000 (approximately $0.8 million) for working capital
                                                                            purposes as required by local regulation, which is not required to be contributed immediately and will be contributed subject to
                                                                            Avactis&rsquo; discretion;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">assist AVAR in setting up its business operations and obtaining all required permits and licenses
                                                                            from the Chinese government;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">assisting AVAR in recruiting, hiring and retaining personnel;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">providing AVAR with access to various hospital networks in China to assist in the testing and
                                                                            commercialization of the CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology in China;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">assisting AVAR in managing the Good Manufacturing Practices (GMP) facility and clinic to be
                                                                            developed by AVAR;</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">providing AVAR with advice pertaining to conducting clinicals in China; and</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in; text-align: left">&#9679; </TD><TD STYLE="text-align: justify">Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a
                                                                            research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed
                                                                            upon milestones.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under AVAR Agreement, Arbele shall be responsible
for the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entering into a License Agreement with AVAR; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing AVAR with research and development expertise
    pertaining to clinical laboratory medicine when hired by AVAR.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, Avactis
has paid $900,000 to Arbele as research and development fee. As of March 31, 2021, License Agreement has not been finalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Line of Credit Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &ldquo;Line of Credit Agreement&rdquo;) providing the Company with a $20 million line of credit (the
&ldquo;Line of Credit&rdquo;) from Wenzhao Lu (the &ldquo;Lender&rdquo;), a significant shareholder and director of the Company. The
Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital and operating
expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into equity of the
Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable three years
from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related party
Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to maturity,
without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default occurs, the
Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021, $3,305,249
was outstanding under the Line of Credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>NOTE 14 &ndash;&nbsp;<U>SUBSEQUENT
EVENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events through
the date of the filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_008"></A>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The&nbsp;following discussion
and analysis of our financial condition and results of operations for the three months ended March 31, 2021 and 2020 should be read in
conjunction with our condensed consolidated financial statements and related notes to those condensed consolidated financial statements
that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve
risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ
materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under
the Risk Factors, Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as filed with the Securities
and Exchange Commission on March 30, 2021. We use words such as &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;plan,&rdquo;
&ldquo;project,&rdquo; &ldquo;continuing,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo;
&ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; and similar expressions to identify forward-looking
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Impact of COVID-19
on Our Operations, Financial Condition, Liquidity and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the COVID-19 vaccines have generally
been introduced to the public, the ultimate impact of the COVID-19 pandemic on our operations is unknown and will depend on future developments,
which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information
which may emerge concerning the severity of the COVID-19 pandemic, a significant increase in new and variant strains of COVID-19 cases,
availability and effectiveness of COVID-19 vaccines and therapeutics, the level of acceptance of the vaccine by the general population
and any additional preventative and protective actions that governments, or us, may determine are needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of COVID-19 pandemic had negative
impact on our operations. Some tenants have delayed on rent payment and some of the universities and laboratories with which we collaborate
were temporarily closed. Our general development operations have continued during the COVID-19 pandemic and we have not had significant
disruption. However, we are uncertain if the COVID-19 pandemic will impact future operations at our laboratory, or our ability to collaborate
with other laboratories and universities. In addition, we are unsure if the COVID-19 pandemic will impact future clinical trials. Given
the dynamic nature of these circumstances, the duration of business disruption and reduced traffic, the related financial effect cannot
be reasonably estimated at this time but is expected to adversely impact the Company&rsquo;s business for the rest of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have limited cash available to fund planned
operations and although we have other sources of capital described below under &ldquo;Liquidity and Capital Resources,&rdquo; management
continues to pursue various financing alternatives to fund our operations so we can continue as a going concern. However, the COVID-19
pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the
necessary financing through the issue of new equity and/or the entering into of strategic partnership arrangements but the ultimate impact
of the COVID-19 pandemic on our ability to raise additional capital is unknown and will depend on future developments, which are highly
uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and new information which may emerge
concerning the severity of the COVID-19 pandemic. We may not be able to raise sufficient additional capital and may tailor our operations
based on the amount of funding we are able to raise in the future. Nevertheless, there is no assurance that these initiatives will be
successful. Further, there is no assurance that capital available to us in any future financing will be on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&trade;), and regenerative therapeutics. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon achieves and fosters seamless integration
of unique verticals to bridge and accelerate innovative research, bio-process development, clinical programs and product commercialization.
Avalon&rsquo;s upstream innovative research includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
<TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify">Development of Avalon Clinical-grade Tissue-specific Exosome (&ldquo;ACTEX&trade;&rdquo;).</TD>
</TR></TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;
                               </FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Novel
                                            therapeutic and diagnostic targets development utilizing QTY-code protein design technology
                                            with Massachusetts Institute of Technology (MIT) including using the QTY code protein design
                                            technology for development of a hemofiltration device to treat Cytokine Storm.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Strategic
                                            partnership with the University of Natural Resources and Life Sciences (BOKU) in Vienna,
                                            Austria to develop an S-layer vaccine that can be administered by an intranasal or oral route
                                            against SARS-CoV-2, the novel coronavirus that causes COVID-19 disease.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Avalon&rsquo;s midstream bio-processing and bio-production
facility is located in Nanjing, China with state-of-the-art, automated GMP and QC/QA infrastructure for standardized bio-manufacturing
of clinical-grade cellular products involved in our clinical programs in immune effector cell therapy, regenerative therapeutics, as well
as bio-banking. As a result of the COVID pandemic, the operation of this facility has not been at full capacity. However, the Company
expects to slowly increase operations during 2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Avalon&rsquo;s
downstream medical team and facility consists of top-rated affiliated hospital network and experts specialized in hematology, oncology,
cellular immunotherapy, hematopoietic stem/progenitor cell transplant, as well as regenerative therapeutics. Our major clinical programs
include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVA-001:
                                            Avalon has initiated its first-in-human clinical trial of CD19 CAR-T candidate, AVA-001 in
                                            August 2019 at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China
                                            (the world&rsquo;s single largest CAR-T treatment network with over 600 patients being treated
                                            with CAR-T) for the indication of relapsed/refractory B-cell acute lymphoblastic leukemia
                                            and non-Hodgkin Lymphoma. The AVA-001 candidate (co-developed with China Immunotech Co. Ltd)
                                            is characterized by the utilization of 4-1BB (CD137) co-stimulatory signaling pathway, conferring
                                            a strong anti-cancer activity during pre-clinical study. It also features a shorter bio-manufacturing
                                            time which leads to the advantage of prompt treatment to patients where timing is important
                                            related hematologic malignancies. Avalon has successfully completed the first-in-human clinical
                                            trial of its AVA-001 anti-CD19 CAR-T cell therapy as a bridge to allogeneic bone marrow transplantation
                                            for patients with relapsed/refractory B-cell acute lymphoblastic leukemia at the Lu Daopei
                                            Hospital (registered clinical trial number NCT03952923) with excellent efficacy (90% complete
                                            remission rate) and minimal adverse side effects. Avalon is currently expanding the patient
                                            recruitment for AVA-001 to include relapsed/refractory non-Hodgkin lymphoma patients.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ACTEX&trade;:
                                            Stem cell-derived Avalon Clinical-grade Tissue-specific Exosomes (ACTEX&trade;) is one of
                                            the core technology platforms that has been co-developed by Avalon GloboCare and Weill Cornell
                                            Medicine. The Company formed a strategic partnership with HydroPeptide, LLC, a leading epigenetics
                                            skin care company, to engage in co-development and commercialization of a series of clinical-grade,
                                            exosome-based cosmeceutical and orthopedic products. As part of this agreement, the Company
                                            signed a three-way Material Transfer Agreement between Avalon GloboCare, HydroPeptide and
                                            Weill Cornell Medicine.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FLASH-CAR&trade;:
                                            The Company advanced its next generation immune cell therapy using RNA-based, non-viral FLASH-CAR&trade;
                                            technology co-developed with the Company&rsquo;s strategic partner Arbele Limited. The adaptable
                                            FLASH-CAR&trade; platform can be used to create personalized cell therapy from a patient&rsquo;s
                                            own cells, as well as off-the-shelf cell therapy from a universal donor.&nbsp;Our leading
                                            candidate, AVA-011, is currently at process development stage to generate clinical-grade
                                            cell-therapy products for subsequent clinical studies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AVA-Trap&trade;:
                                            Avalon&rsquo;s AVA-Trap&trade; therapeutic program plans to enter animal model testing followed
                                            by expedited clinical studies with the goal of providing an effective therapeutic option
                                            to combat COVID-19 and other life-threatening conditions involving cytokine storms. The Company
                                            initiated a sponsored research and co-development project with Massachusetts Institute of
                                            Technology (MIT) led by Professor Shuguang Zhang as Principal Investigator in May 2019. Using
                                            the unique QTY code protein design platform, six water-soluble variant cytokine receptors
                                            have been successfully designed and tested to show binding affinity to the respective cytokines.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
provide medical related consulting services in advanced areas of immunotherapy and second opinion/referral services through our wholly-owned
subsidiary Avalon (Shanghai) Healthcare Technology Co., Ltd., or Avalon Shanghai. We also own and operate rental commercial real property
in New Jersey, where we are headquartered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the first quarter of 2021, we did not have any revenue from medical related consulting services. Although we maintain close working relationships
with our related parties, the consulting agreements with our related parties expired as of December 31, 2020. There was no order from
related party and third party customers in the three months ended March 31, 2021. Currently, we are negotiating with our potential customers
and consulting services agreements are not finalized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
value of the Renminbi (&ldquo;RMB&rdquo;), the main currency used in China, fluctuates and is affected by, among other things, changes
in China&rsquo;s political and economic conditions. The conversion of RMB into foreign currencies such as the U.S. dollar have generally
been based on rates set by the People&rsquo;s Bank of China, which are set daily based on the previous day&rsquo;s interbank foreign
exchange market rates and current exchange rates on the world financial markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative,
transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. The Company
also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness
in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&amp;D
to automated bioproduction and accelerated clinical development, the Company is establishing a leading role in the fields of cellular
immunotherapy (including CAR-T/NK), exosome technology (ACTEX&trade;), and regenerative therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the Company owns commercial real estate that houses its headquarters in Freehold, New Jersey and <FONT STYLE="background-color: white">provides
outsourced, customized international healthcare services to the rapidly changing health care industry primarily focused in the People&rsquo;s
Republic of China. </FONT>The Company did not generate any revenue from medical related consulting services segment during the three
months ended March 31, 2021. These condensed consolidated financial statements have been prepared assuming that the Company will continue
as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal
course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
reflected in the accompanying condensed consolidated financial statements, the Company had working capital deficit of $1,059,606 as of
March 31, 2021 and has incurred recurring net loss and generated negative cash flow from operating activities of $2,367,118 and $1,515,525
for the three months ended March 31, 2021, respectively. The Company has a limited operating history and its continued growth is dependent
upon the continuation of providing medical consulting services to its only few clients who are related parties and generating rental
revenue from its income-producing real estate property in New Jersey; hence generating revenues, and obtaining additional financing to
fund future obligations and pay liabilities arising from normal business operations. In addition, the current cash balance cannot be
projected to cover the operating expenses for the next twelve months from the release date of this report. These matters raise substantial
doubt about the Company&rsquo;s ability to continue as a going concern. The ability of the Company to continue as a going concern is
dependent on the Company&rsquo;s ability to raise additional capital, implement its business plan, and generate significant revenues.
There are no assurances that the Company will be successful in its efforts to generate significant revenues, maintain sufficient cash
balance or report profitable operations or to continue as a going concern. The Company plans on raising capital through the sale of equity
to implement its business plan. However, there is no assurance these plans will be realized and that any additional financings will be
available to the Company on satisfactory terms and conditions, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
occurrence of an uncontrollable event such as the COVID-19 pandemic had negatively impact on the Company&rsquo;s operations. Some tenants
have delayed on rent payment. Our general development operations have continued during the COVID-19 pandemic and we have not had significant
disruption. However, we are uncertain if the COVID-19 pandemic will impact future operations at our laboratory, or our ability to collaborate
with other laboratories and universities. In addition, we are unsure if the COVID-19 pandemic will impact future clinical trials. Given
the dynamic nature of these circumstances, the duration of business disruption and reduced traffic, the related financial effect cannot
be reasonably estimated at this time but is expected to adversely impact the Company&rsquo;s business for the rest of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification
of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as
a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"><B>Critical
Accounting Policies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements,
which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed
consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including
those related to the useful life of property and equipment and investment in real estate, assumptions used in assessing impairment of
long-term assets, valuation of deferred tax assets and the associated valuation allowances, and valuation of stock-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We&nbsp;base
our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent
from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues,
expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Revenue
Recognition </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">We
recognize revenue under Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 606, Revenue from Contracts with Customers (&ldquo;ASC
606&rdquo;). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised
goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for
those goods or services. The following five steps are applied to achieve that core principle:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step 1: Identify the contract
    with the customer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step 2: Identify the performance
    obligations in the contract</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step 3: Determine the transaction
    price</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step 4: Allocate the transaction
    price to the performance obligations in the contract</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step 5: Recognize revenue
    when the company satisfies a performance obligation</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
order to identify the performance obligations in a contract with a customer, a company must assess the promised goods or services in
the contract and identify each promised goods or service that is distinct. A performance obligation meets ASC 606&rsquo;s definition
of a &ldquo;distinct&rdquo; goods or service (or bundle of goods or services) if both of the following criteria are met:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                            customer can benefit from the goods or service either on its own or together with other resources
                                            that are readily available to the customer (i.e., the goods or service is capable of being
                                            distinct).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 38.25pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                            entity&rsquo;s promise to transfer the goods or service to the customer is separately identifiable
                                            from other promises in the contract (i.e., the promise to transfer the goods or service is
                                            distinct within the context of the contract).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
a goods or service is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or
services is identified that is distinct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods
or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). The consideration
promised in a contract with a customer may include fixed amounts, variable amounts, or both. Variable consideration is included in the
transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will
not occur when the uncertainty associated with the variable consideration is subsequently resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
transaction price is allocated to each performance obligation on a relative standalone selling price basis. The transaction price allocated
to each performance obligation is recognized when that performance obligation is satisfied, at a point in time or over time as appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company&rsquo;s revenues are derived from providing medial related consulting services for its&rsquo; related parties. Revenues related
to its service offerings are recognized as the services are performed. <FONT STYLE="background-color: white">Any payments received in
advance of the performance of services are recorded as&nbsp;deferred revenue&nbsp;until such time as the services are performed. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have determined that the ASC 606 does not apply to rental contracts, which are within the scope of other revenue recognition accounting
standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rental
income from operating leases is recognized on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases
are recognized on a straight-line basis over the term of the related leases. The cumulative difference between lease revenue recognized
under the straight-line method and contractual lease payments are included in rent receivable on the condensed consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not offer promotional payments, customer coupons, rebates or other cash redemption offers to our customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are governed by the income tax laws of China and the United States. Income taxes are accounted for pursuant to ASC 740 &ldquo;Accounting
for Income Taxes,&rdquo; which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. The charge for
taxes is based on the results for the period as adjusted for items, which are non-assessable or disallowed. It is calculated using tax
rates that have been enacted or substantively enacted by the balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred
tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the
carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of assessable
tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences, and deferred tax assets are
recognized to the extent that it is probably that taxable profit will be available against which deductible temporary differences can
be utilized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred
tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred
tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which
case the deferred tax is changed to equity. Deferred tax assets and liabilities are offset when they related to income taxes levied by
the same taxation authority and we intend to settle its current tax assets and liabilities on a net basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Recent
Accounting Standards&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
details of applicable new accounting standards, please, refer to&nbsp;Recent Accounting Standards&nbsp;in Note 3<I>&nbsp;</I>of our condensed
consolidated<I>&nbsp;</I>financial statements accompanying this report.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RESULTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Comparison
of Results of Operations for the Three Months Ended March 31, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Revenues</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the three months ended March 31, 2021, we had real property rental revenue of $289,774, as compared to $296,956 for the three months
ended March 31, 2020, a decrease of $7,182, or 2.4%. The slight decrease was primarily attributable to a tenant moved out in August 2020.
We expect that our revenue from real property rent will remain in its current quarterly level with minimal increase in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Costs
and Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Real
property operating expenses consist of property management fees, property insurance, real estate taxes, depreciation, repairs and maintenance
fees, utilities and other expenses related to our rental properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the three months ended March 31, 2021, our real property operating expenses amounted to $216,894, as compared to $254,501 for the three
months ended March 31, 2020, a decrease of $37,607, or 14.8%. The decrease was mainly due to a decrease in repairs and maintenance fees
of approximately $22,000, and a decrease in other miscellaneous items of approximately $16,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Real
Property Operating Income</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
real property operating income for the three months ended March 31, 2021 was $72,880, representing an increase of $30,425, or 71.7%,
as compared to $42,455 for the three months ended March 31, 2020. The increase was mainly attributable to the decrease in real property
operating expenses as described above. We expect our real property operating income will remain in its current quarterly level with minimal
increase in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Other
Operating Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the three months ended March 31, 2021 and 2020, other operating expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Three Months Ended<BR>
    March 31,</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Professional fees</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,381,178</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,553,698</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Compensation and related benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">562,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,128,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,188</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,402</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Directors and officers liability insurance premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Travel and entertainment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">32,150</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Rent and related utilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,741</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Advertising expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,823</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,903</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81,842</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,376,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,264,647</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Professional
                                            fees primarily consisted of accounting fees, audit fees, legal service fees, consulting fees,
                                            investor relations service charges and other fees incurred for service related to being a
                                            public company. For the three months ended March 31, 2021, professional fees decreased by
                                            $172,520, or 11.1%, as compared to the three months ended March 31, 2020. The decrease was
                                            primarily attributable to a decrease in investor relations service fees of approximately
                                            $171,000 mainly due to the decrease in use of investor relations service providers, and a
                                            decrease in other miscellaneous items of approximately $1,000. We expect that our professional
                                            fees will remain in its current quarterly level with minimal increase in the near future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, compensation and related benefits decreased by $566,462,
                                            or 50.2%, as compared to the three months ended March 31, 2020. The significant decrease
                                            was primarily attributable to a decrease in stock-based compensation of approximately $578,000
                                            which reflected the value of options granted and vested to our management, offset by an increase
                                            in compensation and related benefits for other employees of approximately $12,000. We expect
                                            that our compensation and related benefits will remain in its current quarterly level with
                                            minimal increase in the near future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, research and development expenses decreased by $62,214,
                                            or 22.6%, as compared to the three months ended March 31, 2020. The decrease was primarily
                                            attributable to our first project with Arbele was completed in 2020 and no further research
                                            and development project was incurred in 2021. We expect our research and development expenses
                                            will increase in the near future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, Directors and Officers Liability Insurance premium
                                            increased by $23,128, or 39.9%, as compared to the three months ended March 31, 2020. The
                                            increase was mainly due to different insurance provider with different premium.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, travel and entertainment expense decreased by $41,430,
                                            or 56.3%, as compared to the three months ended March 31, 2020. The decrease was mainly due
                                            to decreased business travel activities and decreased entertainment expenditure resulting
                                            from COVID-19. The spread of COVID-19 has caused public health officials to recommend precautions
                                            to mitigate the spread of the virus, such as, cease traveling to non-essential jobs and curtail
                                            all unnecessary travel, and stay at home as much as possible.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, rent and related utilities expenses decreased by $114,
                                            or 0.5%, as compared to the three months ended March 31, 2020.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
                                            the three months ended March 31, 2021, advertising expenses decreased by $62,080 or 87.6%
                                            as compared to the three months ended March 31, 2020. The decrease was primarily due to decreased
                                            advertising activities incurred as a result of stricter control on corporation spending.
                                            We expect that our advertising expenses will increase in the near&nbsp;future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
                                            general and administrative expenses mainly consisted of NASDAQ listing fee, office supplies,
                                            and other miscellaneous items. For the three months ended March 31, 2021, other general and
                                            administrative expenses decreased by $6,487, or 7.9%, as compared to the three months ended
                                            March 31, 2020, reflecting our efforts at stricter controls on corporate expenditure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Loss
from Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">As
a result of the foregoing, for the three months ended March 31, 2021, loss from operations amounted to $2,303,588, as compared to $3,222,192
for the three months ended March 31, 2020, a decrease of $918,604, or 28.5%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Other
Income (Expense)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
income (expense) mainly includes interest expense and&nbsp;<FONT STYLE="background-color: white">loss from equity method investment</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
expense, net, totaled $63,530 for the three months ended March 31, 2021, as compared to $48,589 for the three months ended March 31,
2020, an increase of $14,941, or 30.7%, which was primarily attributable to an increase in loss from equity method investment of approximately
$9,000, an increase in interest expense of approximately $3,000, and a decrease in miscellaneous income of approximately $3,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
did not have any income taxes expense for the three months ended March 31, 2021 and 2020 since we incurred losses in these periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Net
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result of the factors described above, our net loss was $2,367,118 for the three months ended March 31, 2021, as compared to $3,270,781
for the three months ended March 31, 2020, a decrease of $903,663 or 27.6%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Net
Loss Attributable to Avalon GloboCare Corp. Common Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
net loss attributable to Avalon GloboCare Corp. common shareholders was $2,367,118 or $(0.03) per share (basic and diluted) for the three
months ended March 31, 2021, as compared with $3,270,781, or $(0.04) per share (basic and diluted) for the three months ended March 31,
2020, a change of $903,663 or 27.6%.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Foreign
Currency Translation Adjustment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
reporting currency is the U.S. dollar. The functional currency of our parent company, AHS, Avalon RT 9, Genexosome, Avactis, and Exosome,
is the U.S. dollar and the functional currency of Avalon Shanghai and Beijing Genexosome is the Chinese Renminbi (&ldquo;RMB&rdquo;).
The financial statements of our subsidiaries whose functional currency is the RMB are translated to U.S. dollars using period end rates
of exchange for assets and liabilities, average rate of exchange for revenues, costs, and expenses and cash flows, and at historical
exchange rates for equity. Net gains and losses resulting from foreign exchange transactions are included in the results of operations.
As a result of foreign currency translations, which are a non-cash adjustment, we reported a foreign currency translation loss of $2,722
and $22,066 for the three months ended March 31, 2021 and 2020, respectively. This non-cash loss had the effect of increasing our reported
comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Comprehensive
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result of our foreign currency translation adjustment, we had comprehensive loss of $2,369,840 and $3,292,847 for the three months
ended March 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has a limited operating history and its continued growth is dependent upon the continuation of providing medical consulting services
to its only few clients who are related parties and generating rental revenue from its income-producing real estate property in New Jersey;
hence generating revenues, and obtaining additional financing to fund future obligations and pay liabilities arising from normal business
operations. In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve months from
the release date of this report. These matters raise substantial doubt about the Company&rsquo;s ability to continue as a going concern.
The ability of the Company to continue as a going concern is dependent on the Company&rsquo;s ability to raise additional capital, implement
its business plan, and generate significant revenues. There are no assurances that the Company will be successful in its efforts to generate
significant revenues, maintain sufficient cash balance or report profitable operations or to continue as a going concern. The Company
plans on raising capital through the sale of equity to implement its business plan. However, there is no assurance these plans will be
realized and that any additional financings will be available to the Company on satisfactory terms and conditions, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
occurrence of an uncontrollable event such as the COVID-19 pandemic is likely to negatively affect the Company&rsquo;s operations. Efforts
to contain the spread of the&nbsp;coronavirus&nbsp;have intensified, including social distancing, travel bans and quarantine, and these
are likely to negatively impact our tenants, employees and consultants. These, in turn, will not only impact our operations, financial
condition and demand for our medical related consulting services but our overall ability to react timely to mitigate the impact of this
event. Given the dynamic nature of these circumstances, the duration of business disruption and reduced traffic, the related financial
effect cannot be reasonably estimated at this time but is expected to adversely impact our business for the rest of 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liquidity
is the ability of a company to generate funds to support its current and future operations, satisfy its obligations and otherwise operate
on an ongoing basis. At March 31, 2021 and December&nbsp;31, 2020, we had cash balance of approximately $1,693,000 and $727,000, respectively.
These funds are kept in financial institutions located as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>Country:</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>March 31, <BR>
2021</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>December 31, <BR>
2020</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">United States</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,527,257</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">90.2</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">559,711</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">77.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>China</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">165,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">166,866</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23.0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total cash</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,692,540</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">726,577</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100.0</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Under
applicable PRC regulations, foreign invested enterprises, or FIEs, in China may pay dividends only out of their accumulated profits,
if any, determined in accordance with PRC accounting standards and regulations. In addition, a foreign invested enterprise in China is
required to set aside at least 10% of its after-tax profit based on PRC accounting standards each year to its general reserves until
the cumulative amount of such reserves reach 50% of its registered capital. These reserves are not distributable as cash dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, a portion of our businesses and assets are denominated in RMB, which is not freely convertible into foreign currencies. All
foreign exchange transactions take place either through the People&rsquo;s Bank of China or other banks authorized to buy and sell foreign
currencies at the exchange rates quoted by the People&rsquo;s Bank of China. Approval of foreign currency payments by the People&rsquo;s
Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers&rsquo; invoices,
shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict
the ability of our PRC subsidiary to transfer its net assets to the Parent Company through loans, advances or cash dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
current PRC Enterprise Income Tax (&ldquo;EIT&rdquo;) Law and its implementing rules generally provide that a 10% withholding tax applies
to China-sourced income derived by non-resident enterprises for PRC enterprise income tax purposes unless the jurisdiction of incorporation
of such enterprises&rsquo; shareholder has a tax treaty with China that provides for a different withholding arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth a summary of changes in our working capital from December 31, 2019 to September 30, 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><B>March 31,</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><B>December 31,</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><B>Changes in</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Amount</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Percentage</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Working capital deficit:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Total current assets</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,164,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,286,337</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">877,843</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">68.2</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,223,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,592,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">631,393</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24.4</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Working capital deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,059,606</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,306,056</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">246,450</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18.9</TD><TD STYLE="text-align: left">)%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
working capital deficit decreased by $246,450 to $1,059,606 at March 31, 2021 from $1,306,056 at December&nbsp;31, 2020. The decrease
in working capital deficit was primarily attributable to an increase in cash of approximately $966,000, and a decrease in accrued research
and development fees of approximately $81,000, offset by a decrease in deferred financing costs of approximately $70,000, an increase
in accrued professional fees of approximately $232,000, an increase in accrued liabilities and other payables &ndash; related parties
of approximately $45,000, an increase in operating lease obligation of approximately $56,000, and an increase in note payable &ndash;
related party of $390,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
the exchange rate conversion is different for the condensed consolidated balance sheets and the condensed consolidated statements of
cash flows, the changes in assets and liabilities reflected on the condensed consolidated statements of cash flows are not necessarily
identical with the comparable changes reflected on the condensed consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash
Flows for the Three Months Ended March 31, 2021 Compared to the Three Months Ended March 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following summarizes the key components of our cash flows for the three months ended March 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center"><B>Three Months Ended<BR>
March 31,</B></TD><TD STYLE="white-space: nowrap"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2021</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>2020</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,515,525</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,998,796</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,844</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,512,212</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,874,877</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of exchange rate on cash</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,701</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">965,963</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(129,620</TD><TD STYLE="text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash flow used in operating activities for the three months ended March 31, 2021 was $1,515,525, which primarily reflected our consolidated
net loss of approximately $2,367,000, and the changes in operating assets and liabilities, primarily consisting of an increase in prepaid
expenses and other current assets of approximately $41,000, and a decrease in operating lease obligation of approximately $33,000, offset
by an increase in accrued liabilities and other payables of approximately $163,000, an increase in accrued liabilities and other payables
&ndash; related parties of approximately $45,000, and the non-cash items adjustment primarily consisting of depreciation of approximately
$79,000, and stock-based compensation and service expense of approximately $574,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash flow used in operating activities for the three months ended March 31, 2020 was $1,998,796, which primarily reflected our consolidated
net loss of approximately $3,271,000, and the changes in operating assets and liabilities, primarily consisting of an increase in prepaid
expenses and other current assets of approximately $97,000, offset by a decrease in accounts receivable &ndash; related party of approximately
$86,000, and the non-cash items adjustment primarily consisting of depreciation of approximately $77,000, and stock-based compensation
and service expense of approximately $1,189,000.&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect our cash used in operating activities to increase due to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                            development and commercialization of new products;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                            increase in professional staff and services; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an
                                            increase in public relations and/or sales promotions for existing and/or new brands as we
                                            expand within existing markets or enter new markets.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Net
cash flow used in investing activities was $30,844 for the three months ended March 31, 2021. During the three months ended March 31,
2021, we made additional investment in equity method investment of approximately $31,000.&nbsp;There were no investing activities during
the three months ended March 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash flow provided by financing activities was $2,512,212 for the three months ended March 31, 2021 as compared to $1,874,877 for the
three months ended March 31, 2020. During the three months ended March 31, 2021, we received proceeds from related party borrowings of
approximately $105,000 and net proceeds from equity offering of approximately $2,407,000 (net of cash paid for commission of approximately
$74,000). During the three months ended March 31, 2020, we received proceeds from related party borrowings of $300,000 and net proceeds
from equity offering of approximately $1,575,000 (net of cash paid for commission of approximately $49,000).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
capital requirements for the next twelve months primarily relate to working capital requirements, including salaries, fees related to
third parties&rsquo; professional services, reduction of accrued liabilities, mergers, acquisitions and the development of business opportunities.
These uses of cash will depend on numerous factors including our sales and other revenues, and our ability to control costs. All funds
received have been expended in the furtherance of growing the business. The following trends are reasonably likely to result in a material
decrease in our liquidity over the near to long term:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">an increase in working
    capital requirements to finance our current business, including ongoing research and development programs, clinical studies, as well
    as commercial strategies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the use of capital for
    mergers, acquisitions and the development of business opportunities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">addition of administrative
    personnel as the business grows; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the cost of being a public
    company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the third quarter of 2019, we had secured a $20 million credit facility (Line of Credit) provided by our Chairman, Wenzhao Lu.&nbsp;
The unsecured credit facility bears interest at a rate of 5% and provides for maturity on drawn loans 36 months after funding. The note
is not convertible to equity. As of March 31, 2021, the total principal amount outstanding under the Credit Line was approximately $3.3
million and we have approximately $16.7 million remaining available under the&nbsp;Line Credit.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
December&nbsp;13, 2019, we entered into an Open Market Sale Agreement<SUP>SM&nbsp;</SUP>(the &ldquo;Sales Agreement&rdquo;) with Jefferies
LLC, as sales agent (&ldquo;Jefferies&rdquo;), pursuant to which we may offer and sell, from time to time, through Jefferies, shares
of our common stock, par value $0.0001 per share, having an aggregate offering price of up to $20.0 million. On April 6, 2020, the date
on which we filed our Annual Report on Form&nbsp;10-K&nbsp;for the fiscal year ended December&nbsp;31, 2019, our registration statement
became subject to the offering limits set forth in General Instruction I.B.6 of Form&nbsp;S-3.&nbsp;As of April 6, 2020, the aggregate
market value of our outstanding common stock held by&nbsp;non-affiliates,&nbsp;or public float, was $39,564,237, based on 23,691,160
shares of our outstanding common stock that were held by&nbsp;non-affiliates&nbsp;on such date and a price of $1.67 per share, which
was the price at which our common stock was last sold on The Nasdaq Capital Market on February 19, 2020 (a date within 60 days of the
date hereof), calculated in accordance with General Instruction I.B.6 of&nbsp;Form&nbsp;S-3.&nbsp;We have not offered any securities
pursuant to General Instruction I.B.6 of Form&nbsp;S-3&nbsp;in the 12 calendar months preceding the date of this prospectus supplement.
We filed a prospectus supplement to amend and supplement the information in our prospectus and original prospectus supplement based on
the amount of securities that we are eligible to sell under General Instruction I.B.6 of&nbsp;Form&nbsp;S-3.&nbsp;After giving effect
to the $13,000,000 offering limit imposed by General Instruction I.B.6 of&nbsp;Form&nbsp;S-3,&nbsp;we may offer and sell additional shares
of our common stock having an aggregate offering price of up to $13,000,000 from time to time through Jefferies acting as our sales agent
in accordance with the terms of the&nbsp;sales agreement. As of March 31, 2021, we sold a total of 5,900,275 shares of our common stock
through Jefferies with an aggregate offering price of $9,559,240 and we have approximately $5.4 million offering price remaining available
under the&nbsp;Sales Agreement.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
estimate that based on current plans and assumptions, that our available cash will be insufficient to satisfy our cash requirements under
our present operating expectations through cash available under our Credit Line and sales of equity through our Sales Agreement. Other
than funds received from the sale of our equity and advances from our related party, and cash resource generating from our operations,
we presently have no other significant alternative source of working capital. We have used these funds to fund our operating expenses,
pay our obligations and grow our company. We will need to raise significant additional capital to fund our operations and to provide
working capital for our ongoing operations and obligations. Therefore, our future operation is dependent on our ability to secure additional
financing. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing
mechanisms. However, the trading price of our common stock and a downturn in the U.S. equity and debt markets could make it more difficult
to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible
that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative
financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new
equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. The inability to
obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If
we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not considered this alternative,
nor do we view it as a likely occurrence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Contractual
Obligations and Off-Balance Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Contractual
Obligations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have certain fixed contractual obligations and commitments that include future estimated payments. Changes in our business needs, cancellation
provisions, and other factors may result in actual payments differing from the estimates. We cannot provide certainty regarding the timing
and amounts of payments. We have presented below a summary of the most significant assumptions used in our determination of amounts presented
in the tables, in order to assist in the review of this information within the context of our consolidated financial position, results
of operations, and cash flows. The following tables summarize our contractual obligations as of March 31, 2021, and the effect these
obligations are expected to have on our liquidity and cash flows in future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="18" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Payments Due by Period</B></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>Contractual obligations:</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Total</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Less than 1 year</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>1-3 years</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>3-5 years</B></TD><TD><B>&nbsp;</B></TD><TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5<SUP>+
    </SUP>years</B></FONT></TD><TD><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Operating lease commitment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">273,108</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">148,752</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">124,356</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Acquisition consideration</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Borrowings from related party (principal)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,695,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">390,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,305,249</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest &ndash; related party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,105</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Epicon equity investment obligation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">808,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">269,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">539,218</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">AVAR joint venture commitment</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,763,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">763,044</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Total</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">15,853,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,884,510</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,968,823</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Off-balance
Sheet Arrangements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
presently do not have off-balance sheet arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Foreign
Currency Exchange Rate Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
portion of our operations are in China. Thus, a portion of our revenues and operating results may be impacted by exchange rate fluctuations
between RMB and US dollars. For the three months ended March 31, 2021 and 2020, we had an unrealized foreign currency translation loss
of approximately $3,000 and $22,000, respectively, because of changes in the exchange rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B><I>&nbsp;&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Inflation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
effect of inflation on our revenue and operating results was not significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_009"></A>ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a smaller reporting company, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by
this Item<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_010"></A>ITEM
4. CONTROLS AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Evaluation
of Disclosure Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosure
controls and procedures are designed to ensure that information required to be disclosed by us in reports filed or submitted under the
Securities Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;) is recorded, processed, summarized and reported within the time
periods specified in the SEC&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed under the Exchange Act is accumulated and communicated to management, including
the principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. There are inherent
limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the
circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide
reasonable assurance of achieving their control objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the preparation of the quarterly report on Form 10-Q for the quarter ended March 31, 2021, our management, including
our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of our disclosure controls
and procedures, which are defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it
files or submits under the Exchange Act is accumulated and communicated to the issuer&rsquo;s management, including its principal executive
and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required
disclosure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
on this evaluation, management concluded that our internal control over financial reporting were not effective as of March 31, 2021 due
to the significant deficiencies which aggregate to a material weakness and was previously reported in our Form 10-K Annual Report for
the year ended December&nbsp;31, 2020 (&ldquo;2020 10-K&rdquo;), that have not yet been remediated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Changes
in Internal Controls Over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
were no changes in our internal controls over financial reporting that occurred during the period covered by this report that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_011"></A>PART
II - OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_012"></A>ITEM
1. LEGAL PROCEEDINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, we are subject to ordinary routine litigation incidental to our normal business operations. We are not currently a party
to, and our property is not subject to, any material legal proceedings, except as set forth below.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
October 25, 2017, Genexosome entered into and closed a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole
shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome
in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome
entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual
property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome
technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of
the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome. Further, The Company had not been able to realize
the financial projections provided by Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated
with this acquisition to zero. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research
Institute at Nationwide Children&rsquo;s Hospital (&ldquo;Research Institute&rdquo;) filed a Complaint in the United States District
Court for the Southern District of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against
the Company and Genexosome including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation
of Ohio Uniform Trade Secrets Act. Research Institute is seeking monetary damages, injunctive relief, exemplary damages, injunctive relief
and other equitable relief. The Company intends to vigorously defend against this action and pursue all available legal remedies. The
civil case against Avalon is stayed pending resolution of the criminal proceedings against Dr. Zhou and Li Chen, and while there can
be no assurances, the Company believes it has substantial legal and factual defenses to the Research Institute&rsquo;s claims and the
likelihood of any findings of liability for the Company cannot be assessed at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_013"></A>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">There
were no material changes from the risk factors set forth under Part I, Item 1A., &ldquo;Risk Factors&rdquo; in our Annual Report on Form
10-K for the fiscal year ended December&nbsp;31, 2020. You should carefully consider these factors in addition to the other information
set forth in this report which could materially affect our business, financial condition or future results. The risks and uncertainties
described in this report and in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2020, as well as other reports and
statements that we file with the SEC, are not the only risks and uncertainties facing us. Additional risks and uncertainties not currently
known to us or that we currently deem to be immaterial may also have a material adverse effect on our financial position, results of
operations or cash flows.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amidst
the COVID-19 outbreak, some tenants have delayed on rent payment. Our general development operations have continued during the COVID-19
pandemic and we have not had significant disruption. Currently we are unable to accurately predict the future impact of COVID-19 due
to the developing circumstances and uncertainty surrounding this current pandemic, including the ultimate geographic spread of COVID-19,
the severity of the disease, the duration of the outbreak, and effectiveness of the actions that may be taken by governmental authorities.
Our management has been closely monitoring the impact caused by COVID-19 and we will continue to operate our business as steadily and
safely as we can.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_014"></A>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Shares Issued for Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the three months ended March 31, 2021, the Company issued a total of 300,000 shares of its common stock for services rendered. These
shares were valued at $360,000, the fair market values on the grant dates using the reported closing share prices on the dates of grant
and the Company <FONT STYLE="background-color: white">recorded stock-based compensation expense of $98,968 for the three months ended
March 31, 2021</FONT> and reduced accrued liabilities of $261,032.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
offers, sales, and issuances of the securities described above were deemed to be exempt from registration under the Securities Act of
1933 in reliance on Section 4(a)(2) of the Securities Act of 1933 or Regulation D promulgated thereunder as transactions by an issuer
not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only
and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities
issued in these transactions. Each of the recipients of securities in these transactions was an accredited or sophisticated person and
had adequate access, through employment, business or other relationships, to information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_015"></A>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_016"></A>ITEM
4. MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_017"></A>ITEM
5. OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">On
December&nbsp;13, 2019, the Company entered into an Open Market Sale Agreement</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>SM&nbsp;</SUP><FONT STYLE="background-color: white">(the
&ldquo;Sales Agreement&rdquo;) with Jefferies LLC, as sales agent (&ldquo;Jefferies&rdquo;), pursuant to which the Company may offer
and sell, from time to time, through Jefferies, shares of its common stock, par value $0.0001 per share, having an aggregate offering
price of up to $20.0 million. On April 6, 2020, the date on which the Company filed its Annual Report on Form&nbsp;10-K&nbsp;for the
fiscal year ended December&nbsp;31, 2019, the Company&rsquo;s registration statement became subject to the offering limits set forth
in General Instruction I.B.6 of Form&nbsp;S-3.&nbsp;From December 13, 2019 through May 12, 2021, Jefferies sold an aggregate of 5,900,275
shares of common stock at an average price of $1.62 per share to investors. The Company received net cash proceeds of $9,272,463, net
of commission paid to sales agent of $286,777.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_018"></A>ITEM
6. EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></P></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019026166/f8k121319ex1-1_avalong.htm">Open Market Sale AgreementSM, dated as of December 13, 2019, by and between Avalon GloboCare Corp. and Jefferies LLC. (incorporated by reference to Exhibit 1.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex3-1.htm">Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex3-2.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577416009001/s105001_ex4-1.htm">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the December 2016 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 21, 2016)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex4-1.htm">Stock Option issued to Luisa Ingargiola dated February 21, 2017 (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.3</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-1.htm">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the March 2017 Accredited Investor (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.4</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-2.htm">Share Subscription Agreement between Avalon GloboCare Corp., Avalon (Shanghai) Healthcare Technology Co., Ltd., Beijing DOING Biomedical Technology Co., Ltd. and Daron Liang (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000921/s105501_ex4-3.htm">Warranty Agreement between Lu Wenzhao and Beijing DOING Biomedical Technology Co., Ltd. (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 7, 2017)</A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.6</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex4-1.htm">Form of Subscription Agreement between Avalon GloboCare Corp. and the October 2017 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.7</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1630212/000161577418007670/s111877_ex4-8.htm">Form of Warrant to Boustead Securities, LLC in connection with the private placements (incorporated by reference to Exhibit 4.8 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 27, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.8</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019007230/f8k042519ex4-1_avalon.htm">Form of Warrant (April 2019) (Incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577416007680/s104353_ex10-1.htm">Share Exchange Agreement dated as of October 19, 2016 by and among Avalon Healthcare System, Inc., the shareholders of Avalon Healthcare System, Inc. and Avalon GloboCare Corp. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 19, 2016)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577416008673/s104827_ex10-1.htm">Executive Employment Agreement, effective December 1, 2016, by and between Avalon GloboCare Corp. and David Jin (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 2, 2016)</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577416009065/s105026_ex10-1.htm">Agreement of Sale by and between Freehold Craig Road Partnership, as Seller, and Avalon GloboCare Corp., as Buyer dated as of December 22, 2016 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December 23, 2016)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000115/s105112_ex10-1.htm">Executive Employment Agreement by and between Avalon (Shanghai) Healthcare Technology Ltd. and Meng Li dated January 11, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 11, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex10-1.htm">Executive Retention Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated February&nbsp;21, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6 &dagger;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417000729/s105400_ex10-2.htm">Indemnification Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated February 21, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 21, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417001927/s105965_ex10-1.htm">Director Agreement by and between Avalon GloboCare Corp. and Steven P. Sukel dated April 28, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8 &dagger;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417001927/s105965_ex10-2.htm">Director Agreement by and between Avalon GloboCare Corp. and Yancen Lu dated April 28, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 28, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-8.htm">Consultation Service Contract between Daopei Investment Management (Shanghai) Co., Ltd. and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.8 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-9.htm">Consultation Service Contract between Hebei Yanda Ludaopei Hospital Co., Ltd and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.9 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417003531/s106743_ex10-10.htm">Consultation Service Contract between Nanshan Memorial Stem Cell Biotechnology Co., Ltd. and Avalon HealthCare System Inc. dated April 1, 2016 (English translation) (incorporated by reference to Exhibit 10.10 of Amendment No. 1 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on July 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417004366/s107144_ex10-12.htm">Loan Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated April 19, 2017 (English translation) (incorporated by reference to Exhibit 10.12 of the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2017)</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-1.htm">Securities Purchase Agreement between Avalon GloboCare Corp. and Genexosome Technologies Inc. dated October 25, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-2.htm">Asset Purchase Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-3.htm">Stock Purchase Agreement between Genexosome Technologies Inc., Beijing Jieteng (Genexosome) Biotech Co. Ltd. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-4.htm">Executive Retention Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417005933/s107865_ex10-5.htm">Invention Assignment, Confidentiality, Non-Compete and Non-Solicit Agreement between Genexosome Technologies Inc. and Yu Zhou dated October 25, 2017 (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 26, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417006312/s108045_ex10-1.htm">Director Agreement by and between Avalon GloboCare Corp. and Wilbert J. Tauzin II dated November 1, 2017 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577417006312/s108045_ex10-2.htm">Agreement between Avalon GloboCare Corp. and Tauzin Consultants, LLC dated November 1, 2017 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2017)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.20 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002405/s109567_ex10-1.htm">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated April 3, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2018)&nbsp;&nbsp;</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002405/s109567_ex10-2.htm">Letter Agreement by and between Avalon GloboCare Corp. and Meng Li dated April 3, 2018 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 4, 2018)&nbsp;&nbsp;</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.22</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002732/s109701_ex10-22.htm">Advisory Service Contract between Ludaopei Hematology Research Institute Co., Ltd. and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated April 1, 2018 (English translation) (Incorporated by reference to that Form S-1 Registration Statement filed with the Securities and Exchange Commission on April 19, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.23</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002711/s109704_ex4-1.htm">Form of Subscription Agreement by and between Avalon GloboCare Corp. and the April 2018 Accredited Investors (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 18, 2018)&nbsp;</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418002931/s109781_ex4-2.htm">Supplementary Agreement Related to Share Subscription by and between Avalon GloboCare Corp., Avalon (Shanghai) Healthcare Technology Co., Ltd., Beijing DOING Biomedical Technology Co., Ltd. and Daron Liang dated April 23, 2018 (English translation) (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on April 26, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.25</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418003636/s110081_ex10-18.htm">Loan Extension Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated May 3, 2018 (English translation) (incorporated by reference to Exhibit 10.18 of the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418004916/s110675_ex10-1.htm">Director Agreement by and between Avalon GloboCare Corp. and Tevi Troy dated June 4, 2018&nbsp;(incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2018)</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418004916/s110675_ex99-1.htm">Joint Venture Agreement by and between Avalon (Shanghai) Healthcare Technology Co., Ltd. and Jiangsu Unicorn Biological Technology Co., Ltd. dated May 29, 2018 (English translation) (incorporated by reference to Exhibit 99.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on June 6, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418006328/s111307_ex10-1.htm">Director Agreement by and between Avalon GloboCare Corp. and William Stilley, III dated July 5, 2018&nbsp;(incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 10, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29 &dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007235/s111738_ex10-1.htm">Director Agreement by and between Avalon GloboCare Corp. and Steven A. Sanders dated July 30, 2018&nbsp;(incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 31, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007670/s111877_ex10-30.htm">Loan Extension Agreement between Lotus Capital Overseas Limited and Avalon (Shanghai) Healthcare Technology Co., Ltd. dated August 3, 2018 (English translation) (incorporated by reference to Exhibit 10.30 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on August 7, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418007670/s111877_ex10-31.htm">Strategic Partnership Agreement between Avalon GloboCare Corp. and Weill Cornell Medical College of Cornell University dated August 6, 2018 (incorporated by reference to Exhibit 10.31 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on August 7, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418011426/s113520_ex10-1.htm">Equity Joint Venture Agreement by and between Avactis Biosciences, Inc., a wholly-owned subsidiary of Avalon GloboCare Corp., and Arbele Limited for the establishment of AVAR (China) BioTherapeutics Ltd. dated October 23, 2018 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-1.htm">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated January 3, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-2.htm">Letter Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated January 3, 2019 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.35</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577419000241/s115219_ex10-3.htm">Letter Agreement by and between Avalon (Shanghai) Healthcare Technology Co. Ltd. and Meng Li dated January 3, 2019 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on January 4, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.36</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019004695/f8k031819ex10-1_avalonglobo.htm">Promissory Note issued to Daniel Lu dated Mach 18, 2019 (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 22, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.37&dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019005932/f8k040519ex10-1_avalonare.htm">Director Agreement by and between Avalon GloboCare Corp. and Meng Li dated April 5, 2019 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.38&dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019005932/f8k040519ex10-2_avalonare.htm">Director Agreement by and between Avalon GloboCare Corp. and Yue &ldquo;Charles&rdquo; Li dated April 5, 2019 (Incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.39</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019007230/f8k042519ex10-1_avalon.htm">Form of Securities Purchase Agreement dated April 25, 2019 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on April 26, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.40</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019017131/f8k082919ex10-1_avalonglob.htm">Revolving Line of Credit Agreement dated as of August 29, 2019 between Avalon GloboCare Corp. and Wenzhao &ldquo;Daniel&rdquo; Lu dated August 29, 2019 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 3, 2019)</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.41</FONT></TD>
    <TD STYLE="width: 1%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390019020662/f8k101819ex10-1_avalong.htm">Form of Warrant Redemption and Cancellation Agreement (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on October 21, 2019)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.42</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-1_avalonglobo.htm">Letter Agreement by and between Avalon GloboCare Corp. and David Jin dated February 20, 2020 (Incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; width: 9%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.43</FONT></TD>
    <TD STYLE="text-align: justify; width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-2_avalonglobo.htm">Letter Agreement by and between Avalon GloboCare Corp. and Meng Li dated February 20, 2020 (Incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.44</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000121390020004616/f8k022020ex10-3_avalonglobo.htm">Letter Agreement by and between Avalon GloboCare Corp. and Luisa Ingargiola dated February 20, 2020 (Incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 24, 2020)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1630212/000161577418006733/s111400_ex21-1.htm">List of Subsidiaries (incorporated by reference to Exhibit 21.1 of the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on July 20, 2018)</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0321ex31-1_avalonglobo.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Chief
    Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.2*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0321ex31-2_avalonglobo.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Chief
    Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.1*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="f10q0321ex32-1_avalonglobo.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Chief
    Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL INSTANCE DOCUMENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION
    SCHEMA DOCUMENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION
    CALCULATION LINKBASE DOCUMENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.DEF*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION
    DEFINITION LINKBASE DOCUMENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION
    LABEL LINKBASE DOCUMENT</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL TAXONOMY EXTENSION
    PRESENTATION LINKBASE DOCUMENT</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed herewith</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;
&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0px"></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management contract or
    compensatory plan or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>AVALON GLOBOCARE CORP.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ David K. Jin&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">David K. Jin</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer, President and Director (Principal Executive
    Officer)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 14, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Luisa Ingargiola</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Luisa Ingargiola</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer<BR>
    (Principal Financial and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0321ex31-1_avalonglobo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U STYLE="text-decoration: none">Exhibit
31.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David K. Jin, certify
that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Quarterly
    Report on Form 10-Q (the &ldquo;report&rdquo;) of Avalon GloboCare Corp.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15
    (f) and 15d-15 (f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
    over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies
    and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 14, 2021</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    David K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">David K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Director (Principal
    Executive Officer)</FONT></TD></TR></TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0321ex31-2_avalonglobo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U STYLE="text-decoration: none">Exhibit
31.2</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Certification
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Luisa Ingargiola,
certify that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed this Quarterly
    Report on Form 10-Q (the &ldquo;report&rdquo;) of Avalon GloboCare Corp.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
    made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
    report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects the financial
    condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
    Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15
    (f) and 15d-15 (f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
    information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
    particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
    external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this report
    any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent
    fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control
    over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant deficiencies
    and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely
    affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether or not
    material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over
    financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 14, 2021</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Luisa Ingargiola</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Luisa Ingargiola</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer (Principal Financial and Accounting
    Officer)</FONT></TD></TR></TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0321ex32-1_avalonglobo.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U STYLE="text-decoration: none">Exhibit
32.1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Certifications
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification
of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
undersigned, David K. Jin and Luisa Ingargiola, in their capacities as Chief Executive Officer and Chief Financial Officer, respectively,
of Avalon GloboCare Corp. (the &ldquo;Registrant&rdquo;) do each hereby certify with respect to the Quarterly Report on Form 10-Q of
the Registrant for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;),
that, to the best of their knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Report
    fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The information
    contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant
    as of, and for, the periods presented in this Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 14, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    David K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">David K. Jin</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer, President and Director (Principal
    Executive Officer)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: May 14, 2021</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Luisa Ingargiola</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Luisa Ingargiola</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer (Principal Financial and Accounting
    Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>avco-20210331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:pf0="http://xbrl.sec.gov/country/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:avco="http://www.avalonglobocare.com/20210331" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="avco-20210331.xsd"/>
  <context id="c0_From1Jan2021To31Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf14May2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2021-05-14</instant>
    </period>
  </context>
  <context id="c2_AsOf31Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_From1Jan2020To31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c5_AsOf31Dec2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2020_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31Dec2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c13_From1Jan2021To31Mar2021_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2021To31Mar2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c16_From1Jan2021To31Mar2021_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c17_From1Jan2021To31Mar2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c18_From1Jan2021To31Mar2021_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c21_AsOf31Mar2021_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c22_AsOf31Mar2021_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c23_AsOf31Mar2021_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Mar2021_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Mar2021_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Mar2021_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Mar2021_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c28_AsOf31Mar2021_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c29_AsOf31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c30_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c31_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c32_AsOf31Dec2019_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c33_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c34_AsOf31Dec2019_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c35_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c36_AsOf31Dec2019_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c37_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c38_From1Jan2020To31Mar2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c39_From1Jan2020To31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c41_From1Jan2020To31Mar2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c42_From1Jan2020To31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c43_From1Jan2020To31Mar2020_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c46_AsOf31Mar2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c47_AsOf31Mar2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c48_AsOf31Mar2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c49_AsOf31Mar2020_TreasuryStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c50_AsOf31Mar2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c51_AsOf31Mar2020_StatutoryReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:StatutoryReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c52_AsOf31Mar2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c53_AsOf31Mar2020_NoncontrollingInterestMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c54_AsOf31Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="c55_AsOf19Oct2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2016-10-19</instant>
    </period>
  </context>
  <context id="c56_From1Oct2016To19Oct2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-10-19</endDate>
    </period>
  </context>
  <context id="c57_From1Jan2021To31Mar2021_AvalonRT9PropertiesLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:AvalonRT9PropertiesLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c58_AsOf31Jul2017_BeijingJietengGenExosomeBiotechCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:BeijingJietengGenExosomeBiotechCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="c59_AsOf31Jul2017_GenExosomeTechnologiesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="c60_AsOf31Jul2017_DrYuZhouMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="c61_From1Jan2021To31Mar2021_AvalonHealthcareSystemIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:AvalonHealthcareSystemIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c62_From1Jan2021To31Mar2021_AvalonBVILtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:AvalonBVILtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c63_From1Jan2021To31Mar2021_AvalonShanghaiHealthcareTechnologyCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:AvalonShanghaiHealthcareTechnologyCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c64_From1Jan2021To31Mar2021_GenExosomeTechnologiesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:GenExosomeTechnologiesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c65_From1Jan2021To31Mar2021_BeijingJietengGenExosomeBiotechCoLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:BeijingJietengGenExosomeBiotechCoLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2021To31Mar2021_AvactisBiosciencesIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:AvactisBiosciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c67_From1Jan2021To31Mar2021_InternationalExosomeAssociationLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avco:InternationalExosomeAssociationLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c68_From1Jan2021To31Mar2021_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c69_AsOf31Mar2021_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c70_AsOf31Dec2020_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c71_From1Jan2020To31Dec2020_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c72_AsOf31Mar2021_CN">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:CN</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c73_From1Jan2021To31Mar2021_CN">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:CN</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c74_AsOf31Dec2020_CN">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:CN</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c75_From1Jan2020To31Dec2020_CN">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pf0:CN</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c76_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c77_From1Jan2021To31Mar2021_StockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c78_From1Jan2020To31Mar2020_StockOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">avco:StockOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c79_AsOf31Mar2021_OtherUnrelatedCompanyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="avco:SubsidiaryAxis">avco:OtherUnrelatedCompanyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c80_AsOf31Dec2020_UnicornMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="avco:SubsidiaryAxis">avco:UnicornMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c81_AsOf31Mar2021_ChiefExecutiveOfficerMember_DavidJinMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DavidJinMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c82_AsOf31Mar2021_ChiefOperatingOfficerMember_DrYuZhouMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c83_AsOf31Mar2021_GenExosomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:GenExosomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c84_AsOf31Mar2021_BoardOfDirectorsChairmanMember_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c85_AsOf31Dec2020_BoardOfDirectorsChairmanMember_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c86_AsOf18Mar2019_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-18</instant>
    </period>
  </context>
  <context id="c87_From1Mar2019To18Mar2019_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-18</endDate>
    </period>
  </context>
  <context id="c88_From1Jan2019To30Sep2019_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="c89_From1Jan2020To30Jun2020_WenzhaoLuMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WenzhaoLuMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="c90_AsOf29Aug2019_LineOfCreditAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-29</instant>
    </period>
  </context>
  <context id="c91_AsOf31Dec2020_ChiefOperatingOfficerMember_DrYuZhouMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:DrYuZhouMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c92_AsOf31Dec2020_GenExosomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:GenExosomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c93_From2Aug2019To29Aug2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2019-08-02</startDate>
      <endDate>2019-08-29</endDate>
    </period>
  </context>
  <context id="c94_AsOf4Aug2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <instant>2020-08-04</instant>
    </period>
  </context>
  <context id="c95_From1Jan2021To31Mar2021_JefferiesLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c96_AsOf31Mar2021_JefferiesLLCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">avco:JefferiesLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c97_From1Jan2021To31Mar2021_CommonSharesIssuedForServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">avco:CommonSharesIssuedForServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c98_From1Jan2021To31Mar2021_CompensationAndRelatedBenefitsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avco:CompensationAndRelatedBenefitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c99_From1Jan2020To31Mar2020_CompensationAndRelatedBenefitsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avco:CompensationAndRelatedBenefitsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c100_From1Jan2021To31Mar2021_ProfessionalFeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avco:ProfessionalFeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c101_From1Jan2020To31Mar2020_ProfessionalFeesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">avco:ProfessionalFeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c102_From1Jan2021To31Mar2021_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c103_From1Jan2020To31Mar2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c104_From1Jan2021To31Mar2021_ExercisePriceRangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c105_AsOf31Mar2021_ExercisePriceRangeOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c106_From1Jan2021To31Mar2021_ExercisePriceRangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c107_AsOf31Mar2021_ExercisePriceRangeTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c108_From1Jan2021To31Mar2021_ExercisePriceRangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c109_AsOf31Mar2021_ExercisePriceRangeThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c110_From1Jan2021To31Mar2021_ExercisePriceRangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c111_AsOf31Mar2021_ExercisePriceRangeFourMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c112_From1Jan2021To31Mar2021_ExercisePriceRangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c113_AsOf31Mar2021_ExercisePriceRangeFiveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">avco:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c114_AsOf31Dec2020_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c115_AsOf31Dec2020_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c116_From1Jan2021To31Mar2021_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c117_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c118_AsOf31Mar2021_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c119_AsOf31Mar2021_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c120_AsOf31Dec2020_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c121_AsOf31Dec2020_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c122_From1Jan2021To31Mar2021_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c123_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c124_AsOf31Mar2021_NumberOfOptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:NumberOfOptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c125_AsOf31Mar2021_WeightedAverageExercisePriceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avco:WeightedAverageExercisePriceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c126_From1Jan2021To31Mar2021_CustomerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">avco:CustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c127_From1Jan2020To31Mar2020_CustomerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">avco:CustomerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c128_From1Jan2021To31Mar2021_SalesRevenueNetMember_AccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c129_From1Jan2021To31Mar2021_AccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c130_From1Jan2020To31Dec2020_SalesRevenueNetMember_AccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c131_From1Jan2020To31Dec2020_AccountsReceivableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c132_From1Jan2021To31Mar2021_PublicUtilitiesInventorySuppliesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c133_From1Jan2020To31Mar2020_PublicUtilitiesInventorySuppliesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:PublicUtilitiesInventorySuppliesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c134_From1Jan2021To31Mar2021_ProductMember_AccountsPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c135_From1Jan2021To31Mar2021_AccountsPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c136_From1Jan2020To31Dec2020_ProductMember_AccountsPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c137_From1Jan2020To31Dec2020_AccountsPayableMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c138_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c139_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c140_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c141_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c142_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c143_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskThreeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">avco:CustomerConcentrationRiskThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperationsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c146_From1Jan2021To31Mar2021_MedicalRelatedConsultingServicesRelatedPartyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:MedicalRelatedConsultingServicesRelatedPartyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c147_From1Jan2020To31Mar2020_MedicalRelatedConsultingServicesRelatedPartyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:MedicalRelatedConsultingServicesRelatedPartyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c148_From1Jan2021To31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:DevelopmentServicesAndSalesOfDevelopedProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c149_From1Jan2020To31Mar2020_DevelopmentServicesAndSalesOfDevelopedProductMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:DevelopmentServicesAndSalesOfDevelopedProductMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c150_From1Jan2021To31Mar2021_CorporateOtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c151_From1Jan2020To31Mar2020_CorporateOtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="c152_AsOf31Mar2021_RealPropertyOperatingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c153_AsOf31Dec2020_RealPropertyOperatingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:RealPropertyOperatingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c154_AsOf31Mar2021_MedicalRelatedConsultingServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:MedicalRelatedConsultingServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c155_AsOf31Dec2020_MedicalRelatedConsultingServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:MedicalRelatedConsultingServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c156_AsOf31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:DevelopmentServicesAndSalesOfDevelopedProductsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c157_AsOf31Dec2020_DevelopmentServicesAndSalesOfDevelopedProductsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:DevelopmentServicesAndSalesOfDevelopedProductsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c158_AsOf31Mar2021_CorporateOtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-31</instant>
    </period>
  </context>
  <context id="c159_AsOf31Dec2020_CorporateOtherMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avco:CorporateOtherMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c160_From2Oct2017To25Oct2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2017-10-02</startDate>
      <endDate>2017-10-25</endDate>
    </period>
  </context>
  <context id="c161_From2May2018To29May2018_AvalonShanghaiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AvalonShanghaiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-05-02</startDate>
      <endDate>2018-05-29</endDate>
    </period>
  </context>
  <context id="c162_From1Oct2018To23Oct2018_AVARBioTherapeuticsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AVARBioTherapeuticsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-01</startDate>
      <endDate>2018-10-23</endDate>
    </period>
  </context>
  <context id="c163_AsOf23Oct2018_AVARBioTherapeuticsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AVARBioTherapeuticsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-10-23</instant>
    </period>
  </context>
  <context id="c164_From1Oct2018To23Oct2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
    </entity>
    <period>
      <startDate>2018-10-01</startDate>
      <endDate>2018-10-23</endDate>
    </period>
  </context>
  <context id="c165_From1Jan2021To31Mar2021_AVARBioTherapeuticsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AVARBioTherapeuticsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <context id="c166_From1Jan2020To31Dec2020_AVARBioTherapeuticsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avco:AVARBioTherapeuticsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c167_AsOf29Aug2019_LineOfCreditAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-29</instant>
    </period>
  </context>
  <context id="c168_From2Aug2019To29Aug2019_LineOfCreditAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-02</startDate>
      <endDate>2019-08-29</endDate>
    </period>
  </context>
  <context id="c169_From1Jan2021To31Mar2021_LineOfCreditAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001630212</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avco:LineOfCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-31</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="cny">
    <measure>iso4217:CNY</measure>
  </unit>
  <dei:AmendmentFlag contextRef="c0_From1Jan2021To31Mar2021">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2021To31Mar2021">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2021To31Mar2021">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2021To31Mar2021">2021</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2021To31Mar2021">2021-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2021To31Mar2021">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2021To31Mar2021">0001630212</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2021To31Mar2021">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2021To31Mar2021">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFileNumber contextRef="c0_From1Jan2021To31Mar2021">001-38728</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2021To31Mar2021">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2021To31Mar2021">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2021To31Mar2021">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2021To31Mar2021">Avalon GloboCare Corp.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2021To31Mar2021">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2021To31Mar2021">true</dei:EntitySmallBusiness>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf14May2021" decimals="INF">84423564</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1692540</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">726577</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">23471</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:AccountsAndOtherReceivablesNetCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">35395</us-gaap:AccountsAndOtherReceivablesNetCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">152438</us-gaap:DeferredCostsCurrent>
  <us-gaap:DeferredCostsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">222141</us-gaap:DeferredCostsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">295731</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">302224</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2164180</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1286337</us-gaap:AssetsCurrent>
  <avco:TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">109174</avco:TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts>
  <avco:TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">111840</avco:TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">19662</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">133359</us-gaap:DeferredCosts>
  <us-gaap:DeferredCosts unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">144197</us-gaap:DeferredCosts>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">241729</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:OperatingLeaseRightOfUseAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">137333</us-gaap:OperatingLeaseRightOfUseAsset>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">439962</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">479115</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RealEstateInvestments unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">7644950</us-gaap:RealEstateInvestments>
  <us-gaap:RealEstateInvestments unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">7685686</us-gaap:RealEstateInvestments>
  <us-gaap:EquityMethodInvestmentAggregateCost unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">532199</us-gaap:EquityMethodInvestmentAggregateCost>
  <us-gaap:EquityMethodInvestmentAggregateCost unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">521758</us-gaap:EquityMethodInvestmentAggregateCost>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">9121035</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">9079929</us-gaap:AssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">11285215</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">10366266</us-gaap:Assets>
  <us-gaap:AccruedProfessionalFeesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1445225</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1212822</us-gaap:AccruedProfessionalFeesCurrent>
  <avco:AccruedResearchAndDevelopmentsFees unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">432500</avco:AccruedResearchAndDevelopmentsFees>
  <avco:AccruedResearchAndDevelopmentsFees unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">513533</avco:AccruedResearchAndDevelopmentsFees>
  <us-gaap:AccruedPayrollTaxesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">165846</us-gaap:AccruedPayrollTaxesCurrent>
  <us-gaap:AccruedPayrollTaxesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">154292</us-gaap:AccruedPayrollTaxesCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">344453</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">367411</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">313105</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">267956</us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">132657</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:OperatingLeaseLiabilityCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">76379</us-gaap:OperatingLeaseLiabilityCurrent>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">390000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3223786</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2592393</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">109337</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:OperatingLeaseLiabilityNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">66954</us-gaap:OperatingLeaseLiabilityNoncurrent>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">390000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:LongTermLoansPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3305249</us-gaap:LongTermLoansPayable>
  <us-gaap:LongTermLoansPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3200000</us-gaap:LongTermLoansPayable>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3414586</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:LiabilitiesNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3656954</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">6638372</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6249347</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf31Mar2021" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">8494</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8279</us-gaap:CommonStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c2_AsOf31Mar2021" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">490000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">490000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">84943564</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">82795297</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockOtherSharesOutstanding unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">84423564</us-gaap:CommonStockOtherSharesOutstanding>
  <us-gaap:CommonStockOtherSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">82275297</us-gaap:CommonStockOtherSharesOutstanding>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">49755996</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">46856447</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">522500</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">522500</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockShares unitRef="shares" contextRef="c2_AsOf31Mar2021" decimals="INF">520000</us-gaap:TreasuryStockShares>
  <us-gaap:TreasuryStockShares unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">520000</us-gaap:TreasuryStockShares>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-44408493</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-42041375</us-gaap:RetainedEarningsAccumulatedDeficit>
  <avco:StatutoryReserve unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">6578</avco:StatutoryReserve>
  <avco:StatutoryReserve unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6578</avco:StatutoryReserve>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-193232</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-190510</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">4646843</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">4116919</us-gaap:StockholdersEquity>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:MinorityInterest unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">4646843</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">4116919</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">11285215</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">10366266</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RevenueFromRelatedParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">289774</us-gaap:RevenueFromRelatedParties>
  <us-gaap:RevenueFromRelatedParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">296956</us-gaap:RevenueFromRelatedParties>
  <avco:RealPropertyOperatingExpenses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">216894</avco:RealPropertyOperatingExpenses>
  <avco:RealPropertyOperatingExpenses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">254501</avco:RealPropertyOperatingExpenses>
  <avco:RealPropertiesOperatingIncome unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-72880</avco:RealPropertiesOperatingIncome>
  <avco:RealPropertiesOperatingIncome unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-42455</avco:RealPropertiesOperatingIncome>
  <us-gaap:ProfessionalFees unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1381178</us-gaap:ProfessionalFees>
  <us-gaap:ProfessionalFees unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1553698</us-gaap:ProfessionalFees>
  <us-gaap:LaborAndRelatedExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">562006</us-gaap:LaborAndRelatedExpense>
  <us-gaap:LaborAndRelatedExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1128468</us-gaap:LaborAndRelatedExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">213188</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">275402</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OtherGeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">220096</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:OtherGeneralAndAdministrativeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">307079</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2376468</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">3264647</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2303588</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3222192</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpenseRelatedParty unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">45149</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">42169</us-gaap:InterestExpenseRelatedParty>
  <avco:OtherIncomeLossFromEquityMethodInvestment unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-18514</avco:OtherIncomeLossFromEquityMethodInvestment>
  <avco:OtherIncomeLossFromEquityMethodInvestment unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-9084</avco:OtherIncomeLossFromEquityMethodInvestment>
  <us-gaap:OtherIncome unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">133</us-gaap:OtherIncome>
  <us-gaap:OtherIncome unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">2664</us-gaap:OtherIncome>
  <us-gaap:OtherNoncashIncomeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-63530</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-48589</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2367118</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3270781</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2367118</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3270781</us-gaap:NetIncomeLoss>
  <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2367118</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3270781</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2722</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-22066</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2369840</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3292847</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2369840</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-3292847</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">-0.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare unitRef="usdPershares" contextRef="c4_From1Jan2020To31Mar2020" decimals="2">-0.04</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2021To31Mar2021" decimals="INF">83413154</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c4_From1Jan2020To31Mar2020" decimals="INF">76712054</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c5_AsOf31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c6_AsOf31Dec2020_CommonStockMember" decimals="INF">82795297</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c6_AsOf31Dec2020_CommonStockMember" decimals="0">8279</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">46856447</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c8_AsOf31Dec2020_TreasuryStockMember" decimals="INF">-520000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2020_TreasuryStockMember" decimals="0">-522500</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-42041375</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31Dec2020_StatutoryReserveMember" decimals="0">6578</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-190510</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31Dec2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c13_From1Jan2021To31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" decimals="INF">1848267</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" decimals="0">185</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember" decimals="0">2337074</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c16_From1Jan2021To31Mar2021_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c17_From1Jan2021To31Mar2021_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c18_From1Jan2021To31Mar2021_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2337259</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c13_From1Jan2021To31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" decimals="0">30</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember" decimals="0">359970</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c16_From1Jan2021To31Mar2021_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c17_From1Jan2021To31Mar2021_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c18_From1Jan2021To31Mar2021_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">360000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c13_From1Jan2021To31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember" decimals="0">202505</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c16_From1Jan2021To31Mar2021_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c17_From1Jan2021To31Mar2021_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c18_From1Jan2021To31Mar2021_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">202505</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c13_From1Jan2021To31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c16_From1Jan2021To31Mar2021_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c17_From1Jan2021To31Mar2021_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c18_From1Jan2021To31Mar2021_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-2722</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2722</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c13_From1Jan2021To31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c14_From1Jan2021To31Mar2021_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c15_From1Jan2021To31Mar2021_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c16_From1Jan2021To31Mar2021_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c17_From1Jan2021To31Mar2021_RetainedEarningsMember" decimals="0">-2367118</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c18_From1Jan2021To31Mar2021_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c19_From1Jan2021To31Mar2021_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c20_From1Jan2021To31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c21_AsOf31Mar2021_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c22_AsOf31Mar2021_CommonStockMember" decimals="INF">84943564</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c22_AsOf31Mar2021_CommonStockMember" decimals="0">8494</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31Mar2021_AdditionalPaidInCapitalMember" decimals="0">49755996</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c24_AsOf31Mar2021_TreasuryStockMember" decimals="INF">-520000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31Mar2021_TreasuryStockMember" decimals="0">-522500</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Mar2021_RetainedEarningsMember" decimals="0">-44408493</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Mar2021_StatutoryReserveMember" decimals="0">6578</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf31Mar2021_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-193232</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c28_AsOf31Mar2021_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c29_AsOf31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c30_AsOf31Dec2019_CommonStockMember" decimals="INF">76730802</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c30_AsOf31Dec2019_CommonStockMember" decimals="0">7673</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c31_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">34593006</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c32_AsOf31Dec2019_TreasuryStockMember" decimals="INF">-520000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c32_AsOf31Dec2019_TreasuryStockMember" decimals="0">-522500</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c33_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-29361937</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c34_AsOf31Dec2019_StatutoryReserveMember" decimals="0">6578</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c35_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-257747</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c36_AsOf31Dec2019_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c37_AsOf31Dec2019" decimals="0">4465073</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c38_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" decimals="INF">980358</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" decimals="0">98</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">1539153</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c41_From1Jan2020To31Mar2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c42_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c43_From1Jan2020To31Mar2020_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1539251</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c38_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" decimals="INF">222577</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" decimals="0">22</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">213278</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c41_From1Jan2020To31Mar2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c42_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c43_From1Jan2020To31Mar2020_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">213300</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c38_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" decimals="0">785350</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c41_From1Jan2020To31Mar2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c42_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c43_From1Jan2020To31Mar2020_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">785350</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c38_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c41_From1Jan2020To31Mar2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c42_From1Jan2020To31Mar2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c43_From1Jan2020To31Mar2020_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-22066</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-22066</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c38_From1Jan2020To31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c39_From1Jan2020To31Mar2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c40_From1Jan2020To31Mar2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c41_From1Jan2020To31Mar2020_TreasuryStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c42_From1Jan2020To31Mar2020_RetainedEarningsMember" decimals="0">-3270781</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c43_From1Jan2020To31Mar2020_StatutoryReserveMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c44_From1Jan2020To31Mar2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c45_From1Jan2020To31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c46_AsOf31Mar2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c47_AsOf31Mar2020_CommonStockMember" decimals="INF">77933737</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c47_AsOf31Mar2020_CommonStockMember" decimals="0">7793</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c48_AsOf31Mar2020_AdditionalPaidInCapitalMember" decimals="0">37130787</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c49_AsOf31Mar2020_TreasuryStockMember" decimals="INF">-520000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c49_AsOf31Mar2020_TreasuryStockMember" decimals="0">-522500</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c50_AsOf31Mar2020_RetainedEarningsMember" decimals="0">-32632718</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c51_AsOf31Mar2020_StatutoryReserveMember" decimals="0">6578</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c52_AsOf31Mar2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-279813</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c53_AsOf31Mar2020_NoncontrollingInterestMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c54_AsOf31Mar2020" decimals="0">3710127</us-gaap:StockholdersEquity>
  <us-gaap:ProvisionForOtherLosses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:ProvisionForOtherLosses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">4698</us-gaap:ProvisionForOtherLosses>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">78875</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">76535</us-gaap:DepreciationAndAmortization>
  <us-gaap:StraightLineRent unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-943</us-gaap:StraightLineRent>
  <us-gaap:StraightLineRent unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-16988</us-gaap:StraightLineRent>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">27531</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
  <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">573982</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1189101</us-gaap:ShareBasedCompensation>
  <avco:LossOnEquityMethodInvestment unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">18514</avco:LossOnEquityMethodInvestment>
  <avco:LossOnEquityMethodInvestment unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">9084</avco:LossOnEquityMethodInvestment>
  <avco:LossOnFixedAssetsDisposal unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <avco:LossOnFixedAssetsDisposal unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">2648</avco:LossOnFixedAssetsDisposal>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-85932</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
  <us-gaap:IncreaseDecreaseInOtherReceivables unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-13647</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInOtherReceivables unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">23733</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:IncreaseDecreaseInSecurityDeposits unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">6003</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:IncreaseDecreaseInSecurityDeposits unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <avco:DeferredLeasingCosts unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-2364</avco:DeferredLeasingCosts>
  <avco:DeferredLeasingCosts unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">40803</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInPrepaidExpensesOther unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">96669</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">163442</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-38817</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">45149</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">28218</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <avco:IncreaseDecreaseOperatingLease unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">33326</avco:IncreaseDecreaseOperatingLease>
  <avco:IncreaseDecreaseOperatingLease unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-18000</avco:IncreaseDecreaseOperatingLease>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-1515525</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-1998796</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <avco:AdditionalInvestmentInEquityMethodInvestment unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">30844</avco:AdditionalInvestmentInEquityMethodInvestment>
  <avco:AdditionalInvestmentInEquityMethodInvestment unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-30844</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <avco:ProceedsReceivedFromLoanPayable unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">105249</avco:ProceedsReceivedFromLoanPayable>
  <avco:ProceedsReceivedFromLoanPayable unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">300000</avco:ProceedsReceivedFromLoanPayable>
  <avco:ProceedsReceivedFromEquityOffering unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2481405</avco:ProceedsReceivedFromEquityOffering>
  <avco:ProceedsReceivedFromEquityOffering unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1623584</avco:ProceedsReceivedFromEquityOffering>
  <avco:DisbursementsForEqutyOfferingCosts unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">74442</avco:DisbursementsForEqutyOfferingCosts>
  <avco:DisbursementsForEqutyOfferingCosts unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">48707</avco:DisbursementsForEqutyOfferingCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">2512212</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">1874877</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">120</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-5701</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">965963</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-129620</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c37_AsOf31Dec2019" decimals="0">764891</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c54_AsOf31Mar2020" decimals="0">635271</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <avco:CommonStockIssuedForFutureServices unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <avco:CommonStockIssuedForFutureServices unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-57207</avco:CommonStockIssuedForFutureServices>
  <avco:DeferredFinancingCostsInAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-261032</avco:DeferredFinancingCostsInAccruedLiabilities>
  <avco:DeferredFinancingCostsInAccruedLiabilities unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbs5fwdha51R1DbNuzVlSvOm] CSR-->
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 1 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;ORGANIZATION
AND NATURE OF OPERATIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Avalon GloboCare Corp. (the &amp;#x201c;Company&amp;#x201d;
or &amp;#x201c;AVCO&amp;#x201d;) is a Delaware corporation. The Company was incorporated under the laws of the State of Delaware on July 28, 2014.
On October 19, 2016, the Company entered into and closed a Share Exchange Agreement with the shareholders of Avalon Healthcare System,
Inc., a Delaware corporation (&amp;#x201c;AHS&amp;#x201d;), each of which were accredited investors (&amp;#x201c;AHS Shareholders&amp;#x201d;) pursuant to
which we acquired 100% of the outstanding securities of AHS in exchange for 50,000,000 shares of the Company&amp;#x2019;s common stock (the
&amp;#x201c;AHS Acquisition&amp;#x201d;). AHS was incorporated on May 18, 2015 under the laws of the State of Delaware.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For accounting purposes, AHS was the surviving
entity. The transaction was accounted for as a recapitalization of AHS pursuant to which AHS was treated as the accounting acquirer,
surviving and continuing entity although the Company is the legal acquirer. The Company did not recognize goodwill or any intangible
assets in connection with this transaction. Accordingly, the Company&amp;#x2019;s historical financial statements are those of AHS and its
wholly-owned subsidiary, Avalon (Shanghai) Healthcare Technology Co., Ltd. (&amp;#x201c;Avalon Shanghai&amp;#x201d;) immediately following the
consummation of this reverse merger transaction. AHS owns 100% of the capital stock of Avalon Shanghai, which is a wholly foreign-owned
enterprise organized under the laws of the People&amp;#x2019;s Republic of China (&amp;#x201c;PRC&amp;#x201d;). Avalon Shanghai was incorporated on
April 29, 2016 and is engaged in medical related consulting services for customers.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients&apos; growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&amp;#x2122;), and regenerative therapeutics. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On January 23, 2017, the Company incorporated
Avalon (BVI) Ltd., a British Virgin Island company. There was no activity for the subsidiary since its incorporation through March 31,
2021. Avalon (BVI) Ltd. is dormant and is in process of being dissolved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&amp;#x201c;Avalon RT 9&amp;#x201d;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&amp;#x2019;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Currently, Avalon RT 9&amp;#x2019;s business consists
of the ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2021, the occupancy rate of
the building is 89.4%.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 31, 2017, the Company formed Genexosome
Technologies Inc. (&amp;#x201c;Genexosome&amp;#x201d;) in Nevada. Genexosome was engaged in developing proprietary diagnostic and therapeutic products
using exosomes. Genexosome owns 100% of the capital stock of Beijing Jieteng (Genexosome) Biotech Co., Ltd., a corporation incorporated
in the People&amp;#x2019;s Republic of China on August 7, 2015 (&amp;#x201c;Beijing Genexosome&amp;#x201d;), and the Company holds 60% of Genexosome
and Dr. Yu Zhou holds 40% of Genexosome. The Company had not been able to realize the financial projections provided by Dr. Zhou at the
time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero. Dr. Zhou was terminated
as Co-CEO of Genexosome on August 14, 2019. Since the fourth quarter of 2019, the non-controlling interest keeps inactive.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc., a Nevada corporation, which will focus on accelerating commercial activities related to cellular
therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T
and others. The subsidiary is designed to integrate and optimize our global scientific and clinical resources to further advance the
use of cellular therapies to treat certain cancers.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On June 13, 2019, the Company formed a wholly
owned subsidiary, International Exosome Association LLC, a Delaware company. There was no activity for the subsidiary since its incorporation
through March 31, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Details of the Company&amp;#x2019;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2021 are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 25%; padding-right: 0pt; padding-left: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Name
    of Subsidiary&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 16%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Place
    and date of Incorporation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: top; width: 2%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 13%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Percentage
    of Ownership&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 40%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Principal
    Activities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon Healthcare System, Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;AHS&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Delaware&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;May 18, 2015&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&amp;#x201c;USA&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon (BVI) Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon BVI&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;British Virgin Island&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;January 23, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Dormant,&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;is in process of being dissolved&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon RT 9 Properties LLC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon RT 9&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;New Jersey&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;February 7, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Owns
    and operates an income-producing real property and holds and manages the corporate headquarters&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon (Shanghai) Healthcare Technology Co.,
    Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon Shanghai&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;PRC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;April 29, 2016&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AHS&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in China&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Genexosome Technologies Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Genexosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Nevada&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;July 31, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;60%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Dormant
    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Beijing Jieteng (Genexosome) Biotech Co.,
    Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Beijing Genexosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;PRC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;August 7, 2015&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by Genexosome&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    development services for hospitals and other customers and sells developed items to hospitals and other customers in China&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avactis Biosciences Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avactis&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Nevada&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;July 18, 2018&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Integrate
    and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with
    stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;International Exosome Association LLC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Exosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Delaware&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;June 13, 2019&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Promotes
    standardization related to exosome industry&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired unitRef="pure" contextRef="c55_AsOf19Oct2016" decimals="2">1.00</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
  <avco:ExchangeForCommonStock unitRef="shares" contextRef="c56_From1Oct2016To19Oct2016" decimals="INF">50000000</avco:ExchangeForCommonStock>
  <avco:PercentageOfCapitalStock unitRef="pure" contextRef="c56_From1Oct2016To19Oct2016" decimals="2">1.00</avco:PercentageOfCapitalStock>
  <avco:BuildingOccupancyRate unitRef="pure" contextRef="c57_From1Jan2021To31Mar2021_AvalonRT9PropertiesLLCMember" decimals="3">0.894</avco:BuildingOccupancyRate>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c58_AsOf31Jul2017_BeijingJietengGenExosomeBiotechCoLtdMember" decimals="2">1.00</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c59_AsOf31Jul2017_GenExosomeTechnologiesIncMember" decimals="2">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c60_AsOf31Jul2017_DrYuZhouMember" decimals="2">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
  &lt;tr&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 25%; padding-right: 0pt; padding-left: 0pt; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Name
    of Subsidiary&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 16%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Place
    and date of Incorporation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: top; width: 2%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 13%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Percentage
    of Ownership&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 40%; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&lt;b&gt;Principal
    Activities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon Healthcare System, Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;AHS&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Delaware&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;May 18, 2015&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&amp;#x201c;USA&amp;#x201d;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon (BVI) Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon BVI&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;British Virgin Island&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;January 23, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Dormant,&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;is in process of being dissolved&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon RT 9 Properties LLC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon RT 9&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;New Jersey&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;February 7, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Owns
    and operates an income-producing real property and holds and manages the corporate headquarters&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avalon (Shanghai) Healthcare Technology Co.,
    Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avalon Shanghai&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;PRC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;April 29, 2016&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AHS&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in China&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Genexosome Technologies Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Genexosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Nevada&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;July 31, 2017&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;60%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Dormant
    &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Beijing Jieteng (Genexosome) Biotech Co.,
    Ltd.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Beijing Genexosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;PRC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;August 7, 2015&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by Genexosome&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Provides
    development services for hospitals and other customers and sells developed items to hospitals and other customers in China&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Avactis Biosciences Inc.&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Avactis&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Nevada&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;July 18, 2018&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Integrate
    and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with
    stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;International Exosome Association LLC&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;(&amp;#x201c;Exosome&amp;#x201d;)&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Delaware&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;June 13, 2019&lt;/p&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;100%
    held by AVCO&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Promotes
    standardization related to exosome industry&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
  <avco:EntityIncorporationsStateCountryName contextRef="c61_From1Jan2021To31Mar2021_AvalonHealthcareSystemIncMember">Delaware May 18, 2015</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c61_From1Jan2021To31Mar2021_AvalonHealthcareSystemIncMember">100% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c61_From1Jan2021To31Mar2021_AvalonHealthcareSystemIncMember">Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&quot;USA&quot;)</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c62_From1Jan2021To31Mar2021_AvalonBVILtdMember">British Virgin Island January 23, 2017</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c62_From1Jan2021To31Mar2021_AvalonBVILtdMember">100% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c62_From1Jan2021To31Mar2021_AvalonBVILtdMember">Dormant, is in process of being dissolved</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c57_From1Jan2021To31Mar2021_AvalonRT9PropertiesLLCMember">New Jersey February 7, 2017</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c57_From1Jan2021To31Mar2021_AvalonRT9PropertiesLLCMember">100% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c57_From1Jan2021To31Mar2021_AvalonRT9PropertiesLLCMember">Owns and operates an income-producing real property and holds and manages the corporate headquarters</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c63_From1Jan2021To31Mar2021_AvalonShanghaiHealthcareTechnologyCoLtdMember">PRC April 29, 2016</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c63_From1Jan2021To31Mar2021_AvalonShanghaiHealthcareTechnologyCoLtdMember">100% held by AHS</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c63_From1Jan2021To31Mar2021_AvalonShanghaiHealthcareTechnologyCoLtdMember">Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in China</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c64_From1Jan2021To31Mar2021_GenExosomeTechnologiesIncMember">Nevada July 31, 2017</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c64_From1Jan2021To31Mar2021_GenExosomeTechnologiesIncMember">60% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c64_From1Jan2021To31Mar2021_GenExosomeTechnologiesIncMember">Dormant</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c65_From1Jan2021To31Mar2021_BeijingJietengGenExosomeBiotechCoLtdMember">PRC August 7, 2015</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c65_From1Jan2021To31Mar2021_BeijingJietengGenExosomeBiotechCoLtdMember">100% held by Genexosome</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c65_From1Jan2021To31Mar2021_BeijingJietengGenExosomeBiotechCoLtdMember">Provides development services for hospitals and other customers and sells developed items to hospitals and other customers in China</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c66_From1Jan2021To31Mar2021_AvactisBiosciencesIncMember">Nevada July 18, 2018</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c66_From1Jan2021To31Mar2021_AvactisBiosciencesIncMember">100% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c66_From1Jan2021To31Mar2021_AvactisBiosciencesIncMember">Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <avco:EntityIncorporationsStateCountryName contextRef="c67_From1Jan2021To31Mar2021_InternationalExosomeAssociationLlcMember">Delaware June 13, 2019</avco:EntityIncorporationsStateCountryName>
  <avco:PercentageOfOwnership contextRef="c67_From1Jan2021To31Mar2021_InternationalExosomeAssociationLlcMember">100% held by AVCO</avco:PercentageOfOwnership>
  <us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities contextRef="c67_From1Jan2021To31Mar2021_InternationalExosomeAssociationLlcMember">Promotes standardization related to exosome industry</us-gaap:EquityMethodInvestmentDescriptionOfPrincipalActivities>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;NOTE 2 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;BASIS OF PRESENTATION
AND GOING CONCERN CONDITION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;These&amp;#xa0;interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission and do not include all information and footnotes
necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United
States (&amp;#x201c;U.S. GAAP&amp;#x201d;). The Company&amp;#x2019;s condensed consolidated financial statements include the accounts of the Company
and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Certain&amp;#xa0;information and footnote disclosures
normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
These condensed consolidated financial statements should be read in conjunction with the Company&amp;#x2019;s audited consolidated financial
statements and notes thereto included in the Company&amp;#x2019;s Annual Report on Form 10-K for the year ended December&amp;#xa0;31, 2020 filed
with the Securities and Exchange Commission on March 30, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Going Concern&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients&apos; growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&amp;#x2122;), and regenerative therapeutics. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In addition, the Company owns commercial real
estate that houses its headquarters in Freehold, New Jersey and provides outsourced, customized international healthcare services to
the rapidly changing health care industry primarily focused in the People&amp;#x2019;s Republic of China. The Company did not generate any
revenue from medical related consulting services segment during the three months ended March 31, 2021. These condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the
realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As reflected in the accompanying condensed consolidated
financial statements, the Company had working capital deficit of $1,059,606 as of March 31, 2021 and has incurred recurring net loss
and generated negative cash flow from operating activities of $2,367,118 and $1,515,525 for the three months ended March 31, 2021, respectively.
The Company has a limited operating history and its continued growth is dependent upon the continuation of providing medical consulting
services to its only few clients who are related parties and generating rental revenue from its income-producing real estate property
in New Jersey; hence generating revenues, and obtaining additional financing to fund future obligations and pay liabilities arising from
normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve
months from the release date of this report. These matters raise substantial doubt about the Company&amp;#x2019;s ability to continue as a
going concern. The ability of the Company to continue as a going concern is dependent on the Company&amp;#x2019;s ability to raise additional
capital, implement its business plan, and generate significant revenues. There are no assurances that the Company will be successful
in its efforts to generate significant revenues, maintain sufficient cash balance or report profitable operations or to continue as a
going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However, there is no assurance
these plans will be realized and that any additional financings will be available to the Company on satisfactory terms and conditions,
if any.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The occurrence of an uncontrollable event such
as the COVID-19 pandemic had negatively impact on the Company&amp;#x2019;s operations. Some tenants have delayed on rent payment. Our general
development operations have continued during the COVID-19 pandemic and we have not had significant disruption. However, we are uncertain
if the COVID-19 pandemic will impact future operations at our laboratory, or our ability to collaborate with other laboratories and universities.
In addition, we are unsure if the COVID-19 pandemic will impact future clinical trials. Given the dynamic nature of these circumstances,
the duration of business disruption and reduced traffic, the related financial effect cannot be reasonably estimated at this time but
is expected to adversely impact the Company&amp;#x2019;s business for the rest of 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.&lt;/p&gt;&lt;br/&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <avco:WorkingCapitalDeficit unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-1059606</avco:WorkingCapitalDeficit>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 3 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The preparation of the
condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant
estimates during the three months ended March 31, 2021 and 2020 include the useful life of property and equipment and investment in real
estate, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances,
and valuation of stock-based compensation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;Fair Value of Financial Instruments and
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company adopted
the guidance of Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 820 for fair value measurements which clarifies the definition
of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring
fair value as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&amp;#x202f;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                            1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities
                                            available at the measurement date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                            2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets,
                                            quoted prices for identical or similar assets and liabilities in markets that are not active,
                                            inputs other than quoted prices that are observable, and inputs derived from or corroborated
                                            by observable market data. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                            3-Inputs are unobservable inputs which reflect the reporting entity&amp;#x2019;s own assumptions
                                            on what assumptions the market participants would use in pricing the asset or liability based
                                            on the best available information. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The carrying amounts
reported in the condensed consolidated balance sheets for cash, rent receivable, accrued liabilities and other payables, accrued liabilities
and other payables &amp;#x2013; related parties, operating lease obligation, and note payable, approximate their fair market value as of March
31, 2021 and December 31, 2020 based on the short-term maturity of these instruments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;ASC 825-10 &amp;#x201c;Financial Instruments&amp;#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;At March 31, 2021 and December 31, 2020, the
Company&amp;#x2019;s cash balances by geographic area were as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Country:&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31, &lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December 31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt&quot;&gt;United States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,527,257&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;90.2&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;559,711&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77.0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;China&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;165,283&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9.8&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;166,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;23.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total cash&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,692,540&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;726,577&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2021 and December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A portion of the Company&amp;#x2019;s cash is maintained
with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately
$76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered. At March 31, 2021, cash balances held in the PRC
are RMB 1,083,049 (approximately $165,000), of which, RMB 556,726 (approximately $85,000) was not covered by such limited insurance.
The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company maintains a portion of its cash in
bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages
this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit
quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2021, the Company&amp;#x2019;s cash balances in United
States bank accounts had approximately $986,000 in excess of the federally-insured limits.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Currently, a portion of the Company&amp;#x2019;s operations
are carried out in PRC. Accordingly, the Company&amp;#x2019;s business, financial condition and results of operations may be influenced by
the political, economic and legal environment in the PRC, and by the general state of the PRC&amp;#x2019;s economy. The Company&amp;#x2019;s operations
in PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company&amp;#x2019;s
results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion and remittance abroad, and rates and methods of taxation, among other things.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company&amp;#x2019;s sales
are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however,
concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also
performs ongoing credit evaluations of its customers to help further reduce credit risk.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Investment in Unconsolidated
Company &amp;#x2013; Epicon Biosciences Co., Ltd.&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The
Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events
or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than
temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down
would be recorded to estimated fair value. See Note 5 for discussion of equity method investment.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company recognizes
revenue under Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) Topic 606, Revenue from Contracts with Customers (&amp;#x201c;ASC 606&amp;#x201d;).
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or
services. The following five steps are applied to achieve that core principle:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 1: Identify the contract
    with the customer&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 2: Identify the performance
    obligations in the contract&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 3: Determine the transaction
    price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 4: Allocate the transaction
    price to the performance obligations in the contract&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 5: Recognize revenue
    when the company satisfies a performance obligation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;In order to identify
the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify
each promised goods or service that is distinct. A performance obligation meets ASC 606&amp;#x2019;s definition of a &amp;#x201c;distinct&amp;#x201d;
goods or service (or bundle of goods or services) if both of the following criteria are met:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The customer can benefit
    from the goods or service either on its own or together with other resources that are readily available to the customer (i.e., the
    goods or service is capable of being distinct).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The entity&amp;#x2019;s promise
    to transfer the goods or service to the customer is separately identifiable from other promises in the contract (i.e., the promise
    to transfer the goods or service is distinct within the context of the contract).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;If a goods or service
is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or services is identified
that is distinct.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company&amp;#x2019;s
revenues are derived from providing medial related consulting services for its&amp;#x2019; related parties. Revenues related to its service
offerings are recognized as the services are performed. Any payments received in advance of the performance of services are recorded
as&amp;#xa0;deferred revenue&amp;#xa0;until such time as the services are performed. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has determined that the ASC 606 does
not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company does not offer promotional payments,
customer coupons, rebates or other cash redemption offers to its customers.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;ASC Topic 260 &amp;#x201c;Earnings per Share,&amp;#x201d;
requires presentation of both basic and diluted earnings per share (&amp;#x201c;EPS&amp;#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the three months ended March 31, 2021 and 2020, potentially dilutive
common shares consist of the common shares issuable upon the exercise of common stock options (using the treasury stock method). Common
stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period
in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding
as they would have had an anti-dilutive impact.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Stock options&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company uses &amp;#x201c;the management approach&amp;#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&amp;#x2019;s
chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company&amp;#x2019;s
reportable segments. The Company&amp;#x2019;s chief operating decision maker is the Chief Executive Officer (&amp;#x201c;CEO&amp;#x201d;) and president
of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company previously had three reportable business
segments: real property operating segment, medical related consulting services segment, and development services and sales of developed
products segment. Due to the winding down of the development services and sales of developed products segment in 2020, the Company no
longer has any material revenues or expenses in this&amp;#xa0;segment. As a result, commencing from the first quarter of 2021, the Company&amp;#x2019;s
chief operating decision maker no longer reviews development services and sales of developed products operating results and the Company
no longer reports in three&amp;#xa0;segments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the three months ended March 31, 2021,
the Company operates through two business segments: real property operating segment and medical related consulting services segment.
These reportable segments offer different types of services and products, have different types of revenue, and are managed separately
as each requires different operating strategies and management expertise.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Certain prior period amounts have been reclassified
to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position,
results of operations and cash flows.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Recent Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial
Instruments - Credit Losses (&amp;#x201c;Topic 326&amp;#x201d;). &lt;/i&gt;The ASU introduces a new accounting model, the Current Expected Credit Losses
model (&amp;#x201c;CECL&amp;#x201d;), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The
CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial
asset is originated or acquired. ASU 2016-13 is effective for annual period beginning after December 15, 2022, including interim reporting
periods within those annual reporting periods. The Company expects that the adoption will not have a material impact on the Company&amp;#x2019;s
consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,
&lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim
and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019 &amp;#x2013; 12 did not have
a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The preparation of the
condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant
estimates during the three months ended March 31, 2021 and 2020 include the useful life of property and equipment and investment in real
estate, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances,
and valuation of stock-based compensation.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;Fair Value of Financial Instruments and
Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company adopted
the guidance of Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 820 for fair value measurements which clarifies the definition
of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring
fair value as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&amp;#x202f;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;Level
                                            1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities
                                            available at the measurement date.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                            2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets,
                                            quoted prices for identical or similar assets and liabilities in markets that are not active,
                                            inputs other than quoted prices that are observable, and inputs derived from or corroborated
                                            by observable market data. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#xa0;&lt;/font&gt;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Level
                                            3-Inputs are unobservable inputs which reflect the reporting entity&amp;#x2019;s own assumptions
                                            on what assumptions the market participants would use in pricing the asset or liability based
                                            on the best available information. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The carrying amounts
reported in the condensed consolidated balance sheets for cash, rent receivable, accrued liabilities and other payables, accrued liabilities
and other payables &amp;#x2013; related parties, operating lease obligation, and note payable, approximate their fair market value as of March
31, 2021 and December 31, 2020 based on the short-term maturity of these instruments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;ASC 825-10 &amp;#x201c;Financial Instruments&amp;#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;At March 31, 2021 and December 31, 2020, the
Company&amp;#x2019;s cash balances by geographic area were as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Country:&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31, &lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December 31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt&quot;&gt;United States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,527,257&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;90.2&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;559,711&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77.0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;China&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;165,283&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9.8&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;166,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;23.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total cash&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,692,540&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;726,577&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2021 and December 31, 2020.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <avco:CreditRiskAndUncertaintiePolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Credit Risk and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A portion of the Company&amp;#x2019;s cash is maintained
with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately
$76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered. At March 31, 2021, cash balances held in the PRC
are RMB 1,083,049 (approximately $165,000), of which, RMB 556,726 (approximately $85,000) was not covered by such limited insurance.
The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company maintains a portion of its cash in
bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages
this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit
quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2021, the Company&amp;#x2019;s cash balances in United
States bank accounts had approximately $986,000 in excess of the federally-insured limits.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Currently, a portion of the Company&amp;#x2019;s operations
are carried out in PRC. Accordingly, the Company&amp;#x2019;s business, financial condition and results of operations may be influenced by
the political, economic and legal environment in the PRC, and by the general state of the PRC&amp;#x2019;s economy. The Company&amp;#x2019;s operations
in PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company&amp;#x2019;s
results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion and remittance abroad, and rates and methods of taxation, among other things.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company&amp;#x2019;s sales
are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however,
concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also
performs ongoing credit evaluations of its customers to help further reduce credit risk.&lt;/p&gt;</avco:CreditRiskAndUncertaintiePolicyTextBlock>
  <avco:CashAndCashEquivalentsDescription contextRef="c0_From1Jan2021To31Mar2021">the Company&amp;#x2019;s cash is maintained with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately $76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered.</avco:CashAndCashEquivalentsDescription>
  <avco:CashAndDueFromBank unitRef="cny" contextRef="c2_AsOf31Mar2021" decimals="0">1083049</avco:CashAndDueFromBank>
  <avco:CashAndDueFromBank unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">165000</avco:CashAndDueFromBank>
  <avco:LimitedInsurance unitRef="cny" contextRef="c2_AsOf31Mar2021" decimals="0">556726</avco:LimitedInsurance>
  <avco:LimitedInsurance unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">85000</avco:LimitedInsurance>
  <avco:FederallyinsuredLimits unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">250000</avco:FederallyinsuredLimits>
  <avco:FederallyinsuredLimits unitRef="usd" contextRef="c68_From1Jan2021To31Mar2021_US" decimals="0">986000</avco:FederallyinsuredLimits>
  <avco:InvestmentInUnconsolidatedCompanyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Investment in Unconsolidated
Company &amp;#x2013; Epicon Biosciences Co., Ltd.&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company uses the equity method of accounting
for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The
Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events
or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than
temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down
would be recorded to estimated fair value. See Note 5 for discussion of equity method investment.&lt;/p&gt;</avco:InvestmentInUnconsolidatedCompanyPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company recognizes
revenue under Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) Topic 606, Revenue from Contracts with Customers (&amp;#x201c;ASC 606&amp;#x201d;).
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or
services. The following five steps are applied to achieve that core principle:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 1: Identify the contract
    with the customer&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 2: Identify the performance
    obligations in the contract&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 3: Determine the transaction
    price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 4: Allocate the transaction
    price to the performance obligations in the contract&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Step 5: Recognize revenue
    when the company satisfies a performance obligation&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;In order to identify
the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify
each promised goods or service that is distinct. A performance obligation meets ASC 606&amp;#x2019;s definition of a &amp;#x201c;distinct&amp;#x201d;
goods or service (or bundle of goods or services) if both of the following criteria are met:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The customer can benefit
    from the goods or service either on its own or together with other resources that are readily available to the customer (i.e., the
    goods or service is capable of being distinct).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%; &quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;The entity&amp;#x2019;s promise
    to transfer the goods or service to the customer is separately identifiable from other promises in the contract (i.e., the promise
    to transfer the goods or service is distinct within the context of the contract).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;If a goods or service
is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or services is identified
that is distinct.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company&amp;#x2019;s
revenues are derived from providing medial related consulting services for its&amp;#x2019; related parties. Revenues related to its service
offerings are recognized as the services are performed. Any payments received in advance of the performance of services are recorded
as&amp;#xa0;deferred revenue&amp;#xa0;until such time as the services are performed. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has determined that the ASC 606 does
not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company does not offer promotional payments,
customer coupons, rebates or other cash redemption offers to its customers.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Per Share Data&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;ASC Topic 260 &amp;#x201c;Earnings per Share,&amp;#x201d;
requires presentation of both basic and diluted earnings per share (&amp;#x201c;EPS&amp;#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the three months ended March 31, 2021 and 2020, potentially dilutive
common shares consist of the common shares issuable upon the exercise of common stock options (using the treasury stock method). Common
stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period
in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding
as they would have had an anti-dilutive impact.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Stock options&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Segment Reporting&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company uses &amp;#x201c;the management approach&amp;#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&amp;#x2019;s
chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company&amp;#x2019;s
reportable segments. The Company&amp;#x2019;s chief operating decision maker is the Chief Executive Officer (&amp;#x201c;CEO&amp;#x201d;) and president
of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company previously had three reportable business
segments: real property operating segment, medical related consulting services segment, and development services and sales of developed
products segment. Due to the winding down of the development services and sales of developed products segment in 2020, the Company no
longer has any material revenues or expenses in this&amp;#xa0;segment. As a result, commencing from the first quarter of 2021, the Company&amp;#x2019;s
chief operating decision maker no longer reviews development services and sales of developed products operating results and the Company
no longer reports in three&amp;#xa0;segments.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the three months ended March 31, 2021,
the Company operates through two business segments: real property operating segment and medical related consulting services segment.
These reportable segments offer different types of services and products, have different types of revenue, and are managed separately
as each requires different operating strategies and management expertise.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:Reclassifications contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Certain prior period amounts have been reclassified
to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position,
results of operations and cash flows.&lt;/p&gt;</us-gaap:Reclassifications>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Recent Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i&gt;Financial
Instruments - Credit Losses (&amp;#x201c;Topic 326&amp;#x201d;). &lt;/i&gt;The ASU introduces a new accounting model, the Current Expected Credit Losses
model (&amp;#x201c;CECL&amp;#x201d;), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The
CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial
asset is originated or acquired. ASU 2016-13 is effective for annual period beginning after December 15, 2022, including interim reporting
periods within those annual reporting periods. The Company expects that the adoption will not have a material impact on the Company&amp;#x2019;s
consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,
&lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim
and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019 &amp;#x2013; 12 did not have
a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its consolidated financial condition, results of operations, cash flows or disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Country:&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31, &lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December 31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt&quot;&gt;United States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,527,257&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;90.2&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;559,711&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;77.0&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;China&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;165,283&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;9.8&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;166,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;23.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total cash&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,692,540&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;726,577&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;100.0&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c69_AsOf31Mar2021_US" decimals="0">1527257</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c68_From1Jan2021To31Mar2021_US" decimals="3">0.902</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c70_AsOf31Dec2020_US" decimals="0">559711</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c71_From1Jan2020To31Dec2020_US" decimals="3">0.770</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c72_AsOf31Mar2021_CN" decimals="0">165283</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c73_From1Jan2021To31Mar2021_CN" decimals="3">0.098</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c74_AsOf31Dec2020_CN" decimals="0">166866</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c75_From1Jan2020To31Dec2020_CN" decimals="3">0.230</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1692540</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="3">1.000</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:CashAndDueFromBanks unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">726577</us-gaap:CashAndDueFromBanks>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c76_From1Jan2020To31Dec2020" decimals="3">1.000</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Stock options&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;width: 1%; padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Potentially dilutive securities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;6,800,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c77_From1Jan2021To31Mar2021_StockOptionsMember" decimals="INF">7580000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c78_From1Jan2020To31Mar2020_StockOptionsMember" decimals="INF">6800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jan2021To31Mar2021" decimals="INF">7580000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c4_From1Jan2020To31Mar2020" decimals="INF">6800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <avco:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;NOTE 4 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;PREPAID EXPENSES
AND OTHER CURRENT ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;At March 31, 2021 and December 31, 2020,
prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Prepaid NASDAQ listing fee&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;63,417&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid directors and officers liability insurance premium&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;62,038&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,929&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid professional fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;53,364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;78,639&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Recoverable VAT&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;41,934&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;40,446&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Deferred leasing costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31,422&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,220&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid research and development fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30,305&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;13,251&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;39,380&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;295,731&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;302,224&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</avco:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Prepaid NASDAQ listing fee&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;63,417&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid directors and officers liability insurance premium&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;62,038&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;64,929&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid professional fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;53,364&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;78,639&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Recoverable VAT&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;41,934&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;40,446&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Deferred leasing costs&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;31,422&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18,220&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Prepaid research and development fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30,305&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60,610&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;13,251&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;39,380&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;295,731&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;302,224&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <avco:PrepaidNasdaqListingFee unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">63417</avco:PrepaidNasdaqListingFee>
  <avco:PrepaidNasdaqListingFee unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <avco:PrepaidDirectorsAndOfficersLiabilityInsurancePremium unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">62038</avco:PrepaidDirectorsAndOfficersLiabilityInsurancePremium>
  <avco:PrepaidDirectorsAndOfficersLiabilityInsurancePremium unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">64929</avco:PrepaidDirectorsAndOfficersLiabilityInsurancePremium>
  <avco:PrepaidProfessionalFees unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">53364</avco:PrepaidProfessionalFees>
  <avco:PrepaidProfessionalFees unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">78639</avco:PrepaidProfessionalFees>
  <us-gaap:ValueAddedTaxReceivable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">41934</us-gaap:ValueAddedTaxReceivable>
  <us-gaap:ValueAddedTaxReceivable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">40446</us-gaap:ValueAddedTaxReceivable>
  <us-gaap:DeferredCostsLeasingNet unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">31422</us-gaap:DeferredCostsLeasingNet>
  <us-gaap:DeferredCostsLeasingNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">18220</us-gaap:DeferredCostsLeasingNet>
  <avco:PrepaidResearchAndDevelopmentFees unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">30305</avco:PrepaidResearchAndDevelopmentFees>
  <avco:PrepaidResearchAndDevelopmentFees unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">60610</avco:PrepaidResearchAndDevelopmentFees>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">13251</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:OtherPrepaidExpenseCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">39380</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">295731</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">302224</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 5 &amp;#x2013; &lt;font style=&quot;text-decoration:underline&quot;&gt;EQUITY
METHOD INVESTMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021 and December 31, 2020, the
equity method investment amounted to $532,199 and $521,758, respectively. The investment represents the Company&amp;#x2019;s subsidiary, Avalon
Shanghai&amp;#x2019;s interest in Epicon Biotech Co., Ltd. (&amp;#x201c;Epicon&amp;#x201d;). Epicon was incorporated on August 14, 2018 in PRC. Avalon
Shanghai and the other unrelated company, Jiangsu Unicorn Biological Technology Co., Ltd. (&amp;#x201c;Unicorn&amp;#x201d;), accounted for 40%
and 60% of the total ownership, respectively. Epicon is focused on cell preparation, third party testing, biological sample repository
for commercial and scientific research purposes and the clinical transformation of scientific achievements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company treats the equity investment in the
consolidated financial statements under the equity method. Under the equity method, the investment is initially recorded at cost, adjusted
for any excess of the Company&amp;#x2019;s share of the incorporated-date fair values of the investee&amp;#x2019;s identifiable net assets over
the cost of the investment (if any). Thereafter, the investment is adjusted for the post incorporation change in the Company&amp;#x2019;s
share of the investee&amp;#x2019;s net assets and any impairment loss relating to the investment.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the three months ended March 31, 2021 and
2020, the Company&amp;#x2019;s share of Epicon&amp;#x2019;s net loss was $18,514 and $9,084, respectively, which was included in loss from equity
method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In the three months ended March 31, 2021, activity
recorded for the Company&amp;#x2019;s&amp;#xa0;equity method investment&amp;#xa0;in Epicon is summarized in the following table:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Equity investment carrying amount at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;521,758&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Payment made for equity method investment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30,844&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Epicon&apos;s net loss attributable to the Company&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(18,514&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Foreign currency fluctuation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,889&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Equity investment carrying amount at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;532,199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The tables below present
the summarized financial information, as provided to the Company by the investee, for the unconsolidated company:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Current assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,071&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,023&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Noncurrent assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;255,884&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;264,390&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,351&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,615&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Noncurrent liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Equity&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;254,604&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;270,798&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;For the Three Months &lt;br/&gt;
Ended March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Net revenue&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;$&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;$&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Loss from operation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;46,286&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,711&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;46,286&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,711&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">532199</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">521758</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c79_AsOf31Mar2021_OtherUnrelatedCompanyMember" decimals="2">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c80_AsOf31Dec2020_UnicornMember" decimals="2">0.60</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:IncomeLossFromEquityMethodInvestments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-18514</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-9084</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Equity investment carrying amount at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;521,758&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Payment made for equity method investment&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;30,844&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt&quot;&gt;Epicon&apos;s net loss attributable to the Company&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(18,514&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Foreign currency fluctuation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,889&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Equity investment carrying amount at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;532,199&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
  <avco:PaymentMadeForEquityMethodInvestments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">30844</avco:PaymentMadeForEquityMethodInvestments>
  <us-gaap:IncomeLossAttributableToParent unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">18514</us-gaap:IncomeLossAttributableToParent>
  <avco:ForeignCurrencyFluctuationEquityMethodInvestments unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">1889</avco:ForeignCurrencyFluctuationEquityMethodInvestments>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Current assets&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,071&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;13,023&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Noncurrent assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;255,884&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;264,390&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Current liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;14,351&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,615&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Noncurrent liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Equity&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;254,604&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;270,798&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</avco:EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">13071</avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">13023</avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">255884</avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">264390</avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">14351</avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6615</avco:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfEquity unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">254604</avco:EquityMethodInvestmentSummarizedFinancialInformationOfEquity>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">270798</avco:EquityMethodInvestmentSummarizedFinancialInformationOfEquity>
  <avco:ScheduleOfFinancialInformationByInvestee contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;For the Three Months &lt;br/&gt;
Ended March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Net revenue&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;$&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;$&lt;/td&gt;
    &lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Loss from operation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;46,286&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;22,711&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;46,286&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;22,711&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</avco:ScheduleOfFinancialInformationByInvestee>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfRevenue unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfRevenue unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">46286</avco:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">22711</avco:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">46286</avco:EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss>
  <avco:EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">22711</avco:EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 6 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;ACCRUED
LIABILITIES AND OTHER PAYABLES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;At March 31, 2021 and
December 31, 2020, accrued liabilities and other payables consisted of the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued professional fees&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,445,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,212,822&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued research and development fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;432,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;513,533&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued payroll liability and directors&amp;#x2019; compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;165,846&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;154,292&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued tenants&amp;#x2019; improvement reimbursement&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;81,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;81,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Tenants&amp;#x2019; security deposit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,533&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,634&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;56,374&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;87,190&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Deferred rental income&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;26,286&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,510&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;110,360&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;105,177&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,388,024&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,248,058&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued professional fees&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,445,225&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,212,822&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued research and development fees&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;432,500&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;513,533&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued payroll liability and directors&amp;#x2019; compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;165,846&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;154,292&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accrued tenants&amp;#x2019; improvement reimbursement&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;81,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;81,900&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Tenants&amp;#x2019; security deposit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,533&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,634&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;56,374&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;87,190&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Deferred rental income&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;26,286&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;23,510&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;110,360&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;105,177&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,388,024&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,248,058&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <avco:AccruedResearchAndDevelopmentFee unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">432500</avco:AccruedResearchAndDevelopmentFee>
  <avco:AccruedResearchAndDevelopmentFee unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">513533</avco:AccruedResearchAndDevelopmentFee>
  <us-gaap:AccruedBonusesCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">165846</us-gaap:AccruedBonusesCurrent>
  <us-gaap:AccruedBonusesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">154292</us-gaap:AccruedBonusesCurrent>
  <avco:AccruedTenantsImprovementReimbursement unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">81900</avco:AccruedTenantsImprovementReimbursement>
  <avco:AccruedTenantsImprovementReimbursement unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">81900</avco:AccruedTenantsImprovementReimbursement>
  <us-gaap:Deposits unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">69533</us-gaap:Deposits>
  <us-gaap:Deposits unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">69634</us-gaap:Deposits>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">56374</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">87190</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredIncome unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">26286</us-gaap:DeferredIncome>
  <us-gaap:DeferredIncome unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">23510</us-gaap:DeferredIncome>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">110360</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">105177</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">2388024</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2248058</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;NOTE 7 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Accrued Liabilities and Other Payables &amp;#x2013;
Related Parties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company acquired Beijing Genexosome for a
cash payment of $450,000. As of March 31, 2021 and December 31, 2020, the unpaid acquisition consideration of $100,000, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been included in accrued liabilities
and other payables &amp;#x2013; related parties on the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021 and December 31, 2020, the
accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&amp;#x2019;s largest shareholder and chairman of the Board
of Directors, amounted to $213,105 and $167,956, respectively, and have been included in accrued liabilities and other payables &amp;#x2013;
related parties on the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Borrowings from Related Party&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Promissory Note&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;On March 18, 2019, the
Company issued Wenzhao Lu, the Company&amp;#x2019;s largest shareholder and Chairman of the Board of Directors, a Promissory Note in the principal
amount of $1,000,000 (&amp;#x201c;Promissory Note&amp;#x201d;) in consideration of cash in the amount of $1,000,000. The Promissory Note accrues
interest at the rate of 5% per annum and matures March 19, 2022. The Company repaid principal of $410,000 and $200,000 in the third quarter
of 2019 and second quarter of 2020, respectively. As of both March 31, 2021 and December 31, 2020, the outstanding principal balance
was $390,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Line of Credit&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &amp;#x201c;Line of Credit Agreement&amp;#x201d;) providing the Company with a $20 million line of credit (the
&amp;#x201c;Line of Credit&amp;#x201d;) from Wenzhao Lu (the &amp;#x201c;Lender&amp;#x201d;), the largest shareholder and Chairman of the Board of Directors
of the Company. The Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital
and operating expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into
equity of the Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable
three years from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related
party Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to
maturity, without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default
occurs, the Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021
and December 31, 2020, $3,305,249 and $3,200,000 was outstanding under the Line of Credit, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the three months ended March 31, 2021 and
2020, the interest expense related to above borrowings amounted to $45,149 and $42,169, respectively, and has been included in interest
expense &amp;#x2013; related party on the accompanying condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;As of March 31, 2021
and December 31, 2020, the related accrued and unpaid interest for above borrowings was $213,105 and $167,956, respectively, and has
been included in accrued liabilities and other payables &amp;#x2013; related parties on the accompanying condensed consolidated balance sheets.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Office Space from
Related Party&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;Beijing Genexosome uses
office space of a related party, free of rent, which is considered immaterial.&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c81_AsOf31Mar2021_ChiefExecutiveOfficerMember_DavidJinMember" decimals="0">450000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <avco:ConsiderationCash unitRef="usd" contextRef="c82_AsOf31Mar2021_ChiefOperatingOfficerMember_DrYuZhouMember" decimals="0">100000</avco:ConsiderationCash>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c83_AsOf31Mar2021_GenExosomeMember" decimals="2">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c84_AsOf31Mar2021_BoardOfDirectorsChairmanMember_WenzhaoLuMember" decimals="0">213105</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c85_AsOf31Dec2020_BoardOfDirectorsChairmanMember_WenzhaoLuMember" decimals="0">167956</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:NotesPayable unitRef="usd" contextRef="c86_AsOf18Mar2019_WenzhaoLuMember" decimals="0">1000000</us-gaap:NotesPayable>
  <avco:ConsiderationCash unitRef="usd" contextRef="c86_AsOf18Mar2019_WenzhaoLuMember" decimals="0">1000000</avco:ConsiderationCash>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage unitRef="pure" contextRef="c86_AsOf18Mar2019_WenzhaoLuMember" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c87_From1Mar2019To18Mar2019_WenzhaoLuMember">2022-03-19</us-gaap:DebtInstrumentMaturityDate>
  <avco:PrincipalRepaidAmount unitRef="usd" contextRef="c88_From1Jan2019To30Sep2019_WenzhaoLuMember" decimals="0">410000</avco:PrincipalRepaidAmount>
  <avco:PrincipalRepaidAmount unitRef="usd" contextRef="c89_From1Jan2020To30Jun2020_WenzhaoLuMember" decimals="0">200000</avco:PrincipalRepaidAmount>
  <us-gaap:NotesPayable unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">390000</us-gaap:NotesPayable>
  <us-gaap:LineOfCredit unitRef="usd" contextRef="c90_AsOf29Aug2019_LineOfCreditAgreementMember" decimals="-6">20000000</us-gaap:LineOfCredit>
  <us-gaap:ShortTermDebtPercentageBearingFixedInterestRate unitRef="pure" contextRef="c90_AsOf29Aug2019_LineOfCreditAgreementMember" decimals="2">0.05</us-gaap:ShortTermDebtPercentageBearingFixedInterestRate>
  <avco:LoanFromLender unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">3305249</avco:LoanFromLender>
  <avco:LoanFromLender unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">3200000</avco:LoanFromLender>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">213105</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">167956</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:NotesPayable unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">390000</us-gaap:NotesPayable>
  <avco:ConsiderationCash unitRef="usd" contextRef="c91_AsOf31Dec2020_ChiefOperatingOfficerMember_DrYuZhouMember" decimals="0">100000</avco:ConsiderationCash>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage unitRef="pure" contextRef="c92_AsOf31Dec2020_GenExosomeMember" decimals="2">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="c93_From2Aug2019To29Aug2019">2024-12-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 8 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;2020 Incentive Stock
Plan&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company held its
annual meeting on August 4, 2020. During its annual meeting, the Company approved 2020 Incentive Stock Plan and reserved 5,000,000 shares
of common stock for issuance thereunder.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Common Shares Sold
for Cash&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On December 13, 2019, the Company entered into
an Open Market Sale Agreement&lt;sup&gt;SM &lt;/sup&gt;(the &amp;#x201c;Sales Agreement&amp;#x201d;) with Jefferies LLC, as sales agent (&amp;#x201c;Jefferies&amp;#x201d;),
pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock. During the three
months ended March 31, 2021, Jefferies sold an aggregate of 1,848,267 shares of common stock at an average price of $1.34 per share to
investors. The Company recorded net proceeds of $2,337,259, net of commission and other offering costs of $144,146.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Common Shares Issued
for Services&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;During the three months ended March 31, 2021,
the Company issued a total of 300,000 shares of its common stock for services rendered. These shares were valued at $360,000, the fair
market values on the grant dates using the reported closing share prices on the dates of grant and the Company recorded stock-based compensation
expense of $98,968 for the three months ended March 31, 2021 and reduced accrued liabilities of $261,032.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following table summarizes the shares of
the Company&amp;#x2019;s common stock issuable upon exercise of options outstanding at March 31, 2021:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Range of&lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number&lt;br/&gt;
    Outstanding at&lt;br/&gt;
    March 31, &lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual Life&lt;br/&gt;
    (Years)&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number&lt;br/&gt;
    Exercisable at&lt;br/&gt;
    March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;2,000,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;5.86&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;2,000,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 13%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1.00 &amp;#x2013; 1.93&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,810,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.37&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,366,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2.00 &amp;#x2013; 2.80&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,740,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.52&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,740,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3.01&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;0.50 &amp;#x2013; 4.76&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.46&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,136,666&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.47&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;Stock option activities
for the three months ended March 31, 2021 were as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number of&lt;br/&gt;
    Options&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: 0pt; padding-left: 0pt&quot;&gt;Outstanding at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,140,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.48&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;440,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Terminated / Exercised / Expired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Outstanding at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Options exercisable at March 31, 2021&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,136,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.47&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Options expected to vest&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;443,334&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.14&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The aggregate intrinsic value of both stock options
outstanding and stock options exercisable at March 31, 2021 was $1,161,700.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The fair values of options granted during the
three months ended March 31, 2021 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 128.42%, risk-free rate of 0.36%, annual dividend yield of 0% and expected life of 5.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2021 was $419,020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The fair values of options
granted during the three months ended March 31, 2020 were estimated at the date of grant using the Black-Scholes option-pricing model
with the following assumptions: volatility of 137.42% - 139.58%, risk-free rate of 1.39% - 1.67%, annual dividend yield of 0% and expected
life of 5.00 &amp;#x2013; 10.00 years. The aggregate fair value of the options granted during the three months ended March 31, 2020 was $2,422,225.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the three months ended March 31, 2021 and
2020, stock-based compensation expense associated with stock options granted amounted to $202,505 and $785,350, respectively, of which,
$139,507 and $674,998 was recorded as compensation and related benefits, $43,443 and $103,818 was recorded as professional fees, and
$19,555 and $6,534 was recorded as research and development expenses, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A summary of the status of the Company&amp;#x2019;s
nonvested stock options granted as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number of&lt;br/&gt;
    Options&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; padding-left: 0pt&quot;&gt;Nonvested at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;218,334&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;440,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Vested&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(215,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1.15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Nonvested at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;443,334&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.14&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance unitRef="shares" contextRef="c94_AsOf4Aug2020" decimals="INF">5000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c95_From1Jan2021To31Mar2021_JefferiesLLCMember" decimals="INF">1848267</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c96_AsOf31Mar2021_JefferiesLLCMember" decimals="2">1.34</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c95_From1Jan2021To31Mar2021_JefferiesLLCMember" decimals="0">2337259</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts unitRef="usd" contextRef="c95_From1Jan2021To31Mar2021_JefferiesLLCMember" decimals="0">144146</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices unitRef="shares" contextRef="c97_From1Jan2021To31Mar2021_CommonSharesIssuedForServicesMember" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices unitRef="usd" contextRef="c97_From1Jan2021To31Mar2021_CommonSharesIssuedForServicesMember" decimals="0">360000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <avco:SharesBasedCompensation unitRef="usd" contextRef="c97_From1Jan2021To31Mar2021_CommonSharesIssuedForServicesMember" decimals="0">98968</avco:SharesBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities unitRef="usd" contextRef="c97_From1Jan2021To31Mar2021_CommonSharesIssuedForServicesMember" decimals="0">261032</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">1161700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="4">1.2842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="4">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0_From1Jan2021To31Mar2021">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">419020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <avco:FairValueOfOptionGrantedDescription contextRef="c0_From1Jan2021To31Mar2021">The fair values of options granted during the three months ended March 31, 2020 were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: volatility of 137.42% - 139.58%, risk-free rate of 1.39% - 1.67%, annual dividend yield of 0% and expected life of 5.00 &amp;#x2013; 10.00 years. The aggregate fair value of the options granted during the three months ended March 31, 2020 was $2,422,225.</avco:FairValueOfOptionGrantedDescription>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">202505</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">785350</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c98_From1Jan2021To31Mar2021_CompensationAndRelatedBenefitsMember" decimals="0">139507</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c99_From1Jan2020To31Mar2020_CompensationAndRelatedBenefitsMember" decimals="0">674998</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c100_From1Jan2021To31Mar2021_ProfessionalFeesMember" decimals="0">43443</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c101_From1Jan2020To31Mar2020_ProfessionalFeesMember" decimals="0">103818</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c102_From1Jan2021To31Mar2021_ResearchAndDevelopmentExpenseMember" decimals="0">19555</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense unitRef="usd" contextRef="c103_From1Jan2020To31Mar2020_ResearchAndDevelopmentExpenseMember" decimals="0">6534</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;14&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Options Outstanding&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Options Exercisable&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Range of&lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number&lt;br/&gt;
    Outstanding at&lt;br/&gt;
    March 31, &lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted Average&lt;br/&gt;
    Remaining&lt;br/&gt;
    Contractual Life&lt;br/&gt;
    (Years)&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number&lt;br/&gt;
    Exercisable at&lt;br/&gt;
    March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;2,000,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;5.86&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 14%; text-align: right&quot;&gt;2,000,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 13%; text-align: right&quot;&gt;0.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;1.00 &amp;#x2013; 1.93&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,810,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.37&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.40&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,366,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;2.00 &amp;#x2013; 2.80&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,740,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.52&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,740,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3.01&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.76&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;0.50 &amp;#x2013; 4.76&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;4.46&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,136,666&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.47&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <avco:ExercisePrice unitRef="usdPershares" contextRef="c104_From1Jan2021To31Mar2021_ExercisePriceRangeOneMember" decimals="2">0.50</avco:ExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c105_AsOf31Mar2021_ExercisePriceRangeOneMember" decimals="INF">2000000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c104_From1Jan2021To31Mar2021_ExercisePriceRangeOneMember">P5Y313D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c105_AsOf31Mar2021_ExercisePriceRangeOneMember" decimals="2">0.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c105_AsOf31Mar2021_ExercisePriceRangeOneMember" decimals="INF">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c105_AsOf31Mar2021_ExercisePriceRangeOneMember" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c106_From1Jan2021To31Mar2021_ExercisePriceRangeTwoMember" decimals="2">1.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c106_From1Jan2021To31Mar2021_ExercisePriceRangeTwoMember" decimals="2">1.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c107_AsOf31Mar2021_ExercisePriceRangeTwoMember" decimals="INF">2810000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c106_From1Jan2021To31Mar2021_ExercisePriceRangeTwoMember">P5Y135D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c107_AsOf31Mar2021_ExercisePriceRangeTwoMember" decimals="2">1.40</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c107_AsOf31Mar2021_ExercisePriceRangeTwoMember" decimals="INF">2366666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c107_AsOf31Mar2021_ExercisePriceRangeTwoMember" decimals="2">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c108_From1Jan2021To31Mar2021_ExercisePriceRangeThreeMember" decimals="2">2.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c108_From1Jan2021To31Mar2021_ExercisePriceRangeThreeMember" decimals="2">2.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c109_AsOf31Mar2021_ExercisePriceRangeThreeMember" decimals="INF">2740000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c108_From1Jan2021To31Mar2021_ExercisePriceRangeThreeMember">P2Y189D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c109_AsOf31Mar2021_ExercisePriceRangeThreeMember" decimals="2">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c109_AsOf31Mar2021_ExercisePriceRangeThreeMember" decimals="INF">2740000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c109_AsOf31Mar2021_ExercisePriceRangeThreeMember" decimals="2">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <avco:ExercisePrice unitRef="usdPershares" contextRef="c110_From1Jan2021To31Mar2021_ExercisePriceRangeFourMember" decimals="2">4.76</avco:ExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c111_AsOf31Mar2021_ExercisePriceRangeFourMember" decimals="INF">30000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c110_From1Jan2021To31Mar2021_ExercisePriceRangeFourMember">P3Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c111_AsOf31Mar2021_ExercisePriceRangeFourMember" decimals="2">4.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c111_AsOf31Mar2021_ExercisePriceRangeFourMember" decimals="INF">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c111_AsOf31Mar2021_ExercisePriceRangeFourMember" decimals="2">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit unitRef="usdPershares" contextRef="c112_From1Jan2021To31Mar2021_ExercisePriceRangeFiveMember" decimals="2">0.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit unitRef="usdPershares" contextRef="c112_From1Jan2021To31Mar2021_ExercisePriceRangeFiveMember" decimals="2">4.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions unitRef="shares" contextRef="c113_AsOf31Mar2021_ExercisePriceRangeFiveMember" decimals="INF">7580000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c112_From1Jan2021To31Mar2021_ExercisePriceRangeFiveMember">P4Y167D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 unitRef="usdPershares" contextRef="c113_AsOf31Mar2021_ExercisePriceRangeFiveMember" decimals="2">1.45</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c113_AsOf31Mar2021_ExercisePriceRangeFiveMember" decimals="INF">7136666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c113_AsOf31Mar2021_ExercisePriceRangeFiveMember" decimals="2">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number of&lt;br/&gt;
    Options&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-indent: 0pt; padding-left: 0pt&quot;&gt;Outstanding at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,140,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.48&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;440,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Terminated / Exercised / Expired&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt&quot;&gt;Outstanding at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;7,580,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.45&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-indent: 0pt; padding-left: 0pt&quot;&gt;Options exercisable at March 31, 2021&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;7,136,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.47&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; text-indent: 0pt; padding-left: 0pt&quot;&gt;Options expected to vest&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;443,334&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.14&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c114_AsOf31Dec2020_NumberOfOptionsMember" decimals="INF">7140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c115_AsOf31Dec2020_WeightedAverageExercisePriceMember" decimals="2">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c116_From1Jan2021To31Mar2021_NumberOfOptionsMember" decimals="INF">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c117_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <avco:StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised unitRef="shares" contextRef="c116_From1Jan2021To31Mar2021_NumberOfOptionsMember" xs:nil="true"/>
  <avco:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice unitRef="usdPershares" contextRef="c117_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c118_AsOf31Mar2021_NumberOfOptionsMember" decimals="INF">7580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c119_AsOf31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c118_AsOf31Mar2021_NumberOfOptionsMember" decimals="INF">7136666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c119_AsOf31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber unitRef="shares" contextRef="c118_AsOf31Mar2021_NumberOfOptionsMember" decimals="INF">443334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c119_AsOf31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Number of&lt;br/&gt;
    Options&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Weighted&lt;br/&gt;
    Average&lt;br/&gt;
    Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; padding-left: 0pt&quot;&gt;Nonvested at January 1, 2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;218,334&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.18&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;440,000&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Vested&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(215,000&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1.15&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 4pt; padding-left: 0pt&quot;&gt;Nonvested at March 31, 2021&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;443,334&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1.14&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c120_AsOf31Dec2020_NumberOfOptionsMember" decimals="INF">218334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c121_AsOf31Dec2020_WeightedAverageExercisePriceMember" decimals="2">1.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted unitRef="shares" contextRef="c122_From1Jan2021To31Mar2021_NumberOfOptionsMember" decimals="INF">440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c123_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod unitRef="shares" contextRef="c122_From1Jan2021To31Mar2021_NumberOfOptionsMember" decimals="INF">215000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c123_From1Jan2021To31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares unitRef="shares" contextRef="c124_AsOf31Mar2021_NumberOfOptionsMember" decimals="INF">443334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c125_AsOf31Mar2021_WeightedAverageExercisePriceMember" decimals="2">1.14</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
  <avco:StatutoryReserveTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 9 -&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;STATUTORY
RESERVE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Avalon Shanghai and Beijing Genexosome operate
in the PRC, are required to reserve 10% of their net profit after income tax, as determined in accordance with the PRC accounting rules
and regulations. Appropriation to the statutory reserve by the Company is based on profit arrived at under PRC accounting standards for
business enterprises for each year.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The profit arrived at must be set off against
any accumulated losses sustained by the Company in prior years, before allocation is made to the statutory reserve. Appropriation to
the statutory reserve must be made before distribution of dividends to shareholders. The appropriation is required until the statutory
reserve reaches 50% of the registered capital. This statutory reserve is not distributable in the form of cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai and Beijing Genexosome during the three months ended March 31,
2021 and 2020 as they incurred net losses in these periods.&lt;/p&gt;&lt;br/&gt;</avco:StatutoryReserveTextBlock>
  <avco:StatutoryReservePercent unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">0.10</avco:StatutoryReservePercent>
  <avco:RegisteredCapitalPercentage unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="2">0.50</avco:RegisteredCapitalPercentage>
  <avco:RestrictedNetAssetsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 10 &amp;#x2013; &lt;font style=&quot;text-decoration:underline&quot;&gt;RESTRICTED
NET ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;A portion of the Company&amp;#x2019;s operations are
conducted through its PRC subsidiaries, which can only pay dividends out of their retained earnings determined in accordance with the
accounting standards and regulations in the PRC and after they have met the PRC requirements for appropriation to statutory reserve.
In addition, a portion of the Company&amp;#x2019;s businesses and assets are denominated in RMB, which is not freely convertible into foreign
currencies. All foreign exchange transactions take place either through the People&amp;#x2019;s Bank of China or other banks authorized to
buy and sell foreign currencies at the exchange rates quoted by the People&amp;#x2019;s Bank of China. Approval of foreign currency payments
by the People&amp;#x2019;s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers&amp;#x2019;
invoices, shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities
may restrict the ability of the Company&amp;#x2019;s PRC subsidiaries to transfer their net assets to the Parent Company through loans, advances
or cash dividends.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Schedule I of Article 5-04 of Regulation S-X
requires the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries
exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of this test, restricted
net assets of consolidated subsidiaries shall mean that amount of the registrant&amp;#x2019;s proportionate share of net assets of its consolidated
subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent
company in the form of loans, advances or cash dividends without the consent of a third party.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s PRC subsidiaries&amp;#x2019; net
assets as of March 31, 2021 and December 31, 2020 did not exceed 25% of the Company&amp;#x2019;s consolidated net assets. Accordingly, the
Parent Company&amp;#x2019;s condensed consolidated financial statements have not been required in accordance with Rule 5-04 and Rule 12-04
of SEC Regulation S-X.&lt;/p&gt;&lt;br/&gt;</avco:RestrictedNetAssetsTextBlock>
  <us-gaap:RestrictedInvestmentsPercentOfNetAssets unitRef="pure" contextRef="c2_AsOf31Mar2021" decimals="2">0.25</us-gaap:RestrictedInvestmentsPercentOfNetAssets>
  <us-gaap:NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets unitRef="pure" contextRef="c2_AsOf31Mar2021" decimals="2">0.25</us-gaap:NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets>
  <us-gaap:NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="2">0.25</us-gaap:NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets>
  <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;NOTE 11 -&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;CONCENTRATIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Customers&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following table sets forth information as
to each customer that accounted for 10% or more of the Company&amp;#x2019;s revenues for the three months ended March 31, 2021 and 2020.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; padding-left: 0pt; text-align: left&quot;&gt;&lt;b&gt;Customer&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; padding-left: 0pt&quot;&gt;A&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;B&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;C&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;*&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Less than 10%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;One customer, whose outstanding receivable accounted
for 10% or more of the Company&amp;#x2019;s total outstanding accounts receivable, accounts receivable &amp;#x2013; related party, and rent receivable
at March 31, 2021, accounted for 70.3% of the Company&amp;#x2019;s total outstanding accounts receivable, accounts receivable &amp;#x2013; related
party, and rent receivable at March 31, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;Two customers, whose
outstanding receivable accounted for 10% or more of the Company&amp;#x2019;s total outstanding accounts receivable, accounts receivable &amp;#x2013;
related party, and rent receivable at December 31, 2020, accounted for 78.3% of the Company&amp;#x2019;s total outstanding accounts receivable,
accounts receivable &amp;#x2013; related party, and rent receivable at December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Suppliers&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;No supplier accounted for 10% or more of the
Company&amp;#x2019;s purchase during the three months ended March 31, 2021 and 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;One supplier, whose outstanding payable accounted
for 10% or more of the Company&amp;#x2019;s total outstanding accounts payable at March 31, 2021, accounted for 90.2% of the Company&amp;#x2019;s
total outstanding accounts payable at March 31, 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;One supplier, whose outstanding payable accounted
for 10% or more of the Company&amp;#x2019;s total outstanding accounts payable at December 31, 2020, accounted for 93.6% of the Company&amp;#x2019;s
total outstanding accounts payable at December 31, 2020.&lt;/p&gt;&lt;br/&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c126_From1Jan2021To31Mar2021_CustomerMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c127_From1Jan2020To31Mar2020_CustomerMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <avco:NumberOfCustomer unitRef="pure" contextRef="c128_From1Jan2021To31Mar2021_SalesRevenueNetMember_AccountsReceivableMember" decimals="INF">1</avco:NumberOfCustomer>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c129_From1Jan2021To31Mar2021_AccountsReceivableMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c128_From1Jan2021To31Mar2021_SalesRevenueNetMember_AccountsReceivableMember" decimals="3">0.703</us-gaap:ConcentrationRiskPercentage1>
  <avco:NumberOfCustomer unitRef="pure" contextRef="c130_From1Jan2020To31Dec2020_SalesRevenueNetMember_AccountsReceivableMember" decimals="INF">2</avco:NumberOfCustomer>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c131_From1Jan2020To31Dec2020_AccountsReceivableMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c130_From1Jan2020To31Dec2020_SalesRevenueNetMember_AccountsReceivableMember" decimals="3">0.783</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c132_From1Jan2021To31Mar2021_PublicUtilitiesInventorySuppliesMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c133_From1Jan2020To31Mar2020_PublicUtilitiesInventorySuppliesMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <avco:NumberOfSupplier unitRef="pure" contextRef="c134_From1Jan2021To31Mar2021_ProductMember_AccountsPayableMember" decimals="INF">1</avco:NumberOfSupplier>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c135_From1Jan2021To31Mar2021_AccountsPayableMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c134_From1Jan2021To31Mar2021_ProductMember_AccountsPayableMember" decimals="3">0.902</us-gaap:ConcentrationRiskPercentage1>
  <avco:NumberOfSupplier unitRef="pure" contextRef="c136_From1Jan2020To31Dec2020_ProductMember_AccountsPayableMember" decimals="INF">1</avco:NumberOfSupplier>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c137_From1Jan2020To31Dec2020_AccountsPayableMember" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c136_From1Jan2020To31Dec2020_ProductMember_AccountsPayableMember" decimals="3">0.936</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SupplyCommitmentTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Months Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; padding-left: 0pt; text-align: left&quot;&gt;&lt;b&gt;Customer&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; padding-left: 0pt&quot;&gt;A&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;30&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;B&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;18&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;C&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;13&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;15&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;*&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Less than 10%&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:SupplyCommitmentTableTextBlock>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c138_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskOneMember" decimals="2">0.30</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c139_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskOneMember" decimals="2">0.30</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c140_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskTwoMember" decimals="2">0.20</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c141_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskTwoMember" decimals="2">0.18</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c142_From1Jan2021To31Mar2021_SalesRevenueNetMember_CustomerConcentrationRiskThreeMember" decimals="2">0.13</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 unitRef="pure" contextRef="c143_From1Jan2020To31Mar2020_SalesRevenueNetMember_CustomerConcentrationRiskThreeMember" decimals="2">0.15</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 12 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;SEGMENT
INFORMATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the three months ended March 31, 2020, the
Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting
services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals
and other customers segment.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Due to the winding down of the development services
and sales of developed products segment in 2020, the Company no longer has any material revenues or expenses in this&amp;#xa0;segment. As
a result, commencing from the first quarter of 2021, the Company&amp;#x2019;s chief operating decision maker no longer reviews development
services and sales of developed products operating results. &lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;For the three months ended March 31, 2021, the
Company operated in two reportable business segments - (1) the real property operating segment, and (2) the medical related consulting
services segment.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company&amp;#x2019;s reportable segments are strategic
business units that offer different services and products. They are managed separately based on the fundamental differences in their
operations. Information with respect to these reportable business segments for the three months ended March 31, 2021 and 2020 was as
follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three&amp;#xa0; Months&amp;#xa0;Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;289,774&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;296,956&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Costs and expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;216,894&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;254,501&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,880&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42,455&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;101,423&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;110,816&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;161,553&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;155,235&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,999&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,113,492&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,962,597&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,376,468&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,264,647&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other income (expense)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Interest expense&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(45,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(42,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(45,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(42,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other income (expense)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;104&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(935&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(18,486&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(5,487&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(18,381&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(6,420&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total other expense, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(63,530&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(48,589&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;28,439&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,039&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160,722&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,997&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,158,640&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,004,766&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,367,118&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,270,781&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Identifiable long-lived tangible assets at
    March 31, 2021 and December 31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,655,918&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,697,473&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;208,561&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;223,459&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;243,869&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;220,433&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 10pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,084,912&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,164,801&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Identifiable long-lived tangible assets at
    March 31, 2021 and December 31, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt&quot;&gt;United States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,718,174&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,764,947&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;China&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;366,738&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;399,854&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 10pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,084,912&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,164,801&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
  <avco:NumberOfReportableBusinessSegments unitRef="pure" contextRef="c4_From1Jan2020To31Mar2020" decimals="INF">3</avco:NumberOfReportableBusinessSegments>
  <avco:NumberOfReportableBusinessSegments unitRef="pure" contextRef="c0_From1Jan2021To31Mar2021" decimals="INF">2</avco:NumberOfReportableBusinessSegments>
  <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three&amp;#xa0; Months&amp;#xa0;Ended&lt;br/&gt;
March&amp;#xa0;31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td&gt;Revenues&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;289,774&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;296,956&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Costs and expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;216,894&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;254,501&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Gross profit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;72,880&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;42,455&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other operating expenses&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;101,423&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;110,816&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;161,553&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;155,235&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,999&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,113,492&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,962,597&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,376,468&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,264,647&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other income (expense)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Interest expense&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(45,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(42,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(45,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(42,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Other income (expense)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;104&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(935&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(18,486&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(5,487&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;&amp;#xa0;&amp;#xa0;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(18,381&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(6,420&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 1.5pt; padding-left: 0pt&quot;&gt;Total other expense, net&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(63,530&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(48,589&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Net loss&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;28,439&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;69,296&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,039&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;160,722&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;35,997&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 10pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,158,640&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,004,766&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; padding-left: 20pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,367,118&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;3,270,781&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
  <us-gaap:Revenues unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">289774</us-gaap:Revenues>
  <us-gaap:Revenues unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">296956</us-gaap:Revenues>
  <us-gaap:CostsAndExpenses unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">216894</us-gaap:CostsAndExpenses>
  <us-gaap:CostsAndExpenses unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">254501</us-gaap:CostsAndExpenses>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">72880</us-gaap:GrossProfit>
  <us-gaap:GrossProfit unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">42455</us-gaap:GrossProfit>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">101423</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">110816</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c146_From1Jan2021To31Mar2021_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">161553</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c147_From1Jan2020To31Mar2020_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">155235</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c148_From1Jan2021To31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductMember" xs:nil="true"/>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c149_From1Jan2020To31Mar2020_DevelopmentServicesAndSalesOfDevelopedProductMember" decimals="0">35999</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c150_From1Jan2021To31Mar2021_CorporateOtherMember" decimals="0">2113492</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c151_From1Jan2020To31Mar2020_CorporateOtherMember" decimals="0">2962597</us-gaap:OperatingExpenses>
  <avco:InterestExpenses unitRef="usd" contextRef="c150_From1Jan2021To31Mar2021_CorporateOtherMember" decimals="0">-45149</avco:InterestExpenses>
  <avco:InterestExpenses unitRef="usd" contextRef="c151_From1Jan2020To31Mar2020_CorporateOtherMember" decimals="0">-42169</avco:InterestExpenses>
  <avco:InterestExpenses unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-45149</avco:InterestExpenses>
  <avco:InterestExpenses unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-42169</avco:InterestExpenses>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">104</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">-935</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c146_From1Jan2021To31Mar2021_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">-18486</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c147_From1Jan2020To31Mar2020_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">-5487</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c148_From1Jan2021To31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductMember" xs:nil="true"/>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c149_From1Jan2020To31Mar2020_DevelopmentServicesAndSalesOfDevelopedProductMember" decimals="0">2</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c150_From1Jan2021To31Mar2021_CorporateOtherMember" decimals="0">1</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c151_From1Jan2020To31Mar2020_CorporateOtherMember" xs:nil="true"/>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">-18381</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">-6420</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c144_From1Jan2021To31Mar2021_RealPropertyOperationsMember" decimals="0">28439</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c145_From1Jan2020To31Mar2020_RealPropertyOperationsMember" decimals="0">69296</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c146_From1Jan2021To31Mar2021_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">180039</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c147_From1Jan2020To31Mar2020_MedicalRelatedConsultingServicesRelatedPartyMember" decimals="0">160722</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c148_From1Jan2021To31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c149_From1Jan2020To31Mar2020_DevelopmentServicesAndSalesOfDevelopedProductMember" decimals="0">35997</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c150_From1Jan2021To31Mar2021_CorporateOtherMember" decimals="0">2158640</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c151_From1Jan2020To31Mar2020_CorporateOtherMember" decimals="0">3004766</us-gaap:NetIncomeLoss>
  <us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Identifiable long-lived tangible assets at
    March 31, 2021 and December 31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March&amp;#xa0;31, &lt;br/&gt;
2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31, &lt;br/&gt;
2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt&quot;&gt;Real property operations&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,655,918&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,697,473&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Medical related consulting services&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;208,561&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;223,459&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Development services and sales of developed products&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;243,869&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Corporate/Other&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;220,433&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 10pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,084,912&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,164,801&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c152_AsOf31Mar2021_RealPropertyOperatingMember" decimals="0">7655918</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c153_AsOf31Dec2020_RealPropertyOperatingMember" decimals="0">7697473</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c154_AsOf31Mar2021_MedicalRelatedConsultingServicesMember" decimals="0">208561</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c155_AsOf31Dec2020_MedicalRelatedConsultingServicesMember" decimals="0">223459</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c156_AsOf31Mar2021_DevelopmentServicesAndSalesOfDevelopedProductsMember" xs:nil="true"/>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c157_AsOf31Dec2020_DevelopmentServicesAndSalesOfDevelopedProductsMember" decimals="0">243869</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c158_AsOf31Mar2021_CorporateOtherMember" decimals="0">220433</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c159_AsOf31Dec2020_CorporateOtherMember" xs:nil="true"/>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">8084912</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:OtherFiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8164801</us-gaap:OtherFiniteLivedIntangibleAssetsGross>
  <us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;Identifiable long-lived tangible assets at
    March 31, 2021 and December 31, &lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;March 31,&lt;br/&gt;
    2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;December&amp;#xa0;31,&lt;br/&gt;
    2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt&quot;&gt;United States&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,718,174&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7,764,947&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;China&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;366,738&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;399,854&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 10pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,084,912&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,164,801&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c69_AsOf31Mar2021_US" decimals="0">7718174</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c70_AsOf31Dec2020_US" decimals="0">7764947</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c72_AsOf31Mar2021_CN" decimals="0">366738</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c74_AsOf31Dec2020_CN" decimals="0">399854</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">8084912</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8164801</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 13 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;COMMITMENTS
AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;From time to time, the Company is subject to
ordinary routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is
not subject to, any material legal proceedings, except as set forth below.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify&quot;&gt;On October 25, 2017, Genexosome entered into and closed
a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which
Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount
of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement
with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems,
held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the
assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr.
Zhou 400 shares of common stock of Genexosome. Further, the Company had not been able to realize the financial projections provided by
Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero on September
30, 2019. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&amp;#x2019;s Hospital (&amp;#x201c;Research Institute&amp;#x201d;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome
including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation of Ohio Uniform Trade Secrets
Act. Research Institute is seeking monetary damages, injunctive relief, exemplary damages, injunctive relief and other equitable relief.
The Company intends to vigorously defend against this action and pursue all available legal remedies. The civil case against Avalon is
stayed pending resolution of the criminal proceedings against Dr. Zhou and Li Chen, and while there can be no assurances, the Company
believes it has substantial legal and factual defenses to the Research Institute&amp;#x2019;s claims and the likelihood of any findings of
liability for the Company cannot be assessed at this time.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Operating Leases Commitment&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;The Company is a party
to leases for office space. Rent expense under all operating leases amounted to approximately $39,000 for both the three months ended
March 31, 2021 and 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Supplemental cash flow information related to
leases for the&amp;#xa0;three months ended March 31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Month Ended&lt;br/&gt;
March 31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; text-align: left; padding-left: 10pt&quot;&gt;Operating cash flows paid for operating lease&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;29,590&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Operating lease&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;133,201&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;185,401&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The following table summarizes the lease term
and discount rate for the Company&amp;#x2019;s operating lease as of March 31, 2021:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Operating&amp;#xa0;Lease&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left; padding-left: 0pt&quot;&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.83&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2021:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;For the Twelve-month Period Ending March
    31:&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Operating&amp;#xa0;Lease&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt&quot;&gt;2022&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;140,817&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;111,347&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;2024 and thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;252,164&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Amount of lease payments representing interest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(10,170&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total present value of operating lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;241,994&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Current portion&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;132,657&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Long-term portion&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;109,337&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;241,994&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Equity Investment Commitment&amp;#xa0;&lt;/b&gt;&amp;#xa0;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On May 29, 2018, Avalon Shanghai entered into
a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (&amp;#x201c;Unicorn&amp;#x201d;), pursuant to which a company named
Epicon Biotech Co., Ltd. (&amp;#x201c;Epicon&amp;#x201d;) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai.
Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000
(approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon,
and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused
on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical
transformation of scientific achievements. As of March 31, 2021, Avalon Shanghai has contributed RMB 4,700,000 (approximately $0.7 million)
that was included in equity method investment on the accompanying condensed consolidated balance sheets. The Company intends to use its
present working capital together with borrowings from related party and equity raises to fund the project cost.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Joint Venture &amp;#x2013; AVAR BioTherapeutics
(China) Co. Ltd.&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On October 23, 2018, Avactis Biosciences, Inc.
(&amp;#x201c;Avactis&amp;#x201d;), a wholly-owned subsidiary of the Company, and Arbele Limited (&amp;#x201c;Arbele&amp;#x201d;) agreed to the establishment
of AVAR BioTherapeutics (China) Co. Ltd. (&amp;#x201c;AVAR&amp;#x201d;), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture
Agreement (the &amp;#x201c;AVAR Agreement&amp;#x201d;), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of
the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular
immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be
contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis&amp;#x2019; cash reserves.
Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting
AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal
cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed
upon Avactis and AVAR and services.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;In addition, Avactis is responsible for:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Contributing registered capital of RMB 5,000,000 (approximately $0.8 million) for working capital
                                                                            purposes as required by local regulation, which is not required to be contributed immediately and will be contributed subject to
                                                                            Avactis&amp;#x2019; discretion;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;assist AVAR in setting up its business operations and obtaining all required permits and licenses
                                                                            from the Chinese government;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;assisting AVAR in recruiting, hiring and retaining personnel;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;providing AVAR with access to various hospital networks in China to assist in the testing and
                                                                            commercialization of the CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology in China;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;assisting AVAR in managing the Good Manufacturing Practices (GMP) facility and clinic to be
                                                                            developed by AVAR;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;providing AVAR with advice pertaining to conducting clinicals in China; and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
    &lt;td style=&quot;width: 0.25in&quot;&gt;&amp;#xa0;&lt;/td&gt;
&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf; &lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a
                                                                            research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed
                                                                            upon milestones.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Under AVAR Agreement, Arbele shall be responsible
for the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; width: 100%&quot;&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 24px&quot;&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;Entering into a License Agreement with AVAR; and&lt;/p&gt;
    &lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;&amp;#x25cf;&lt;/font&gt;&lt;/td&gt;
    &lt;td&gt;&lt;font style=&quot;font-family: Times New Roman, Times, Serif; font-size: 10pt&quot;&gt;Providing AVAR with research and development expertise
    pertaining to clinical laboratory medicine when hired by AVAR.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;As of March 31, 2021 and December 31, 2020, Avactis
has paid $900,000 to Arbele as research and development fee. As of March 31, 2021, License Agreement has not been finalized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Line of Credit Agreement&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &amp;#x201c;Line of Credit Agreement&amp;#x201d;) providing the Company with a $20 million line of credit (the
&amp;#x201c;Line of Credit&amp;#x201d;) from Wenzhao Lu (the &amp;#x201c;Lender&amp;#x201d;), a significant shareholder and director of the Company. The
Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital and operating
expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into equity of the
Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable three years
from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related party
Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to maturity,
without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default occurs, the
Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021, $3,305,249
was outstanding under the Line of Credit.&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <avco:StockPurchaseAgreementDescription contextRef="c160_From2Oct2017To25Oct2017">Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome.</avco:StockPurchaseAgreementDescription>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">39000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">39000</us-gaap:LeaseAndRentalExpense>
  <avco:JointVentureAgreementDescription contextRef="c161_From2May2018To29May2018_AvalonShanghaiMember">Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (&amp;#x201c;Unicorn&amp;#x201d;), pursuant to which a company named Epicon Biotech Co., Ltd. (&amp;#x201c;Epicon&amp;#x201d;) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of March 31, 2021, Avalon Shanghai has contributed RMB 4,700,000 (approximately $0.7 million) that was included in equity method investment on the accompanying condensed consolidated balance sheets</avco:JointVentureAgreementDescription>
  <avco:JointVentureAgreementDescription contextRef="c162_From1Oct2018To23Oct2018_AVARBioTherapeuticsMember">Avactis Biosciences, Inc. (&amp;#x201c;Avactis&amp;#x201d;), a wholly-owned subsidiary of the Company, and Arbele Limited (&amp;#x201c;Arbele&amp;#x201d;) agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (&amp;#x201c;AVAR&amp;#x201d;), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the &amp;#x201c;AVAR Agreement&amp;#x201d;), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis&amp;#x2019; cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.</avco:JointVentureAgreementDescription>
  <avco:WorkingCapital unitRef="cny" contextRef="c163_AsOf23Oct2018_AVARBioTherapeuticsMember" decimals="0">5000000</avco:WorkingCapital>
  <avco:WorkingCapital unitRef="usd" contextRef="c163_AsOf23Oct2018_AVARBioTherapeuticsMember" decimals="-5">800000</avco:WorkingCapital>
  <avco:JointVentureAgreementDescription contextRef="c164_From1Oct2018To23Oct2018">&amp;#x25cf; Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.</avco:JointVentureAgreementDescription>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c165_From1Jan2021To31Mar2021_AVARBioTherapeuticsMember" decimals="0">900000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c166_From1Jan2020To31Dec2020_AVARBioTherapeuticsMember" decimals="0">900000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:LineOfCredit unitRef="usd" contextRef="c167_AsOf29Aug2019_LineOfCreditAgreementMember" decimals="-6">20000000</us-gaap:LineOfCredit>
  <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod unitRef="pure" contextRef="c168_From2Aug2019To29Aug2019_LineOfCreditAgreementMember" decimals="2">0.05</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
  <avco:LoanRecevied unitRef="usd" contextRef="c169_From1Jan2021To31Mar2021_LineOfCreditAgreementMember" decimals="0">3305249</avco:LoanRecevied>
  <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Three Month Ended&lt;br/&gt;
March 31,&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 72%; text-align: left; padding-left: 10pt&quot;&gt;Operating cash flows paid for operating lease&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;29,590&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 11%; text-align: right&quot;&gt;&amp;#xa0;&amp;#xa0;&amp;#xa0;&amp;#xa0;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0pt&quot;&gt;Right-of-use assets obtained in exchange for lease obligation:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 10pt&quot;&gt;Operating lease&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;133,201&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;185,401&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
  <avco:OperatingCashFlowPaidForOperatingLease unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">29590</avco:OperatingCashFlowPaidForOperatingLease>
  <avco:OperatingCashFlowPaidForOperatingLease unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" xs:nil="true"/>
  <avco:OperatingLease unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">133201</avco:OperatingLease>
  <avco:OperatingLease unitRef="usd" contextRef="c4_From1Jan2020To31Mar2020" decimals="0">185401</avco:OperatingLease>
  <avco:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Operating&amp;#xa0;Lease&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 88%; text-align: left; padding-left: 0pt&quot;&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.83&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0pt&quot;&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.88&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</avco:ScheduleOfSupplementalBalanceSheetInformationTableTextBlock>
  <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2_AsOf31Mar2021">P1Y302D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
  <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent unitRef="pure" contextRef="c2_AsOf31Mar2021" decimals="4">0.0488</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
  <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
  &lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt&quot;&gt;&lt;b&gt;For the Twelve-month Period Ending March
    31:&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;&lt;b&gt;Operating&amp;#xa0;Lease&lt;/b&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&lt;b&gt;&amp;#xa0;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt&quot;&gt;2022&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;140,817&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;2023&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;111,347&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;2024 and thereafter&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;252,164&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Amount of lease payments representing interest&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(10,170&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total present value of operating lease liabilities&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;241,994&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; text-align: left; padding-left: 0pt&quot;&gt;Current portion&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;132,657&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Long-term portion&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;109,337&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 0pt; padding-left: 0pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;241,994&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">140817</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">111347</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive unitRef="usd" contextRef="c2_AsOf31Mar2021" xs:nil="true"/>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">252164</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <avco:AmountOfLeasePaymentsRepresentingInterest unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">-10170</avco:AmountOfLeasePaymentsRepresentingInterest>
  <avco:OperatingLeaseLiabilities unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">241994</avco:OperatingLeaseLiabilities>
  <avco:CurrentPortion unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">132657</avco:CurrentPortion>
  <avco:LongtermPortion unitRef="usd" contextRef="c0_From1Jan2021To31Mar2021" decimals="0">109337</avco:LongtermPortion>
  <us-gaap:LongTermDebt unitRef="usd" contextRef="c2_AsOf31Mar2021" decimals="0">241994</us-gaap:LongTermDebt>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2021To31Mar2021">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;NOTE 14 &amp;#x2013;&amp;#xa0;&lt;font style=&quot;text-decoration:underline&quot;&gt;SUBSEQUENT
EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Management has evaluated subsequent events through
the date of the filing.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>avco-20210331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://www.avalonglobocare.com/20210331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:avco="http://www.avalonglobocare.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20210331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20210331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20210331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="avco-20210331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet" id="avco_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals" id="avco_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement" id="avco_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatementAlt0" id="avco_r_ConsolidatedIncomeStatementAlt0">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Alternate 0</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ShareholdersEquityType2or3" id="avco_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow" id="avco_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations" id="avco_r_OrganizationandNatureofOperations">
        <link:definition>006 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition" id="avco_r_BasisofPresentationandGoingConcernCondition">
        <link:definition>007 - Disclosure - Basis of Presentation and Going Concern Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies" id="avco_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets" id="avco_r_PrepaidExpensesandOtherCurrentAssets">
        <link:definition>009 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestment" id="avco_r_EquityMethodInvestment">
        <link:definition>010 - Disclosure - Equity Method Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables" id="avco_r_AccruedLiabilitiesandOtherPayables">
        <link:definition>011 - Disclosure - Accrued Liabilities and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions" id="avco_r_RelatedPartyTransactions">
        <link:definition>012 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/Equity" id="avco_r_Equity">
        <link:definition>013 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/StatutoryReserve" id="avco_r_StatutoryReserve">
        <link:definition>014 - Disclosure - Statutory Reserve</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssets" id="avco_r_RestrictedNetAssets">
        <link:definition>015 - Disclosure - Restricted Net Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/Concentrations" id="avco_r_Concentrations">
        <link:definition>016 - Disclosure - Concentrations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformation" id="avco_r_SegmentInformation">
        <link:definition>017 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies" id="avco_r_CommitmentsandContingencies">
        <link:definition>018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SubsequentEvents" id="avco_r_SubsequentEvents">
        <link:definition>019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy" id="avco_r_AccountingPoliciesByPolicy">
        <link:definition>020 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables" id="avco_r_OrganizationandNatureofOperationsTables">
        <link:definition>021 - Disclosure - Organization and Nature of Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables" id="avco_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables" id="avco_r_PrepaidExpensesandOtherCurrentAssetsTables">
        <link:definition>023 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentTables" id="avco_r_EquityMethodInvestmentTables">
        <link:definition>024 - Disclosure - Equity Method Investment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables" id="avco_r_AccruedLiabilitiesandOtherPayablesTables">
        <link:definition>025 - Disclosure - Accrued Liabilities and Other Payables (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityTables" id="avco_r_EquityTables">
        <link:definition>026 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables" id="avco_r_ConcentrationsTables">
        <link:definition>027 - Disclosure - Concentrations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables" id="avco_r_SegmentInformationTables">
        <link:definition>028 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables" id="avco_r_CommitmentsandContingenciesTables">
        <link:definition>029 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails" id="avco_r_OrganizationandNatureofOperationsDetails">
        <link:definition>030 - Disclosure - Organization and Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable" id="avco_r_ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable">
        <link:definition>031 - Disclosure - Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails" id="avco_r_BasisofPresentationandGoingConcernConditionDetails">
        <link:definition>032 - Disclosure - Basis of Presentation and Going Concern Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails" id="avco_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>033 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable" id="avco_r_ScheduleofcashbalancesbygeographicareaTable">
        <link:definition>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of cash balances by geographic area</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable" id="avco_r_ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable">
        <link:definition>035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of the effect of including these potential shares was antidilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable" id="avco_r_ScheduleofprepaidexpensesandothercurrentassetsTable">
        <link:definition>036 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails" id="avco_r_EquityMethodInvestmentDetails">
        <link:definition>037 - Disclosure - Equity Method Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable" id="avco_r_ScheduleofequitymethodinvestmentTable">
        <link:definition>038 - Disclosure - Equity Method Investment (Details) - Schedule of equity method investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable" id="avco_r_ScheduleoffinancialinformationinvesteeTable">
        <link:definition>039 - Disclosure - Equity Method Investment (Details) - Schedule of financial information investee</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable" id="avco_r_ScheduleoffinancialinformationTable">
        <link:definition>040 - Disclosure - Equity Method Investment (Details) - Schedule of financial information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable" id="avco_r_ScheduleofaccruedliabilitiesandotherpayablesTable">
        <link:definition>041 - Disclosure - Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails" id="avco_r_RelatedPartyTransactionsDetails">
        <link:definition>042 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/EquityDetails" id="avco_r_EquityDetails">
        <link:definition>043 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbtzhXYdL2Gm8/2/R9gSAhST] CSR-->
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable" id="avco_r_ScheduleofstockoptionsoutstandingTable">
        <link:definition>044 - Disclosure - Equity (Details) - Schedule of stock options outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable" id="avco_r_ScheduleofstockoptionactivitiesTable">
        <link:definition>045 - Disclosure - Equity (Details) - Schedule of stock option activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" id="avco_r_ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable">
        <link:definition>046 - Disclosure - Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/StatutoryReserveDetails" id="avco_r_StatutoryReserveDetails">
        <link:definition>047 - Disclosure - Statutory Reserve (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails" id="avco_r_RestrictedNetAssetsDetails">
        <link:definition>048 - Disclosure - Restricted Net Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails" id="avco_r_ConcentrationsDetails">
        <link:definition>049 - Disclosure - Concentrations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofcustomersTable" id="avco_r_ScheduleofcustomersTable">
        <link:definition>050 - Disclosure - Concentrations (Details) - Schedule of customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails" id="avco_r_SegmentInformationDetails">
        <link:definition>051 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable" id="avco_r_ScheduleofsegmentreportinginformationTable">
        <link:definition>052 - Disclosure - Segment Information (Details) - Schedule of segment reporting information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable" id="avco_r_ScheduleofrealpropertyoperatingTable">
        <link:definition>053 - Disclosure - Segment Information (Details) - Schedule of real property operating</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable" id="avco_r_ScheduleofidentifiablelonglivedtangibleassetsTable">
        <link:definition>054 - Disclosure - Segment Information (Details) - Schedule of identifiable long-lived tangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails" id="avco_r_CommitmentsandContingenciesDetails">
        <link:definition>055 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable" id="avco_r_ScheduleofsupplementalcashflowinformationTable">
        <link:definition>056 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental cash flow information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable" id="avco_r_ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable">
        <link:definition>057 - Disclosure - Commitments and Contingencies (Details) - Schedule of lease term and discount rate for the Company&#8217;s operating lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable" id="avco_r_ScheduleofmaturityofleaseliabilityTable">
        <link:definition>058 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of lease liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.avalonglobocare.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract"/>
  <xs:element name="ScheduleOfCashBalancesByGeographicAreaAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
  <xs:element name="ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
  <xs:element name="ScheduleOfEquityMethodInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfEquityMethodInvestmentAbstract"/>
  <xs:element name="ScheduleOfFinancialInformationInvesteeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfFinancialInformationInvesteeAbstract"/>
  <xs:element name="ScheduleOfFinancialInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfFinancialInformationAbstract"/>
  <xs:element name="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract"/>
  <xs:element name="ScheduleOfStockOptionsOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfStockOptionsOutstandingAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfStockOptionActivitiesAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract"/>
  <xs:element name="StatutoryReserveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserveAbstract"/>
  <xs:element name="RestrictedNetAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RestrictedNetAssetsAbstract"/>
  <xs:element name="ScheduleOfCustomersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfCustomersAbstract"/>
  <xs:element name="ScheduleOfSegmentReportingInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfSegmentReportingInformationAbstract"/>
  <xs:element name="ScheduleOfRealPropertyOperatingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfRealPropertyOperatingAbstract"/>
  <xs:element name="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
  <xs:element name="ScheduleOfSupplementalCashFlowInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfSupplementalCashFlowInformationAbstract"/>
  <xs:element name="ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract"/>
  <xs:element name="ScheduleOfMaturityOfLeaseLiabilityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract"/>
  <xs:element name="LiabilitiesAndEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LiabilitiesAndEquityAbstract"/>
  <xs:element name="CommonStock00001ParValue490000000SharesAuthorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract"/>
  <xs:element name="a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract"/>
  <xs:element name="LessCommonStockHeldInTreasuryAtCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LessCommonStockHeldInTreasuryAtCostAbstract"/>
  <xs:element name="RevenuesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RevenuesAbstract0"/>
  <xs:element name="CostsAndExpensesAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CostsAndExpensesAbstract0"/>
  <xs:element name="GrossProfitAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_GrossProfitAbstract0"/>
  <xs:element name="OtherOperatingExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherOperatingExpensesAbstract"/>
  <xs:element name="OtherIncomeExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherIncomeExpenseAbstract"/>
  <xs:element name="OtherIncomeExpenseAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherIncomeExpenseAbstract0"/>
  <xs:element name="NetLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NetLossAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract"/>
  <xs:element name="TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts"/>
  <xs:element name="AccruedResearchAndDevelopmentsFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedResearchAndDevelopmentsFees"/>
  <xs:element name="StatutoryReserve" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserve"/>
  <xs:element name="RealPropertyOperatingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyOperatingExpenses"/>
  <xs:element name="RealPropertiesOperatingIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertiesOperatingIncome"/>
  <xs:element name="OtherIncomeLossFromEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherIncomeLossFromEquityMethodInvestment"/>
  <xs:element name="LossOnEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_LossOnEquityMethodInvestment"/>
  <xs:element name="LossOnFixedAssetsDisposal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_LossOnFixedAssetsDisposal"/>
  <xs:element name="DeferredLeasingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredLeasingCosts"/>
  <xs:element name="IncreaseDecreaseOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_IncreaseDecreaseOperatingLease"/>
  <xs:element name="AdditionalInvestmentInEquityMethodInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AdditionalInvestmentInEquityMethodInvestment"/>
  <xs:element name="ProceedsReceivedFromLoanPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_ProceedsReceivedFromLoanPayable"/>
  <xs:element name="ProceedsReceivedFromEquityOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_ProceedsReceivedFromEquityOffering"/>
  <xs:element name="DisbursementsForEqutyOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DisbursementsForEqutyOfferingCosts"/>
  <xs:element name="CommonStockIssuedForFutureServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonStockIssuedForFutureServices"/>
  <xs:element name="DeferredFinancingCostsInAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_DeferredFinancingCostsInAccruedLiabilities"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <xs:element name="StatutoryReserveTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserveTextBlock"/>
  <xs:element name="RestrictedNetAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RestrictedNetAssetsTextBlock"/>
  <xs:element name="CreditRiskAndUncertaintiePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CreditRiskAndUncertaintiePolicyTextBlock"/>
  <xs:element name="InvestmentInUnconsolidatedCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock"/>
  <xs:element name="ScheduleOfFinancialInformationByInvestee" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfFinancialInformationByInvestee"/>
  <xs:element name="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
  <xs:element name="EntityIncorporationsStateCountryName" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EntityIncorporationsStateCountryName"/>
  <xs:element name="PercentageOfOwnership" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PercentageOfOwnership"/>
  <xs:element name="PrepaidNasdaqListingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidNasdaqListingFee"/>
  <xs:element name="PrepaidDirectorsAndOfficersLiabilityInsurancePremium" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium"/>
  <xs:element name="PrepaidProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidProfessionalFees"/>
  <xs:element name="PrepaidResearchAndDevelopmentFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrepaidResearchAndDevelopmentFees"/>
  <xs:element name="PaymentMadeForEquityMethodInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PaymentMadeForEquityMethodInvestments"/>
  <xs:element name="ForeignCurrencyFluctuationEquityMethodInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_ForeignCurrencyFluctuationEquityMethodInvestments"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationOfEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem"/>
  <xs:element name="EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss"/>
  <xs:element name="AccruedResearchAndDevelopmentFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedResearchAndDevelopmentFee"/>
  <xs:element name="AccruedTenantsImprovementReimbursement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AccruedTenantsImprovementReimbursement"/>
  <xs:element name="ExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePrice"/>
  <xs:element name="EquityDetailsScheduleofstockoptionactivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityDetailsScheduleofstockoptionactivitiesTable"/>
  <xs:element name="EquityDetailsScheduleofstockoptionactivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems"/>
  <xs:element name="StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice"/>
  <xs:element name="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
  <xs:element name="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems"/>
  <xs:element name="InterestExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_InterestExpenses"/>
  <xs:element name="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable"/>
  <xs:element name="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems"/>
  <xs:element name="OperatingCashFlowPaidForOperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_OperatingCashFlowPaidForOperatingLease"/>
  <xs:element name="OperatingLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_OperatingLease"/>
  <xs:element name="AmountOfLeasePaymentsRepresentingInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_AmountOfLeasePaymentsRepresentingInterest"/>
  <xs:element name="OperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_OperatingLeaseLiabilities"/>
  <xs:element name="CurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_CurrentPortion"/>
  <xs:element name="LongtermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_LongtermPortion"/>
  <xs:element name="OrganizationandNatureofOperationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_OrganizationandNatureofOperationsDetailsTable"/>
  <xs:element name="OrganizationandNatureofOperationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OrganizationandNatureofOperationsDetailsLineItems"/>
  <xs:element name="ExchangeForCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExchangeForCommonStock"/>
  <xs:element name="PercentageOfCapitalStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_PercentageOfCapitalStock"/>
  <xs:element name="BuildingOccupancyRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BuildingOccupancyRate"/>
  <xs:element name="WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WorkingCapitalDeficit"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="CashAndCashEquivalentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CashAndCashEquivalentsDescription"/>
  <xs:element name="CashAndDueFromBank" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_CashAndDueFromBank"/>
  <xs:element name="LimitedInsurance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_LimitedInsurance"/>
  <xs:element name="FederallyinsuredLimits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_FederallyinsuredLimits"/>
  <xs:element name="SubsidiaryDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_SubsidiaryDomain"/>
  <xs:element name="EquityMethodInvestmentDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityMethodInvestmentDetailsTable"/>
  <xs:element name="EquityMethodInvestmentDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityMethodInvestmentDetailsLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="ConsiderationCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_ConsiderationCash"/>
  <xs:element name="PrincipalRepaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_PrincipalRepaidAmount"/>
  <xs:element name="LoanFromLender" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_LoanFromLender"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_EquityDetailsLineItems"/>
  <xs:element name="SharesBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="avco_SharesBasedCompensation"/>
  <xs:element name="FairValueOfOptionGrantedDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_FairValueOfOptionGrantedDescription"/>
  <xs:element name="StatutoryReservePercent" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReservePercent"/>
  <xs:element name="RegisteredCapitalPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RegisteredCapitalPercentage"/>
  <xs:element name="ConcentrationsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_ConcentrationsDetailsTable"/>
  <xs:element name="ConcentrationsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ConcentrationsDetailsLineItems"/>
  <xs:element name="NumberOfCustomer" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NumberOfCustomer"/>
  <xs:element name="NumberOfSupplier" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NumberOfSupplier"/>
  <xs:element name="NumberOfReportableBusinessSegments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NumberOfReportableBusinessSegments"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="avco_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="StockPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StockPurchaseAgreementDescription"/>
  <xs:element name="JointVentureAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JointVentureAgreementDescription"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_WorkingCapital"/>
  <xs:element name="LoanRecevied" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="avco_LoanRecevied"/>
  <xs:element name="SubsidiaryAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="avco_SubsidiaryAxis"/>
  <xs:element name="AVARBioTherapeuticsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AVARBioTherapeuticsMember"/>
  <xs:element name="AvactisBiosciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvactisBiosciencesIncMember"/>
  <xs:element name="AvalonBVILtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonBVILtdMember"/>
  <xs:element name="AvalonHealthcareSystemIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonHealthcareSystemIncMember"/>
  <xs:element name="AvalonRT9PropertiesLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonRT9PropertiesLLCMember"/>
  <xs:element name="AvalonShanghaiHealthcareTechnologyCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
  <xs:element name="AvalonShanghaiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_AvalonShanghaiMember"/>
  <xs:element name="BeijingJietengGenExosomeBiotechCoLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
  <xs:element name="CommonSharesIssuedForServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CommonSharesIssuedForServicesMember"/>
  <xs:element name="CompensationAndRelatedBenefitsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CompensationAndRelatedBenefitsMember"/>
  <xs:element name="CorporateOtherMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CorporateOtherMember"/>
  <xs:element name="CustomerConcentrationRiskOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerConcentrationRiskOneMember"/>
  <xs:element name="CustomerConcentrationRiskThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerConcentrationRiskThreeMember"/>
  <xs:element name="CustomerConcentrationRiskTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerConcentrationRiskTwoMember"/>
  <xs:element name="CustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_CustomerMember"/>
  <xs:element name="DavidJinMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DavidJinMember"/>
  <xs:element name="DevelopmentServicesAndSalesOfDevelopedProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DevelopmentServicesAndSalesOfDevelopedProductMember"/>
  <xs:element name="DevelopmentServicesAndSalesOfDevelopedProductsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember"/>
  <xs:element name="DrYuZhouMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DrYuZhouMember"/>
  <xs:element name="ExercisePriceRangeFiveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeFiveMember"/>
  <xs:element name="ExercisePriceRangeFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeFourMember"/>
  <xs:element name="ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeOneMember"/>
  <xs:element name="ExercisePriceRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeThreeMember"/>
  <xs:element name="ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ExercisePriceRangeTwoMember"/>
  <xs:element name="GenExosomeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_GenExosomeMember"/>
  <xs:element name="GenExosomeTechnologiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_GenExosomeTechnologiesIncMember"/>
  <xs:element name="InternationalExosomeAssociationLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_InternationalExosomeAssociationLlcMember"/>
  <xs:element name="JefferiesLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_JefferiesLLCMember"/>
  <xs:element name="LineOfCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_LineOfCreditAgreementMember"/>
  <xs:element name="MedicalRelatedConsultingServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MedicalRelatedConsultingServicesMember"/>
  <xs:element name="MedicalRelatedConsultingServicesRelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_MedicalRelatedConsultingServicesRelatedPartyMember"/>
  <xs:element name="NumberOfOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_NumberOfOptionsMember"/>
  <xs:element name="OtherUnrelatedCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_OtherUnrelatedCompanyMember"/>
  <xs:element name="ProfessionalFeesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_ProfessionalFeesMember"/>
  <xs:element name="RealPropertyOperatingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyOperatingMember"/>
  <xs:element name="RealPropertyOperationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_RealPropertyOperationsMember"/>
  <xs:element name="StatutoryReserveMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StatutoryReserveMember"/>
  <xs:element name="StockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_StockOptionsMember"/>
  <xs:element name="UnicornMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_UnicornMember"/>
  <xs:element name="WeightedAverageExercisePriceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WeightedAverageExercisePriceMember"/>
  <xs:element name="WenzhaoLuMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_WenzhaoLuMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="avco_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>avco-20210331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedIncomeStatementAlt0" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatementAlt0"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofaccruedliabilitiesandotherpayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofmaturityofleaseliabilityTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredCostsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:href="avco-20210331.xsd#avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_DeferredCosts" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealEstateInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RealEstateInvestments" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="avco_AccruedResearchAndDevelopmentsFees" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermLoansPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserve" xlink:href="avco-20210331.xsd#avco_StatutoryReserve"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="avco_StatutoryReserve" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="avco_RealPropertiesOperatingIncome" xlink:href="avco-20210331.xsd#avco_RealPropertiesOperatingIncome"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingExpenses" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="avco_RealPropertiesOperatingIncome" xlink:to="avco_RealPropertyOperatingExpenses" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="avco_RealPropertiesOperatingIncome" xlink:to="us-gaap_RevenueFromRelatedParties" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ProfessionalFees" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_LaborAndRelatedExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="avco_RealPropertiesOperatingIncome" order="1" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="avco_OtherIncomeLossFromEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_OtherIncomeLossFromEquityMethodInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="avco_OtherIncomeLossFromEquityMethodInvestment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbvyZnnAU6XYrj+PKCc9YlZQ] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_InterestExpenseRelatedParty" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatementAlt0">
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForOtherLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForOtherLosses" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_LossOnEquityMethodInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_LossOnEquityMethodInvestment" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnFixedAssetsDisposal" xlink:href="avco-20210331.xsd#avco_LossOnFixedAssetsDisposal"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_LossOnFixedAssetsDisposal" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredLeasingCosts" xlink:href="avco-20210331.xsd#avco_DeferredLeasingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_DeferredLeasingCosts" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StraightLineRent" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseOperatingLease" xlink:href="avco-20210331.xsd#avco_IncreaseDecreaseOperatingLease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="avco_IncreaseDecreaseOperatingLease" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_AdditionalInvestmentInEquityMethodInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="avco_AdditionalInvestmentInEquityMethodInvestment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromLoanPayable" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromLoanPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="avco_ProceedsReceivedFromLoanPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromEquityOffering" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromEquityOffering"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="avco_ProceedsReceivedFromEquityOffering" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_DisbursementsForEqutyOfferingCosts" xlink:href="avco-20210331.xsd#avco_DisbursementsForEqutyOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="avco_DisbursementsForEqutyOfferingCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentFee" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentFee"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="avco_AccruedResearchAndDevelopmentFee" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20210331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="avco_AccruedTenantsImprovementReimbursement" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_Deposits" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_DeferredIncome" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingLeaseLiabilities" xlink:href="avco-20210331.xsd#avco_OperatingLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="avco_OperatingLeaseLiabilities" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="avco_AmountOfLeasePaymentsRepresentingInterest" xlink:href="avco-20210331.xsd#avco_AmountOfLeasePaymentsRepresentingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="avco_OperatingLeaseLiabilities" xlink:to="avco_AmountOfLeasePaymentsRepresentingInterest" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>avco-20210331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ShareholdersEquityType2or3" roleURI="http://www.avalonglobocare.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperations" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_BasisofPresentationandGoingConcernCondition" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestment" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestment"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccruedLiabilitiesandOtherPayables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RelatedPartyTransactions" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_Equity" roleURI="http://www.avalonglobocare.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_StatutoryReserve" roleURI="http://www.avalonglobocare.com/role/StatutoryReserve"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RestrictedNetAssets" roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_Concentrations" roleURI="http://www.avalonglobocare.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformation" roleURI="http://www.avalonglobocare.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingencies" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SubsequentEvents" roleURI="http://www.avalonglobocare.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccountingPoliciesByPolicy" roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperationsTables" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestmentTables" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccruedLiabilitiesandOtherPayablesTables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityTables" roleURI="http://www.avalonglobocare.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConcentrationsTables" roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformationTables" roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingenciesTables" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcashbalancesbygeographicareaTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofequitymethodinvestmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffinancialinformationinvesteeTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffinancialinformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofaccruedliabilitiesandotherpayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofstockoptionsoutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofstockoptionactivitiesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcustomersTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofsegmentreportinginformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofrealpropertyoperatingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofidentifiablelonglivedtangibleassetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofmaturityofleaseliabilityTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperationsDetails" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_BasisofPresentationandGoingConcernConditionDetails" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestmentDetails" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RelatedPartyTransactionsDetails" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityDetails" roleURI="http://www.avalonglobocare.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_StatutoryReserveDetails" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RestrictedNetAssetsDetails" roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConcentrationsDetails" roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformationDetails" roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingenciesDetails" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#DocumentAndEntityInformation" roleURI="http://www.avalonglobocare.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:href="avco-20210331.xsd#avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealEstateInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RealEstateInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_AssetsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LiabilitiesAndEquityAbstract" xlink:href="avco-20210331.xsd#avco_LiabilitiesAndEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="avco_LiabilitiesAndEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_LiabilitiesAndEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="avco_AccruedResearchAndDevelopmentsFees" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_LiabilitiesAndEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_Liabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_LiabilitiesAndEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserve" xlink:href="avco-20210331.xsd#avco_StatutoryReserve"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="avco_StatutoryReserve" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_MinorityInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingExpenses" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="avco_RealPropertyOperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfitAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertiesOperatingIncome" xlink:href="avco-20210331.xsd#avco_RealPropertiesOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GrossProfitAbstract" xlink:to="avco_RealPropertiesOperatingIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherExpensesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_InterestExpenseRelatedParty" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OtherIncomeLossFromEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_OtherIncomeLossFromEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="avco_OtherIncomeLossFromEquityMethodInvestment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveMember" xlink:href="avco-20210331.xsd#avco_StatutoryReserveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_StatutoryReserveMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForOtherLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StraightLineRent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_LossOnEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avco_LossOnEquityMethodInvestment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnFixedAssetsDisposal" xlink:href="avco-20210331.xsd#avco_LossOnFixedAssetsDisposal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="avco_LossOnFixedAssetsDisposal" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredLeasingCosts" xlink:href="avco-20210331.xsd#avco_DeferredLeasingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="avco_DeferredLeasingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseOperatingLease" xlink:href="avco-20210331.xsd#avco_IncreaseDecreaseOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="avco_IncreaseDecreaseOperatingLease" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_AdditionalInvestmentInEquityMethodInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="avco_AdditionalInvestmentInEquityMethodInvestment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromLoanPayable" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromLoanPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="avco_ProceedsReceivedFromLoanPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromEquityOffering" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromEquityOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="avco_ProceedsReceivedFromEquityOffering" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DisbursementsForEqutyOfferingCosts" xlink:href="avco-20210331.xsd#avco_DisbursementsForEqutyOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="avco_DisbursementsForEqutyOfferingCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedForFutureServices" xlink:href="avco-20210331.xsd#avco_CommonStockIssuedForFutureServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="avco_CommonStockIssuedForFutureServices" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20210331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/StatutoryReserve">
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveAbstract" xlink:href="avco-20210331.xsd#avco_StatutoryReserveAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveTextBlock" xlink:href="avco-20210331.xsd#avco_StatutoryReserveTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_StatutoryReserveAbstract" xlink:to="avco_StatutoryReserveTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RestrictedNetAssets">
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsAbstract" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RestrictedNetAssetsAbstract" xlink:to="avco_RestrictedNetAssetsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CreditRiskAndUncertaintiePolicyTextBlock" xlink:href="avco-20210331.xsd#avco_CreditRiskAndUncertaintiePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_CreditRiskAndUncertaintiePolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock" xlink:href="avco-20210331.xsd#avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Reclassifications"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Reclassifications" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationByInvestee" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationByInvestee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="avco_ScheduleOfFinancialInformationByInvestee" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConcentrationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_SupplyCommitmentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20210331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvalonHealthcareSystemIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonBVILtdMember" xlink:href="avco-20210331.xsd#avco_AvalonBVILtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvalonBVILtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20210331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvalonRT9PropertiesLLCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20210331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_GenExosomeTechnologiesIncMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:href="avco-20210331.xsd#avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_BeijingJietengGenExosomeBiotechCoLtdMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20210331.xsd#avco_AvactisBiosciencesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvactisBiosciencesIncMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InternationalExosomeAssociationLlcMember" xlink:href="avco-20210331.xsd#avco_InternationalExosomeAssociationLlcMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_InternationalExosomeAssociationLlcMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EntityIncorporationsStateCountryName" xlink:href="avco-20210331.xsd#avco_EntityIncorporationsStateCountryName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="avco_EntityIncorporationsStateCountryName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfOwnership" xlink:href="avco-20210331.xsd#avco_PercentageOfOwnership"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="avco_PercentageOfOwnership" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndDueFromBanks" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndDueFromBanks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_CashAndDueFromBanks" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockOptionsMember" xlink:href="avco-20210331.xsd#avco_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="avco_StockOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidNasdaqListingFee" xlink:href="avco-20210331.xsd#avco_PrepaidNasdaqListingFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidNasdaqListingFee" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:href="avco-20210331.xsd#avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20210331.xsd#avco_PrepaidProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidProfessionalFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidResearchAndDevelopmentFees" xlink:href="avco-20210331.xsd#avco_PrepaidResearchAndDevelopmentFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidResearchAndDevelopmentFees" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentMadeForEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_PaymentMadeForEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="avco_PaymentMadeForEquityMethodInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ForeignCurrencyFluctuationEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_ForeignCurrencyFluctuationEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="avco_ForeignCurrencyFluctuationEquityMethodInvestments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" order="3" xbrldt:closed="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbsg1TG8omp2M4R2VQvCvdLz] CSR-->
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentFee" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="avco_AccruedResearchAndDevelopmentFee" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20210331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="avco_AccruedTenantsImprovementReimbursement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_Deposits" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_DeferredIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeThreeMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFiveMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="avco_ExercisePriceRangeFiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePrice" xlink:href="avco-20210331.xsd#avco_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="avco_ExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable">
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="avco_EquityDetailsScheduleofstockoptionactivitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfOptionsMember" xlink:href="avco-20210331.xsd#avco_NumberOfOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_NumberOfOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WeightedAverageExercisePriceMember" xlink:href="avco-20210331.xsd#avco_WeightedAverageExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_WeightedAverageExercisePriceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" xlink:href="avco-20210331.xsd#avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" xlink:href="avco-20210331.xsd#avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfOptionsMember" xlink:href="avco-20210331.xsd#avco_NumberOfOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_NumberOfOptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WeightedAverageExercisePriceMember" xlink:href="avco-20210331.xsd#avco_WeightedAverageExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="avco_WeightedAverageExercisePriceMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcustomersTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SupplyCommitmentLineItems" xlink:to="us-gaap_SupplyCommitmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskOneMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="avco_CustomerConcentrationRiskOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskTwoMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="avco_CustomerConcentrationRiskTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskThreeMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="avco_CustomerConcentrationRiskThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplyCommitmentLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperationsMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperationsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperationsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MedicalRelatedConsultingServicesRelatedPartyMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesRelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_MedicalRelatedConsultingServicesRelatedPartyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20210331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostsAndExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_InterestExpenses" xlink:href="avco-20210331.xsd#avco_InterestExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="avco_InterestExpenses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_RealPropertyOperatingMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_MedicalRelatedConsultingServicesMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_MedicalRelatedConsultingServicesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20210331.xsd#avco_CorporateOtherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="avco_CorporateOtherMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable">
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:to="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="avco-20210331.xsd#avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingCashFlowPaidForOperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingCashFlowPaidForOperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="avco_OperatingCashFlowPaidForOperatingLease" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:href="avco-20210331.xsd#avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingLease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:to="avco_OperatingLease" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfMaturityOfLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AmountOfLeasePaymentsRepresentingInterest" xlink:href="avco-20210331.xsd#avco_AmountOfLeasePaymentsRepresentingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="avco_AmountOfLeasePaymentsRepresentingInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingLeaseLiabilities" xlink:href="avco-20210331.xsd#avco_OperatingLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="avco_OperatingLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CurrentPortion" xlink:href="avco-20210331.xsd#avco_CurrentPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="avco_CurrentPortion" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LongtermPortion" xlink:href="avco-20210331.xsd#avco_LongtermPortion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="avco_LongtermPortion" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LongTermDebt" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails">
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="avco_OrganizationandNatureofOperationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20210331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_AvalonRT9PropertiesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:href="avco-20210331.xsd#avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_BeijingJietengGenExosomeBiotechCoLtdMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20210331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_GenExosomeTechnologiesIncMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20210331.xsd#avco_DrYuZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="avco_DrYuZhouMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeForCommonStock" xlink:href="avco-20210331.xsd#avco_ExchangeForCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="avco_ExchangeForCommonStock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfCapitalStock" xlink:href="avco-20210331.xsd#avco_PercentageOfCapitalStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="avco_PercentageOfCapitalStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_BuildingOccupancyRate" xlink:href="avco-20210331.xsd#avco_BuildingOccupancyRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="avco_BuildingOccupancyRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapitalDeficit" xlink:href="avco-20210331.xsd#avco_WorkingCapitalDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="avco_WorkingCapitalDeficit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CashAndCashEquivalentsDescription" xlink:href="avco-20210331.xsd#avco_CashAndCashEquivalentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_CashAndCashEquivalentsDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CashAndDueFromBank" xlink:href="avco-20210331.xsd#avco_CashAndDueFromBank"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_CashAndDueFromBank" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LimitedInsurance" xlink:href="avco-20210331.xsd#avco_LimitedInsurance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_LimitedInsurance" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FederallyinsuredLimits" xlink:href="avco-20210331.xsd#avco_FederallyinsuredLimits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_FederallyinsuredLimits" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails">
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_EquityMethodInvestmentDetailsLineItems" xlink:to="avco_EquityMethodInvestmentDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SubsidiaryAxis" xlink:href="avco-20210331.xsd#avco_SubsidiaryAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityMethodInvestmentDetailsTable" xlink:to="avco_SubsidiaryAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SubsidiaryDomain" xlink:href="avco-20210331.xsd#avco_SubsidiaryDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="avco_SubsidiaryAxis" xlink:to="avco_SubsidiaryDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SubsidiaryDomain_0" xlink:href="avco-20210331.xsd#avco_SubsidiaryDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="avco_SubsidiaryAxis" xlink:to="avco_SubsidiaryDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_OtherUnrelatedCompanyMember" xlink:href="avco-20210331.xsd#avco_OtherUnrelatedCompanyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SubsidiaryDomain" xlink:to="avco_OtherUnrelatedCompanyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_UnicornMember" xlink:href="avco-20210331.xsd#avco_UnicornMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_SubsidiaryDomain" xlink:to="avco_UnicornMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsTable" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="avco_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DavidJinMember" xlink:href="avco-20210331.xsd#avco_DavidJinMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_DavidJinMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20210331.xsd#avco_DrYuZhouMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_DrYuZhouMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeMember" xlink:href="avco-20210331.xsd#avco_GenExosomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_GenExosomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WenzhaoLuMember" xlink:href="avco-20210331.xsd#avco_WenzhaoLuMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_WenzhaoLuMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LineOfCreditAgreementMember" xlink:href="avco-20210331.xsd#avco_LineOfCreditAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="avco_LineOfCreditAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ConsiderationCash" xlink:href="avco-20210331.xsd#avco_ConsiderationCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="avco_ConsiderationCash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_PrincipalRepaidAmount" xlink:href="avco-20210331.xsd#avco_PrincipalRepaidAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="avco_PrincipalRepaidAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LoanFromLender" xlink:href="avco-20210331.xsd#avco_LoanFromLender"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="avco_LoanFromLender" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_EquityDetailsLineItems" xlink:to="avco_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_EquityDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CompensationAndRelatedBenefitsMember" xlink:href="avco-20210331.xsd#avco_CompensationAndRelatedBenefitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="avco_CompensationAndRelatedBenefitsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_ProfessionalFeesMember" xlink:href="avco-20210331.xsd#avco_ProfessionalFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="avco_ProfessionalFeesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CommonSharesIssuedForServicesMember" xlink:href="avco-20210331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="avco_CommonSharesIssuedForServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JefferiesLLCMember" xlink:href="avco-20210331.xsd#avco_JefferiesLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="avco_JefferiesLLCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_SharesBasedCompensation" xlink:href="avco-20210331.xsd#avco_SharesBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="avco_SharesBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_FairValueOfOptionGrantedDescription" xlink:href="avco-20210331.xsd#avco_FairValueOfOptionGrantedDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="avco_FairValueOfOptionGrantedDescription" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_EquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="17" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveDetails">
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveAbstract" xlink:href="avco-20210331.xsd#avco_StatutoryReserveAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReservePercent" xlink:href="avco-20210331.xsd#avco_StatutoryReservePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_StatutoryReserveAbstract" xlink:to="avco_StatutoryReservePercent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_RegisteredCapitalPercentage" xlink:href="avco-20210331.xsd#avco_RegisteredCapitalPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_StatutoryReserveAbstract" xlink:to="avco_RegisteredCapitalPercentage" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails">
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsAbstract" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RestrictedNetAssetsAbstract" xlink:to="us-gaap_RestrictedInvestmentsPercentOfNetAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_RestrictedNetAssetsAbstract" xlink:to="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsTable" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_ConcentrationsDetailsLineItems" xlink:to="avco_ConcentrationsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerMember" xlink:href="avco-20210331.xsd#avco_CustomerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="avco_CustomerMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConcentrationsDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfCustomer" xlink:href="avco-20210331.xsd#avco_NumberOfCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConcentrationsDetailsLineItems" xlink:to="avco_NumberOfCustomer" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfSupplier" xlink:href="avco-20210331.xsd#avco_NumberOfSupplier"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_ConcentrationsDetailsLineItems" xlink:to="avco_NumberOfSupplier" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfReportableBusinessSegments" xlink:href="avco-20210331.xsd#avco_NumberOfReportableBusinessSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="avco_NumberOfReportableBusinessSegments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsTable" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LineOfCreditAgreementMember" xlink:href="avco-20210331.xsd#avco_LineOfCreditAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="avco_LineOfCreditAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_AvalonShanghaiMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_AVARBioTherapeuticsMember" xlink:href="avco-20210331.xsd#avco_AVARBioTherapeuticsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="avco_AVARBioTherapeuticsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_StockPurchaseAgreementDescription" xlink:href="avco-20210331.xsd#avco_StockPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_StockPurchaseAgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_JointVentureAgreementDescription" xlink:href="avco-20210331.xsd#avco_JointVentureAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_JointVentureAgreementDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapital" xlink:href="avco-20210331.xsd#avco_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_WorkingCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="avco_LoanRecevied" xlink:href="avco-20210331.xsd#avco_LoanRecevied"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_LoanRecevied" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="17" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>avco-20210331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Non-current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Avalon GloboCare Corp. stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertiesOperatingIncome" xlink:href="avco-20210331.xsd#avco_RealPropertiesOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="avco_RealPropertiesOperatingIncome_lbl" xml:lang="en-US">Real property operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertiesOperatingIncome" xlink:to="avco_RealPropertiesOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Other Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Total Other Expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Total other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Recurring net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Negative cash flow from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH - beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">CASH - end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US">Schedule of company&apos;s subsidiaries consolidated financial statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract" xlink:to="avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCashBalancesByGeographicAreaAbstract_lbl" xml:lang="en-US">Schedule of cash balances by geographic area [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:to="avco_ScheduleOfCashBalancesByGeographicAreaAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract_lbl" xml:lang="en-US">Schedule of the effect of including these potential shares was antidilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract" xlink:to="avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_PrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfEquityMethodInvestmentAbstract_lbl" xml:lang="en-US">Schedule of equity method investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfEquityMethodInvestmentAbstract" xlink:to="avco_ScheduleOfEquityMethodInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Equity investment carrying amount at January 1, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity investment carrying amount at March 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl1" xml:lang="en-US">Equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationInvesteeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfFinancialInformationInvesteeAbstract_lbl" xml:lang="en-US">Schedule of financial information investee [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="avco_ScheduleOfFinancialInformationInvesteeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfFinancialInformationAbstract_lbl" xml:lang="en-US">Schedule of financial information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationAbstract" xlink:to="avco_ScheduleOfFinancialInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract_lbl" xml:lang="en-US">Schedule of accrued liabilities and other payables [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfStockOptionsOutstandingAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfStockOptionsOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfStockOptionsOutstandingAbstract_lbl" xml:lang="en-US">Schedule of stock options outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfStockOptionsOutstandingAbstract" xlink:to="avco_ScheduleOfStockOptionsOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfStockOptionActivitiesAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfStockOptionActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfStockOptionActivitiesAbstract_lbl" xml:lang="en-US">Schedule of stock option activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfStockOptionActivitiesAbstract" xlink:to="avco_ScheduleOfStockOptionActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Balance at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Balance at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of fair value of the options using the Black-Scholes option-pricing model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Nonvested at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Nonvested at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Nonvested at beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Nonvested at ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveAbstract" xlink:href="avco-20210331.xsd#avco_StatutoryReserveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserveAbstract_lbl" xml:lang="en-US">Statutory Reserve [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveAbstract" xlink:to="avco_StatutoryReserveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsAbstract" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RestrictedNetAssetsAbstract_lbl" xml:lang="en-US">Restricted Net Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsAbstract" xlink:to="avco_RestrictedNetAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfCustomersAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCustomersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfCustomersAbstract_lbl" xml:lang="en-US">Schedule of customers [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfCustomersAbstract" xlink:to="avco_ScheduleOfCustomersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSegmentReportingInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfSegmentReportingInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfSegmentReportingInformationAbstract_lbl" xml:lang="en-US">Schedule of segment reporting information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSegmentReportingInformationAbstract" xlink:to="avco_ScheduleOfSegmentReportingInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfRealPropertyOperatingAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfRealPropertyOperatingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfRealPropertyOperatingAbstract_lbl" xml:lang="en-US">Schedule of real property operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfRealPropertyOperatingAbstract" xlink:to="avco_ScheduleOfRealPropertyOperatingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract_lbl" xml:lang="en-US">Schedule of identifiable long-lived tangible assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:to="avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Schedule of supplemental cash flow information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="avco_ScheduleOfSupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract_lbl" xml:lang="en-US">Schedule of lease term and discount rate for the Company&#8217;s operating lease [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:to="avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfMaturityOfLeaseLiabilityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract_lbl" xml:lang="en-US">Schedule of maturity of lease liability [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:to="avco_ScheduleOfMaturityOfLeaseLiabilityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingLeaseLiabilities" xlink:href="avco-20210331.xsd#avco_OperatingLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="avco_OperatingLeaseLiabilities_lbl" xml:lang="en-US">Total present value of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingLeaseLiabilities" xlink:to="avco_OperatingLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred financing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:href="avco-20210331.xsd#avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl" xml:lang="en-US">Rent receivable - noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:to="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred leasing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealEstateInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateInvestments_lbl" xml:lang="en-US">Investment in real estate, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestments" xlink:to="us-gaap_RealEstateInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xml:lang="en-US">Equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LiabilitiesAndEquityAbstract" xlink:href="avco-20210331.xsd#avco_LiabilitiesAndEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LiabilitiesAndEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LiabilitiesAndEquityAbstract" xlink:to="avco_LiabilitiesAndEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentsFees" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl" xml:lang="en-US">Accrued research and development fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Accrued payroll liability and directors&apos; compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued liabilities and other payables - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl" xml:lang="en-US">Note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation - noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xml:lang="en-US">Note payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US">Loan payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized;	no shares issued and outstanding at March 31, 2021 and December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract" xlink:href="avco-20210331.xsd#avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 490,000,000 shares authorized;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract" xlink:to="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract" xlink:href="avco-20210331.xsd#avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract_lbl" xml:lang="en-US">84,943,564 shares issued and 84,423,564 shares outstanding at March 31, 2021;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract" xlink:to="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 490,000,000 shares authorized;	84,943,564 shares issued and 84,423,564 shares outstanding at March 31, 2021;	82,795,297 shares issued and 82,275,297 shares outstanding at December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl" xml:lang="en-US">Common stock, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:href="avco-20210331.xsd#avco_LessCommonStockHeldInTreasuryAtCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl" xml:lang="en-US">Less: common stock held in treasury, at cost;</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:to="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserve" xlink:href="avco-20210331.xsd#avco_StatutoryReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserve_lbl" xml:lang="en-US">Statutory reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss - foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US">Real property rental</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US">COSTS AND EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingExpenses" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyOperatingExpenses_lbl" xml:lang="en-US">Real property operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingExpenses" xlink:to="avco_RealPropertyOperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfitAbstract_lbl" xml:lang="en-US">GROSS PROFIT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfitAbstract" xlink:to="us-gaap_GrossProfitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OTHER OPERATING EXPENSES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Compensation and related benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">OTHER INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherIncomeLossFromEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_OtherIncomeLossFromEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherIncomeLossFromEquityMethodInvestment_lbl" xml:lang="en-US">Loss from equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeLossFromEquityMethodInvestment" xlink:to="avco_OtherIncomeLossFromEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">COMPREHENSIVE LOSS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">OTHER COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized foreign currency translation loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Aggregate purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Common shares sold for cash, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Common shares issued for services, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Common shares issued for services, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForOtherLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForOtherLosses_lbl" xml:lang="en-US">Bad debt provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation and service expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_LossOnEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LossOnEquityMethodInvestment_lbl" xml:lang="en-US">Loss on equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnEquityMethodInvestment" xlink:to="avco_LossOnEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LossOnFixedAssetsDisposal" xlink:href="avco-20210331.xsd#avco_LossOnFixedAssetsDisposal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LossOnFixedAssetsDisposal_lbl" xml:lang="en-US">Loss on fixed assets disposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnFixedAssetsDisposal" xlink:to="avco_LossOnFixedAssetsDisposal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl" xml:lang="en-US">Security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredLeasingCosts" xlink:href="avco-20210331.xsd#avco_DeferredLeasingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DeferredLeasingCosts_lbl" xml:lang="en-US">Deferred leasing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredLeasingCosts" xlink:to="avco_DeferredLeasingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromLoanPayable" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromLoanPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ProceedsReceivedFromLoanPayable_lbl" xml:lang="en-US">Proceeds received from loan payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromLoanPayable" xlink:to="avco_ProceedsReceivedFromLoanPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ProceedsReceivedFromEquityOffering" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromEquityOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ProceedsReceivedFromEquityOffering_lbl" xml:lang="en-US">Proceeds received from equity offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromEquityOffering" xlink:to="avco_ProceedsReceivedFromEquityOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE ON CASH</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">NON-CASH INVESTING AND FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Less: common stock held in treasury, at cost; 520,000 shares at March 31, 2021 and December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expense - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl0" xml:lang="en-US">Interest expense related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StraightLineRent_lbl" xml:lang="en-US">Amortization of straight-line rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRent" xlink:to="us-gaap_StraightLineRent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xml:lang="en-US">Accounts receivable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl" xml:lang="en-US">Rent receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_IncreaseDecreaseOperatingLease" xlink:href="avco-20210331.xsd#avco_IncreaseDecreaseOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_IncreaseDecreaseOperatingLease_lbl" xml:lang="en-US">Operating lease obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncreaseDecreaseOperatingLease" xlink:to="avco_IncreaseDecreaseOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_AdditionalInvestmentInEquityMethodInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment_lbl" xml:lang="en-US">Additional investment in equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:to="avco_AdditionalInvestmentInEquityMethodInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DisbursementsForEqutyOfferingCosts" xlink:href="avco-20210331.xsd#avco_DisbursementsForEqutyOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_DisbursementsForEqutyOfferingCosts_lbl" xml:lang="en-US">Disbursements for equity offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DisbursementsForEqutyOfferingCosts" xlink:to="avco_DisbursementsForEqutyOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonStockIssuedForFutureServices" xlink:href="avco-20210331.xsd#avco_CommonStockIssuedForFutureServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_CommonStockIssuedForFutureServices_lbl" xml:lang="en-US">Common stock issued for future services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForFutureServices" xlink:to="avco_CommonStockIssuedForFutureServices_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20210331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities_lbl" xml:lang="en-US">Common stock issued for accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveMember" xlink:href="avco-20210331.xsd#avco_StatutoryReserveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserveMember_lbl" xml:lang="en-US">Statutory Reserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveMember" xlink:to="avco_StatutoryReserveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND NATURE OF OPERATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of company&apos;s subsidiaries consolidated financial statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EntityIncorporationsStateCountryName" xlink:href="avco-20210331.xsd#avco_EntityIncorporationsStateCountryName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EntityIncorporationsStateCountryName_lbl" xml:lang="en-US">Place and date of Incorporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EntityIncorporationsStateCountryName" xlink:to="avco_EntityIncorporationsStateCountryName_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfOwnership" xlink:href="avco-20210331.xsd#avco_PercentageOfOwnership"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PercentageOfOwnership_lbl" xml:lang="en-US">Percentage of Ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfOwnership" xlink:to="avco_PercentageOfOwnership_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl" xml:lang="en-US">Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl" xml:lang="en-US">Schedule of cash balances by geographic area</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndDueFromBanks" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndDueFromBanks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndDueFromBanks_lbl" xml:lang="en-US">Total cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndDueFromBanks" xlink:to="us-gaap_CashAndDueFromBanks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Percentage of concentrations of credit risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl0" xml:lang="en-US">Customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl1" xml:lang="en-US">Concentration risk, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of the effect of including these potential shares was antidilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potentially dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidNasdaqListingFee" xlink:href="avco-20210331.xsd#avco_PrepaidNasdaqListingFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidNasdaqListingFee_lbl" xml:lang="en-US">Prepaid NASDAQ listing fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidNasdaqListingFee" xlink:to="avco_PrepaidNasdaqListingFee_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:href="avco-20210331.xsd#avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl" xml:lang="en-US">Prepaid directors and officers liability insurance premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:to="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidProfessionalFees" xlink:href="avco-20210331.xsd#avco_PrepaidProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidProfessionalFees_lbl" xml:lang="en-US">Prepaid professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl" xml:lang="en-US">Recoverable VAT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsLeasingNet_lbl" xml:lang="en-US">Deferred leasing costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsLeasingNet" xlink:to="us-gaap_DeferredCostsLeasingNet_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrepaidResearchAndDevelopmentFees" xlink:href="avco-20210331.xsd#avco_PrepaidResearchAndDevelopmentFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrepaidResearchAndDevelopmentFees_lbl" xml:lang="en-US">Prepaid research and development fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidResearchAndDevelopmentFees" xlink:to="avco_PrepaidResearchAndDevelopmentFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY METHOD INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PaymentMadeForEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_PaymentMadeForEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PaymentMadeForEquityMethodInvestments_lbl" xml:lang="en-US">Payment made for equity method investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentMadeForEquityMethodInvestments" xlink:to="avco_PaymentMadeForEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of financial information investee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl" xml:lang="en-US">Noncurrent assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl" xml:lang="en-US">Noncurrent liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfFinancialInformationByInvestee" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationByInvestee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ScheduleOfFinancialInformationByInvestee_lbl" xml:lang="en-US">Schedule of financial information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationByInvestee" xlink:to="avco_ScheduleOfFinancialInformationByInvestee_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl" xml:lang="en-US">Net revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl" xml:lang="en-US">Loss from operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">ACCRUED LIABILITIES AND OTHER PAYABLES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedResearchAndDevelopmentFee" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedResearchAndDevelopmentFee_lbl" xml:lang="en-US">Accrued research and development fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentFee" xlink:to="avco_AccruedResearchAndDevelopmentFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued directors&#8217; compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AccruedTenantsImprovementReimbursement" xlink:href="avco-20210331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl" xml:lang="en-US">Accrued tenants&#8217; improvement reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Tenants&#8217; security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncome_lbl" xml:lang="en-US">Deferred rental income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePrice" xlink:href="avco-20210331.xsd#avco_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePrice_lbl" xml:lang="en-US">Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePrice" xlink:to="avco_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number Exercisable at March 31, 2021 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number Exercisable at March 31, 2021 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Options exercisable at end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Options exercisable at end</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, lower limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, upper limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" xlink:href="avco-20210331.xsd#avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised_lbl" xml:lang="en-US">Terminated / Exercised / Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" xlink:to="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" xlink:href="avco-20210331.xsd#avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice_lbl" xml:lang="en-US">Terminated / Exercised / Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" xlink:to="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Options expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Options expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of the options using the Black-Scholes option-pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReserveTextBlock" xlink:href="avco-20210331.xsd#avco_StatutoryReserveTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReserveTextBlock_lbl" xml:lang="en-US">STATUTORY RESERVE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveTextBlock" xlink:to="avco_StatutoryReserveTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RestrictedNetAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RestrictedNetAssetsTextBlock_lbl" xml:lang="en-US">RESTRICTED NET ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsTextBlock" xlink:to="avco_RestrictedNetAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">CONCENTRATIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplyCommitmentTableTextBlock_lbl" xml:lang="en-US">Schedule of customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentTableTextBlock" xlink:to="us-gaap_SupplyCommitmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of segment reporting information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RevenuesAbstract0" xlink:href="avco-20210331.xsd#avco_RevenuesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RevenuesAbstract0_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RevenuesAbstract0" xlink:to="avco_RevenuesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CostsAndExpensesAbstract0" xlink:href="avco-20210331.xsd#avco_CostsAndExpensesAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CostsAndExpensesAbstract0_lbl" xml:lang="en-US">Costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CostsAndExpensesAbstract0" xlink:to="avco_CostsAndExpensesAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_GrossProfitAbstract0" xlink:href="avco-20210331.xsd#avco_GrossProfitAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_GrossProfitAbstract0_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GrossProfitAbstract0" xlink:to="avco_GrossProfitAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherOperatingExpensesAbstract" xlink:href="avco-20210331.xsd#avco_OtherOperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherOperatingExpensesAbstract_lbl" xml:lang="en-US">Other operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpensesAbstract" xlink:to="avco_OtherOperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherIncomeExpenseAbstract" xlink:href="avco-20210331.xsd#avco_OtherIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeExpenseAbstract" xlink:to="avco_OtherIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseAbstract_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseAbstract" xlink:to="us-gaap_InterestExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InterestExpenses" xlink:href="avco-20210331.xsd#avco_InterestExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InterestExpenses_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InterestExpenses" xlink:to="avco_InterestExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherIncomeExpenseAbstract0" xlink:href="avco-20210331.xsd#avco_OtherIncomeExpenseAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherIncomeExpenseAbstract0_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeExpenseAbstract0" xlink:to="avco_OtherIncomeExpenseAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NetLossAbstract" xlink:href="avco-20210331.xsd#avco_NetLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NetLossAbstract_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NetLossAbstract" xlink:to="avco_NetLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl" xml:lang="en-US">Schedule of real property operating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl" xml:lang="en-US">Schedule of identifiable long-lived tangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Identifiable long-lived tangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="avco-20210331.xsd#avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingCashFlowPaidForOperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingCashFlowPaidForOperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OperatingCashFlowPaidForOperatingLease_lbl" xml:lang="en-US">Operating cash flows paid for operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingCashFlowPaidForOperatingLease" xlink:to="avco_OperatingCashFlowPaidForOperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:href="avco-20210331.xsd#avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:to="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingLease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OperatingLease_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingLease" xlink:to="avco_OperatingLease_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of lease term and discount rate for the Company&#8217;s operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2024 and thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AmountOfLeasePaymentsRepresentingInterest" xlink:href="avco-20210331.xsd#avco_AmountOfLeasePaymentsRepresentingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AmountOfLeasePaymentsRepresentingInterest_lbl" xml:lang="en-US">Amount of lease payments representing interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AmountOfLeasePaymentsRepresentingInterest" xlink:to="avco_AmountOfLeasePaymentsRepresentingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CurrentPortion" xlink:href="avco-20210331.xsd#avco_CurrentPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CurrentPortion_lbl" xml:lang="en-US">Current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CurrentPortion" xlink:to="avco_CurrentPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LongtermPortion" xlink:href="avco-20210331.xsd#avco_LongtermPortion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LongtermPortion_lbl" xml:lang="en-US">Long-term portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LongtermPortion" xlink:to="avco_LongtermPortion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">Epicon&apos;s net loss attributable to the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ForeignCurrencyFluctuationEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_ForeignCurrencyFluctuationEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl" xml:lang="en-US">Foreign currency fluctuation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ForeignCurrencyFluctuationEquityMethodInvestments" xlink:to="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Options Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonHealthcareSystemIncMember" xlink:href="avco-20210331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonHealthcareSystemIncMember_lbl" xml:lang="en-US">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonHealthcareSystemIncMember" xlink:to="avco_AvalonHealthcareSystemIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonBVILtdMember" xlink:href="avco-20210331.xsd#avco_AvalonBVILtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonBVILtdMember_lbl" xml:lang="en-US">Avalon (BVI) Ltd. (&#8220;Avalon BVI&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonBVILtdMember" xlink:to="avco_AvalonBVILtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonRT9PropertiesLLCMember" xlink:href="avco-20210331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl" xml:lang="en-US">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl0" xml:lang="en-US">Avalon RT 9 Properties, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl" xml:lang="en-US">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeTechnologiesIncMember" xlink:href="avco-20210331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_GenExosomeTechnologiesIncMember_lbl" xml:lang="en-US">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeTechnologiesIncMember" xlink:to="avco_GenExosomeTechnologiesIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_GenExosomeTechnologiesIncMember_lbl0" xml:lang="en-US">GenExosome Technologies Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeTechnologiesIncMember" xlink:to="avco_GenExosomeTechnologiesIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:href="avco-20210331.xsd#avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl" xml:lang="en-US">Beijing Jieteng (Genexosome) Biotech Co., Ltd. (&quot;Beijing Genexosome&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:to="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl0" xml:lang="en-US">Beijing Jieteng (GenExosome) Biotech Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:to="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="avco_AvactisBiosciencesIncMember" xlink:href="avco-20210331.xsd#avco_AvactisBiosciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvactisBiosciencesIncMember_lbl" xml:lang="en-US">Avactis Biosciences Inc. (&apos;&apos;Avactis&apos;&apos;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiosciencesIncMember" xlink:to="avco_AvactisBiosciencesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InternationalExosomeAssociationLlcMember" xlink:href="avco-20210331.xsd#avco_InternationalExosomeAssociationLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InternationalExosomeAssociationLlcMember_lbl" xml:lang="en-US">International Exosome Association LLC (&apos;&apos;Exosome&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InternationalExosomeAssociationLlcMember" xlink:to="avco_InternationalExosomeAssociationLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CN_lbl" xml:lang="en-US">China [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockOptionsMember" xlink:href="avco-20210331.xsd#avco_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockOptionsMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockOptionsMember" xlink:to="avco_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeOneMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">0.50 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeTwoMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">1.00 &#8211; 1.93 Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeThreeMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">2.00 - 2.80 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeThreeMember" xlink:to="avco_ExercisePriceRangeThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFourMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeFourMember_lbl" xml:lang="en-US">4.76 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExercisePriceRangeFiveMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExercisePriceRangeFiveMember_lbl" xml:lang="en-US">0.50 - 4.76 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFiveMember" xlink:to="avco_ExercisePriceRangeFiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfOptionsMember" xlink:href="avco-20210331.xsd#avco_NumberOfOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NumberOfOptionsMember_lbl" xml:lang="en-US">Number of Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfOptionsMember" xlink:to="avco_NumberOfOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WeightedAverageExercisePriceMember" xlink:href="avco-20210331.xsd#avco_WeightedAverageExercisePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WeightedAverageExercisePriceMember_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WeightedAverageExercisePriceMember" xlink:to="avco_WeightedAverageExercisePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">More Than 10% Revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskOneMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerConcentrationRiskOneMember_lbl" xml:lang="en-US">A (Hebei Daopei, a related party) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskOneMember" xlink:to="avco_CustomerConcentrationRiskOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskTwoMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerConcentrationRiskTwoMember_lbl" xml:lang="en-US">B [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskTwoMember" xlink:to="avco_CustomerConcentrationRiskTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerConcentrationRiskThreeMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerConcentrationRiskThreeMember_lbl" xml:lang="en-US">C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskThreeMember" xlink:to="avco_CustomerConcentrationRiskThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperationsMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperationsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyOperationsMember_lbl" xml:lang="en-US">Real property operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperationsMember" xlink:to="avco_RealPropertyOperationsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MedicalRelatedConsultingServicesRelatedPartyMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesRelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MedicalRelatedConsultingServicesRelatedPartyMember_lbl" xml:lang="en-US">Medical related consulting services - related party	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MedicalRelatedConsultingServicesRelatedPartyMember" xlink:to="avco_MedicalRelatedConsultingServicesRelatedPartyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductMember_lbl" xml:lang="en-US">Development services and sales of developed products [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DevelopmentServicesAndSalesOfDevelopedProductMember" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CorporateOtherMember" xlink:href="avco-20210331.xsd#avco_CorporateOtherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CorporateOtherMember_lbl" xml:lang="en-US">Corporate/Other [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CorporateOtherMember" xlink:to="avco_CorporateOtherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RealPropertyOperatingMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RealPropertyOperatingMember_lbl" xml:lang="en-US">Real property operations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_MedicalRelatedConsultingServicesMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_MedicalRelatedConsultingServicesMember_lbl" xml:lang="en-US">Medical related consulting services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MedicalRelatedConsultingServicesMember" xlink:to="avco_MedicalRelatedConsultingServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember_lbl" xml:lang="en-US">Development services and sales of developed products[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SubsidiaryAxis" xlink:href="avco-20210331.xsd#avco_SubsidiaryAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SubsidiaryAxis_lbl" xml:lang="en-US">Subsidiary [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SubsidiaryAxis" xlink:to="avco_SubsidiaryAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Business acquired percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ExchangeForCommonStock" xlink:href="avco-20210331.xsd#avco_ExchangeForCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ExchangeForCommonStock_lbl" xml:lang="en-US">Exchange for common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeForCommonStock" xlink:to="avco_ExchangeForCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PercentageOfCapitalStock" xlink:href="avco-20210331.xsd#avco_PercentageOfCapitalStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PercentageOfCapitalStock_lbl" xml:lang="en-US">Percentage of capital stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCapitalStock" xlink:to="avco_PercentageOfCapitalStock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_BuildingOccupancyRate" xlink:href="avco-20210331.xsd#avco_BuildingOccupancyRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_BuildingOccupancyRate_lbl" xml:lang="en-US">Building occupancy rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BuildingOccupancyRate" xlink:to="avco_BuildingOccupancyRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Total ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Ownership of percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapitalDeficit" xlink:href="avco-20210331.xsd#avco_WorkingCapitalDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashAndCashEquivalentsDescription" xlink:href="avco-20210331.xsd#avco_CashAndCashEquivalentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashAndCashEquivalentsDescription_lbl" xml:lang="en-US">Cash and cash equivalents, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashAndCashEquivalentsDescription" xlink:to="avco_CashAndCashEquivalentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CashAndDueFromBank" xlink:href="avco-20210331.xsd#avco_CashAndDueFromBank"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CashAndDueFromBank_lbl" xml:lang="en-US">Cash balance held in PRC</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashAndDueFromBank" xlink:to="avco_CashAndDueFromBank_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LimitedInsurance" xlink:href="avco-20210331.xsd#avco_LimitedInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LimitedInsurance_lbl" xml:lang="en-US">Limited insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LimitedInsurance" xlink:to="avco_LimitedInsurance_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FederallyinsuredLimits" xlink:href="avco-20210331.xsd#avco_FederallyinsuredLimits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FederallyinsuredLimits_lbl" xml:lang="en-US">Federally-insured limits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FederallyinsuredLimits" xlink:to="avco_FederallyinsuredLimits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConsiderationCash" xlink:href="avco-20210331.xsd#avco_ConsiderationCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ConsiderationCash_lbl" xml:lang="en-US">Consideration cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConsiderationCash" xlink:to="avco_ConsiderationCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Outstanding principal balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Promissory Note interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Promissory note maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_PrincipalRepaidAmount" xlink:href="avco-20210331.xsd#avco_PrincipalRepaidAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_PrincipalRepaidAmount_lbl" xml:lang="en-US">Principal repaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrincipalRepaidAmount" xlink:to="avco_PrincipalRepaidAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LoanFromLender" xlink:href="avco-20210331.xsd#avco_LoanFromLender"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LoanFromLender_lbl" xml:lang="en-US">Outstanding line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanFromLender" xlink:to="avco_LoanFromLender_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares reserved for issuance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Net proceeds, net of commission and other offering costs</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbtBaiEPSVo1jnidxwjsIVUZ] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SharesBasedCompensation" xlink:href="avco-20210331.xsd#avco_SharesBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_SharesBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharesBasedCompensation" xlink:to="avco_SharesBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Reduction in accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic values of stock options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility rate, minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility rate, maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate fair value of the options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_FairValueOfOptionGrantedDescription" xlink:href="avco-20210331.xsd#avco_FairValueOfOptionGrantedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_FairValueOfOptionGrantedDescription_lbl" xml:lang="en-US">Fair value description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairValueOfOptionGrantedDescription" xlink:to="avco_FairValueOfOptionGrantedDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StatutoryReservePercent" xlink:href="avco-20210331.xsd#avco_StatutoryReservePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StatutoryReservePercent_lbl" xml:lang="en-US">Statutory reserve percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReservePercent" xlink:to="avco_StatutoryReservePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RegisteredCapitalPercentage" xlink:href="avco-20210331.xsd#avco_RegisteredCapitalPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_RegisteredCapitalPercentage_lbl" xml:lang="en-US">Registered capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegisteredCapitalPercentage" xlink:to="avco_RegisteredCapitalPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsPercentOfNetAssets_lbl" xml:lang="en-US">Restricted net assets, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsPercentOfNetAssets" xlink:to="us-gaap_RestrictedInvestmentsPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets_lbl" xml:lang="en-US">Net assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" xlink:to="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfCustomer" xlink:href="avco-20210331.xsd#avco_NumberOfCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NumberOfCustomer_lbl" xml:lang="en-US">Number of customer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfCustomer" xlink:to="avco_NumberOfCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfSupplier" xlink:href="avco-20210331.xsd#avco_NumberOfSupplier"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NumberOfSupplier_lbl" xml:lang="en-US">Number of supplier</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfSupplier" xlink:to="avco_NumberOfSupplier_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_NumberOfReportableBusinessSegments" xlink:href="avco-20210331.xsd#avco_NumberOfReportableBusinessSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_NumberOfReportableBusinessSegments_lbl" xml:lang="en-US">Number of reportable business segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfReportableBusinessSegments" xlink:to="avco_NumberOfReportableBusinessSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_StockPurchaseAgreementDescription" xlink:href="avco-20210331.xsd#avco_StockPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_StockPurchaseAgreementDescription_lbl" xml:lang="en-US">Stock purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockPurchaseAgreementDescription" xlink:to="avco_StockPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JointVentureAgreementDescription" xlink:href="avco-20210331.xsd#avco_JointVentureAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JointVentureAgreementDescription_lbl" xml:lang="en-US">Joint venture agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JointVentureAgreementDescription" xlink:to="avco_JointVentureAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WorkingCapital" xlink:href="avco-20210331.xsd#avco_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapital" xlink:to="avco_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Line of Credit bears interest at an annual rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LoanRecevied" xlink:href="avco-20210331.xsd#avco_LoanRecevied"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LoanRecevied_lbl" xml:lang="en-US">Received Loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanRecevied" xlink:to="avco_LoanRecevied_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments and Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CreditRiskAndUncertaintiePolicyTextBlock" xlink:href="avco-20210331.xsd#avco_CreditRiskAndUncertaintiePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CreditRiskAndUncertaintiePolicyTextBlock_lbl" xml:lang="en-US">Credit Risk and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CreditRiskAndUncertaintiePolicyTextBlock" xlink:to="avco_CreditRiskAndUncertaintiePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock" xlink:href="avco-20210331.xsd#avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock_lbl" xml:lang="en-US">Investment in Unconsolidated Company &#8211; Epicon Biosciences Co., Ltd.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock" xlink:to="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Per Share Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Reclassifications"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Reclassifications_lbl" xml:lang="en-US">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DrYuZhouMember" xlink:href="avco-20210331.xsd#avco_DrYuZhouMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DrYuZhouMember_lbl" xml:lang="en-US">Dr. Yu Zhou [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrYuZhouMember" xlink:to="avco_DrYuZhouMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OtherUnrelatedCompanyMember" xlink:href="avco-20210331.xsd#avco_OtherUnrelatedCompanyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_OtherUnrelatedCompanyMember_lbl" xml:lang="en-US">Other Unrelated Company [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherUnrelatedCompanyMember" xlink:to="avco_OtherUnrelatedCompanyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_UnicornMember" xlink:href="avco-20210331.xsd#avco_UnicornMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_UnicornMember_lbl" xml:lang="en-US">Jiangsu Unicorn Biological Technology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnicornMember" xlink:to="avco_UnicornMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_DavidJinMember" xlink:href="avco-20210331.xsd#avco_DavidJinMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_DavidJinMember_lbl" xml:lang="en-US">David Jin [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DavidJinMember" xlink:to="avco_DavidJinMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_GenExosomeMember" xlink:href="avco-20210331.xsd#avco_GenExosomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_GenExosomeMember_lbl" xml:lang="en-US">Genexosome [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeMember" xlink:to="avco_GenExosomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_WenzhaoLuMember" xlink:href="avco-20210331.xsd#avco_WenzhaoLuMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_WenzhaoLuMember_lbl" xml:lang="en-US">Wenzhao Lu [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WenzhaoLuMember" xlink:to="avco_WenzhaoLuMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_LineOfCreditAgreementMember" xlink:href="avco-20210331.xsd#avco_LineOfCreditAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_LineOfCreditAgreementMember_lbl" xml:lang="en-US">Line of Credit Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LineOfCreditAgreementMember" xlink:to="avco_LineOfCreditAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_JefferiesLLCMember" xlink:href="avco-20210331.xsd#avco_JefferiesLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JefferiesLLCMember" xlink:to="avco_JefferiesLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommonSharesIssuedForServicesMember" xlink:href="avco-20210331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CommonSharesIssuedForServicesMember_lbl" xml:lang="en-US">Common Shares Issued for Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonSharesIssuedForServicesMember" xlink:to="avco_CommonSharesIssuedForServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CompensationAndRelatedBenefitsMember" xlink:href="avco-20210331.xsd#avco_CompensationAndRelatedBenefitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CompensationAndRelatedBenefitsMember_lbl" xml:lang="en-US">Compensation and Related Benefits [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CompensationAndRelatedBenefitsMember" xlink:to="avco_CompensationAndRelatedBenefitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ProfessionalFeesMember" xlink:href="avco-20210331.xsd#avco_ProfessionalFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_ProfessionalFeesMember_lbl" xml:lang="en-US">Professional Fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProfessionalFeesMember" xlink:to="avco_ProfessionalFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CustomerMember" xlink:href="avco-20210331.xsd#avco_CustomerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerMember" xlink:to="avco_CustomerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Outstanding accounts receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl0" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl" xml:lang="en-US">Supplies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">10% or more of purchase [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Outstanding accounts payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AvalonShanghaiMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AvalonShanghaiMember_lbl" xml:lang="en-US">Avalon Shanghai [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiMember" xlink:to="avco_AvalonShanghaiMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_AVARBioTherapeuticsMember" xlink:href="avco-20210331.xsd#avco_AVARBioTherapeuticsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="avco_AVARBioTherapeuticsMember_lbl" xml:lang="en-US">AVAR BioTherapeutics (China) Co. Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AVARBioTherapeuticsMember" xlink:to="avco_AVARBioTherapeuticsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of stock option activities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesTable" xlink:to="avco_EquityDetailsScheduleofstockoptionactivitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of stock option activities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="avco_EquityDetailsScheduleofstockoptionactivitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable_lbl" xml:lang="en-US">Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:to="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems_lbl" xml:lang="en-US">Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentTable_lbl" xml:lang="en-US">Supply Commitment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_SupplyCommitmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentLineItems_lbl" xml:lang="en-US">Supply Commitment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentLineItems" xlink:to="us-gaap_SupplyCommitmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable_lbl" xml:lang="en-US">Segment Information (Details) - Schedule of identifiable long-lived tangible assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:to="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems_lbl" xml:lang="en-US">Segment Information (Details) - Schedule of identifiable long-lived tangible assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:to="avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OrganizationandNatureofOperationsDetailsTable_lbl" xml:lang="en-US">Organization and Nature of Operations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OrganizationandNatureofOperationsDetailsTable" xlink:to="avco_OrganizationandNatureofOperationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OrganizationandNatureofOperationsDetailsLineItems_lbl" xml:lang="en-US">Organization and Nature of Operations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OrganizationandNatureofOperationsDetailsLineItems" xlink:to="avco_OrganizationandNatureofOperationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="avco_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_SubsidiaryDomain" xlink:href="avco-20210331.xsd#avco_SubsidiaryDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SubsidiaryDomain_lbl" xml:lang="en-US">Subsidiary [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SubsidiaryDomain" xlink:to="avco_SubsidiaryDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentDetailsTable_lbl" xml:lang="en-US">Equity Method Investment (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentDetailsTable" xlink:to="avco_EquityMethodInvestmentDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityMethodInvestmentDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentDetailsLineItems_lbl" xml:lang="en-US">Equity Method Investment (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentDetailsLineItems" xlink:to="avco_EquityMethodInvestmentDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsTable" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyTransactionsDetailsTable" xlink:to="avco_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_RelatedPartyTransactionsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RelatedPartyTransactionsDetailsLineItems" xlink:to="avco_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsTable" xlink:to="avco_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_EquityDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityDetailsLineItems" xlink:to="avco_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsTable" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConcentrationsDetailsTable_lbl" xml:lang="en-US">Concentrations (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConcentrationsDetailsTable" xlink:to="avco_ConcentrationsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_ConcentrationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConcentrationsDetailsLineItems_lbl" xml:lang="en-US">Concentrations (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConcentrationsDetailsLineItems" xlink:to="avco_ConcentrationsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsTable" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommitmentsandContingenciesDetailsTable" xlink:to="avco_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="avco_CommitmentsandContingenciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommitmentsandContingenciesDetailsLineItems" xlink:to="avco_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedResearchAndDevelopmentFee_lbl0" xml:lang="en-US">Accrued research and development fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentFee" xlink:to="avco_AccruedResearchAndDevelopmentFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl0" xml:lang="en-US">Amount of accrued research and development fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl0" xml:lang="en-US">Accrued tenants&#8217; improvement reimbursement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment_lbl0" xml:lang="en-US">Additional investment in equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:to="avco_AdditionalInvestmentInEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_BuildingOccupancyRate_lbl0" xml:lang="en-US">Building occupancy rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BuildingOccupancyRate" xlink:to="avco_BuildingOccupancyRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CashAndDueFromBank_lbl0" xml:lang="en-US">For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashAndDueFromBank" xlink:to="avco_CashAndDueFromBank_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CommonStockIssuedForFutureServices_lbl0" xml:lang="en-US">Common stock issued for future services.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForFutureServices" xlink:to="avco_CommonStockIssuedForFutureServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DeferredLeasingCosts_lbl0" xml:lang="en-US">Deferred leasing costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredLeasingCosts" xlink:to="avco_DeferredLeasingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_DisbursementsForEqutyOfferingCosts_lbl0" xml:lang="en-US">Disbursements for equity offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DisbursementsForEqutyOfferingCosts" xlink:to="avco_DisbursementsForEqutyOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EntityIncorporationsStateCountryName_lbl0" xml:lang="en-US">Place and date of incorporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EntityIncorporationsStateCountryName" xlink:to="avco_EntityIncorporationsStateCountryName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl0" xml:lang="en-US">The amount of current assets reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl0" xml:lang="en-US">The amount of current liabilities reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl0" xml:lang="en-US">Amount of income (loss) from continuing operations reported by an equity method investee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl0" xml:lang="en-US">The amount of noncurrent assets reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl0" xml:lang="en-US">The amount of noncurrent liabilities reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl0" xml:lang="en-US">Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl0" xml:lang="en-US">The amount of gross profit (loss) reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl0" xml:lang="en-US">The amount of net income (loss) reported by an equity method investment of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl0" xml:lang="en-US">Amount of revenue from sale of product and rendering of service reported by equity method investee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ExchangeForCommonStock_lbl0" xml:lang="en-US">Exchange for common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeForCommonStock" xlink:to="avco_ExchangeForCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ExercisePrice_lbl0" xml:lang="en-US">Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePrice" xlink:to="avco_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl0" xml:lang="en-US">Foreign currency fluctuation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ForeignCurrencyFluctuationEquityMethodInvestments" xlink:to="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_InterestExpenses_lbl0" xml:lang="en-US">Interest and debt related expenses associated with nonoperating financing activities of the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InterestExpenses" xlink:to="avco_InterestExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_LoanFromLender_lbl0" xml:lang="en-US">Loan received from the Lender.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanFromLender" xlink:to="avco_LoanFromLender_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_LoanRecevied_lbl0" xml:lang="en-US">The amount of loans recevied.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanRecevied" xlink:to="avco_LoanRecevied_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_LossOnEquityMethodInvestment_lbl0" xml:lang="en-US">Loss on equity method investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnEquityMethodInvestment" xlink:to="avco_LossOnEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_LossOnFixedAssetsDisposal_lbl0" xml:lang="en-US">The amount of Loss on fixed assets disposal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnFixedAssetsDisposal" xlink:to="avco_LossOnFixedAssetsDisposal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_OperatingCashFlowPaidForOperatingLease_lbl0" xml:lang="en-US">Operating cash flows paid for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingCashFlowPaidForOperatingLease" xlink:to="avco_OperatingCashFlowPaidForOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_OperatingLeaseLiabilities_lbl0" xml:lang="en-US">Total present value of operating lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingLeaseLiabilities" xlink:to="avco_OperatingLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PercentageOfCapitalStock_lbl0" xml:lang="en-US">Percentage of capital stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCapitalStock" xlink:to="avco_PercentageOfCapitalStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PercentageOfOwnership_lbl0" xml:lang="en-US">Percentage of ownership.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfOwnership" xlink:to="avco_PercentageOfOwnership_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl0" xml:lang="en-US">Prepaid directors and officers liability insurance premium.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:to="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrepaidNasdaqListingFee_lbl0" xml:lang="en-US">Prepaid NASDAQ listing fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidNasdaqListingFee" xlink:to="avco_PrepaidNasdaqListingFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrepaidProfessionalFees_lbl0" xml:lang="en-US">Prepaid professional fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrepaidResearchAndDevelopmentFees_lbl0" xml:lang="en-US">Amount of asset related to consideration paid in advance for prepaid research and development fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidResearchAndDevelopmentFees" xlink:to="avco_PrepaidResearchAndDevelopmentFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_PrincipalRepaidAmount_lbl0" xml:lang="en-US">Amount of principal repaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrincipalRepaidAmount" xlink:to="avco_PrincipalRepaidAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ProceedsReceivedFromEquityOffering_lbl0" xml:lang="en-US">Proceeds received from equity offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromEquityOffering" xlink:to="avco_ProceedsReceivedFromEquityOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ProceedsReceivedFromLoanPayable_lbl0" xml:lang="en-US">Proceeds receivable from loan payable during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromLoanPayable" xlink:to="avco_ProceedsReceivedFromLoanPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RealPropertyOperatingExpenses_lbl0" xml:lang="en-US">Operating expenses related to real propert for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingExpenses" xlink:to="avco_RealPropertyOperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RestrictedNetAssetsTextBlock_lbl0" xml:lang="en-US">The entire disclosure for restricted net assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsTextBlock" xlink:to="avco_RestrictedNetAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ScheduleOfFinancialInformationByInvestee_lbl0" xml:lang="en-US">Tabular disclosure of financial information by the investee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationByInvestee" xlink:to="avco_ScheduleOfFinancialInformationByInvestee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0" xml:lang="en-US">Schedule of supplemental balance sheet information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_SharesBasedCompensation_lbl0" xml:lang="en-US">Amount of noncash expense for share-based payment arrangement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharesBasedCompensation" xlink:to="avco_SharesBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StatutoryReserve_lbl0" xml:lang="en-US">Statutory reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StatutoryReserveTextBlock_lbl0" xml:lang="en-US">The entire disclosure for statutory reserve.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveTextBlock" xlink:to="avco_StatutoryReserveTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_StockPurchaseAgreementDescription_lbl0" xml:lang="en-US">Stock purchase agreement, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockPurchaseAgreementDescription" xlink:to="avco_StockPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl0" xml:lang="en-US">Prepaid realtors&#8217; commission - noncurrent portion.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:to="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_WorkingCapitalDeficit_lbl0" xml:lang="en-US">Working capital deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CustomerConcentrationRiskOneMember_lbl0" xml:lang="en-US">Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskOneMember" xlink:to="avco_CustomerConcentrationRiskOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_CustomerConcentrationRiskThreeMember_lbl0" xml:lang="en-US">Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskThreeMember" xlink:to="avco_CustomerConcentrationRiskThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_MedicalRelatedConsultingServicesMember_lbl0" xml:lang="en-US">Information by business segments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MedicalRelatedConsultingServicesMember" xlink:to="avco_MedicalRelatedConsultingServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avco_RealPropertyOperatingMember_lbl0" xml:lang="en-US">Information by business segments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationOfEquity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserveTextBlock_lbl1" xml:lang="en-US">StatutoryReserveTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveTextBlock" xlink:to="avco_StatutoryReserveTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AmountOfLeasePaymentsRepresentingInterest_lbl0" xml:lang="en-US">AmountOfLeasePaymentsRepresentingInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AmountOfLeasePaymentsRepresentingInterest" xlink:to="avco_AmountOfLeasePaymentsRepresentingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock_lbl0" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OperatingCashFlowPaidForOperatingLease_lbl1" xml:lang="en-US">OperatingCashFlowPaidForOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingCashFlowPaidForOperatingLease" xlink:to="avco_OperatingCashFlowPaidForOperatingLease_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReservePercent_lbl0" xml:lang="en-US">StatutoryReservePercent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReservePercent" xlink:to="avco_StatutoryReservePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WenzhaoLuMember_lbl0" xml:lang="en-US">WenzhaoLuMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WenzhaoLuMember" xlink:to="avco_WenzhaoLuMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PaymentMadeForEquityMethodInvestments_lbl0" xml:lang="en-US">PaymentMadeForEquityMethodInvestments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PaymentMadeForEquityMethodInvestments" xlink:to="avco_PaymentMadeForEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyOperatingMember_lbl1" xml:lang="en-US">RealPropertyOperatingMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingMember" xlink:to="avco_RealPropertyOperatingMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NetLossAbstract_lbl0" xml:lang="en-US">NetLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NetLossAbstract" xlink:to="avco_NetLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AVARBioTherapeuticsMember_lbl0" xml:lang="en-US">AVARBioTherapeuticsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AVARBioTherapeuticsMember" xlink:to="avco_AVARBioTherapeuticsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SubsidiaryAxis_lbl0" xml:lang="en-US">SubsidiaryAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SubsidiaryAxis" xlink:to="avco_SubsidiaryAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrincipalRepaidAmount_lbl1" xml:lang="en-US">PrincipalRepaidAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrincipalRepaidAmount" xlink:to="avco_PrincipalRepaidAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" xlink:to="avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CostsAndExpensesAbstract0_lbl0" xml:lang="en-US">CostsAndExpensesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CostsAndExpensesAbstract0" xlink:to="avco_CostsAndExpensesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WorkingCapital_lbl0" xml:lang="en-US">WorkingCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapital" xlink:to="avco_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherIncomeExpenseAbstract0_lbl0" xml:lang="en-US">OtherIncomeExpenseAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeExpenseAbstract0" xlink:to="avco_OtherIncomeExpenseAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NumberOfCustomer_lbl0" xml:lang="en-US">NumberOfCustomer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfCustomer" xlink:to="avco_NumberOfCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeFourMember_lbl0" xml:lang="en-US">ExercisePriceRangeFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFourMember" xlink:to="avco_ExercisePriceRangeFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationOfRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExchangeForCommonStock_lbl1" xml:lang="en-US">ExchangeForCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExchangeForCommonStock" xlink:to="avco_ExchangeForCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidResearchAndDevelopmentFees_lbl1" xml:lang="en-US">PrepaidResearchAndDevelopmentFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidResearchAndDevelopmentFees" xlink:to="avco_PrepaidResearchAndDevelopmentFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LimitedInsurance_lbl0" xml:lang="en-US">LimitedInsurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LimitedInsurance" xlink:to="avco_LimitedInsurance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_UnicornMember_lbl0" xml:lang="en-US">UnicornMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_UnicornMember" xlink:to="avco_UnicornMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonStockIssuedForFutureServices_lbl1" xml:lang="en-US">CommonStockIssuedForFutureServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStockIssuedForFutureServices" xlink:to="avco_CommonStockIssuedForFutureServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeFiveMember_lbl0" xml:lang="en-US">ExercisePriceRangeFiveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeFiveMember" xlink:to="avco_ExercisePriceRangeFiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeThreeMember_lbl0" xml:lang="en-US">ExercisePriceRangeThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeThreeMember" xlink:to="avco_ExercisePriceRangeThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerConcentrationRiskThreeMember_lbl1" xml:lang="en-US">CustomerConcentrationRiskThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskThreeMember" xlink:to="avco_CustomerConcentrationRiskThreeMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LongtermPortion_lbl0" xml:lang="en-US">LongtermPortion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LongtermPortion" xlink:to="avco_LongtermPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LiabilitiesAndEquityAbstract_lbl0" xml:lang="en-US">LiabilitiesAndEquityAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LiabilitiesAndEquityAbstract" xlink:to="avco_LiabilitiesAndEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CompensationAndRelatedBenefitsMember_lbl0" xml:lang="en-US">CompensationAndRelatedBenefitsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CompensationAndRelatedBenefitsMember" xlink:to="avco_CompensationAndRelatedBenefitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockPurchaseAgreementDescription_lbl1" xml:lang="en-US">StockPurchaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockPurchaseAgreementDescription" xlink:to="avco_StockPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OperatingLeaseLiabilities_lbl1" xml:lang="en-US">OperatingLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingLeaseLiabilities" xlink:to="avco_OperatingLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InternationalExosomeAssociationLlcMember_lbl0" xml:lang="en-US">InternationalExosomeAssociationLlcMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InternationalExosomeAssociationLlcMember" xlink:to="avco_InternationalExosomeAssociationLlcMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyOperationsMember_lbl0" xml:lang="en-US">RealPropertyOperationsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperationsMember" xlink:to="avco_RealPropertyOperationsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductMember_lbl0" xml:lang="en-US">DevelopmentServicesAndSalesOfDevelopedProductMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DevelopmentServicesAndSalesOfDevelopedProductMember" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ProfessionalFeesMember_lbl0" xml:lang="en-US">ProfessionalFeesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProfessionalFeesMember" xlink:to="avco_ProfessionalFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:to="avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OperatingLease_lbl0" xml:lang="en-US">OperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OperatingLease" xlink:to="avco_OperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherOperatingExpensesAbstract_lbl0" xml:lang="en-US">OtherOperatingExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherOperatingExpensesAbstract" xlink:to="avco_OtherOperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonSharesIssuedForServicesMember_lbl0" xml:lang="en-US">CommonSharesIssuedForServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonSharesIssuedForServicesMember" xlink:to="avco_CommonSharesIssuedForServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AdditionalInvestmentInEquityMethodInvestment_lbl1" xml:lang="en-US">AdditionalInvestmentInEquityMethodInvestment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AdditionalInvestmentInEquityMethodInvestment" xlink:to="avco_AdditionalInvestmentInEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MedicalRelatedConsultingServicesRelatedPartyMember_lbl0" xml:lang="en-US">MedicalRelatedConsultingServicesRelatedPartyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MedicalRelatedConsultingServicesRelatedPartyMember" xlink:to="avco_MedicalRelatedConsultingServicesRelatedPartyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerConcentrationRiskOneMember_lbl1" xml:lang="en-US">CustomerConcentrationRiskOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskOneMember" xlink:to="avco_CustomerConcentrationRiskOneMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockOptionsMember_lbl0" xml:lang="en-US">StockOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockOptionsMember" xlink:to="avco_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl0" xml:lang="en-US">LessCommonStockHeldInTreasuryAtCostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LessCommonStockHeldInTreasuryAtCostAbstract" xlink:to="avco_LessCommonStockHeldInTreasuryAtCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LossOnFixedAssetsDisposal_lbl1" xml:lang="en-US">LossOnFixedAssetsDisposal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnFixedAssetsDisposal" xlink:to="avco_LossOnFixedAssetsDisposal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ProceedsReceivedFromLoanPayable_lbl1" xml:lang="en-US">ProceedsReceivedFromLoanPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromLoanPayable" xlink:to="avco_ProceedsReceivedFromLoanPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserve_lbl1" xml:lang="en-US">StatutoryReserve</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserve" xlink:to="avco_StatutoryReserve_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NumberOfOptionsMember_lbl0" xml:lang="en-US">NumberOfOptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfOptionsMember" xlink:to="avco_NumberOfOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DrYuZhouMember_lbl0" xml:lang="en-US">DrYuZhouMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DrYuZhouMember" xlink:to="avco_DrYuZhouMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherIncomeLossFromEquityMethodInvestment_lbl0" xml:lang="en-US">OtherIncomeLossFromEquityMethodInvestment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeLossFromEquityMethodInvestment" xlink:to="avco_OtherIncomeLossFromEquityMethodInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PercentageOfOwnership_lbl1" xml:lang="en-US">PercentageOfOwnership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfOwnership" xlink:to="avco_PercentageOfOwnership_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherIncomeExpenseAbstract_lbl0" xml:lang="en-US">OtherIncomeExpenseAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherIncomeExpenseAbstract" xlink:to="avco_OtherIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CurrentPortion_lbl0" xml:lang="en-US">CurrentPortion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CurrentPortion" xlink:to="avco_CurrentPortion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WorkingCapitalDeficit_lbl1" xml:lang="en-US">WorkingCapitalDeficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WorkingCapitalDeficit" xlink:to="avco_WorkingCapitalDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InterestExpenses_lbl1" xml:lang="en-US">InterestExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InterestExpenses" xlink:to="avco_InterestExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CorporateOtherMember_lbl0" xml:lang="en-US">CorporateOtherMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CorporateOtherMember" xlink:to="avco_CorporateOtherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_GrossProfitAbstract0_lbl0" xml:lang="en-US">GrossProfitAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GrossProfitAbstract0" xlink:to="avco_GrossProfitAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl1" xml:lang="en-US">BeijingJietengGenExosomeBiotechCoLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BeijingJietengGenExosomeBiotechCoLtdMember" xlink:to="avco_BeijingJietengGenExosomeBiotechCoLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl1" xml:lang="en-US">ForeignCurrencyFluctuationEquityMethodInvestments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ForeignCurrencyFluctuationEquityMethodInvestments" xlink:to="avco_ForeignCurrencyFluctuationEquityMethodInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LineOfCreditAgreementMember_lbl0" xml:lang="en-US">LineOfCreditAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LineOfCreditAgreementMember" xlink:to="avco_LineOfCreditAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvactisBiosciencesIncMember_lbl0" xml:lang="en-US">AvactisBiosciencesIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvactisBiosciencesIncMember" xlink:to="avco_AvactisBiosciencesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredFinancingCostsInAccruedLiabilities_lbl0" xml:lang="en-US">DeferredFinancingCostsInAccruedLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredFinancingCostsInAccruedLiabilities" xlink:to="avco_DeferredFinancingCostsInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl1" xml:lang="en-US">TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:to="avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract_lbl0" xml:lang="en-US">a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract" xlink:to="avco_a84943564SharesIssuedAnd84423564SharesOutstandingAtMarch312021Abstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl1" xml:lang="en-US">PrepaidDirectorsAndOfficersLiabilityInsurancePremium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:to="avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedTenantsImprovementReimbursement_lbl1" xml:lang="en-US">AccruedTenantsImprovementReimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedTenantsImprovementReimbursement" xlink:to="avco_AccruedTenantsImprovementReimbursement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_SharesBasedCompensation_lbl1" xml:lang="en-US">SharesBasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_SharesBasedCompensation" xlink:to="avco_SharesBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonShanghaiMember_lbl0" xml:lang="en-US">AvalonShanghaiMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiMember" xlink:to="avco_AvalonShanghaiMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StatutoryReserveMember_lbl0" xml:lang="en-US">StatutoryReserveMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StatutoryReserveMember" xlink:to="avco_StatutoryReserveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePrice_lbl1" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePrice" xlink:to="avco_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract_lbl0" xml:lang="en-US">CommonStock00001ParValue490000000SharesAuthorizedAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract" xlink:to="avco_CommonStock00001ParValue490000000SharesAuthorizedAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_MedicalRelatedConsultingServicesMember_lbl1" xml:lang="en-US">MedicalRelatedConsultingServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_MedicalRelatedConsultingServicesMember" xlink:to="avco_MedicalRelatedConsultingServicesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedResearchAndDevelopmentsFees_lbl1" xml:lang="en-US">AccruedResearchAndDevelopmentsFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentsFees" xlink:to="avco_AccruedResearchAndDevelopmentsFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AccruedResearchAndDevelopmentFee_lbl1" xml:lang="en-US">AccruedResearchAndDevelopmentFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AccruedResearchAndDevelopmentFee" xlink:to="avco_AccruedResearchAndDevelopmentFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock_lbl0" xml:lang="en-US">InvestmentInUnconsolidatedCompanyPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock" xlink:to="avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertiesOperatingIncome_lbl0" xml:lang="en-US">RealPropertiesOperatingIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertiesOperatingIncome" xlink:to="avco_RealPropertiesOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JointVentureAgreementDescription_lbl0" xml:lang="en-US">JointVentureAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JointVentureAgreementDescription" xlink:to="avco_JointVentureAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidNasdaqListingFee_lbl1" xml:lang="en-US">PrepaidNasdaqListingFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidNasdaqListingFee" xlink:to="avco_PrepaidNasdaqListingFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeOneMember_lbl0" xml:lang="en-US">ExercisePriceRangeOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeOneMember" xlink:to="avco_ExercisePriceRangeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PercentageOfCapitalStock_lbl1" xml:lang="en-US">PercentageOfCapitalStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PercentageOfCapitalStock" xlink:to="avco_PercentageOfCapitalStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LoanFromLender_lbl1" xml:lang="en-US">LoanFromLender</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanFromLender" xlink:to="avco_LoanFromLender_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DavidJinMember_lbl0" xml:lang="en-US">DavidJinMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DavidJinMember" xlink:to="avco_DavidJinMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_JefferiesLLCMember_lbl0" xml:lang="en-US">JefferiesLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_JefferiesLLCMember" xlink:to="avco_JefferiesLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CreditRiskAndUncertaintiePolicyTextBlock_lbl0" xml:lang="en-US">CreditRiskAndUncertaintiePolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CreditRiskAndUncertaintiePolicyTextBlock" xlink:to="avco_CreditRiskAndUncertaintiePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonRT9PropertiesLLCMember_lbl1" xml:lang="en-US">AvalonRT9PropertiesLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonRT9PropertiesLLCMember" xlink:to="avco_AvalonRT9PropertiesLLCMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised_lbl0" xml:lang="en-US">StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" xlink:to="avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RegisteredCapitalPercentage_lbl0" xml:lang="en-US">RegisteredCapitalPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RegisteredCapitalPercentage" xlink:to="avco_RegisteredCapitalPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DeferredLeasingCosts_lbl1" xml:lang="en-US">DeferredLeasingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DeferredLeasingCosts" xlink:to="avco_DeferredLeasingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RevenuesAbstract0_lbl0" xml:lang="en-US">RevenuesAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RevenuesAbstract0" xlink:to="avco_RevenuesAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ConsiderationCash_lbl0" xml:lang="en-US">ConsiderationCash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ConsiderationCash" xlink:to="avco_ConsiderationCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LoanRecevied_lbl1" xml:lang="en-US">LoanRecevied</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LoanRecevied" xlink:to="avco_LoanRecevied_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DisbursementsForEqutyOfferingCosts_lbl1" xml:lang="en-US">DisbursementsForEqutyOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DisbursementsForEqutyOfferingCosts" xlink:to="avco_DisbursementsForEqutyOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashAndDueFromBank_lbl1" xml:lang="en-US">CashAndDueFromBank</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashAndDueFromBank" xlink:to="avco_CashAndDueFromBank_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_OtherUnrelatedCompanyMember_lbl0" xml:lang="en-US">OtherUnrelatedCompanyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_OtherUnrelatedCompanyMember" xlink:to="avco_OtherUnrelatedCompanyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ExercisePriceRangeTwoMember_lbl0" xml:lang="en-US">ExercisePriceRangeTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ExercisePriceRangeTwoMember" xlink:to="avco_ExercisePriceRangeTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashAndCashEquivalentsDescription_lbl0" xml:lang="en-US">CashAndCashEquivalentsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashAndCashEquivalentsDescription" xlink:to="avco_CashAndCashEquivalentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FairValueOfOptionGrantedDescription_lbl0" xml:lang="en-US">FairValueOfOptionGrantedDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FairValueOfOptionGrantedDescription" xlink:to="avco_FairValueOfOptionGrantedDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonHealthcareSystemIncMember_lbl0" xml:lang="en-US">AvalonHealthcareSystemIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonHealthcareSystemIncMember" xlink:to="avco_AvalonHealthcareSystemIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl0" xml:lang="en-US">AvalonShanghaiHealthcareTechnologyCoLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:to="avco_AvalonShanghaiHealthcareTechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ProceedsReceivedFromEquityOffering_lbl1" xml:lang="en-US">ProceedsReceivedFromEquityOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ProceedsReceivedFromEquityOffering" xlink:to="avco_ProceedsReceivedFromEquityOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_IncreaseDecreaseOperatingLease_lbl0" xml:lang="en-US">IncreaseDecreaseOperatingLease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_IncreaseDecreaseOperatingLease" xlink:to="avco_IncreaseDecreaseOperatingLease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_BuildingOccupancyRate_lbl1" xml:lang="en-US">BuildingOccupancyRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_BuildingOccupancyRate" xlink:to="avco_BuildingOccupancyRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract_lbl0" xml:lang="en-US">RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:to="avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember_lbl0" xml:lang="en-US">DevelopmentServicesAndSalesOfDevelopedProductsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember" xlink:to="avco_DevelopmentServicesAndSalesOfDevelopedProductsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_PrepaidProfessionalFees_lbl1" xml:lang="en-US">PrepaidProfessionalFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_PrepaidProfessionalFees" xlink:to="avco_PrepaidProfessionalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RestrictedNetAssetsTextBlock_lbl1" xml:lang="en-US">RestrictedNetAssetsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RestrictedNetAssetsTextBlock" xlink:to="avco_RestrictedNetAssetsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EntityIncorporationsStateCountryName_lbl1" xml:lang="en-US">EntityIncorporationsStateCountryName</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EntityIncorporationsStateCountryName" xlink:to="avco_EntityIncorporationsStateCountryName_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_FederallyinsuredLimits_lbl0" xml:lang="en-US">FederallyinsuredLimits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_FederallyinsuredLimits" xlink:to="avco_FederallyinsuredLimits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NumberOfReportableBusinessSegments_lbl0" xml:lang="en-US">NumberOfReportableBusinessSegments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfReportableBusinessSegments" xlink:to="avco_NumberOfReportableBusinessSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_LossOnEquityMethodInvestment_lbl1" xml:lang="en-US">LossOnEquityMethodInvestment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_LossOnEquityMethodInvestment" xlink:to="avco_LossOnEquityMethodInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_ScheduleOfFinancialInformationByInvestee_lbl1" xml:lang="en-US">ScheduleOfFinancialInformationByInvestee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_ScheduleOfFinancialInformationByInvestee" xlink:to="avco_ScheduleOfFinancialInformationByInvestee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerConcentrationRiskTwoMember_lbl0" xml:lang="en-US">CustomerConcentrationRiskTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerConcentrationRiskTwoMember" xlink:to="avco_CustomerConcentrationRiskTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_GenExosomeTechnologiesIncMember_lbl1" xml:lang="en-US">GenExosomeTechnologiesIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeTechnologiesIncMember" xlink:to="avco_GenExosomeTechnologiesIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_NumberOfSupplier_lbl0" xml:lang="en-US">NumberOfSupplier</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_NumberOfSupplier" xlink:to="avco_NumberOfSupplier_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_CustomerMember_lbl0" xml:lang="en-US">CustomerMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_CustomerMember" xlink:to="avco_CustomerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_WeightedAverageExercisePriceMember_lbl0" xml:lang="en-US">WeightedAverageExercisePriceMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_WeightedAverageExercisePriceMember" xlink:to="avco_WeightedAverageExercisePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_GenExosomeMember_lbl0" xml:lang="en-US">GenExosomeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_GenExosomeMember" xlink:to="avco_GenExosomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_AvalonBVILtdMember_lbl0" xml:lang="en-US">AvalonBVILtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_AvalonBVILtdMember" xlink:to="avco_AvalonBVILtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_RealPropertyOperatingExpenses_lbl1" xml:lang="en-US">RealPropertyOperatingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_RealPropertyOperatingExpenses" xlink:to="avco_RealPropertyOperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl1" xml:lang="en-US">EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:to="avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl0" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl0" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl0" xml:lang="en-US">Chief Operating Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl1" xml:lang="en-US">Interest Expense, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl0" xml:lang="en-US">Long-term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl0" xml:lang="en-US">Labor and Related Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl0" xml:lang="en-US">Deferred Costs, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl0" xml:lang="en-US">Other Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl0" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl0" xml:lang="en-US">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl2" xml:lang="en-US">Concentration Risk, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Other Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl0" xml:lang="en-US">Loans Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfitAbstract_lbl0" xml:lang="en-US">Gross Profit [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfitAbstract" xlink:to="us-gaap_GrossProfitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncome_lbl0" xml:lang="en-US">Deferred Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Reclassifications_lbl0" xml:lang="en-US">Reclassifications [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Reclassifications" xlink:to="us-gaap_Reclassifications_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsPercentOfNetAssets_lbl0" xml:lang="en-US">Restricted Investments, Percent of Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsPercentOfNetAssets" xlink:to="us-gaap_RestrictedInvestmentsPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl0" xml:lang="en-US">Revenue from Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets_lbl0" xml:lang="en-US">Non Investment Assets Less Non Investment Liabilities, Percent of Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" xlink:to="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl0" xml:lang="en-US">Long-term Line of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl0" xml:lang="en-US">Other Prepaid Expense, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Real Estate Properties [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StraightLineRent_lbl0" xml:lang="en-US">Straight Line Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRent" xlink:to="us-gaap_StraightLineRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl1" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl0" xml:lang="en-US">Accrued Bonuses, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl0" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateInvestments_lbl0" xml:lang="en-US">Real Estate Investments, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateInvestments" xlink:to="us-gaap_RealEstateInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl2" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl0" xml:lang="en-US">Equity Method Investment, Aggregate Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl0" xml:lang="en-US">Revenue Benchmark [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplyCommitmentTableTextBlock_lbl0" xml:lang="en-US">Supply Commitment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplyCommitmentTableTextBlock" xlink:to="us-gaap_SupplyCommitmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl0" xml:lang="en-US">Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValueAddedTaxReceivable_lbl0" xml:lang="en-US">Value Added Tax Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivable" xlink:to="us-gaap_ValueAddedTaxReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl0" xml:lang="en-US">CHINA</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl1" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl1" xml:lang="en-US">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndDueFromBanks_lbl0" xml:lang="en-US">Cash and Due from Banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndDueFromBanks" xlink:to="us-gaap_CashAndDueFromBanks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl0" xml:lang="en-US">Notes Payable, Related Parties, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherLosses_lbl0" xml:lang="en-US">Provision for Other Losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherLosses" xlink:to="us-gaap_ProvisionForOtherLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl0" xml:lang="en-US">Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0" xml:lang="en-US">Short-term Debt, Percentage Bearing Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl0" xml:lang="en-US">Treasury Stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl0" xml:lang="en-US">Deferred Costs, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl0" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockOtherSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockOtherSharesOutstanding" xlink:to="us-gaap_CommonStockOtherSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl0" xml:lang="en-US">Supplies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsLeasingNet_lbl0" xml:lang="en-US">Deferred Costs, Leasing, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsLeasingNet" xlink:to="us-gaap_DeferredCostsLeasingNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl0" xml:lang="en-US">Costs and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl0" xml:lang="en-US">UNITED STATES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl0" xml:lang="en-US">Equity Method Investment, Description of Principal Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseAbstract_lbl0" xml:lang="en-US">Interest Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseAbstract" xlink:to="us-gaap_InterestExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>avco-20210331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri May 14 14:08:13 UTC 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedBalanceSheet" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedIncomeStatement" roleURI="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ShareholdersEquityType2or3" roleURI="http://www.avalonglobocare.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConsolidatedCashFlow" roleURI="http://www.avalonglobocare.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperations" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_BasisofPresentationandGoingConcernCondition" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_PrepaidExpensesandOtherCurrentAssets" roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestment" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestment"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccruedLiabilitiesandOtherPayables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RelatedPartyTransactions" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_Equity" roleURI="http://www.avalonglobocare.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_StatutoryReserve" roleURI="http://www.avalonglobocare.com/role/StatutoryReserve"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RestrictedNetAssets" roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssets"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_Concentrations" roleURI="http://www.avalonglobocare.com/role/Concentrations"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformation" roleURI="http://www.avalonglobocare.com/role/SegmentInformation"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingencies" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SubsequentEvents" roleURI="http://www.avalonglobocare.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccountingPoliciesByPolicy" roleURI="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperationsTables" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_PrepaidExpensesandOtherCurrentAssetsTables" roleURI="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestmentTables" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_AccruedLiabilitiesandOtherPayablesTables" roleURI="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityTables" roleURI="http://www.avalonglobocare.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConcentrationsTables" roleURI="http://www.avalonglobocare.com/role/ConcentrationsTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformationTables" roleURI="http://www.avalonglobocare.com/role/SegmentInformationTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingenciesTables" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcashbalancesbygeographicareaTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofprepaidexpensesandothercurrentassetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofequitymethodinvestmentTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffinancialinformationinvesteeTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffinancialinformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofaccruedliabilitiesandotherpayablesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofstockoptionsoutstandingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofstockoptionactivitiesTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" roleURI="http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofcustomersTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofcustomersTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofsegmentreportinginformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofrealpropertyoperatingTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofidentifiablelonglivedtangibleassetsTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofsupplementalcashflowinformationTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ScheduleofmaturityofleaseliabilityTable" roleURI="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_OrganizationandNatureofOperationsDetails" roleURI="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_BasisofPresentationandGoingConcernConditionDetails" roleURI="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityMethodInvestmentDetails" roleURI="http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RelatedPartyTransactionsDetails" roleURI="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_EquityDetails" roleURI="http://www.avalonglobocare.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_StatutoryReserveDetails" roleURI="http://www.avalonglobocare.com/role/StatutoryReserveDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_RestrictedNetAssetsDetails" roleURI="http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_ConcentrationsDetails" roleURI="http://www.avalonglobocare.com/role/ConcentrationsDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_SegmentInformationDetails" roleURI="http://www.avalonglobocare.com/role/SegmentInformationDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#avco_r_CommitmentsandContingenciesDetails" roleURI="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="avco-20210331.xsd#DocumentAndEntityInformation" roleURI="http://www.avalonglobocare.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" xlink:href="avco-20210331.xsd#avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_DeferredCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealEstateInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealEstateInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RealEstateInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_AssetsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesAndEquityAbstract" xlink:href="avco-20210331.xsd#avco_LiabilitiesAndEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentsFees" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentsFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AccruedResearchAndDevelopmentsFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedPayrollTaxesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLoansPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermLoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_Liabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserve" xlink:href="avco-20210331.xsd#avco_StatutoryReserve"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StatutoryReserve" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_MinorityInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockOtherSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockOtherSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperatingExpenses" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="RealPropertyOperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfitAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfitAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfitAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RealPropertiesOperatingIncome" xlink:href="avco-20210331.xsd#avco_RealPropertiesOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GrossProfitAbstract" xlink:to="RealPropertiesOperatingIncome" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LaborAndRelatedExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LaborAndRelatedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherExpensesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_InterestExpenseRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeLossFromEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_OtherIncomeLossFromEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="OtherIncomeLossFromEquityMethodInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss_0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveMember" xlink:href="avco-20210331.xsd#avco_StatutoryReserveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StatutoryReserveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="8.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProvisionForOtherLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForOtherLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForOtherLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StraightLineRent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StraightLineRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StraightLineRent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_LossOnEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossOnEquityMethodInvestment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnFixedAssetsDisposal" xlink:href="avco-20210331.xsd#avco_LossOnFixedAssetsDisposal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossOnFixedAssetsDisposal" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInSecurityDeposits" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredLeasingCosts" xlink:href="avco-20210331.xsd#avco_DeferredLeasingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="DeferredLeasingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseOperatingLease" xlink:href="avco-20210331.xsd#avco_IncreaseDecreaseOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseOperatingLease" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInvestmentInEquityMethodInvestment" xlink:href="avco-20210331.xsd#avco_AdditionalInvestmentInEquityMethodInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="AdditionalInvestmentInEquityMethodInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsReceivedFromLoanPayable" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromLoanPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsReceivedFromLoanPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsReceivedFromEquityOffering" xlink:href="avco-20210331.xsd#avco_ProceedsReceivedFromEquityOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsReceivedFromEquityOffering" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DisbursementsForEqutyOfferingCosts" xlink:href="avco-20210331.xsd#avco_DisbursementsForEqutyOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="DisbursementsForEqutyOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedForFutureServices" xlink:href="avco-20210331.xsd#avco_CommonStockIssuedForFutureServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="CommonStockIssuedForFutureServices" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredFinancingCostsInAccruedLiabilities" xlink:href="avco-20210331.xsd#avco_DeferredFinancingCostsInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="DeferredFinancingCostsInAccruedLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperations">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/StatutoryReserve">
    <loc xlink:type="locator" xlink:label="StatutoryReserveAbstract" xlink:href="avco-20210331.xsd#avco_StatutoryReserveAbstract"/>
    <loc xlink:type="locator" xlink:label="StatutoryReserveTextBlock" xlink:href="avco-20210331.xsd#avco_StatutoryReserveTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatutoryReserveAbstract" xlink:to="StatutoryReserveTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RestrictedNetAssets">
    <loc xlink:type="locator" xlink:label="RestrictedNetAssetsAbstract" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="RestrictedNetAssetsTextBlock" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedNetAssetsAbstract" xlink:to="RestrictedNetAssetsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/Concentrations">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformation">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CreditRiskAndUncertaintiePolicyTextBlock" xlink:href="avco-20210331.xsd#avco_CreditRiskAndUncertaintiePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CreditRiskAndUncertaintiePolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentInUnconsolidatedCompanyPolicyTextBlock" xlink:href="avco-20210331.xsd#avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="InvestmentInUnconsolidatedCompanyPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Reclassifications" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Reclassifications"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Reclassifications" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationByInvestee" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationByInvestee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="ScheduleOfFinancialInformationByInvestee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConcentrationsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_SupplyCommitmentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ScheduleOfSupplementalBalanceSheetInformationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanysSubsidiariesConsolidatedFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AvalonHealthcareSystemIncMember" xlink:href="avco-20210331.xsd#avco_AvalonHealthcareSystemIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvalonHealthcareSystemIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonBVILtdMember" xlink:href="avco-20210331.xsd#avco_AvalonBVILtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvalonBVILtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9PropertiesLLCMember" xlink:href="avco-20210331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvalonRT9PropertiesLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvalonShanghaiHealthcareTechnologyCoLtdMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiHealthcareTechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvalonShanghaiHealthcareTechnologyCoLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenExosomeTechnologiesIncMember" xlink:href="avco-20210331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="GenExosomeTechnologiesIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingJietengGenExosomeBiotechCoLtdMember" xlink:href="avco-20210331.xsd#avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="BeijingJietengGenExosomeBiotechCoLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AvactisBiosciencesIncMember" xlink:href="avco-20210331.xsd#avco_AvactisBiosciencesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvactisBiosciencesIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InternationalExosomeAssociationLlcMember" xlink:href="avco-20210331.xsd#avco_InternationalExosomeAssociationLlcMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="InternationalExosomeAssociationLlcMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_CondensedFinancialStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="EntityIncorporationsStateCountryName" xlink:href="avco-20210331.xsd#avco_EntityIncorporationsStateCountryName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="EntityIncorporationsStateCountryName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOwnership" xlink:href="avco-20210331.xsd#avco_PercentageOfOwnership"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="PercentageOfOwnership" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCashBalancesByGeographicAreaAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashBalancesByGeographicAreaAbstract" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndDueFromBanks" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndDueFromBanks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_CashAndDueFromBanks" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheEffectOfIncludingThesePotentialSharesWasAntidilutiveAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="avco-20210331.xsd#avco_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="PrepaidNasdaqListingFee" xlink:href="avco-20210331.xsd#avco_PrepaidNasdaqListingFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidNasdaqListingFee" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidDirectorsAndOfficersLiabilityInsurancePremium" xlink:href="avco-20210331.xsd#avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidDirectorsAndOfficersLiabilityInsurancePremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidProfessionalFees" xlink:href="avco-20210331.xsd#avco_PrepaidProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidProfessionalFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_ValueAddedTaxReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCostsLeasingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCostsLeasingNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_DeferredCostsLeasingNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidResearchAndDevelopmentFees" xlink:href="avco-20210331.xsd#avco_PrepaidResearchAndDevelopmentFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="PrepaidResearchAndDevelopmentFees" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityMethodInvestmentAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfEquityMethodInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentMadeForEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_PaymentMadeForEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="PaymentMadeForEquityMethodInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_IncomeLossAttributableToParent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyFluctuationEquityMethodInvestments" xlink:href="avco-20210331.xsd#avco_ForeignCurrencyFluctuationEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="ForeignCurrencyFluctuationEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra/k4DNHXVKIYwN/zLXIt0iwZq6nYg/w27/nmgU3Bs4kyGGa1okQf8wpc8xue3C4gYCyO+De2FMpOhOFB06gcfgiWU4RrsSlFLeTHIiU8hGGgzUrMur97kPcwaMkx0Rm8rOKaMffs1tA6JgUsU2qTq+eCLMln/6lQUJ9vcFEv8wY5L+FjnCBhBlFCcrfQMfVbtBznmqMC59tQQIPm6FJmTh] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityMethodInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestments_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationInvesteeAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationOfEquity" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationInvesteeAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationOfEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFinancialInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationOfRevenue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialInformationAbstract" xlink:to="EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopmentFee" xlink:href="avco-20210331.xsd#avco_AccruedResearchAndDevelopmentFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="AccruedResearchAndDevelopmentFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedTenantsImprovementReimbursement" xlink:href="avco-20210331.xsd#avco_AccruedTenantsImprovementReimbursement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="AccruedTenantsImprovementReimbursement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Deposits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Deposits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_Deposits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_DeferredIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionsOutstandingAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfStockOptionsOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionsOutstandingAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeThreeMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFourMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFourMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeFiveMember" xlink:href="avco-20210331.xsd#avco_ExercisePriceRangeFiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeFiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="avco-20210331.xsd#avco_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="ExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivitiesAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfStockOptionActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofstockoptionactivitiesTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleofstockoptionactivitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivitiesAbstract" xlink:to="EquityDetailsScheduleofstockoptionactivitiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsMember" xlink:href="avco-20210331.xsd#avco_NumberOfOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="NumberOfOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceMember" xlink:href="avco-20210331.xsd#avco_WeightedAverageExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WeightedAverageExercisePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesTable" xlink:to="EquityDetailsScheduleofstockoptionactivitiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" xlink:href="avco-20210331.xsd#avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" xlink:href="avco-20210331.xsd#avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleofstockoptionactivitiesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheOptionsUsingTheBlackScholesOptionPricingModelAbstract" xlink:to="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfOptionsMember" xlink:href="avco-20210331.xsd#avco_NumberOfOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="NumberOfOptionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceMember" xlink:href="avco-20210331.xsd#avco_WeightedAverageExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="WeightedAverageExercisePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable" xlink:to="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofcustomersTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCustomersAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfCustomersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplyCommitmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplyCommitmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCustomersAbstract" xlink:to="us-gaap_SupplyCommitmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationRiskOneMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="CustomerConcentrationRiskOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationRiskTwoMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="CustomerConcentrationRiskTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CustomerConcentrationRiskThreeMember" xlink:href="avco-20210331.xsd#avco_CustomerConcentrationRiskThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="CustomerConcentrationRiskThreeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentTable" xlink:to="us-gaap_SupplyCommitmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplyCommitmentLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSegmentReportingInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfSegmentReportingInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperationsMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperationsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperationsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalRelatedConsultingServicesRelatedPartyMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesRelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="MedicalRelatedConsultingServicesRelatedPartyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentServicesAndSalesOfDevelopedProductMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="DevelopmentServicesAndSalesOfDevelopedProductMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20210331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_CostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OperatingExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestExpenses" xlink:href="avco-20210331.xsd#avco_InterestExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="InterestExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRealPropertyOperatingAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfRealPropertyOperatingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRealPropertyOperatingAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RealPropertyOperatingMember" xlink:href="avco-20210331.xsd#avco_RealPropertyOperatingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="RealPropertyOperatingMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MedicalRelatedConsultingServicesMember" xlink:href="avco-20210331.xsd#avco_MedicalRelatedConsultingServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="MedicalRelatedConsultingServicesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentServicesAndSalesOfDevelopedProductsMember" xlink:href="avco-20210331.xsd#avco_DevelopmentServicesAndSalesOfDevelopedProductsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="DevelopmentServicesAndSalesOfDevelopedProductsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateOtherMember" xlink:href="avco-20210331.xsd#avco_CorporateOtherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="CorporateOtherMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherFiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherFiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherFiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable"/>
    <loc xlink:type="locator" xlink:label="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:href="avco-20210331.xsd#avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIdentifiableLongLivedTangibleAssetsAbstract" xlink:to="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="country_CN" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_CN" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsTable" xlink:to="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfSupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="avco-20210331.xsd#avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingCashFlowPaidForOperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingCashFlowPaidForOperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="OperatingCashFlowPaidForOperatingLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:href="avco-20210331.xsd#avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalCashFlowInformationAbstract" xlink:to="RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLease" xlink:href="avco-20210331.xsd#avco_OperatingLease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract" xlink:to="OperatingLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:href="avco-20210331.xsd#avco_ScheduleOfMaturityOfLeaseLiabilityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturityOfLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfLeasePaymentsRepresentingInterest" xlink:href="avco-20210331.xsd#avco_AmountOfLeasePaymentsRepresentingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="AmountOfLeasePaymentsRepresentingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilities" xlink:href="avco-20210331.xsd#avco_OperatingLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="OperatingLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentPortion" xlink:href="avco-20210331.xsd#avco_CurrentPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="CurrentPortion" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongtermPortion" xlink:href="avco-20210331.xsd#avco_LongtermPortion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="LongtermPortion" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LongTermDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofOperationsDetailsTable" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandNatureofOperationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_OrganizationandNatureofOperationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandNatureofOperationsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvalonRT9PropertiesLLCMember" xlink:href="avco-20210331.xsd#avco_AvalonRT9PropertiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="AvalonRT9PropertiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="BeijingJietengGenExosomeBiotechCoLtdMember" xlink:href="avco-20210331.xsd#avco_BeijingJietengGenExosomeBiotechCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="BeijingJietengGenExosomeBiotechCoLtdMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GenExosomeTechnologiesIncMember" xlink:href="avco-20210331.xsd#avco_GenExosomeTechnologiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="GenExosomeTechnologiesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DrYuZhouMember" xlink:href="avco-20210331.xsd#avco_DrYuZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="DrYuZhouMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsTable" xlink:to="OrganizationandNatureofOperationsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeForCommonStock" xlink:href="avco-20210331.xsd#avco_ExchangeForCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsLineItems" xlink:to="ExchangeForCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCapitalStock" xlink:href="avco-20210331.xsd#avco_PercentageOfCapitalStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsLineItems" xlink:to="PercentageOfCapitalStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BuildingOccupancyRate" xlink:href="avco-20210331.xsd#avco_BuildingOccupancyRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsLineItems" xlink:to="BuildingOccupancyRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandNatureofOperationsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="WorkingCapitalDeficit" xlink:href="avco-20210331.xsd#avco_WorkingCapitalDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="WorkingCapitalDeficit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_StatementGeographicalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="country_US" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CashAndCashEquivalentsDescription" xlink:href="avco-20210331.xsd#avco_CashAndCashEquivalentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="CashAndCashEquivalentsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAndDueFromBank" xlink:href="avco-20210331.xsd#avco_CashAndDueFromBank"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="CashAndDueFromBank" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LimitedInsurance" xlink:href="avco-20210331.xsd#avco_LimitedInsurance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="LimitedInsurance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederallyinsuredLimits" xlink:href="avco-20210331.xsd#avco_FederallyinsuredLimits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="FederallyinsuredLimits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityMethodInvestmentDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="EquityMethodInvestmentDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="SubsidiaryAxis" xlink:href="avco-20210331.xsd#avco_SubsidiaryAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentDetailsTable" xlink:to="SubsidiaryAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubsidiaryDomain" xlink:href="avco-20210331.xsd#avco_SubsidiaryDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryAxis" xlink:to="SubsidiaryDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OtherUnrelatedCompanyMember" xlink:href="avco-20210331.xsd#avco_OtherUnrelatedCompanyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryAxis" xlink:to="OtherUnrelatedCompanyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnicornMember" xlink:href="avco-20210331.xsd#avco_UnicornMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiaryAxis" xlink:to="UnicornMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentDetailsTable" xlink:to="EquityMethodInvestmentDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentDetailsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefOperatingOfficerMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefOperatingOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ChiefOperatingOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DavidJinMember" xlink:href="avco-20210331.xsd#avco_DavidJinMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DavidJinMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DrYuZhouMember" xlink:href="avco-20210331.xsd#avco_DrYuZhouMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="DrYuZhouMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenExosomeMember" xlink:href="avco-20210331.xsd#avco_GenExosomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenExosomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WenzhaoLuMember" xlink:href="avco-20210331.xsd#avco_WenzhaoLuMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="WenzhaoLuMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LineOfCreditAgreementMember" xlink:href="avco-20210331.xsd#avco_LineOfCreditAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LineOfCreditAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsiderationCash" xlink:href="avco-20210331.xsd#avco_ConsiderationCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="ConsiderationCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_NotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrincipalRepaidAmount" xlink:href="avco-20210331.xsd#avco_PrincipalRepaidAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="PrincipalRepaidAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtPercentageBearingFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_ShortTermDebtPercentageBearingFixedInterestRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanFromLender" xlink:href="avco-20210331.xsd#avco_LoanFromLender"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="LoanFromLender" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="avco-20210331.xsd#avco_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="avco-20210331.xsd#avco_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JefferiesLLCMember" xlink:href="avco-20210331.xsd#avco_JefferiesLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="JefferiesLLCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonSharesIssuedForServicesMember" xlink:href="avco-20210331.xsd#avco_CommonSharesIssuedForServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="CommonSharesIssuedForServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CompensationAndRelatedBenefitsMember" xlink:href="avco-20210331.xsd#avco_CompensationAndRelatedBenefitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="CompensationAndRelatedBenefitsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProfessionalFeesMember" xlink:href="avco-20210331.xsd#avco_ProfessionalFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="ProfessionalFeesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesBasedCompensation" xlink:href="avco-20210331.xsd#avco_SharesBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SharesBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueOfOptionGrantedDescription" xlink:href="avco-20210331.xsd#avco_FairValueOfOptionGrantedDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="FairValueOfOptionGrantedDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/StatutoryReserveDetails">
    <loc xlink:type="locator" xlink:label="StatutoryReserveAbstract" xlink:href="avco-20210331.xsd#avco_StatutoryReserveAbstract"/>
    <loc xlink:type="locator" xlink:label="StatutoryReservePercent" xlink:href="avco-20210331.xsd#avco_StatutoryReservePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatutoryReserveAbstract" xlink:to="StatutoryReservePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegisteredCapitalPercentage" xlink:href="avco-20210331.xsd#avco_RegisteredCapitalPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatutoryReserveAbstract" xlink:to="RegisteredCapitalPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails">
    <loc xlink:type="locator" xlink:label="RestrictedNetAssetsAbstract" xlink:href="avco-20210331.xsd#avco_RestrictedNetAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedNetAssetsAbstract" xlink:to="us-gaap_RestrictedInvestmentsPercentOfNetAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedNetAssetsAbstract" xlink:to="us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/ConcentrationsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsTable" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConcentrationsDetailsLineItems" xlink:href="avco-20210331.xsd#avco_ConcentrationsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="ConcentrationsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PublicUtilitiesInventorySuppliesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PublicUtilitiesInventorySuppliesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="us-gaap_PublicUtilitiesInventorySuppliesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CustomerMember" xlink:href="avco-20210331.xsd#avco_CustomerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="CustomerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_AccountsReceivableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProductMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_AccountsPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsTable" xlink:to="ConcentrationsDetailsLineItems" order="6.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfCustomer" xlink:href="avco-20210331.xsd#avco_NumberOfCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="NumberOfCustomer" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSupplier" xlink:href="avco-20210331.xsd#avco_NumberOfSupplier"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationsDetailsLineItems" xlink:to="NumberOfSupplier" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/SegmentInformationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:label="NumberOfReportableBusinessSegments" xlink:href="avco-20210331.xsd#avco_NumberOfReportableBusinessSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="NumberOfReportableBusinessSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="avco-20210331.xsd#avco_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AvalonShanghaiMember" xlink:href="avco-20210331.xsd#avco_AvalonShanghaiMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AvalonShanghaiMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AVARBioTherapeuticsMember" xlink:href="avco-20210331.xsd#avco_AVARBioTherapeuticsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AVARBioTherapeuticsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LineOfCreditAgreementMember" xlink:href="avco-20210331.xsd#avco_LineOfCreditAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LineOfCreditAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="StockPurchaseAgreementDescription" xlink:href="avco-20210331.xsd#avco_StockPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="StockPurchaseAgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JointVentureAgreementDescription" xlink:href="avco-20210331.xsd#avco_JointVentureAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="JointVentureAgreementDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="avco-20210331.xsd#avco_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="WorkingCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LineOfCredit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanRecevied" xlink:href="avco-20210331.xsd#avco_LoanRecevied"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="LoanRecevied" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.avalonglobocare.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="avco-20210331.xsd#avco_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350086104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Avalon GloboCare Corp.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,423,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001630212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348611928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 1,692,540<span></span>
</td>
<td class="nump">$ 726,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Rent receivable</a></td>
<td class="nump">23,471<span></span>
</td>
<td class="nump">35,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred financing costs</a></td>
<td class="nump">152,438<span></span>
</td>
<td class="nump">222,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">295,731<span></span>
</td>
<td class="nump">302,224<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">2,164,180<span></span>
</td>
<td class="nump">1,286,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts', window );">Rent receivable - noncurrent portion</a></td>
<td class="nump">109,174<span></span>
</td>
<td class="nump">111,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">19,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred leasing costs</a></td>
<td class="nump">133,359<span></span>
</td>
<td class="nump">144,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">241,729<span></span>
</td>
<td class="nump">137,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">439,962<span></span>
</td>
<td class="nump">479,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateInvestments', window );">Investment in real estate, net</a></td>
<td class="nump">7,644,950<span></span>
</td>
<td class="nump">7,685,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity method investment</a></td>
<td class="nump">532,199<span></span>
</td>
<td class="nump">521,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Non-current Assets</a></td>
<td class="nump">9,121,035<span></span>
</td>
<td class="nump">9,079,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">11,285,215<span></span>
</td>
<td class="nump">10,366,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,445,225<span></span>
</td>
<td class="nump">1,212,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedResearchAndDevelopmentsFees', window );">Accrued research and development fees</a></td>
<td class="nump">432,500<span></span>
</td>
<td class="nump">513,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll liability and directors' compensation</a></td>
<td class="nump">165,846<span></span>
</td>
<td class="nump">154,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued liabilities and other payables</a></td>
<td class="nump">344,453<span></span>
</td>
<td class="nump">367,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent', window );">Accrued liabilities and other payables - related parties</a></td>
<td class="nump">313,105<span></span>
</td>
<td class="nump">267,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation</a></td>
<td class="nump">132,657<span></span>
</td>
<td class="nump">76,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Note payable - related party</a></td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,223,786<span></span>
</td>
<td class="nump">2,592,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - noncurrent portion</a></td>
<td class="nump">109,337<span></span>
</td>
<td class="nump">66,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Note payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Loan payable - related party</a></td>
<td class="nump">3,305,249<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Non-current Liabilities</a></td>
<td class="nump">3,414,586<span></span>
</td>
<td class="nump">3,656,954<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">6,638,372<span></span>
</td>
<td class="nump">6,249,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 490,000,000 shares authorized; 84,943,564 shares issued and 84,423,564 shares outstanding at March 31, 2021; 82,795,297 shares issued and 82,275,297 shares outstanding at December 31, 2020</a></td>
<td class="nump">8,494<span></span>
</td>
<td class="nump">8,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">49,755,996<span></span>
</td>
<td class="nump">46,856,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost; 520,000 shares at March 31, 2021 and December 31, 2020</a></td>
<td class="num">(522,500)<span></span>
</td>
<td class="num">(522,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,408,493)<span></span>
</td>
<td class="num">(42,041,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserve', window );">Statutory reserve</a></td>
<td class="nump">6,578<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss - foreign currency translation adjustment</a></td>
<td class="num">(193,232)<span></span>
</td>
<td class="num">(190,510)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Avalon GloboCare Corp. stockholders' equity</a></td>
<td class="nump">4,646,843<span></span>
</td>
<td class="nump">4,116,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="nump">4,646,843<span></span>
</td>
<td class="nump">4,116,919<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 11,285,215<span></span>
</td>
<td class="nump">$ 10,366,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedResearchAndDevelopmentsFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedResearchAndDevelopmentsFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid realtors&#8217; commission - noncurrent portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_TenantsReceivableNoncurrentPortionNetOfAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350469176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">490,000,000<span></span>
</td>
<td class="nump">490,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">84,943,564<span></span>
</td>
<td class="nump">82,795,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">84,423,564<span></span>
</td>
<td class="nump">82,275,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock</a></td>
<td class="nump">520,000<span></span>
</td>
<td class="nump">520,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385351381720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Real property rental</a></td>
<td class="nump">$ 289,774<span></span>
</td>
<td class="nump">$ 296,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>COSTS AND EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RealPropertyOperatingExpenses', window );">Real property operating expenses</a></td>
<td class="nump">216,894<span></span>
</td>
<td class="nump">254,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfitAbstract', window );"><strong>GROSS PROFIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RealPropertiesOperatingIncome', window );">Real property operating income</a></td>
<td class="nump">72,880<span></span>
</td>
<td class="nump">42,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OTHER OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">1,381,178<span></span>
</td>
<td class="nump">1,553,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related benefits</a></td>
<td class="nump">562,006<span></span>
</td>
<td class="nump">1,128,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">213,188<span></span>
</td>
<td class="nump">275,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative</a></td>
<td class="nump">220,096<span></span>
</td>
<td class="nump">307,079<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Other Operating Expenses</a></td>
<td class="nump">2,376,468<span></span>
</td>
<td class="nump">3,264,647<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(2,303,588)<span></span>
</td>
<td class="num">(3,222,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense - related party</a></td>
<td class="num">(45,149)<span></span>
</td>
<td class="num">(42,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OtherIncomeLossFromEquityMethodInvestment', window );">Loss from equity method investment</a></td>
<td class="num">(18,514)<span></span>
</td>
<td class="num">(9,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Total Other Expense, net</a></td>
<td class="num">(63,530)<span></span>
</td>
<td class="num">(48,589)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAXES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>COMPREHENSIVE LOSS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>OTHER COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency translation loss</a></td>
<td class="num">(2,722)<span></span>
</td>
<td class="num">(22,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">COMPREHENSIVE LOSS</a></td>
<td class="num">(2,369,840)<span></span>
</td>
<td class="num">(3,292,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS</a></td>
<td class="num">$ (2,369,840)<span></span>
</td>
<td class="num">$ (3,292,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted (in Shares)</a></td>
<td class="nump">83,413,154<span></span>
</td>
<td class="nump">76,712,054<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OtherIncomeLossFromEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OtherIncomeLossFromEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RealPropertiesOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RealPropertiesOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RealPropertyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating expenses related to real propert for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RealPropertyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118262090&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348295304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Statutory Reserve</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,673<span></span>
</td>
<td class="nump">$ 34,593,006<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">$ (29,361,937)<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="num">$ (257,747)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,465,073<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,730,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">1,539,153<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,539,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">213,278<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">213,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">785,350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">785,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,066)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,066)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,793<span></span>
</td>
<td class="nump">37,130,787<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(32,632,718)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(279,813)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,710,127<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,933,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,279<span></span>
</td>
<td class="nump">46,856,447<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">(42,041,375)<span></span>
</td>
<td class="nump">6,578<span></span>
</td>
<td class="num">(190,510)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,116,919<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,795,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">2,337,074<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,337,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">359,970<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">202,505<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">202,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,722)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,367,118)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,494<span></span>
</td>
<td class="nump">$ 49,755,996<span></span>
</td>
<td class="num">$ (522,500)<span></span>
</td>
<td class="num">$ (44,408,493)<span></span>
</td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="num">$ (193,232)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,646,843<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,943,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(520,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350160760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,367,118)<span></span>
</td>
<td class="num">$ (3,270,781)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForOtherLosses', window );">Bad debt provision</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">78,875<span></span>
</td>
<td class="nump">76,535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Amortization of straight-line rent receivable</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">16,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset</a></td>
<td class="nump">27,531<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and service expense</a></td>
<td class="nump">573,982<span></span>
</td>
<td class="nump">1,189,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LossOnEquityMethodInvestment', window );">Loss on equity method investment</a></td>
<td class="nump">18,514<span></span>
</td>
<td class="nump">9,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LossOnFixedAssetsDisposal', window );">Loss on fixed assets disposal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">85,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Rent receivable</a></td>
<td class="nump">13,647<span></span>
</td>
<td class="num">(23,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Security deposit</a></td>
<td class="nump">6,003<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredLeasingCosts', window );">Deferred leasing costs</a></td>
<td class="num">(2,364)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(40,803)<span></span>
</td>
<td class="num">(96,669)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="nump">163,442<span></span>
</td>
<td class="num">(38,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued liabilities and other payables - related parties</a></td>
<td class="nump">45,149<span></span>
</td>
<td class="nump">28,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_IncreaseDecreaseOperatingLease', window );">Operating lease obligation</a></td>
<td class="num">(33,326)<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
<td class="num">(1,515,525)<span></span>
</td>
<td class="num">(1,998,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AdditionalInvestmentInEquityMethodInvestment', window );">Additional investment in equity method investment</a></td>
<td class="num">(30,844)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(30,844)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ProceedsReceivedFromLoanPayable', window );">Proceeds received from loan payable - related party</a></td>
<td class="nump">105,249<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ProceedsReceivedFromEquityOffering', window );">Proceeds received from equity offering</a></td>
<td class="nump">2,481,405<span></span>
</td>
<td class="nump">1,623,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DisbursementsForEqutyOfferingCosts', window );">Disbursements for equity offering costs</a></td>
<td class="num">(74,442)<span></span>
</td>
<td class="num">(48,707)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
<td class="nump">2,512,212<span></span>
</td>
<td class="nump">1,874,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE ON CASH</a></td>
<td class="nump">120<span></span>
</td>
<td class="num">(5,701)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="nump">965,963<span></span>
</td>
<td class="num">(129,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH - beginning of period</a></td>
<td class="nump">726,577<span></span>
</td>
<td class="nump">764,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH - end of period</a></td>
<td class="nump">1,692,540<span></span>
</td>
<td class="nump">635,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommonStockIssuedForFutureServices', window );">Common stock issued for future services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">57,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_DeferredFinancingCostsInAccruedLiabilities', window );">Common stock issued for accrued liabilities</a></td>
<td class="nump">$ 261,032<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AdditionalInvestmentInEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional investment in equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AdditionalInvestmentInEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CommonStockIssuedForFutureServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for future services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CommonStockIssuedForFutureServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredFinancingCostsInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredFinancingCostsInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DeferredLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred leasing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DeferredLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_DisbursementsForEqutyOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disbursements for equity offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_DisbursementsForEqutyOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_IncreaseDecreaseOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_IncreaseDecreaseOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LossOnEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss on equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LossOnEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LossOnFixedAssetsDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Loss on fixed assets disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LossOnFixedAssetsDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ProceedsReceivedFromEquityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds received from equity offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ProceedsReceivedFromEquityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ProceedsReceivedFromLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds receivable from loan payable during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ProceedsReceivedFromLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to other loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385430467640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND NATURE OF OPERATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 1 &#x2013;&#xa0;<font style="text-decoration:underline">ORGANIZATION
AND NATURE OF OPERATIONS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon GloboCare Corp. (the &#x201c;Company&#x201d;
or &#x201c;AVCO&#x201d;) is a Delaware corporation. The Company was incorporated under the laws of the State of Delaware on July 28, 2014.
On October 19, 2016, the Company entered into and closed a Share Exchange Agreement with the shareholders of Avalon Healthcare System,
Inc., a Delaware corporation (&#x201c;AHS&#x201d;), each of which were accredited investors (&#x201c;AHS Shareholders&#x201d;) pursuant to
which we acquired 100% of the outstanding securities of AHS in exchange for 50,000,000 shares of the Company&#x2019;s common stock (the
&#x201c;AHS Acquisition&#x201d;). AHS was incorporated on May 18, 2015 under the laws of the State of Delaware.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For accounting purposes, AHS was the surviving
entity. The transaction was accounted for as a recapitalization of AHS pursuant to which AHS was treated as the accounting acquirer,
surviving and continuing entity although the Company is the legal acquirer. The Company did not recognize goodwill or any intangible
assets in connection with this transaction. Accordingly, the Company&#x2019;s historical financial statements are those of AHS and its
wholly-owned subsidiary, Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#x201c;Avalon Shanghai&#x201d;) immediately following the
consummation of this reverse merger transaction. AHS owns 100% of the capital stock of Avalon Shanghai, which is a wholly foreign-owned
enterprise organized under the laws of the People&#x2019;s Republic of China (&#x201c;PRC&#x201d;). Avalon Shanghai was incorporated on
April 29, 2016 and is engaged in medical related consulting services for customers.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&#x2122;), and regenerative therapeutics. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 23, 2017, the Company incorporated
Avalon (BVI) Ltd., a British Virgin Island company. There was no activity for the subsidiary since its incorporation through March 31,
2021. Avalon (BVI) Ltd. is dormant and is in process of being dissolved.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2017, the Company formed Avalon
RT 9 Properties, LLC (&#x201c;Avalon RT 9&#x201d;), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real
property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold,
NJ 07728. This property was purchased to serve as the Company&#x2019;s world-wide headquarters for all corporate administration and operations.
In addition, the property generates rental income. Avalon RT 9 owns this office building. Currently, Avalon RT 9&#x2019;s business consists
of the ownership and operation of the income-producing real estate property in New Jersey. As of March 31, 2021, the occupancy rate of
the building is 89.4%.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 31, 2017, the Company formed Genexosome
Technologies Inc. (&#x201c;Genexosome&#x201d;) in Nevada. Genexosome was engaged in developing proprietary diagnostic and therapeutic products
using exosomes. Genexosome owns 100% of the capital stock of Beijing Jieteng (Genexosome) Biotech Co., Ltd., a corporation incorporated
in the People&#x2019;s Republic of China on August 7, 2015 (&#x201c;Beijing Genexosome&#x201d;), and the Company holds 60% of Genexosome
and Dr. Yu Zhou holds 40% of Genexosome. The Company had not been able to realize the financial projections provided by Dr. Zhou at the
time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero. Dr. Zhou was terminated
as Co-CEO of Genexosome on August 14, 2019. Since the fourth quarter of 2019, the non-controlling interest keeps inactive.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 18, 2018, the Company formed a wholly
owned subsidiary, Avactis Biosciences Inc., a Nevada corporation, which will focus on accelerating commercial activities related to cellular
therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T
and others. The subsidiary is designed to integrate and optimize our global scientific and clinical resources to further advance the
use of cellular therapies to treat certain cancers.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 13, 2019, the Company formed a wholly
owned subsidiary, International Exosome Association LLC, a Delaware company. There was no activity for the subsidiary since its incorporation
through March 31, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Details of the Company&#x2019;s subsidiaries which
are included in these condensed consolidated financial statements as of March 31, 2021 are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 25%; padding-right: 0pt; padding-left: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Subsidiary</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 16%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    and date of Incorporation</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: top; width: 2%; padding-right: 0pt; padding-left: 0pt; text-align: center"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 13%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Ownership</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 40%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities</b></font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon Healthcare System, Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;AHS&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 18, 2015</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&#x201c;USA&#x201d;)</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (BVI) Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon BVI&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">British Virgin Island</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 23, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dormant,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">is in process of being dissolved</p></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon RT 9 Properties LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon RT 9&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New Jersey</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 7, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owns
    and operates an income-producing real property and holds and manages the corporate headquarters</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (Shanghai) Healthcare Technology Co.,
    Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon Shanghai&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 29, 2016</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AHS</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in China</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Genexosome Technologies Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Genexosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 31, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dormant
    </font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beijing Jieteng (Genexosome) Biotech Co.,
    Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Beijing Genexosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 7, 2015</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by Genexosome</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    development services for hospitals and other customers and sells developed items to hospitals and other customers in China</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avactis Biosciences Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avactis&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 18, 2018</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrate
    and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with
    stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Exosome Association LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Exosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 13, 2019</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    standardization related to exosome industry</font></td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385454940840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Going Concern Condition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BASIS OF PRESENTATION AND GOING CONCERN CONDITION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 2 &#x2013;&#xa0;<font style="text-decoration:underline">BASIS OF PRESENTATION
AND GOING CONCERN CONDITION</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Basis of Presentation</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These&#xa0;interim condensed consolidated financial
statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring
accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included.
The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the
results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in
accordance with the rules and regulations of the Securities and Exchange Commission and do not include all information and footnotes
necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United
States (&#x201c;U.S. GAAP&#x201d;). The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company
and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain&#xa0;information and footnote disclosures
normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
These condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial
statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#xa0;31, 2020 filed
with the Securities and Exchange Commission on March 30, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Going Concern</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is a clinical-stage, vertically integrated,
leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome
technology, as well as COVID-19 related diagnostics and therapeutics. The Company also provides strategic advisory and outsourcing services
to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets.
Through its subsidiary structure with unique integration of verticals from innovative R&amp;D to automated bioproduction and accelerated
clinical development, the Company is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome
technology (ACTEX&#x2122;), and regenerative therapeutics. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the Company owns commercial real
estate that houses its headquarters in Freehold, New Jersey and provides outsourced, customized international healthcare services to
the rapidly changing health care industry primarily focused in the People&#x2019;s Republic of China. The Company did not generate any
revenue from medical related consulting services segment during the three months ended March 31, 2021. These condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the
realization of assets and the satisfaction of liabilities in the normal course of business.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As reflected in the accompanying condensed consolidated
financial statements, the Company had working capital deficit of $1,059,606 as of March 31, 2021 and has incurred recurring net loss
and generated negative cash flow from operating activities of $2,367,118 and $1,515,525 for the three months ended March 31, 2021, respectively.
The Company has a limited operating history and its continued growth is dependent upon the continuation of providing medical consulting
services to its only few clients who are related parties and generating rental revenue from its income-producing real estate property
in New Jersey; hence generating revenues, and obtaining additional financing to fund future obligations and pay liabilities arising from
normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve
months from the release date of this report. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a
going concern. The ability of the Company to continue as a going concern is dependent on the Company&#x2019;s ability to raise additional
capital, implement its business plan, and generate significant revenues. There are no assurances that the Company will be successful
in its efforts to generate significant revenues, maintain sufficient cash balance or report profitable operations or to continue as a
going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However, there is no assurance
these plans will be realized and that any additional financings will be available to the Company on satisfactory terms and conditions,
if any.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The occurrence of an uncontrollable event such
as the COVID-19 pandemic had negatively impact on the Company&#x2019;s operations. Some tenants have delayed on rent payment. Our general
development operations have continued during the COVID-19 pandemic and we have not had significant disruption. However, we are uncertain
if the COVID-19 pandemic will impact future operations at our laboratory, or our ability to collaborate with other laboratories and universities.
In addition, we are unsure if the COVID-19 pandemic will impact future clinical trials. Given the dynamic nature of these circumstances,
the duration of business disruption and reduced traffic, the related financial effect cannot be reasonably estimated at this time but
is expected to adversely impact the Company&#x2019;s business for the rest of 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated financial
statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and
classification of liabilities that may result should the Company be unable to continue as a going concern.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352725544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 3 &#x2013;&#xa0;<font style="text-decoration:underline">SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Use of Estimates</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The preparation of the
condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant
estimates during the three months ended March 31, 2021 and 2020 include the useful life of property and equipment and investment in real
estate, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances,
and valuation of stock-based compensation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Fair Value of Financial Instruments and
Fair Value Measurements</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company adopted
the guidance of Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value measurements which clarifies the definition
of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring
fair value as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;&#x202f;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Level
                                            1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities
                                            available at the measurement date.</font></td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;</font></td><td style="text-align: justify">Level
                                            2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets,
                                            quoted prices for identical or similar assets and liabilities in markets that are not active,
                                            inputs other than quoted prices that are observable, and inputs derived from or corroborated
                                            by observable market data. </td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;</font></td><td style="text-align: justify">Level
                                            3-Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions
                                            on what assumptions the market participants would use in pricing the asset or liability based
                                            on the best available information. </td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The carrying amounts
reported in the condensed consolidated balance sheets for cash, rent receivable, accrued liabilities and other payables, accrued liabilities
and other payables &#x2013; related parties, operating lease obligation, and note payable, approximate their fair market value as of March
31, 2021 and December 31, 2020 based on the short-term maturity of these instruments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#x201c;Financial Instruments&#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Cash and Cash Equivalents</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021 and December 31, 2020, the
Company&#x2019;s cash balances by geographic area were as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Country:</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31, <br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December 31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt">United States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,527,257</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">90.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">559,711</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">77.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">China</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">165,283</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total cash</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,692,540</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">726,577</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2021 and December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company&#x2019;s cash is maintained
with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately
$76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered. At March 31, 2021, cash balances held in the PRC
are RMB 1,083,049 (approximately $165,000), of which, RMB 556,726 (approximately $85,000) was not covered by such limited insurance.
The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a portion of its cash in
bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages
this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit
quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2021, the Company&#x2019;s cash balances in United
States bank accounts had approximately $986,000 in excess of the federally-insured limits.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, a portion of the Company&#x2019;s operations
are carried out in PRC. Accordingly, the Company&#x2019;s business, financial condition and results of operations may be influenced by
the political, economic and legal environment in the PRC, and by the general state of the PRC&#x2019;s economy. The Company&#x2019;s operations
in PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company&#x2019;s
results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion and remittance abroad, and rates and methods of taxation, among other things.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company&#x2019;s sales
are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however,
concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also
performs ongoing credit evaluations of its customers to help further reduce credit risk.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Investment in Unconsolidated
Company &#x2013; Epicon Biosciences Co., Ltd.</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The
Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events
or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than
temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down
would be recorded to estimated fair value. See Note 5 for discussion of equity method investment.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company recognizes
revenue under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;).
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or
services. The following five steps are applied to achieve that core principle:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract
    with the customer</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance
    obligations in the contract</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction
    price</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction
    price to the performance obligations in the contract</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue
    when the company satisfies a performance obligation</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In order to identify
the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify
each promised goods or service that is distinct. A performance obligation meets ASC 606&#x2019;s definition of a &#x201c;distinct&#x201d;
goods or service (or bundle of goods or services) if both of the following criteria are met:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit
    from the goods or service either on its own or together with other resources that are readily available to the customer (i.e., the
    goods or service is capable of being distinct).</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&#x2019;s promise
    to transfer the goods or service to the customer is separately identifiable from other promises in the contract (i.e., the promise
    to transfer the goods or service is distinct within the context of the contract).</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">If a goods or service
is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or services is identified
that is distinct.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#x2019;s
revenues are derived from providing medial related consulting services for its&#x2019; related parties. Revenues related to its service
offerings are recognized as the services are performed. Any payments received in advance of the performance of services are recorded
as&#xa0;deferred revenue&#xa0;until such time as the services are performed. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined that the ASC 606 does
not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not offer promotional payments,
customer coupons, rebates or other cash redemption offers to its customers.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Per Share Data</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the three months ended March 31, 2021 and 2020, potentially dilutive
common shares consist of the common shares issuable upon the exercise of common stock options (using the treasury stock method). Common
stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period
in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding
as they would have had an anti-dilutive impact.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Months Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Stock options</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">7,580,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">6,800,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Potentially dilutive securities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">6,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Segment Reporting</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses &#x201c;the management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company&#x2019;s
reportable segments. The Company&#x2019;s chief operating decision maker is the Chief Executive Officer (&#x201c;CEO&#x201d;) and president
of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously had three reportable business
segments: real property operating segment, medical related consulting services segment, and development services and sales of developed
products segment. Due to the winding down of the development services and sales of developed products segment in 2020, the Company no
longer has any material revenues or expenses in this&#xa0;segment. As a result, commencing from the first quarter of 2021, the Company&#x2019;s
chief operating decision maker no longer reviews development services and sales of developed products operating results and the Company
no longer reports in three&#xa0;segments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the Company operates through two business segments: real property operating segment and medical related consulting services segment.
These reportable segments offer different types of services and products, have different types of revenue, and are managed separately
as each requires different operating strategies and management expertise.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassification</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified
to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position,
results of operations and cash flows.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Standards</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, <i>Financial
Instruments - Credit Losses (&#x201c;Topic 326&#x201d;). </i>The ASU introduces a new accounting model, the Current Expected Credit Losses
model (&#x201c;CECL&#x201d;), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The
CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial
asset is originated or acquired. ASU 2016-13 is effective for annual period beginning after December 15, 2022, including interim reporting
periods within those annual reporting periods. The Company expects that the adoption will not have a material impact on the Company&#x2019;s
consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<i>Simplifying the Accounting for Income Taxes</i>, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim
and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019 &#x2013; 12 did not have
a material impact on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its consolidated financial condition, results of operations, cash flows or disclosures.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385356064840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 4 &#x2013;&#xa0;<font style="text-decoration:underline">PREPAID EXPENSES
AND OTHER CURRENT ASSETS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">At March 31, 2021 and December 31, 2020,
prepaid expenses and other current assets consisted of the following:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Prepaid NASDAQ listing fee</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">63,417</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepaid directors and officers liability insurance premium</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">62,038</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,929</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Prepaid professional fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">53,364</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">78,639</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Recoverable VAT</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">41,934</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">40,446</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Deferred leasing costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31,422</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,220</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepaid research and development fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30,305</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60,610</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,251</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">295,731</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">302,224</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385354832616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">EQUITY METHOD INVESTMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 5 &#x2013; <font style="text-decoration:underline">EQUITY
METHOD INVESTMENT</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
equity method investment amounted to $532,199 and $521,758, respectively. The investment represents the Company&#x2019;s subsidiary, Avalon
Shanghai&#x2019;s interest in Epicon Biotech Co., Ltd. (&#x201c;Epicon&#x201d;). Epicon was incorporated on August 14, 2018 in PRC. Avalon
Shanghai and the other unrelated company, Jiangsu Unicorn Biological Technology Co., Ltd. (&#x201c;Unicorn&#x201d;), accounted for 40%
and 60% of the total ownership, respectively. Epicon is focused on cell preparation, third party testing, biological sample repository
for commercial and scientific research purposes and the clinical transformation of scientific achievements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company treats the equity investment in the
consolidated financial statements under the equity method. Under the equity method, the investment is initially recorded at cost, adjusted
for any excess of the Company&#x2019;s share of the incorporated-date fair values of the investee&#x2019;s identifiable net assets over
the cost of the investment (if any). Thereafter, the investment is adjusted for the post incorporation change in the Company&#x2019;s
share of the investee&#x2019;s net assets and any impairment loss relating to the investment.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, the Company&#x2019;s share of Epicon&#x2019;s net loss was $18,514 and $9,084, respectively, which was included in loss from equity
method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the three months ended March 31, 2021, activity
recorded for the Company&#x2019;s&#xa0;equity method investment&#xa0;in Epicon is summarized in the following table:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt; text-indent: 0pt">Equity investment carrying amount at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">521,758</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Payment made for equity method investment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30,844</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Epicon's net loss attributable to the Company</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(18,514</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Foreign currency fluctuation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,889</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Equity investment carrying amount at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">532,199</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The tables below present
the summarized financial information, as provided to the Company by the investee, for the unconsolidated company:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31, <br/>
2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Current assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,071</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,023</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Noncurrent assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">255,884</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">264,390</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,351</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,615</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Noncurrent liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Equity</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">254,604</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">270,798</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>For the Three Months <br/>
Ended March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Net revenue</td><td>&#xa0;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">-</td><td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">-</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Gross profit</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Loss from operation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">46,286</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,711</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">46,286</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,711</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385454947720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED LIABILITIES AND OTHER PAYABLES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 6 &#x2013;&#xa0;<font style="text-decoration:underline">ACCRUED
LIABILITIES AND OTHER PAYABLES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">At March 31, 2021 and
December 31, 2020, accrued liabilities and other payables consisted of the following:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued professional fees</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,445,225</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,212,822</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued research and development fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">432,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">513,533</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued payroll liability and directors&#x2019; compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">165,846</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">154,292</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued tenants&#x2019; improvement reimbursement</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">81,900</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">81,900</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Tenants&#x2019; security deposit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,533</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,634</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accounts payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">56,374</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">87,190</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Deferred rental income</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">26,286</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,510</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,360</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,388,024</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,248,058</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352739304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>NOTE 7 &#x2013;&#xa0;<font style="text-decoration:underline">RELATED PARTY TRANSACTIONS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Accrued Liabilities and Other Payables &#x2013;
Related Parties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquired Beijing Genexosome for a
cash payment of $450,000. As of March 31, 2021 and December 31, 2020, the unpaid acquisition consideration of $100,000, was payable to
Dr. Yu Zhou, former director and former co-chief executive officer and 40% owner of Genexosome, and has been included in accrued liabilities
and other payables &#x2013; related parties on the accompanying condensed consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, the
accrued and unpaid interest related to borrowings from Wenzhao Lu, the Company&#x2019;s largest shareholder and chairman of the Board
of Directors, amounted to $213,105 and $167,956, respectively, and have been included in accrued liabilities and other payables &#x2013;
related parties on the accompanying condensed consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Borrowings from Related Party</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Promissory Note</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">On March 18, 2019, the
Company issued Wenzhao Lu, the Company&#x2019;s largest shareholder and Chairman of the Board of Directors, a Promissory Note in the principal
amount of $1,000,000 (&#x201c;Promissory Note&#x201d;) in consideration of cash in the amount of $1,000,000. The Promissory Note accrues
interest at the rate of 5% per annum and matures March 19, 2022. The Company repaid principal of $410,000 and $200,000 in the third quarter
of 2019 and second quarter of 2020, respectively. As of both March 31, 2021 and December 31, 2020, the outstanding principal balance
was $390,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Line of Credit</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &#x201c;Line of Credit Agreement&#x201d;) providing the Company with a $20 million line of credit (the
&#x201c;Line of Credit&#x201d;) from Wenzhao Lu (the &#x201c;Lender&#x201d;), the largest shareholder and Chairman of the Board of Directors
of the Company. The Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital
and operating expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into
equity of the Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable
three years from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related
party Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to
maturity, without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default
occurs, the Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021
and December 31, 2020, $3,305,249 and $3,200,000 was outstanding under the Line of Credit, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, the interest expense related to above borrowings amounted to $45,149 and $42,169, respectively, and has been included in interest
expense &#x2013; related party on the accompanying condensed consolidated statements of operations and comprehensive loss.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">As of March 31, 2021
and December 31, 2020, the related accrued and unpaid interest for above borrowings was $213,105 and $167,956, respectively, and has
been included in accrued liabilities and other payables &#x2013; related parties on the accompanying condensed consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Office Space from
Related Party</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Beijing Genexosome uses
office space of a related party, free of rent, which is considered immaterial.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385432119368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 8 &#x2013;&#xa0;<font style="text-decoration:underline">EQUITY</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>2020 Incentive Stock
Plan</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company held its
annual meeting on August 4, 2020. During its annual meeting, the Company approved 2020 Incentive Stock Plan and reserved 5,000,000 shares
of common stock for issuance thereunder.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Common Shares Sold
for Cash</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 13, 2019, the Company entered into
an Open Market Sale Agreement<sup>SM </sup>(the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC, as sales agent (&#x201c;Jefferies&#x201d;),
pursuant to which the Company may offer and sell, from time to time, through Jefferies, shares of its common stock. During the three
months ended March 31, 2021, Jefferies sold an aggregate of 1,848,267 shares of common stock at an average price of $1.34 per share to
investors. The Company recorded net proceeds of $2,337,259, net of commission and other offering costs of $144,146.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Common Shares Issued
for Services</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the Company issued a total of 300,000 shares of its common stock for services rendered. These shares were valued at $360,000, the fair
market values on the grant dates using the reported closing share prices on the dates of grant and the Company recorded stock-based compensation
expense of $98,968 for the three months ended March 31, 2021 and reduced accrued liabilities of $261,032.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Options</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the shares of
the Company&#x2019;s common stock issuable upon exercise of options outstanding at March 31, 2021:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Options Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Options Exercisable</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Range of<br/>
    Exercise <br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number<br/>
    Outstanding at<br/>
    March 31, <br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted Average<br/>
    Remaining<br/>
    Contractual Life<br/>
    (Years)</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number<br/>
    Exercisable at<br/>
    March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise <br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">5.86</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 &#x2013; 1.93</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,810,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.37</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,366,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.45</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00 &#x2013; 2.80</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,740,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.52</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,740,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 &#x2013; 4.76</font></td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.46</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.45</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,136,666</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.47</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Stock option activities
for the three months ended March 31, 2021 were as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of<br/>
    Options</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Outstanding at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7,140,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.48</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">440,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.12</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Terminated / Exercised / Expired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.45</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Options exercisable at March 31, 2021</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,136,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.47</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Options expected to vest</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">443,334</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.14</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The aggregate intrinsic value of both stock options
outstanding and stock options exercisable at March 31, 2021 was $1,161,700.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair values of options granted during the
three months ended March 31, 2021 were estimated at the date of grant using the Black-Scholes option-pricing model with the following
assumptions: volatility of 128.42%, risk-free rate of 0.36%, annual dividend yield of 0% and expected life of 5.00 years. The aggregate
fair value of the options granted during the three months ended March 31, 2021 was $419,020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The fair values of options
granted during the three months ended March 31, 2020 were estimated at the date of grant using the Black-Scholes option-pricing model
with the following assumptions: volatility of 137.42% - 139.58%, risk-free rate of 1.39% - 1.67%, annual dividend yield of 0% and expected
life of 5.00 &#x2013; 10.00 years. The aggregate fair value of the options granted during the three months ended March 31, 2020 was $2,422,225.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021 and
2020, stock-based compensation expense associated with stock options granted amounted to $202,505 and $785,350, respectively, of which,
$139,507 and $674,998 was recorded as compensation and related benefits, $43,443 and $103,818 was recorded as professional fees, and
$19,555 and $6,534 was recorded as research and development expenses, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of the status of the Company&#x2019;s
nonvested stock options granted as of March 31, 2021 and changes during the three months ended March 31, 2021 is presented below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of<br/>
    Options</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0pt">Nonvested at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">218,334</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.18</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">440,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.12</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Vested</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0pt">Nonvested at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">443,334</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.14</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385430522440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Reserve<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserveAbstract', window );"><strong>Statutory Reserve [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserveTextBlock', window );">STATUTORY RESERVE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 9 -&#xa0;<font style="text-decoration:underline">STATUTORY
RESERVE</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Avalon Shanghai and Beijing Genexosome operate
in the PRC, are required to reserve 10% of their net profit after income tax, as determined in accordance with the PRC accounting rules
and regulations. Appropriation to the statutory reserve by the Company is based on profit arrived at under PRC accounting standards for
business enterprises for each year.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The profit arrived at must be set off against
any accumulated losses sustained by the Company in prior years, before allocation is made to the statutory reserve. Appropriation to
the statutory reserve must be made before distribution of dividends to shareholders. The appropriation is required until the statutory
reserve reaches 50% of the registered capital. This statutory reserve is not distributable in the form of cash dividends. The Company
did not make any appropriation to statutory reserve for Avalon Shanghai and Beijing Genexosome during the three months ended March 31,
2021 and 2020 as they incurred net losses in these periods.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355486136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Net Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RestrictedNetAssetsAbstract', window );"><strong>Restricted Net Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RestrictedNetAssetsTextBlock', window );">RESTRICTED NET ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 10 &#x2013; <font style="text-decoration:underline">RESTRICTED
NET ASSETS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company&#x2019;s operations are
conducted through its PRC subsidiaries, which can only pay dividends out of their retained earnings determined in accordance with the
accounting standards and regulations in the PRC and after they have met the PRC requirements for appropriation to statutory reserve.
In addition, a portion of the Company&#x2019;s businesses and assets are denominated in RMB, which is not freely convertible into foreign
currencies. All foreign exchange transactions take place either through the People&#x2019;s Bank of China or other banks authorized to
buy and sell foreign currencies at the exchange rates quoted by the People&#x2019;s Bank of China. Approval of foreign currency payments
by the People&#x2019;s Bank of China or other regulatory institutions requires submitting a payment application form together with suppliers&#x2019;
invoices, shipping documents and signed contracts. These currency exchange control procedures imposed by the PRC government authorities
may restrict the ability of the Company&#x2019;s PRC subsidiaries to transfer their net assets to the Parent Company through loans, advances
or cash dividends.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Schedule I of Article 5-04 of Regulation S-X
requires the condensed financial information of the parent company to be filed when the restricted net assets of consolidated subsidiaries
exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. For purposes of this test, restricted
net assets of consolidated subsidiaries shall mean that amount of the registrant&#x2019;s proportionate share of net assets of its consolidated
subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent
company in the form of loans, advances or cash dividends without the consent of a third party.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s PRC subsidiaries&#x2019; net
assets as of March 31, 2021 and December 31, 2020 did not exceed 25% of the Company&#x2019;s consolidated net assets. Accordingly, the
Parent Company&#x2019;s condensed consolidated financial statements have not been required in accordance with Rule 5-04 and Rule 12-04
of SEC Regulation S-X.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RestrictedNetAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RestrictedNetAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352656552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11 -&#xa0;<font style="text-decoration:underline">CONCENTRATIONS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Customers</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information as
to each customer that accounted for 10% or more of the Company&#x2019;s revenues for the three months ended March 31, 2021 and 2020.</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Months Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0pt; text-align: left"><b>Customer</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 0pt">A</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;30</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;30</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">B</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">C</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15</td><td style="text-align: left">%</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Less than 10%</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One customer, whose outstanding receivable accounted
for 10% or more of the Company&#x2019;s total outstanding accounts receivable, accounts receivable &#x2013; related party, and rent receivable
at March 31, 2021, accounted for 70.3% of the Company&#x2019;s total outstanding accounts receivable, accounts receivable &#x2013; related
party, and rent receivable at March 31, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">Two customers, whose
outstanding receivable accounted for 10% or more of the Company&#x2019;s total outstanding accounts receivable, accounts receivable &#x2013;
related party, and rent receivable at December 31, 2020, accounted for 78.3% of the Company&#x2019;s total outstanding accounts receivable,
accounts receivable &#x2013; related party, and rent receivable at December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Suppliers</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No supplier accounted for 10% or more of the
Company&#x2019;s purchase during the three months ended March 31, 2021 and 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One supplier, whose outstanding payable accounted
for 10% or more of the Company&#x2019;s total outstanding accounts payable at March 31, 2021, accounted for 90.2% of the Company&#x2019;s
total outstanding accounts payable at March 31, 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">One supplier, whose outstanding payable accounted
for 10% or more of the Company&#x2019;s total outstanding accounts payable at December 31, 2020, accounted for 93.6% of the Company&#x2019;s
total outstanding accounts payable at December 31, 2020.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355486136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 12 &#x2013;&#xa0;<font style="text-decoration:underline">SEGMENT
INFORMATION</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2020, the
Company operated in three reportable business segments - (1) the real property operating segment, (2) the medical related consulting
services segment, and (3) the performing development services for hospitals and other customers and sales of developed products to hospitals
and other customers segment.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the winding down of the development services
and sales of developed products segment in 2020, the Company no longer has any material revenues or expenses in this&#xa0;segment. As
a result, commencing from the first quarter of 2021, the Company&#x2019;s chief operating decision maker no longer reviews development
services and sales of developed products operating results. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three months ended March 31, 2021, the
Company operated in two reportable business segments - (1) the real property operating segment, and (2) the medical related consulting
services segment.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#x2019;s reportable segments are strategic
business units that offer different services and products. They are managed separately based on the fundamental differences in their
operations. Information with respect to these reportable business segments for the three months ended March 31, 2021 and 2020 was as
follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three&#xa0; Months&#xa0;Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenues</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left; padding-left: 10pt">Real property operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">289,774</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">296,956</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Costs and expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,894</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Gross profit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,880</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other operating expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">101,423</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">110,816</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">161,553</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">155,235</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,999</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,113,492</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,962,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,376,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,264,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">&#xa0;&#xa0;Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,169</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,169</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">104</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(935</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(18,486</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(5,487</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">&#xa0;&#xa0;Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,530</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48,589</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">28,439</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,296</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,039</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160,722</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,997</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,158,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,004,766</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,367,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,270,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31, <br/>
2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">Real property operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,655,918</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,697,473</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">208,561</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">223,459</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">243,869</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,433</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,084,912</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,164,801</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31, <br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">United States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,718,174</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,764,947</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">China</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">366,738</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">399,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,084,912</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,164,801</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352656552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 13 &#x2013;&#xa0;<font style="text-decoration:underline">COMMITMENTS
AND CONTINGENCIES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Litigation</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company is subject to
ordinary routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is
not subject to, any material legal proceedings, except as set forth below.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 25, 2017, Genexosome entered into and closed
a Stock Purchase Agreement with Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which
Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount
of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement
with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems,
held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the
assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr.
Zhou 400 shares of common stock of Genexosome. Further, the Company had not been able to realize the financial projections provided by
Dr. Zhou at the time of the acquisition and has decided to impair the intangible asset associated with this acquisition to zero on September
30, 2019. Dr. Zhou was terminated as Co-CEO of Genexosome on August 14, 2019. Further, on October 28, 2019, Research Institute at Nationwide
Children&#x2019;s Hospital (&#x201c;Research Institute&#x201d;) filed a Complaint in the United States District Court for the Southern District
of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome
including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation of Ohio Uniform Trade Secrets
Act. Research Institute is seeking monetary damages, injunctive relief, exemplary damages, injunctive relief and other equitable relief.
The Company intends to vigorously defend against this action and pursue all available legal remedies. The civil case against Avalon is
stayed pending resolution of the criminal proceedings against Dr. Zhou and Li Chen, and while there can be no assurances, the Company
believes it has substantial legal and factual defenses to the Research Institute&#x2019;s claims and the likelihood of any findings of
liability for the Company cannot be assessed at this time.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Operating Leases Commitment</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company is a party
to leases for office space. Rent expense under all operating leases amounted to approximately $39,000 for both the three months ended
March 31, 2021 and 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Supplemental cash flow information related to
leases for the&#xa0;three months ended March 31, 2021 and 2020 is as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Month Ended<br/>
March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left; padding-left: 10pt">Operating cash flows paid for operating lease</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">29,590</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligation:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">133,201</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">185,401</td><td style="text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the lease term
and discount rate for the Company&#x2019;s operating lease as of March 31, 2021:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Operating&#xa0;Lease</b></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0pt">Weighted average remaining lease term (in years)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1.83</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Weighted average discount rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">%</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the maturity of lease liabilities under
operating lease as of March 31, 2021:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>For the Twelve-month Period Ending March
    31:</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Operating&#xa0;Lease</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt">2022</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,817</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">111,347</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">2024 and thereafter</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Total lease payments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">252,164</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total present value of operating lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,994</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Current portion</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">132,657</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Long-term portion</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,337</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,994</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Equity Investment Commitment&#xa0;</b>&#xa0;</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 29, 2018, Avalon Shanghai entered into
a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (&#x201c;Unicorn&#x201d;), pursuant to which a company named
Epicon Biotech Co., Ltd. (&#x201c;Epicon&#x201d;) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai.
Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000
(approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon,
and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused
on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical
transformation of scientific achievements. As of March 31, 2021, Avalon Shanghai has contributed RMB 4,700,000 (approximately $0.7 million)
that was included in equity method investment on the accompanying condensed consolidated balance sheets. The Company intends to use its
present working capital together with borrowings from related party and equity raises to fund the project cost.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Joint Venture &#x2013; AVAR BioTherapeutics
(China) Co. Ltd.</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2018, Avactis Biosciences, Inc.
(&#x201c;Avactis&#x201d;), a wholly-owned subsidiary of the Company, and Arbele Limited (&#x201c;Arbele&#x201d;) agreed to the establishment
of AVAR BioTherapeutics (China) Co. Ltd. (&#x201c;AVAR&#x201d;), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture
Agreement (the &#x201c;AVAR Agreement&#x201d;), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of
the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular
immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be
contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis&#x2019; cash reserves.
Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting
AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal
cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed
upon Avactis and AVAR and services.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Avactis is responsible for:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">Contributing registered capital of RMB 5,000,000 (approximately $0.8 million) for working capital
                                                                            purposes as required by local regulation, which is not required to be contributed immediately and will be contributed subject to
                                                                            Avactis&#x2019; discretion;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">assist AVAR in setting up its business operations and obtaining all required permits and licenses
                                                                            from the Chinese government;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">assisting AVAR in recruiting, hiring and retaining personnel;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">providing AVAR with access to various hospital networks in China to assist in the testing and
                                                                            commercialization of the CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology in China;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">assisting AVAR in managing the Good Manufacturing Practices (GMP) facility and clinic to be
                                                                            developed by AVAR;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">providing AVAR with advice pertaining to conducting clinicals in China; and</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in">&#xa0;</td>
<td style="width: 0.25in; text-align: left">&#x25cf; </td><td style="text-align: justify">Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a
                                                                            research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed
                                                                            upon milestones.</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under AVAR Agreement, Arbele shall be responsible
for the following:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Entering into a License Agreement with AVAR; and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Providing AVAR with research and development expertise
    pertaining to clinical laboratory medicine when hired by AVAR.</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2021 and December 31, 2020, Avactis
has paid $900,000 to Arbele as research and development fee. As of March 31, 2021, License Agreement has not been finalized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Line of Credit Agreement</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 29, 2019, the Company entered into
a Line of Credit Agreement (the &#x201c;Line of Credit Agreement&#x201d;) providing the Company with a $20 million line of credit (the
&#x201c;Line of Credit&#x201d;) from Wenzhao Lu (the &#x201c;Lender&#x201d;), a significant shareholder and director of the Company. The
Line of Credit allows the Company to request loans thereunder and to use the proceeds of such loans for working capital and operating
expense purposes until the facility matures on December 31, 2024. The loans are unsecured and are not convertible into equity of the
Company. Loans drawn under the Line of Credit bears interest at an annual rate of 5% and each individual loan will be payable three years
from the date of issuance. The Company has a right to draw down on the line of credit and not at the discretion of the related party
Lender. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to maturity,
without premium or penalty. The Line of Credit Agreement includes customary events of default. If any such event of default occurs, the
Lender may declare all outstanding loans under the Line of Credit to be due and payable immediately. As of March 31, 2021, $3,305,249
was outstanding under the Line of Credit.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355486136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>NOTE 14 &#x2013;&#xa0;<font style="text-decoration:underline">SUBSEQUENT
EVENTS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has evaluated subsequent events through
the date of the filing.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348248904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Use of Estimates</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The preparation of the
condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant
estimates during the three months ended March 31, 2021 and 2020 include the useful life of property and equipment and investment in real
estate, assumptions used in assessing impairment of long-term assets, valuation of deferred tax assets and the associated valuation allowances,
and valuation of stock-based compensation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments and Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>Fair Value of Financial Instruments and
Fair Value Measurements</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company adopted
the guidance of Accounting Standards Codification (&#x201c;ASC&#x201d;) 820 for fair value measurements which clarifies the definition
of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring
fair value as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;&#x202f;</font></td><td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif">Level
                                            1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities
                                            available at the measurement date.</font></td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;</font></td><td style="text-align: justify">Level
                                            2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets,
                                            quoted prices for identical or similar assets and liabilities in markets that are not active,
                                            inputs other than quoted prices that are observable, and inputs derived from or corroborated
                                            by observable market data. </td></tr></table><br/><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"><font style="font-family: Times New Roman, Times, Serif">&#xa0;</font></td>
<td style="width: 0.25in; text-align: left"><font style="font-family: Times New Roman, Times, Serif">&#x25cf;</font></td><td style="text-align: justify">Level
                                            3-Inputs are unobservable inputs which reflect the reporting entity&#x2019;s own assumptions
                                            on what assumptions the market participants would use in pricing the asset or liability based
                                            on the best available information. </td></tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The carrying amounts
reported in the condensed consolidated balance sheets for cash, rent receivable, accrued liabilities and other payables, accrued liabilities
and other payables &#x2013; related parties, operating lease obligation, and note payable, approximate their fair market value as of March
31, 2021 and December 31, 2020 based on the short-term maturity of these instruments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC 825-10 &#x201c;Financial Instruments&#x201d;,
allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair
value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value
option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent
reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Cash and Cash Equivalents</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At March 31, 2021 and December 31, 2020, the
Company&#x2019;s cash balances by geographic area were as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Country:</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31, <br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December 31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt">United States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,527,257</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">90.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">559,711</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">77.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">China</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">165,283</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total cash</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,692,540</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">726,577</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the condensed consolidated statements
of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market
accounts to be cash equivalents. The Company had no cash equivalents at March 31, 2021 and December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CreditRiskAndUncertaintiePolicyTextBlock', window );">Credit Risk and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Credit Risk and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A portion of the Company&#x2019;s cash is maintained
with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately
$76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered. At March 31, 2021, cash balances held in the PRC
are RMB 1,083,049 (approximately $165,000), of which, RMB 556,726 (approximately $85,000) was not covered by such limited insurance.
The Company has not experienced any losses in such accounts and believes it is not exposed to any risks on its cash in bank accounts.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintains a portion of its cash in
bank and financial institution deposits within U.S. that at times may exceed federally-insured limits of $250,000. The Company manages
this credit risk by concentrating its cash balances in high quality financial institutions and by periodically evaluating the credit
quality of the primary financial institutions holding such deposits. The Company has not experienced any losses in such bank accounts
and believes it is not exposed to any risks on its cash in bank accounts. At March 31, 2021, the Company&#x2019;s cash balances in United
States bank accounts had approximately $986,000 in excess of the federally-insured limits.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, a portion of the Company&#x2019;s operations
are carried out in PRC. Accordingly, the Company&#x2019;s business, financial condition and results of operations may be influenced by
the political, economic and legal environment in the PRC, and by the general state of the PRC&#x2019;s economy. The Company&#x2019;s operations
in PRC are subject to specific considerations and significant risks not typically associated with companies in North America. The Company&#x2019;s
results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures,
currency conversion and remittance abroad, and rates and methods of taxation, among other things.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments which potentially subject
the Company to concentrations of credit risk consist principally of trade accounts receivable. A portion of the Company&#x2019;s sales
are credit sales which is to the customer whose ability to pay is dependent upon the industry economics prevailing in these areas; however,
concentrations of credit risk with respect to trade accounts receivable is limited due to short-term payment terms. The Company also
performs ongoing credit evaluations of its customers to help further reduce credit risk.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock', window );">Investment in Unconsolidated Company &#8211; Epicon Biosciences Co., Ltd.</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Investment in Unconsolidated
Company &#x2013; Epicon Biosciences Co., Ltd.</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the equity method of accounting
for its investment in, and earning or loss of, company that it does not control but over which it does exert significant influence. The
Company considers whether the fair value of its equity method investment has declined below its carrying value whenever adverse events
or changes in circumstances indicate that recorded value may not be recoverable. If the Company considers any decline to be other than
temporary (based on various factors, including historical financial results and the overall health of the investee), then a write-down
would be recorded to estimated fair value. See Note 5 for discussion of equity method investment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Revenue Recognition</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company recognizes
revenue under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;).
The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services
to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or
services. The following five steps are applied to achieve that core principle:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 1: Identify the contract
    with the customer</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 2: Identify the performance
    obligations in the contract</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 3: Determine the transaction
    price</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 4: Allocate the transaction
    price to the performance obligations in the contract</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Step 5: Recognize revenue
    when the company satisfies a performance obligation</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">In order to identify
the performance obligations in a contract with a customer, a company must assess the promised goods or services in the contract and identify
each promised goods or service that is distinct. A performance obligation meets ASC 606&#x2019;s definition of a &#x201c;distinct&#x201d;
goods or service (or bundle of goods or services) if both of the following criteria are met:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The customer can benefit
    from the goods or service either on its own or together with other resources that are readily available to the customer (i.e., the
    goods or service is capable of being distinct).</font></td></tr>
  </table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; ">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#x25cf;</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The entity&#x2019;s promise
    to transfer the goods or service to the customer is separately identifiable from other promises in the contract (i.e., the promise
    to transfer the goods or service is distinct within the context of the contract).</font></td></tr>
  </table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">If a goods or service
is not distinct, the goods or service is combined with other promised goods or services until a bundle of goods or services is identified
that is distinct.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is the amount of consideration
to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected
on behalf of third parties (for example, some sales taxes). The consideration promised in a contract with a customer may include fixed
amounts, variable amounts, or both. Variable consideration is included in the transaction price only to the extent that it is probable
that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction price is allocated to each performance
obligation on a relative standalone selling price basis. The transaction price allocated to each performance obligation is recognized
when that performance obligation is satisfied, at a point in time or over time as appropriate.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The Company&#x2019;s
revenues are derived from providing medial related consulting services for its&#x2019; related parties. Revenues related to its service
offerings are recognized as the services are performed. Any payments received in advance of the performance of services are recorded
as&#xa0;deferred revenue&#xa0;until such time as the services are performed. </p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has determined that the ASC 606 does
not apply to rental contracts, which are within the scope of other revenue recognition accounting standards.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rental income from operating leases is recognized
on a straight-line basis under the guidance of ASC 842. Lease payments under tenant leases are recognized on a straight-line basis over
the term of the related leases. The cumulative difference between lease revenue recognized under the straight-line method and contractual
lease payments are included in rent receivable on the condensed consolidated balance sheets.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company does not offer promotional payments,
customer coupons, rebates or other cash redemption offers to its customers.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Per Share Data</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Per Share Data</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC Topic 260 &#x201c;Earnings per Share,&#x201d;
requires presentation of both basic and diluted earnings per share (&#x201c;EPS&#x201d;) with a reconciliation of the numerator and denominator
of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic net loss per share is computed by dividing
net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted
net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents
and potentially dilutive securities outstanding during each period. For the three months ended March 31, 2021 and 2020, potentially dilutive
common shares consist of the common shares issuable upon the exercise of common stock options (using the treasury stock method). Common
stock equivalents are not included in the calculation of diluted net loss per share if their effect would be anti-dilutive. In a period
in which the Company has a net loss, all potentially dilutive securities are excluded from the computation of diluted shares outstanding
as they would have had an anti-dilutive impact.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the securities
that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Months Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Stock options</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">7,580,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">6,800,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Potentially dilutive securities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">6,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Segment Reporting</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses &#x201c;the management approach&#x201d;
in determining reportable operating segments. The management approach considers the internal organization and reporting used by the Company&#x2019;s
chief operating decision maker for making operating decisions and assessing performance as the source for determining the Company&#x2019;s
reportable segments. The Company&#x2019;s chief operating decision maker is the Chief Executive Officer (&#x201c;CEO&#x201d;) and president
of the Company, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company previously had three reportable business
segments: real property operating segment, medical related consulting services segment, and development services and sales of developed
products segment. Due to the winding down of the development services and sales of developed products segment in 2020, the Company no
longer has any material revenues or expenses in this&#xa0;segment. As a result, commencing from the first quarter of 2021, the Company&#x2019;s
chief operating decision maker no longer reviews development services and sales of developed products operating results and the Company
no longer reports in three&#xa0;segments.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2021,
the Company operates through two business segments: real property operating segment and medical related consulting services segment.
These reportable segments offer different types of services and products, have different types of revenue, and are managed separately
as each requires different operating strategies and management expertise.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Reclassifications', window );">Reclassifications</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Reclassification</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior period amounts have been reclassified
to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position,
results of operations and cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recent Accounting Standards</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU 2016-13, <i>Financial
Instruments - Credit Losses (&#x201c;Topic 326&#x201d;). </i>The ASU introduces a new accounting model, the Current Expected Credit Losses
model (&#x201c;CECL&#x201d;), which requires earlier recognition of credit losses and additional disclosures related to credit risk. The
CECL model utilizes a lifetime expected credit loss measurement objective for the recognition of credit losses at the time the financial
asset is originated or acquired. ASU 2016-13 is effective for annual period beginning after December 15, 2022, including interim reporting
periods within those annual reporting periods. The Company expects that the adoption will not have a material impact on the Company&#x2019;s
consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2019, the FASB issued ASU 2019-12,
<i>Simplifying the Accounting for Income Taxes</i>, as part of its Simplification Initiative to reduce the cost and complexity in accounting
for income taxes. This standard removes certain exceptions related to the approach for intra period tax allocation, the methodology for
calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also
amends other aspects of the guidance to help simplify and promote consistent application of GAAP. The guidance is effective for interim
and annual periods beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019 &#x2013; 12 did not have
a material impact on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other accounting standards that have been issued
or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial
statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated
to its consolidated financial condition, results of operations, cash flows or disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CreditRiskAndUncertaintiePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CreditRiskAndUncertaintiePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_InvestmentInUnconsolidatedCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Reclassifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for classifying current financial statements, which may be different from classifications in the prior year's financial statements. Disclose any material changes in classification including an explanation of the reason for the change and the areas impacted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Reclassifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385430434728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of company's subsidiaries consolidated financial statements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 25%; padding-right: 0pt; padding-left: 0pt; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of Subsidiary</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 16%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Place
    and date of Incorporation</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: top; width: 2%; padding-right: 0pt; padding-left: 0pt; text-align: center"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: top; width: 13%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage
    of Ownership</b></font></td>
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; vertical-align: bottom; width: 2%; padding-right: 0pt; padding-left: 0pt"><b>&#xa0;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-indent: 0pt; vertical-align: bottom; width: 40%; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principal
    Activities</b></font></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon Healthcare System, Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;AHS&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 18, 2015</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (&#x201c;USA&#x201d;)</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (BVI) Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon BVI&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">British Virgin Island</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">January 23, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dormant,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">is in process of being dissolved</p></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon RT 9 Properties LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon RT 9&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New Jersey</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 7, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Owns
    and operates an income-producing real property and holds and manages the corporate headquarters</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avalon (Shanghai) Healthcare Technology Co.,
    Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avalon Shanghai&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 29, 2016</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AHS</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    medical related consulting services and developing Avalon Cell and Avalon Rehab in China</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Genexosome Technologies Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Genexosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 31, 2017</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dormant
    </font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Beijing Jieteng (Genexosome) Biotech Co.,
    Ltd.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Beijing Genexosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 7, 2015</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by Genexosome</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provides
    development services for hospitals and other customers and sells developed items to hospitals and other customers in China</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Avactis Biosciences Inc.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Avactis&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nevada</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">July 18, 2018</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Integrate
    and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with
    stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers</font></td></tr>
  <tr>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">International Exosome Association LLC</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(&#x201c;Exosome&#x201d;)</p></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-align: center; text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Delaware</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 13, 2019</p></td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%
    held by AVCO</font></td>
    <td style="text-indent: 0pt; vertical-align: bottom; padding-right: 0pt; padding-left: 0pt; text-align: center">&#xa0;</td>
    <td style="text-indent: 0pt; vertical-align: top; padding-right: 0pt; padding-left: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promotes
    standardization related to exosome industry</font></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355443080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of cash balances by geographic area</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Country:</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31, <br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December 31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 52%; text-align: left; padding-left: 0pt">United States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,527,257</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">90.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">559,711</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">77.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">China</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">165,283</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9.8</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">166,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total cash</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,692,540</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">726,577</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">100.0</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of the effect of including these potential shares was antidilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Months Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-right: 0pt; text-align: center; padding-bottom: 0pt; padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-right: 0pt; width: 72%; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Stock options</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">7,580,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="width: 1%; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="width: 11%; border-bottom: Black 1.5pt solid; text-align: right">6,800,000</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-right: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Potentially dilutive securities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">6,800,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352681688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Prepaid NASDAQ listing fee</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">63,417</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepaid directors and officers liability insurance premium</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">62,038</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">64,929</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Prepaid professional fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">53,364</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">78,639</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Recoverable VAT</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">41,934</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">40,446</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Deferred leasing costs</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">31,422</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18,220</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepaid research and development fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30,305</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60,610</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,251</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,380</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">295,731</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">302,224</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350044584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity method investment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt; text-indent: 0pt">Equity investment carrying amount at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">521,758</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Payment made for equity method investment</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">30,844</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt; text-indent: 0pt">Epicon's net loss attributable to the Company</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(18,514</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Foreign currency fluctuation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,889</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; text-align: left; padding-bottom: 0pt; padding-left: 0pt">Equity investment carrying amount at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">532,199</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock', window );">Schedule of financial information investee</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31, <br/>
2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Current assets</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,071</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,023</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Noncurrent assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">255,884</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">264,390</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">14,351</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,615</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Noncurrent liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Equity</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">254,604</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">270,798</td><td style="text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfFinancialInformationByInvestee', window );">Schedule of financial information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>For the Three Months <br/>
Ended March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Net revenue</td><td>&#xa0;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">-</td><td>&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: right">$</td>
    <td style="text-align: right">-</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Gross profit</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">-</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Loss from operation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">46,286</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">22,711</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">46,286</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">22,711</td><td style="text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfFinancialInformationByInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial information by the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfFinancialInformationByInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385430476728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities and other payables</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued professional fees</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,445,225</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,212,822</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued research and development fees</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">432,500</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">513,533</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued payroll liability and directors&#x2019; compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">165,846</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">154,292</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accrued tenants&#x2019; improvement reimbursement</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">81,900</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">81,900</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Tenants&#x2019; security deposit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,533</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,634</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Accounts payable</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">56,374</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">87,190</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Deferred rental income</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">26,286</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">23,510</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,360</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">105,177</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,388,024</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,248,058</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355545576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of stock options outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Options Outstanding</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Options Exercisable</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Range of<br/>
    Exercise <br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number<br/>
    Outstanding at<br/>
    March 31, <br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted Average<br/>
    Remaining<br/>
    Contractual Life<br/>
    (Years)</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number<br/>
    Exercisable at<br/>
    March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise <br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">5.86</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 14%; text-align: right">2,000,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">0.50</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00 &#x2013; 1.93</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,810,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.37</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.40</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,366,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.45</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00 &#x2013; 2.80</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,740,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.52</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,740,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.17</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">30,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.76</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.50 &#x2013; 4.76</font></td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">4.46</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.45</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,136,666</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.47</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock option activities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of<br/>
    Options</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Outstanding at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7,140,000</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.48</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">440,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.12</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Terminated / Exercised / Expired</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Outstanding at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">7,580,000</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.45</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Options exercisable at March 31, 2021</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">7,136,666</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.47</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Options expected to vest</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">443,334</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.14</td><td style="text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of the options using the Black-Scholes option-pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Number of<br/>
    Options</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Weighted<br/>
    Average<br/>
    Exercise<br/>
    Price</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0pt">Nonvested at January 1, 2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">218,334</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.18</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Granted</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">440,000</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1.12</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Vested</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(215,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1.15</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0pt">Nonvested at March 31, 2021</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">443,334</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1.14</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385356137544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentTableTextBlock', window );">Schedule of customers</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Months Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0pt; text-align: left"><b>Customer</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; padding-left: 0pt">A</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;30</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;30</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">B</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">20</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">18</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">C</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">15</td><td style="text-align: left">%</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Less than 10%</td>
</tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of arrangements in which the entity has committed resources to supply goods or services to a customer. May include identification of the goods or services to be furnished, identity of the purchasing party, pricing, effects on pricing for failing to deliver the [minimum] quantities required to be furnished, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350054216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment reporting information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three&#xa0; Months&#xa0;Ended<br/>
March&#xa0;31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenues</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left; padding-left: 10pt">Real property operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">289,774</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">296,956</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Costs and expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">216,894</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">254,501</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Gross profit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Real property operations</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72,880</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,455</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other operating expenses</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">101,423</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">110,816</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">161,553</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">155,235</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,999</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,113,492</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,962,597</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,376,468</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,264,647</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">&#xa0;&#xa0;Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,169</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(45,149</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(42,169</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">104</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(935</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(18,486</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(5,487</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">&#xa0;&#xa0;Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">&#xa0;&#xa0;Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">&#xa0;&#xa0;&#xa0;&#xa0;Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,381</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,420</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(63,530</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(48,589</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net loss</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Real property operations</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">28,439</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">69,296</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,039</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">160,722</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">35,997</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,158,640</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,004,766</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt">Total</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,367,118</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,270,781</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock', window );">Schedule of real property operating</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March&#xa0;31, <br/>
2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31, <br/>
2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">Real property operations</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,655,918</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,697,473</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Medical related consulting services</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">208,561</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">223,459</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Development services and sales of developed products</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">243,869</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">Corporate/Other</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">220,433</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,084,912</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,164,801</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock', window );">Schedule of identifiable long-lived tangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>Identifiable long-lived tangible assets at
    March 31, 2021 and December 31, <br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>March 31,<br/>
    2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>December&#xa0;31,<br/>
    2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 76%; text-align: left; padding-left: 0pt">United States</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,718,174</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,764,947</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">China</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">366,738</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">399,854</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,084,912</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,164,801</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352867560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental cash flow information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Three Month Ended<br/>
March 31,</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2021</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>2020</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt">Cash paid for amounts included in the measurement of lease liabilities:</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2">&#xa0;</td><td>&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 72%; text-align: left; padding-left: 10pt">Operating cash flows paid for operating lease</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">29,590</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">&#xa0;&#xa0;&#xa0;&#xa0;-</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Right-of-use assets obtained in exchange for lease obligation:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">133,201</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">185,401</td><td style="text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock', window );">Schedule of lease term and discount rate for the Company&#8217;s operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Operating&#xa0;Lease</b></td><td style="padding-bottom: 1.5pt">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0pt">Weighted average remaining lease term (in years)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1.83</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0pt">Weighted average discount rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.88</td><td style="text-align: left">%</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 0pt; border-bottom: Black 1.5pt solid; padding-left: 0pt"><b>For the Twelve-month Period Ending March
    31:</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><b>Operating&#xa0;Lease</b></td><td style="padding-bottom: 1.5pt"><b>&#xa0;</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; width: 88%; text-align: left; padding-left: 0pt">2022</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,817</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">2023</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">111,347</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">2024 and thereafter</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Total lease payments</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">252,164</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Amount of lease payments representing interest</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Total present value of operating lease liabilities</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,994</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 0pt; padding-left: 0pt">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; text-align: left; padding-left: 0pt">Current portion</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">132,657</td><td style="text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 0pt; padding-left: 0pt">Long-term portion</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,337</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 0pt; padding-left: 0pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">241,994</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental balance sheet information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfSupplementalBalanceSheetInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350347128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 19, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OrganizationandNatureofOperationsDetailsLineItems', window );"><strong>Organization and Nature of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquired percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExchangeForCommonStock', window );">Exchange for common stock (in Shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfCapitalStock', window );">Percentage of capital stock</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OrganizationandNatureofOperationsDetailsLineItems', window );"><strong>Organization and Nature of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_BuildingOccupancyRate', window );">Building occupancy rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember', window );">Beijing Jieteng (GenExosome) Biotech Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OrganizationandNatureofOperationsDetailsLineItems', window );"><strong>Organization and Nature of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember', window );">GenExosome Technologies Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OrganizationandNatureofOperationsDetailsLineItems', window );"><strong>Organization and Nature of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_DrYuZhouMember', window );">Dr. Yu Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OrganizationandNatureofOperationsDetailsLineItems', window );"><strong>Organization and Nature of Operations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_BuildingOccupancyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Building occupancy rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_BuildingOccupancyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ExchangeForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ExchangeForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OrganizationandNatureofOperationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OrganizationandNatureofOperationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PercentageOfCapitalStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PercentageOfCapitalStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_DrYuZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_DrYuZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385351120104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvalonHealthcareSystemIncMember', window );">Avalon Healthcare System, Inc. (&#8220;AHS&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">Delaware May 18, 2015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AVCO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America ("USA")<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvalonBVILtdMember', window );">Avalon (BVI) Ltd. (&#8220;Avalon BVI&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">British Virgin Island January 23, 2017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AVCO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Dormant, is in process of being dissolved<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember', window );">Avalon RT 9 Properties LLC (&#8220;Avalon RT 9&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">New Jersey February 7, 2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AVCO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Owns and operates an income-producing real property and holds and manages the corporate headquarters<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember', window );">Avalon (Shanghai) Healthcare Technology Co., Ltd. (&#8220;Avalon Shanghai&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">PRC April 29, 2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AHS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in China<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember', window );">Genexosome Technologies Inc. (&#8220;Genexosome&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">Nevada July 31, 2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">60% held by AVCO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Dormant<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember', window );">Beijing Jieteng (Genexosome) Biotech Co., Ltd. ("Beijing Genexosome") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">PRC August 7, 2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by Genexosome<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Provides development services for hospitals and other customers and sells developed items to hospitals and other customers in China<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_AvactisBiosciencesIncMember', window );">Avactis Biosciences Inc. (''Avactis'') [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">Nevada July 18, 2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AVCO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=avco_InternationalExosomeAssociationLlcMember', window );">International Exosome Association LLC (''Exosome") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EntityIncorporationsStateCountryName', window );">Place and date of Incorporation</a></td>
<td class="text">Delaware June 13, 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PercentageOfOwnership', window );">Percentage of Ownership</a></td>
<td class="text">100% held by AVCO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities', window );">Principal Activities</a></td>
<td class="text">Promotes standardization related to exosome industry<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EntityIncorporationsStateCountryName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Place and date of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EntityIncorporationsStateCountryName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PercentageOfOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PercentageOfOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the principal activities of an investee accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDescriptionOfPrincipalActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvalonHealthcareSystemIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvalonHealthcareSystemIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvalonBVILtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvalonBVILtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvalonRT9PropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvalonShanghaiHealthcareTechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_GenExosomeTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_BeijingJietengGenExosomeBiotechCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_AvactisBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_AvactisBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avco_InternationalExosomeAssociationLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avco_InternationalExosomeAssociationLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355792088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Going Concern Condition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="num">$ (1,059,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Recurring net loss</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">$ (3,270,781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Negative cash flow from operating activities</a></td>
<td class="num">$ (1,515,525)<span></span>
</td>
<td class="num">$ (1,998,796)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355594728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - 3 months ended Mar. 31, 2021<br></strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CNY (&#165;)</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashAndCashEquivalentsDescription', window );">Cash and cash equivalents, description</a></td>
<td class="text">the Company&#x2019;s cash is maintained with state-owned banks within the PRC. Balances at state-owned banks within the PRC are covered by insurance up to RMB 500,000 (approximately $76,000) per bank. Any balance over RMB 500,000 per bank in PRC will not be covered.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashAndDueFromBank', window );">Cash balance held in PRC</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">&#165; 1,083,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LimitedInsurance', window );">Limited insurance</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">&#165; 556,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FederallyinsuredLimits', window );">Federally-insured limits</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FederallyinsuredLimits', window );">Federally-insured limits</a></td>
<td class="nump">$ 986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CashAndCashEquivalentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CashAndCashEquivalentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CashAndDueFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CashAndDueFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_FederallyinsuredLimits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_FederallyinsuredLimits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LimitedInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LimitedInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348186376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of cash balances by geographic area - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndDueFromBanks', window );">Total cash</a></td>
<td class="nump">$ 1,692,540<span></span>
</td>
<td class="nump">$ 726,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentrations of credit risk</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndDueFromBanks', window );">Total cash</a></td>
<td class="nump">$ 1,527,257<span></span>
</td>
<td class="nump">$ 559,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentrations of credit risk</a></td>
<td class="nump">90.20%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndDueFromBanks', window );">Total cash</a></td>
<td class="nump">$ 165,283<span></span>
</td>
<td class="nump">$ 166,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentrations of credit risk</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndDueFromBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndDueFromBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385441753912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of the effect of including these potential shares was antidilutive - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">7,580,000<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">7,580,000<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=avco_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348176856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Schedule of prepaid expenses and other current assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidNasdaqListingFee', window );">Prepaid NASDAQ listing fee</a></td>
<td class="nump">$ 63,417<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium', window );">Prepaid directors and officers liability insurance premium</a></td>
<td class="nump">62,038<span></span>
</td>
<td class="nump">64,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidProfessionalFees', window );">Prepaid professional fees</a></td>
<td class="nump">53,364<span></span>
</td>
<td class="nump">78,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">Recoverable VAT</a></td>
<td class="nump">41,934<span></span>
</td>
<td class="nump">40,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsLeasingNet', window );">Deferred leasing costs</a></td>
<td class="nump">31,422<span></span>
</td>
<td class="nump">18,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrepaidResearchAndDevelopmentFees', window );">Prepaid research and development fees</a></td>
<td class="nump">30,305<span></span>
</td>
<td class="nump">60,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">13,251<span></span>
</td>
<td class="nump">39,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 295,731<span></span>
</td>
<td class="nump">$ 302,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid directors and officers liability insurance premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidDirectorsAndOfficersLiabilityInsurancePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidNasdaqListingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid NASDAQ listing fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidNasdaqListingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrepaidResearchAndDevelopmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for prepaid research and development fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrepaidResearchAndDevelopmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsLeasingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents costs incurred by the lessor that are (a) costs to originate a lease incurred in transactions with independent third parties that (i) result directly from and are essential to acquire that lease and (ii) would not have been incurred had that leasing transaction not occurred and (b) certain costs directly related to specified activities performed by the lessor for that lease. Those activities are: evaluating the prospective lessee's financial condition; evaluating and recording guarantees, collateral, and other security arrangements; negotiating lease terms; preparing and processing lease documents; and closing the transaction. This element is net of accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121585684&amp;loc=d3e40246-112709<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121585684&amp;loc=d3e40588-112709<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121598990&amp;loc=d3e40879-112712<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsLeasingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385351218184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentDetailsLineItems', window );"><strong>Equity Method Investment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment</a></td>
<td class="nump">$ 532,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Net loss</a></td>
<td class="num">$ (18,514)<span></span>
</td>
<td class="num">$ (9,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SubsidiaryAxis=avco_OtherUnrelatedCompanyMember', window );">Other Unrelated Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentDetailsLineItems', window );"><strong>Equity Method Investment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Total ownership percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SubsidiaryAxis=avco_UnicornMember', window );">Jiangsu Unicorn Biological Technology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentDetailsLineItems', window );"><strong>Equity Method Investment (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Total ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SubsidiaryAxis=avco_OtherUnrelatedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SubsidiaryAxis=avco_OtherUnrelatedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SubsidiaryAxis=avco_UnicornMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SubsidiaryAxis=avco_UnicornMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355510808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - Schedule of equity method investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfEquityMethodInvestmentAbstract', window );"><strong>Schedule of equity method investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount at January 1, 2021</a></td>
<td class="nump">$ 521,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PaymentMadeForEquityMethodInvestments', window );">Payment made for equity method investment</a></td>
<td class="nump">30,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Epicon's net loss attributable to the Company</a></td>
<td class="num">(18,514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ForeignCurrencyFluctuationEquityMethodInvestments', window );">Foreign currency fluctuation</a></td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity investment carrying amount at March 31, 2021</a></td>
<td class="nump">$ 532,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ForeignCurrencyFluctuationEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency fluctuation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ForeignCurrencyFluctuationEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PaymentMadeForEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PaymentMadeForEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfEquityMethodInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfEquityMethodInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350164504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity Method Investment (Details) - Schedule of financial information investee - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfFinancialInformationInvesteeAbstract', window );"><strong>Schedule of financial information investee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset', window );">Current assets</a></td>
<td class="nump">$ 13,071<span></span>
</td>
<td class="nump">$ 13,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset', window );">Noncurrent assets</a></td>
<td class="nump">255,884<span></span>
</td>
<td class="nump">264,390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie', window );">Current liabilities</a></td>
<td class="nump">14,351<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability', window );">Noncurrent liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity', window );">Equity</a></td>
<td class="nump">$ 254,604<span></span>
</td>
<td class="nump">$ 270,798<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilitie</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfFinancialInformationInvesteeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfFinancialInformationInvesteeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352938968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investment (Details) - Schedule of financial information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfFinancialInformationAbstract', window );"><strong>Schedule of financial information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue', window );">Net revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem', window );">Loss from operation</a></td>
<td class="nump">46,286<span></span>
</td>
<td class="nump">22,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 46,286<span></span>
</td>
<td class="nump">$ 22,711<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations reported by an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross profit (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationOfGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationOfNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from sale of product and rendering of service reported by equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityMethodInvestmentSummarizedFinancialInformationOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385351221352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract', window );"><strong>Schedule of accrued liabilities and other payables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 1,445,225<span></span>
</td>
<td class="nump">$ 1,212,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedResearchAndDevelopmentFee', window );">Accrued research and development fees</a></td>
<td class="nump">432,500<span></span>
</td>
<td class="nump">513,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued directors&#8217; compensation</a></td>
<td class="nump">165,846<span></span>
</td>
<td class="nump">154,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AccruedTenantsImprovementReimbursement', window );">Accrued tenants&#8217; improvement reimbursement</a></td>
<td class="nump">81,900<span></span>
</td>
<td class="nump">81,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Deposits', window );">Tenants&#8217; security deposit</a></td>
<td class="nump">69,533<span></span>
</td>
<td class="nump">69,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">56,374<span></span>
</td>
<td class="nump">87,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Deferred rental income</a></td>
<td class="nump">26,286<span></span>
</td>
<td class="nump">23,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Other</a></td>
<td class="nump">110,360<span></span>
</td>
<td class="nump">105,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 2,388,024<span></span>
</td>
<td class="nump">$ 2,248,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedResearchAndDevelopmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedResearchAndDevelopmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AccruedTenantsImprovementReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued tenants&#8217; improvement reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AccruedTenantsImprovementReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfAccruedLiabilitiesAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385347573848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2019</div></th>
<th class="th"><div>Mar. 18, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note maturity date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LoanFromLender', window );">Outstanding line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,305,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,149<span></span>
</td>
<td class="nump">$ 42,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=avco_LineOfCreditAgreementMember', window );">Line of Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_GenExosomeMember', window );">Genexosome [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership of percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember', window );">Wenzhao Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConsiderationCash', window );">Consideration cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Promissory Note interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Promissory note maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 19,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_PrincipalRepaidAmount', window );">Principal repaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | David Jin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer [Member] | Dr. Yu Zhou [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConsiderationCash', window );">Consideration cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Wenzhao Lu [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued liabilities and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LoanFromLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan received from the Lender.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LoanFromLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_PrincipalRepaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal repaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_PrincipalRepaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=avco_LineOfCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=avco_LineOfCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_GenExosomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_GenExosomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WenzhaoLuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DavidJinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DavidJinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DrYuZhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_DrYuZhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385347957128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Aggregate purchase price</a></td>
<td class="nump">$ 2,337,259<span></span>
</td>
<td class="nump">$ 1,539,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for services, value</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">213,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of stock options outstanding</a></td>
<td class="nump">$ 1,161,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility rate, minimum</a></td>
<td class="nump">128.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility rate, maximum</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate fair value of the options granted</a></td>
<td class="nump">$ 419,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_FairValueOfOptionGrantedDescription', window );">Fair value description</a></td>
<td class="text">The fair values of options granted during the three months ended March 31, 2020 were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: volatility of 137.42% - 139.58%, risk-free rate of 1.39% - 1.67%, annual dividend yield of 0% and expected life of 5.00 &#x2013; 10.00 years. The aggregate fair value of the options granted during the three months ended March 31, 2020 was $2,422,225.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 202,505<span></span>
</td>
<td class="nump">785,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=avco_CompensationAndRelatedBenefitsMember', window );">Compensation and Related Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">139,507<span></span>
</td>
<td class="nump">674,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=avco_ProfessionalFeesMember', window );">Professional Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">43,443<span></span>
</td>
<td class="nump">103,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 19,555<span></span>
</td>
<td class="nump">$ 6,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember', window );">Common Shares Issued for Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common shares issued for services, shares (in Shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common shares issued for services, value</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SharesBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">98,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Reduction in accrued liabilities</a></td>
<td class="nump">$ 261,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=avco_JefferiesLLCMember', window );">Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common shares sold for cash, shares (in Shares)</a></td>
<td class="nump">1,848,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in Dollars per share)</a></td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Aggregate purchase price</a></td>
<td class="nump">$ 2,337,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds, net of commission and other offering costs</a></td>
<td class="nump">$ 144,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_FairValueOfOptionGrantedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_FairValueOfOptionGrantedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SharesBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SharesBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=avco_CompensationAndRelatedBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=avco_CompensationAndRelatedBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=avco_ProfessionalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=avco_ProfessionalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=avco_CommonSharesIssuedForServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=avco_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=avco_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348366072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of stock options outstanding<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember', window );">0.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 313 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember', window );">1.00 &#8211; 1.93 Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">5 years 135 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,366,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember', window );">2.00 - 2.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,740,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">2 years 189 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">2,740,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember', window );">4.76 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ExercisePrice', window );">Range of Exercise Price</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">3 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember', window );">0.50 - 4.76 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, lower limit</a></td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, upper limit</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">7,580,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years)</a></td>
<td class="text">4 years 167 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number Exercisable at March 31, 2021 (in Shares) | shares</a></td>
<td class="nump">7,136,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=avco_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348467048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of stock option activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_NumberOfOptionsMember', window );">Number of Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsScheduleofstockoptionactivitiesLineItems', window );"><strong>Equity (Details) - Schedule of stock option activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning balance | shares</a></td>
<td class="nump">7,140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted | shares</a></td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised', window );">Terminated / Exercised / Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at ending balance | shares</a></td>
<td class="nump">7,580,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end | shares</a></td>
<td class="nump">7,136,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options expected to vest | shares</a></td>
<td class="nump">443,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WeightedAverageExercisePriceMember', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsScheduleofstockoptionactivitiesLineItems', window );"><strong>Equity (Details) - Schedule of stock option activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning balance | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted | $ / shares</a></td>
<td class="nump">1.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice', window );">Terminated / Exercised / Expired | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at ending balance | $ / shares</a></td>
<td class="nump">1.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end | $ / shares</a></td>
<td class="nump">1.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options expected to vest | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityDetailsScheduleofstockoptionactivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityDetailsScheduleofstockoptionactivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageTerminatedAndExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockIssuedDuringPeriodValueSharesBasedCompensationTerminatedExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_NumberOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_NumberOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WeightedAverageExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_WeightedAverageExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385351145064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_NumberOfOptionsMember', window );">Number of Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems', window );"><strong>Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested at beginning balance | shares</a></td>
<td class="nump">218,334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Options Granted | shares</a></td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Options Vested | shares</a></td>
<td class="num">(215,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Nonvested at ending balance | shares</a></td>
<td class="nump">443,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avco_WeightedAverageExercisePriceMember', window );">Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems', window );"><strong>Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning balance | $ / shares</a></td>
<td class="nump">$ 1.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Granted | $ / shares</a></td>
<td class="nump">1.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Vested | $ / shares</a></td>
<td class="num">(1.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at ending balance | $ / shares</a></td>
<td class="nump">$ 1.14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_EquityDetailsScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_NumberOfOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_NumberOfOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avco_WeightedAverageExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avco_WeightedAverageExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385438674664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statutory Reserve (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReserveAbstract', window );"><strong>Statutory Reserve [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StatutoryReservePercent', window );">Statutory reserve percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RegisteredCapitalPercentage', window );">Registered capital percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RegisteredCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RegisteredCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReserveAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReserveAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StatutoryReservePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StatutoryReservePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385355539528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Net Assets (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RestrictedNetAssetsAbstract', window );"><strong>Restricted Net Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsPercentOfNetAssets', window );">Restricted net assets, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets', window );">Net assets</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net assets of non investment assets and liabilities. This represents the percentage difference between the investments, including long and short positions, and net assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonInvestmentAssetsLessNonInvestmentLiabilitiesPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net assets of the aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611133-123010<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Footnote 11(c)))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350395784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccountsPayableMember', window );">Outstanding accounts payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">10% or more of purchase [Member] | Outstanding accounts payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">90.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_NumberOfSupplier', window );">Number of supplier</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=avco_CustomerMember', window );">Customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AccountsReceivableMember', window );">Outstanding accounts receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AccountsReceivableMember', window );">Outstanding accounts receivable [Member] | More Than 10% Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">70.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_NumberOfCustomer', window );">Number of customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_PublicUtilitiesInventorySuppliesMember', window );">Supplies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ConcentrationsDetailsLineItems', window );"><strong>Concentrations (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ConcentrationsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ConcentrationsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_NumberOfCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_NumberOfCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_NumberOfSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_NumberOfSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=avco_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=avco_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_PublicUtilitiesInventorySuppliesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_PublicUtilitiesInventorySuppliesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385434363080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Concentrations (Details) - Schedule of customers - More Than 10% Revenues [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskOneMember', window );">A (Hebei Daopei, a related party) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskTwoMember', window );">B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskThreeMember', window );">C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Customer</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=avco_CustomerConcentrationRiskThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385356836280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_NumberOfReportableBusinessSegments', window );">Number of reportable business segments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_NumberOfReportableBusinessSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_NumberOfReportableBusinessSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350356360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of segment reporting information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">$ 2,376,468<span></span>
</td>
<td class="nump">$ 3,264,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_InterestExpenses', window );">Interest expense</a></td>
<td class="num">(45,149)<span></span>
</td>
<td class="num">(42,169)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(18,381)<span></span>
</td>
<td class="num">(6,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(63,530)<span></span>
</td>
<td class="num">(48,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(2,367,118)<span></span>
</td>
<td class="num">(3,270,781)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember', window );">Real property operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">289,774<span></span>
</td>
<td class="nump">296,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="nump">216,894<span></span>
</td>
<td class="nump">254,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit (loss)</a></td>
<td class="nump">72,880<span></span>
</td>
<td class="nump">42,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">101,423<span></span>
</td>
<td class="nump">110,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">104<span></span>
</td>
<td class="num">(935)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">28,439<span></span>
</td>
<td class="nump">69,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesRelatedPartyMember', window );">Medical related consulting services - related party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">161,553<span></span>
</td>
<td class="nump">155,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(18,486)<span></span>
</td>
<td class="num">(5,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">180,039<span></span>
</td>
<td class="nump">160,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductMember', window );">Development services and sales of developed products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Other operating expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">35,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate/Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">2,113,492<span></span>
</td>
<td class="nump">2,962,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_InterestExpenses', window );">Interest expense</a></td>
<td class="num">(45,149)<span></span>
</td>
<td class="num">(42,169)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,158,640<span></span>
</td>
<td class="nump">$ 3,004,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_InterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_InterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348459768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of real property operating - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 8,084,912<span></span>
</td>
<td class="nump">$ 8,164,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember', window );">Real property operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">7,655,918<span></span>
</td>
<td class="nump">7,697,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesMember', window );">Medical related consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">208,561<span></span>
</td>
<td class="nump">223,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductsMember', window );">Development services and sales of developed products[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">243,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember', window );">Corporate/Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross', window );">Total</a></td>
<td class="nump">$ 220,433<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherFiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of finite-lived intangible assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherFiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_RealPropertyOperatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_MedicalRelatedConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_DevelopmentServicesAndSalesOfDevelopedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avco_CorporateOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385350447944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Details) - Schedule of identifiable long-lived tangible assets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems', window );"><strong>Segment Information (Details) - Schedule of identifiable long-lived tangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 8,084,912<span></span>
</td>
<td class="nump">$ 8,164,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems', window );"><strong>Segment Information (Details) - Schedule of identifiable long-lived tangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Identifiable long-lived tangible assets</a></td>
<td class="nump">7,718,174<span></span>
</td>
<td class="nump">7,764,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems', window );"><strong>Segment Information (Details) - Schedule of identifiable long-lived tangible assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Identifiable long-lived tangible assets</a></td>
<td class="nump">$ 366,738<span></span>
</td>
<td class="nump">$ 399,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_SegmentInformationDetailsScheduleofidentifiablelonglivedtangibleassetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385348012984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 29, 2018</div></th>
<th class="th"><div>Oct. 25, 2017</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2018 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_StockPurchaseAgreementDescription', window );">Stock purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_JointVentureAgreementDescription', window );">Joint venture agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#x25cf; Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avco_LineOfCreditAgreementMember', window );">Line of Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Line of credit</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Line of Credit bears interest at an annual rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LoanRecevied', window );">Received Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,305,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonShanghaiMember', window );">Avalon Shanghai [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_JointVentureAgreementDescription', window );">Joint venture agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (&#x201c;Unicorn&#x201d;), pursuant to which a company named Epicon Biotech Co., Ltd. (&#x201c;Epicon&#x201d;) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of March 31, 2021, Avalon Shanghai has contributed RMB 4,700,000 (approximately $0.7 million) that was included in equity method investment on the accompanying condensed consolidated balance sheets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AVARBioTherapeuticsMember', window );">AVAR BioTherapeutics (China) Co. Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_JointVentureAgreementDescription', window );">Joint venture agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Avactis Biosciences, Inc. (&#x201c;Avactis&#x201d;), a wholly-owned subsidiary of the Company, and Arbele Limited (&#x201c;Arbele&#x201d;) agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (&#x201c;AVAR&#x201d;), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the &#x201c;AVAR Agreement&#x201d;), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis&#x2019; cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_JointVentureAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_JointVentureAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LoanRecevied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loans recevied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LoanRecevied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_StockPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_StockPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avco_LineOfCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avco_LineOfCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AvalonShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AVARBioTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avco_AVARBioTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385352878456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of supplemental cash flow information - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OperatingCashFlowPaidForOperatingLease', window );">Operating cash flows paid for operating lease</a></td>
<td class="nump">$ 29,590<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OperatingLease', window );">Operating lease</a></td>
<td class="nump">$ 133,201<span></span>
</td>
<td class="nump">$ 185,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OperatingCashFlowPaidForOperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows paid for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OperatingCashFlowPaidForOperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OperatingLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OperatingLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_RightOfUseAssetsObtainedInExchangeForLeaseObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385454402264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of lease term and discount rate for the Company&#8217;s operating lease<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract', window );"><strong>Schedule of lease term and discount rate for the Company&#8217;s operating lease [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">1 year 302 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.88%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfLeaseTermAndDiscountRateForTheCompanySOperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140385346663976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - Schedule of maturity of lease liability<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_ScheduleOfMaturityOfLeaseLiabilityAbstract', window );"><strong>Schedule of maturity of lease liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">$ 140,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">111,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2024 and thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">252,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_AmountOfLeasePaymentsRepresentingInterest', window );">Amount of lease payments representing interest</a></td>
<td class="num">(10,170)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_OperatingLeaseLiabilities', window );">Total present value of operating lease liabilities</a></td>
<td class="nump">241,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_CurrentPortion', window );">Current portion</a></td>
<td class="nump">132,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avco_LongtermPortion', window );">Long-term portion</a></td>
<td class="nump">109,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 241,994<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_AmountOfLeasePaymentsRepresentingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_AmountOfLeasePaymentsRepresentingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_CurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_CurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_LongtermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_LongtermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total present value of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avco_ScheduleOfMaturityOfLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avco_ScheduleOfMaturityOfLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avco_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M!O!\+81^FY@;0'WCF_T%4$L#!!0    ( 'V$KE(CNLKZB@8  ! :   8
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M3E6QI1E=L'$-&[\STU+JL]4VA[RF!Q#]'1<%::F5,<]KC:A6BVV!G:EK"NY
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M'0<M<JIN)-#K*0GPB&^@TX,_]+I7@.GW;2Y_@I+*-<M 7CW1IE1844,331Q
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M-3;E: &>SRT\BA>T0?-Y_M5_ 5!+ P04    " !]A*Y2,^ZRE0T+   !'
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M"E.PJ>!ENY!9J2&WQLI*X"\+!E5878F9:HJF5$4M;(L'L-#6"M70(G(2JMU
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MG[ <Y^.+DWS\XG*+3/$+&0'1F1.G.<'('5VG9SE4?&?]A5LNUK!0(B_ACNU
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M:&5E=#$R+GAM;'U5VV[;.!!]]U<,M,4^"9%$72RGM@$[\:(&TL9(W%TL%OM
M2V.;J"1J23IN_KY#RE;<1>,7\3;GS)DA9S0^2O5-[Q$-?*^K1D^\O3'M;1#H
M8H\UUS>RQ89.ME+5W-!2[0+=*N2E ]55P,(P"VHN&F\Z=GLK-1W+@ZE$@RL%
M^E#77+W.L9+'B1=YYXTGL=L;NQ%,QRW?X3.:K^U*T2KH64I18Z.%;$#A=N+-
MHMMY8NV=P9\"C_IB#C:2C93?[&)93KS0"L(*"V,9. TO>(=598E(QG\G3J]W
M:8&7\S/['RYVBF7#-=[)ZB]1FOW$RSTH<<L/E7F2QT]XBB>U?(6LM/O"L;.-
M1QX4!VUD?0*3@EHTW<B_G_)P <C#=P#L!&!.=^?(J;SGAD_'2AY!66MBLQ,7
MJD.3.-'82WDVBDX%X<QT5A3J@"4\"+X1E3 "-?"FA$>S1P4K_LHW%>IQ8,B7
M103%B7?>\;)W>&/X+!NSU[!H2BQ_Q@>DL1?*SD+G["KA9ZYN((Y\8"&+KO#%
M?>"QXXO?X3N'YJ)U6>"5AG]F&VT4/95_K[A(>A>)<Y&\E]N[NZ>OBWMX6,[F
MRX?E>KEXAMF7>WA<?UH\P6KV]VS^L'C^56ZO\MHZO=4M+W#B42%J5"_H3;\\
MKA>0P>^_Y2R*/L+)]^"Z;Y@9H,06^SZS-AV#>RRPWM#]GW9#GZJG>R?5_]Z)
M=.^D/2>SD%2NVI"AW (=P5965/>BV=T.WAQ=\@_.+[!5<HO:%CNO8(M$]@$B
M/TE2G['4S5G$_)RQ'F%C=YQ62(DOU&%:ZA>F0R<Q\],PA#2*_32.W_SP5T6B
M^DA>.[A0U">DTBZ!PX\424V-3W/7.Z(L]?,D@RA-?#9Z4V"PX8WI,:*F(%[0
M:5 HZLU!Z6Z51_Z(M'3#8/TS3&-Q4%9(B:W4PD VLHKMD,6)=28/9'[.,J29
M'P\3R(=^- KILK:HE$M'8RAUHB'I""SS69X!H^"C<-"5<Q2%?IR%$(6I'PV'
M@[6T@ _ _#C/_9 E;LX2FJ<Y_*H"@HM.4Z/:N7YJKYT$=DVGW^U;]JSK5&_F
M7;^GY[ 3C88*MP0-;X:I!ZKKH=W"R-;UK8TTU 7==$^_'536@,ZW4IKSPCKH
M?V33'U!+ P04    " !]A*Y2DM,T^/P&  "U$@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6RM6&MSX[85_<Y?@5&=3C*C6D_OKK.V9V1[D^Z,L_;8
M;C-IIQ\@$A+1D 07 "VKOS[G7H"TI)4\V30?+)-XW.>Y!Q<\6QG[J\N5\N*Y
M+"IWWLN]K[\?#%R:JU*Z8U.K"C,+8TOI\6J7 U=;)3/>5!:#\7#X9E!*7?4N
MSGCLSEZ<F<87NE)W5KBF+*5=7ZK"K,Y[HUX[<*^7N:>!P<59+9?J0?E_U'<6
M;X-.2J9+53EM*F'5XKPW&WU_.:7UO."?6JW<QK,@3^;&_$HO'[/SWI ,4H5*
M/4F0^/>DKE11D""8\3G*['4J:>/F<RO]!_8=OLRE4U>F^%EG/C_OO>N)3"UD
M4_A[L_J[BOZ<D+S4%(Y_Q2JLG6!QVCAORK@9%I2Z"O_E<XS#QH9WPP,;QG'#
MF.T.BMC*:^GEQ9DU*V%I-:31 [O*NV&<KB@I#]YB5F.?O[A7A?0J$W?2^K5X
MM+)RDN/ES@8>\FG5((VR+H.L\0%9$_&3J7SNQ(<J4]GV_@'LZHP;M\9=CE\5
M^).TQV(RZHOQ<#QZ1=ZD<W;"\B9?[:SX]VSNO,7;?U[1,^WT3%G/])">#S>S
MQP_7XFYV__B+>+R??7J873U^O/WTL"^HK\OZ=/OX0;P5?_W+N_%H]%X<%BUF
M:6H;>'>CY5P7VFOEA*PR<>MS9>'S6LX+#$5)R68P:.ECKL25*6M9K5$KGQMM
M,7FI]']UM10_JDH]&V=*)4 $0B:I=+FHY1KUZ859B*/IR; _' Z/Q<S1.U*7
MYEWNV(YKE:IR#E/BZ+ O8)EHJEKJ+*ATFDLU149TIJSD-Y(^&K+TOEA)1VK)
M%>%-<@V _-*(?^6FZ9-E)<1GL#SU9"64QK'4_"W-M5H(]:S2AH@ 8A<Z56'5
M=/B-,*L*;U#VXFN?)W.HG"M5"5VE10-DXP'FAF 7+\%.:+'A8-<[P09]A6#7
M,=APBWR'E!!QBC&\SL!V6$7^FT)GO&4N"UFE2G"-NZ^.;]):2DMBK'7EE57.
M=V9Y(^;& N6PPXF%-:7X657_RZ41-TU(4X0&._3VO1.%M$L2X7)I56Z*+(8R
MS:4&6W+::-^ED39+\'(=T^(0U=(T5=1[-!Y-^J/A"6\^&KUYVS\]>=.'9:Y6
MS-C%NDT#DO9[\B .YR'Y$_-PN1.P;7*YPY!VSMBU^&2\$K=53-GH'25G=!J2
MTQ8<EI(7?S3H5_N"+G:"_H5-.CA?6P14U[)(0EY"P7&YX4]\2]K'P_<[NWET
M]/X[DO)%O3([1/'[A!XSV^S:$W+ID@Z>TK,$R*5R%2??B)H=KIJ2W<:AW&!A
M&]E3AOWX>(O*K&+(=TX&LAH%WQASX^AHM-?G&K'[W""-RA)P*5N\TBF"1CLE
M>(JJ;!.K;7W. <"O($&T2\YCGO#W8FJ$7$*D=S0YC:&[P0E!*JY T-H3LF;-
M$IV"&)]N0*L+@.)H<M&;1.[NGBVM4DSBW]*FF.M#B[JDU]8\:;9V4]5*PVE)
M$46K4A0$AB)*2H,D4I+L5=*)WF&?;;L42M.V2X.??[PFDC@3S0^XV7%=%FA;
MW9:7("VK/C>DLS!H(6C2JJ9J%6.^<2J6EDF5RA@1K@$6P@8Z0JE99;:1M?94
M>T1:-=<01M5S310DZL;6Q@'B*"%=L,R%3(GHUAWZ$>5=5$V#+T$;PH+M &]C
MXS% (Y7Q5+=/"D1(ARG# VZ1Y-VXW+"<S,I5)8*?_LM(S96T3FS6+F)/M0H@
M;U0PZ5<R)7K(-#!$TV0GP%, \:KE[,3G )U8LU3&!.G,HB#B2RJ-[5JGDUH*
M2XTX98$,%AG.]9;F=\!(IE 8(LUDVF&BI3 FGD#I2<V4'L"WK;&4=#IYH3WR
M4-/>/I(.RD$/A>F-0_50W/K$.RO@%F.6GDE9B!Z@AOL/\0%FD!U../+3YT(#
M99"J4H,,,0^\R,+O!_%+D<>CT\6K!:YA0CUA@A$:+S/'XN."M3-B>7IC-C$I
M@.1"[8604!0PG1:$*Q3,%IL%#!Y$#74>"'VC.!MM9Z?+$K.(_0NA;G-I<H!+
MCR;]R?"D/YX&QL9KR^[$H9MV'<['-IW_8&P\%@B.9;C@D-O9'GI/7AB]*X2V
ME#=Z+3DWU,N\@&.K(9J>]$>M_=-Q?_3F='\[M*<K;94FK=)]_>?Z:[H>Q,LS
M=#@)D:#HPL2]'K:#<^F*_D1LXPZTIX>RM5%CXK4VE:\<NS'C0_'W-X\N^3][
MQS^SA[_ENX=XJ"5^B=R2[>YQS[4+1PH=6+S/\3Z$66XG%E<@ BDF+#(&FL@U
M$:WK&C3RNP2-**ME<;SOICO8^)2 B].2/YB0 . S?%7H1KMO,K/P*>)E>?B@
M PPL-9!2J 6V#H_?GO0"-[<OWM3\80*]$KB('W,E828MP/S"H"N,+Z2@^U)U
M\1M02P,$%     @ ?82N4GF@3\RZ!@  =1$  !D   !X;"]W;W)K<VAE971S
M+W-H965T,30N>&ULK5A;4]M&%'[7KSCC.FTR(V1=;4. &2"DI3,!&N<RG4X?
M%FEM:9"TSNX:0W]]S]F5Y N8DDX> .GH7+YSW^5P*>2MRCG7<%^5M3KJY5K/
M#P8#E>:\8LH3<U[CEZF0%=/X*F<#-9><94:H*@>A[P\'%2OJWO&AH5W+XT.Q
MT&51\VL):E%53#Z<\E(LCWI!KR5\+&:Y)L+@^'#.9GS"]>?YM<2W0:<E*RI>
MJT+4(/GTJ'<2')S&Q&\8OA1\J=:>@3RY$>*67BZRHYY/@'C)4TT:&/ZYXV>\
M+$D1POC6Z.QU)DEP_;G5_M[XCK[<,,7/1/FUR'1^U!OW(.-3MBCU1['\C3?^
M)*0O%:4ROV%I>:-1#]*%TJ)JA!%!5=3V+[MOXK F,/9W"(2-0&AP6T,&Y3NF
MV?&A%$N0Q(W:Z,&X:J017%%34B9:XM<"Y?3Q^;=%H1\.!QIU$660-G*G5B[<
M(1?!!U'K7,%YG?%L4WZ &#H@80OD-'Q6X0<F/8@"%T(_#)[1%W6.149?M$/?
M1(OT-A=EQJ7Z!:R;<"DTA[].;I266 Y_/V,F[LS$QDR\*WY_?+[X].=3\7M6
MCGKM0,U9RH]ZV$R*RSO>.[Z\^G0.8_CYIW$8!&_!ZJ: ^'!1I[RF @;CF'-=
MLAH^Y1S.1#5G]0/DO,R@T,IA=;U@)518$44] ZS\D\4,"PEB$UO?@W<+25^0
M&3:97=!K&ME\+L4=SYX$  8 JS-HT&>0N+[OTP^HG"'5$5-(154A F5$<(1
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MO*:;QYPS/+\3 WZ?"KQN-B]DH/M/R_&_4$L#!!0    ( 'V$KE*Q>MF8J@,
M #\(   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;(U6VX[;-A!]]U<,
M!/1MN[+EW38); /VUKT\I%G83H*@Z ,MCBQV*5(AJ?7Z[SM#7?:^R(O%VYPY
M,SPS].QHW8TO$0/<5=KX>5*&4'](4Y^76 E_;FLTM%-85XE 4W=(?>U0R&A4
MZ30;CW])*Z%,LIC%M6NWF-DF:&7PVH%OJDJXTPJU/<Z32=(O;-2A#+R0+F:U
M.. 6P^?ZVM$L'5"DJM!X90TX+.;)<O)A=<'GXX$O"H_^P1@XDKVU-SSY2\Z3
M,1-"C7E@!$&?6[Q"K1F(:'SO,)/!)1L^'/?HO\?8*9:]\'AE]5<E0SE/WB4@
ML1"-#AM[_!.[>"X9+[?:QU\XMF>S]PGDC0^VZHR)0:5,^Q5W71X>&+P;OV*0
M=099Y-TZBBQ_$T$L9LX>P?%I0N-!##5:$SEE^%*VP=&N(KNPV 81FF#="3;H
MT=WB+ T$RYMIWD&L6HCL%8@I?+0FE![61J)\;)\2G8%3UG-:96\"?A3N'*:3
M,\C&V>0-O.D0XS3B37\T1OAGN??!D2+^?0/^8H"_B/ 7K\'OEKO/NT^;;[!9
M;]>;+^N74O@VQ-^?=FMX#S_#@#7JL&!Y*S2I=UL*<RB% F$DK%#]I\P!_D"#
M=];;"H&JU(F (V4@E C7FZLS$ ZI;KXWRJ&$8&G<1C\9_P2VX'/*@:'"KYTM
M5 !1!'2@3,Z 0=P1@B>%TR()CR 4%U%NG10F1])I*'M?<;TQ@4FY1J,?,4V'
MAT8++CY_#LN:O-1.Q3FS85,_W$S/;7^*&U>VJH4Y@?*QYB203<_2.:IC"2)
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M5BN]=6@&3[8(>XK[+3$VE3HA4-IGK!7Q7J4]I(7S4J?2 A7_ ;:M\L9=Z')
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M 9QO#.ZM9L$&NE\_5_\"4$L#!!0    ( 'V$KE*TE5_N:P,  -,*   9
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MY5Q!@4LR#;Q3&I!D,T(U"RTJ.[8LA*;[QHH939THC0)]7PJA-POCH)MC1]\
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M'B#5WN?:!R,7[@XUE08^$-VR@BLP4U8 WL^D-/V#-;"^5$_^!E!+ P04
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M7-P#7 :_HWV]'%"J';8XN=&XT"B0,T-NVPJLMV.]/T,O&Q'65&7DDG70%ZK
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M;"]W;W)K<VAE971S+W-H965T,C0N>&ULC53!;N,V$+W[*P;"'EI C2125NS
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M!LX^LU6#^NT\,.3&*@?%#O)F@(Q?@4S@7@I3:[@3)98O[0.B-W*,]QQOXI.
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M,@TOIE1W:AA+@V!DYT;!2AH:+&Y9TR1'917H>R6EV0O6P?C?8/D?4$L#!!0
M   ( 'V$KE)M7*ED"@,  $<&   9    >&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;'U536_C-A"]^U<,U$71 D(D4A]64MM LNFB!;IHL$G;0]$#+8TL8BE1
M):EX\^\[I&PE6VQR,3GDO'EO1ISQYJC-9]LA.OC2J\%NH\ZY\2I);-UA+^R%
M'G&@FU:;7C@RS2&QHT'1!%"O$IZF9=(+.42[33B[,[N-GIR2 ]X9L%/?"_-T
M@TH?MQ&+S@>?Y*%S_B#9;49QP'MT?XQWAJQDB=+('@<K]0 &VVUTS:YN<N\?
M'/Z4>+0O]N SV6O]V1N_-MLH]8)08>U\!$'+([Y'I7P@DO'O*6:T4'K@R_TY
M^H>0.^6R%Q;?:_67;%RWC:H(&FS%I-PG??P%3_D4/EZME0V_<)Q]"V*L)^MT
M?P*3W<MA7L674QU> *KT%0 _ 7C0/1,%E;?"B=W&Z",8[TW1_":D&M D3@[^
MH]P[0[>2<&YW7==FP@9^DV(OE702+8BA@=]=AP;NQ)/8*SKZX2&L/VX21Z0>
MFM0G@IN9@+]"D,%'/;C.PL]#@\W7^(3$+HKY6?$-?S/@1V$N(&,Q\)2S-^)E
M2P6R$"][)=Z2HT\[E$,H"W]?[ZTS]&;^>8,B7RCR0)&_0G%/K=1,"D&W] SG
M@JO_%5R'@H\G,=^J\YL<OGFO["AJW$;4G1;-(T:^5G47BG6+-?9[8B!C=?[H
MH]$M6M]?0D&+I.0=L#C/BYCS(NPYXW'%^8+PD4-,+[G!1VKJD5K4S>@\XW&1
MIE"P+"ZR[)E'/!FMU)+STPR7AEI3&_O]=Q5GZY^@UCW-&BM"N[*RB*N\!%;D
M,;]\5N!P$(-;,+*G)!XQ:# H^_UD[&Q5++XD+?.R>O@:9K&>C!?2X*BM=%!>
M>L5^*;/<D^F)W,_? XHRSM8Y5.N87::K6VS1F%".P5'IY$#2$7@9\ZH$3LFS
M=#5W$&-IG)4IL+2(V7J]>M >\ YXG%55G/(\['E.^Z*";[VUY$5S]V@.8819
M" +G/E].EREY/0^'9_=YQ-)S.,C!@L*6H.G%NHC S&-K-IP>PZC8:T>#)VP[
MFO1HO /=MUJ[L^$)EO^.W7]02P,$%     @ ?82N4BJ\MPN! P  \@@  !D
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M16^D66;TIP2%%J#S-:<KOMMH \/?G,5/4$L#!!0    ( 'V$KE+X_+<9*0(
M *@$   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;'U4VXK;,!!]WZ\0
MAH6VE/B6M&%Q#$G:TL(NA&2W?2A]4.QQ+")+J32IMW_?D>RX6=CD19X9S3ES
MT8RS5IN]K0&0/3=2V5E0(Q[NPM 6-33<CO0!%-U4VC0<236[T!X,\-*#&ADF
M4?0A;+A009YYV\KDF3ZB% I6AMECTW#S=P%2M[,@#DZ&M=C5Z QAGAWX#C:
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M*726Z=;)[N#TIEWA%MK!0MB2:]C A?$,\+[4VNT/WL"PT\__!5!+ P04
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MJ=IIVFZ,K-T$6TE#\] M"_H!@LI>H/.UE&:WL0[ZGS3S?P!02P,$%     @
M?82N4H8,*H-T P  T@P  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
MQ5=M;]LV$/XKA( !"=!9HOQ>V 9B.]M2)(N1="O:HA\8Z2QQD4B5I.)TOWY'
MR9&,0:']H4#\P1(I/L_=/4>>3K.=5(\Z!3#D.<^$GGNI,<5[W]=1"CG3/5F
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MQOSTR"[E6<Q%0F04E043T0^"-KLVZ,I--)GV!D[=:= 6X,#M$_!_K$L?.!C
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MF-9YZ2 1M@.)1C,E),J/OTD#1X69D#"_4AG5F)63,YA<R7+/$.)BGRF@1&4
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M\PZ;C5>%&)E!U?[!,7S:97$P6-QHD=G#N*G0P%I[:79!B#0%X/U,0(_*&]-
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MF5^@@;9^]X>F=5^\SQ43FG HD3(8C+"ZJG6T=F#DQIG"6AJT&->M\2< RF[
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M9'V#UA,M2G<)S84V5YH;YN9/!TH;8)XOA-#;B;W7VK\QXQ]02P,$%     @
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M3<=*[I%RUC::&_C<>&^KAE=N&Y=&V;?<^IGIC8*:\1R]N;>%H4$C5N7HD]F
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M)2X:Q$5'Q?W@+']77T<1[V0.XG@RB?8$CH0E47CNC2N,!X7QA^RC!*\()8K
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M*L2A-LKH*C?1R>$I,G2TZ-QMOA;:O U<<V.>;R"M@?E>"Z$/'?M &!^$R_\
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M]P_A+\WXD0'?U;$N T[6 3\C1L+39'F$R.AG1"P\JM$S-<-OJ3A">-@(G[6
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MT&SKP[ '6KJVB4BD2M)V"NSC=TG)DK-8M L,F!]L4N(]Y_!>ZNAZNI?J46\
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M\>+*>3+#"1L"U&WHZJ-&=T;"L'&7$AB?X-9/6N,Y\!M,UUSQ!U!+ P04
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M4V RY@P)6$V==_AZ088&8$?\$\-6[IPC(V7)^9-I? RGCF=6! D$RE!0?=C
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MS/ _ 91=@/-+*<VF8P,T?QZ3?U!+ P04    " !]A*Y2SG+MT2,"  #Z!
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M*W-AW5%#LU3)@2CKC6QVX7+CT!@-$[:*>Z/PE"'.9'NHL2:&W O?$3:U+^[
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M*A!H! 0&][006PY^+A*2G/K;,J$F*W3,Z@89 ]['[ I@^!$@!T$-GN5T=\<
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M("> 58>7U8V@N_+\[YD*0?/R<DOBA#!E(-^O*17'&S5 <X2\^ ]02P,$%
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M5_HFL<-.W_4@3()>;SA73X&Y3MR_A^HO4$L#!!0    ( 'V$KE*MSJ5DJPD
M %@>   9    >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;+U9:V_;N!+]*T0V
MNT@ U[;\BMVD ?)JF]VD6R1]8._B?J EVF(CB5Z1BN/[Z^\9BI)LQU;<+M!^
M2"V*,YSWG*%.YBI]T*$0ACW%4:+?[(7&S%ZW6MH/1<QU4\U$@C<3E<;<X#&=
MMO0L%3RP1''4ZK3;@U;,9;)W>F+7/J:G)RHSD4S$QY3I+(YYNC@7D9J_V?/V
MBH4[.0T-+;1.3V9\*NZ%^3S[F.*I57()9"P2+57"4C%YLW?FO;[V1D1@=WR1
M8JZ7?C-29:S4 SU<!V_VVB21B(1OB 7'?X_B0D01<8(<_SBF>^691+C\N^#^
MUBH/9<9<BPL5?96!"=_L#?=8("8\B\R=FK\73J$^\?-5I.U?-L_W]KM[S,^T
M4;$CA@2Q3/+_^9,SQ!)!Q]M"T'$$G36"87L+0=<1='<EZ#F"WJX$?4?0WU6'
M@2,8[$IPY B.=B48.H+AK@0C1V#CJY7[SSK_DAM^>I*J.4MI-[C1#QM!EAH^
MEPD%^[U)\5:"SIQ>J#B6!M%K-.-)P"Y48F0R%8DOA68'E\)P&>G#DY;!8432
M\AWC\YQQ9PMCC]V"5:C951*(8 /]VWKZ[DOT[U\XOU/#H 4KE:;J%*8Z[]1R
M/,NF3=89-5BG[8T^WU^R@_U-=KFHY_*G;\"E:[D,MW.YK.=RRQ>%*,,-U%>[
MR-"WY$>;7//2X6F3=3TB[WC;57BW.Y?V=B[OZ[E<"G\7+M??X92+#W^Q@]]^
M\0;]X\.:L.F6&=:UO+O_+L/8WS<@9-=&Q/J_-<?VRF-[]MC>EF/OC?(?V"Q+
M_1"]@/%I*@0)T4 KT'XJ9]1K-H5./=MS(;]!>O9.).)):14+J]1?&?M/J+(&
MN[ULL(\A_IA0,*TB_ EY*D(5!2)E:L*>,VB0E#KCB6%&L7DH_7"%O?]/)E,1
M,!Y%Q( 82ZTS6L'):.#:X ?QU,+/4FG(KAM/8C)AOD*CABS<]EILX\SG.F0S
MOB#ST!8Z@<<JPQ/>[_?Z[4:[W6[00R[=OM>V2Y"#:2-)KKD(FNQMEH(VQ<Z$
M(:34&"H7:=98E@,'"5)))M"8M/ CI:U"[$QK0)R/A=_."K^A+YB072)G<D,_
MMQF)C6";\62Q:C1.+'4#I_E19@U%JS@;$ .8(^,1FZ6 3ZE96&$**;68<6<G
MO= 4F T6BBA@XT4I"",R8"KB"DE(AG&F$33:^B 56G"H@M<4>(\ 5S,K .F,
MQ!"I+WDD_T=KQ;%&^&&B(C6%'YOL>H/+K(.<4DM6G7$95(+M#X\&C?;PR#H=
M'D9(ICS1$Y&27?K.@S8ZK:@D#FEJ\\8=4I@3FI5\2707?^5:KY93)6*S)K'[
M96+W:S/PSYFU! QV(Q A,,$=A<?5$_"O%INJ><YO8/D1^'T\[8Z@^TGK<;E:
MO[1K1=A!*>R@5MC?%<*,/4+ +/V.(G11S_4W'L^.?WGJ]/W),?N*O("+!RS@
M"VM^+:=Y.,*!9U_.[JH<:K"S1T+7FA(W%2Y%X%PD/_UWEHZ!PME^UP4'1\4N
M0]@ZWH6P3<B)$'E2(FMY$$C2!:EDYJHH)E:<DML!1A/P,\IP6\CV1_F+0SIZ
M[,(WFR%RXHR2,EKD!BL692004LBLNB@Z*AUS5&M"VVP@Q 4L(,U2F?G[5L2H
M6W4M:%B>,?R9G6]4'CO:237?JK8)N8Z>A3IF0_MO<[1[[0I-M[_'K&-$CK:5
M%E%D&#<V5I*$2BZ2>%.VGK]P0K_9;O]:8R5O"?E[M9SNA"\P: ;L1O%-2?C6
MT?>72T*WW>_T1EO,U*F.[M0>C32,$-+W(4^F(9>[!)U7X2WOIP(NKT)<7CTV
M^L%B=_D"VW5CK8('EI_ZQ9VZAA=^ER#2&?N<2%^E"3N7MK'ZB+]/19M=P$+-
M!KLQ0# '16EM>_ZQ(ZJ6@N/#3<"#4\>S?3+A,02[FH'.GD6M?!OW?-<*<S9'
MQ:4+'# ! PQ<&("9U\MQ>;-@C.*MY@GV#-J_$A8IE"-G]_*E-9LUBRXQ0<"S
MA<U*9*EX F!<!A5;;-DHCT"3M]#ID=+9XD;KA4*PQ.9W#AT395A$,,A "'9W
M>\Z&%D;:5L!G0%Q/,D8-0)G?]YH=JN\11#FT:I PLU3$4N>0@IXC/E8H&BIU
M^/8#3RR^?:_T3+J><A$2]!+L%N7'I_"FGB.>@/LT:9[A%:R3B]NP)ZU'U[_2
MT&O7J-@O55SVY$3YF<[][0./DM8%ZJ0A0J8!&B,A4P.!+(P<5S&L$3UHV"!1
M6L(R"ZMO!2RMAAIYCPHPD7[5RQ'$(!&Z-+:/K+,L<Y!H[]%<8"S1<R!9( !;
M6YJ ZO3ZUC(LQN'&,X,"QA."-:D<9P:*DIUZC:,M9FHWCZI(@%V-S8D<N=N<
M9P1;8(Y8F% %SE$VX96;7'R7C10;.#@@6!A8$*TB&7"28<PCGO@TFPF Z+KB
M5Z%2KQZ66J2%E/^$ 8C/!-+*1[&E>.2'5 +R"K!+H:^PI3?XJ86^PDY>/7CZ
M453[ ML"G,**-N9\ O?7B;]6.-VVM;+,48P5,..KO#3J;(R927*DQ.HLX[(^
M1[HW$@;$[E7^]MUJ879 U$UXB#@^CJ0.\[B;L-V<OWH*2)ZI<"\3]0K))P#A
MBT#_MFSLU?:#JG.5;]K6! ](W/5CJ_=K N3M;$X#/?#X2H\I?+/<8ZR=FNP3
MU>J\GMC7Y?RK?0S5FUL+.$'^HAR5HW&#!O$@\Z&G1C'$NM2N<%C6B&T8F":#
MY>$9OCV[>_6I17\__-'Z=$$/68*"GVI4-"JK6<13)N,X0\VV/EI0*;$.:FX;
MBJJB11<>155B!]11L MESMV7H*(=%E,VB=G"#BW21VD#.#=JWE9@U>522'<M
M*+=^B'2E+Q:V"U1SCIN+ @&\$TMRAHT%:$_6)T>Z!I9+G[ Y7?[0/5 V_B9\
M&R+/DF5TG,M)MD\?Z8;!08-NVTZ0C2(W<HEC_B LP'%2NYZP/V@.!J5)W)T1
M=0T+*PB@D1P.H=W $,GSNQRKP13Z6YGM4S%.5AT[I8\U5L_(<2G\1MI)5#Y3
MX3A[-;'Q6F?UEN9'PF7M&'O)M#3T5F]=*#OWDEDR&_)6-_*D=K<_24Y=N'GC
MT+N<=J7'B]BJFX.]:DCUAK55]ZM*'VRKY!9%;:S;PV<#XW!U7,POF=V^T=*^
M?NU<68VT7OU,>[?M$D)LO_;QGH^YHPU2OW]Y7RYT:^DK$VK/U'ZB)&P#+)A?
MAY>KY6?0,_OQ;VW]W'M]Y6U8?^N]?I=_Y*S8Y]]<@;&F$I$2B0F. D8"%DGS
MSYCY@U$S^XUKK(Q1L?T9"AZ(E#;@_41A%G$/=$#Y,?GT_U!+ P04    " !]
MA*Y2M.DP;KT"  "\!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6R-
M55UOFS 4_2M7: ^MM!0"2=9&"5*3;MH>JE6-NCT[< E6C<ULDW3_OM>&T*Q+
MHKZ O^[Q.>=>+K.=TL^F1+3P4@EIYD%I;3T-0Y.56#%SI6J4M%,H73%+4[T)
M3:V1Y3ZH$F$<19.P8EP&Z<RO/>ATIAHKN,0'#::I*J;_+E"HW3P8!ON%1[XI
MK5L(TUG--KA"^U0_:)J%/4K.*Y2&*PD:BWEP.YPN)^Z\/_"+X\X<C,$I62OU
M["8_\GD0.4(H,+,.@=%KBTL4P@$1C3\=9M!?Z0(/QWOT;UX[:5DS@TLE?O/<
MEO/@.H <"]8(^ZAVW['3,W9XF1+&/V'7G8T"R!IC5=4%$X.*R_;-7CH?#@((
MYWA W 7$[P-&)P*2+B#Q0EMF7M8=LRR=:;4#[4X3FAMX;WPTJ>'297%E->UR
MBK/I4E45MY06:X#)')9*6BXW*#..!B[NT#(NS"4,8$4%E#<"0164\[H6Z**8
M@(R9$@HJ!^"R+2N7GP$\K>[@XM/E++3$T]T69AVG1<LI/L$I@7MB41KX*G/,
M_XT/25\O,MZ+7,1G >^9OH)D^!GB*!X>X;/\>'ATAD[2>YYXO.24Y\ZPFO$<
MR"Y@E6J<^UQFHB&]- !;(E3(3*.]R<YR05,$P=F:"VXI.=,S3$8]DY%G,CK!
MY&>-FKE\OR71O#%3_:Z__%@B6_B)AW<-8YO&-^,;,FE[:.]9$JY/34W-,IP'
MU(@,ZBT&*9Q1-^[5C<_Z[%O20!6#AIQCQB"YK-94T+)U&5^RDE&M>[&MOVHM
M^,87\#E[)SV!R0?M/6G@Y#\#ATD21\-W#AXY=CT>'1QK^84'C:!"O?']T4#F
M*JS]7/K5O@7?^L[S;GU!K;GMI&\P;5^GCV'#I2%%!4%&5U\H![KME>W$JMJW
MF[6RU+S\L*3?"VIW@/8+I>Q^XB[H?UCI*U!+ P04    " !]A*Y2/XG^:3 "
M   A!0  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RME-MN&C$0AE]E
MM%6K1&K9 R1!*2 %HJJYJ(02M;FH>F%V!]:*#UM[".'M.S;+ED@!J5)O6)_^
MW]\,,QYMK'OR-2+!BU;&CY.:J+E.4U_6J(7OV08-[RRMTX)XZE:I;QR**HJT
M2HLLNTRUD":9C.+:W$U&=DU*&IP[\&NMA=M.4=G-.,F3_<*]7-44%M+)J!$K
M?$#ZWLP=S]+.I9(:C9?6@,/E.+G)KZ>#<#X>^"%QXP_&$")96/L4)G?5.,D"
M$"HL*3@(_CSC#)4*1HSQN_5,NBN#\'"\=_\28^=8%L+CS*I'65$]3H8)5+@4
M:T7W=O,5VW@N@E]IE8^_L&G/9@F4:T]6MV(FT-+LON*ES<.!(+\\(BA:01&Y
M=Q=%REM!8C)R=@,NG&:W,(BA1C7#21/^E =RO"M91Y.9U5H29YD\"%/!S!J2
M9H6FE.CA[!9)2.7/X1,\<#U4:X5@EZ"0$P&$3D=1)7UIUX; "4+@2@&JD:UT
M(\SVP[MAD5]]]L"%Q/MLOI./4F+^0)&6+>MTQUH<8?TF7 _Z^4<HLB)_+4\Y
M["[VHHN]B'[](W[_.R+X>;/PY+C0?IV@ZW=T_4@W.$+W& L**Q#/?,L*N05"
MD_V]+<*>20-;%,Z?OY7/TS?D40G]K(!*;/T)YD''//@WYE=Y?(OPM-^@-QR^
M?XLK/:CX\'AP::RD\9R9)1MEO:N+!-RN(7<3LDUL@H4E;JDXK/D-0Q<.\/[2
M6MI/0E]UK^+D#U!+ P04    " !]A*Y2!'GUA04#  "O"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U.2YX;6R-5M]OVC 0_E>L: ^MM#9QPL\*D"C=M$FK
M5)5U>YCV8,@!5AT[LQUH__N=G1"H"&E?$MOQW??=Y_-=1CNEG\T&P)*73$@S
M#C;6YC=A:)8;R)BY5CE(_+)2.F,6IWH=FEP#2[U1)L(XBGIAQK@,)B._]J G
M(U58P24\:&**+&/Z]1:$VHT#&NP7'OEZ8]U".!GE; USL$_Y@\996'M)>0;2
M<"6)AM4XF-*;6QH[ [_C%X>=.1H3%\I"J6<W^9Z.@\@Q @%+ZUPP?&UA!D(X
M3\CC7^4TJ#&=X?%X[_VK#QZ#63 #,R5^\]1NQL$@("FL6"'LH]I]@RJ@KO.W
M5,+X)]E5>Z. + MC5589(X.,R_+-7BHAC@QB>L8@K@R\$&$)Y%G>,<LF(ZUV
M1+O=Z,T-?*C>&LEQZ4YE;C5^Y6AG)S.59=RBS-80)E,R4])RN0:YY&#(Q1U8
MQH6Y)%=DC@F1%@*(6B$!6VAN7]U8 (I"!&<++G!I%%JDY9R'RXK";4DA/D,A
M(?<(NC'DBTPA?6L?8CAU3/$^IMNXU>$]T]<DH9])',7T:7Y'+CY=MKA-:JD2
M[S8YX_:# I _TX6Q&M/M;PMHIP;M>-#.&5 ,(6Z2M+3J>2MW\[83VHD&M#\*
MMPUHW1JM^QY:TH166G6/T2A-.F?0>C5:[SVTCD\ZNP&L*"L+N@F\U8FK6C<F
M9TL8!UB6#.@M!!/2HGR_9M=O9?=362:JP\W9J[\B3?3Z)]K$W9CV.LW:#&KT
M02OZ-%.%M(?TVC/ 2NC#]+>4<(F:@;%-O 8GO*YH1/M1,Z]AS6OX 54J"F3+
M1.'O W8)S3REM[<!BT@3M^&I9ATZ')[1C$:'8A:ULIL56CM>N=*NYC?6HN@T
MEY.XUSV3R_2HD-)6[!]*KJ_P.+)6='J*'@V3Y!QZ?$"/WS^71L3XI%(T:AT>
M]9 ,]-IW2D.6+@W+=E*OUMUX6O:@P_:RE6/]77-I,!56:!I=]S%<77;'<F)5
M[CO20EGL;WZXP3\*T&X#?E\I9?<3!U#_HTS^ U!+ P04    " !]A*Y2]U19
M*B0#   N$@  #0   'AL+W-T>6QE<RYX;6S=6.%JVS 0?A6CCM'"J..X<>,U
M#FR!PF ;A?;'_A4EEA.!+'FRTB5]G[W(GFPZRW'25%>Z_MB:.:26[M-]]^GN
M7)F,:K,6['K!F E6I9!U1A;&5._#L)XM6$GK4U4Q:9%"Z9(:.]7SL*XTHWD-
M3J4(^[U>$I:42S(>R65Y69HZF*FE-!DYZTR!NWW*,Q(E9R1P=!.5LXS<'K_]
MOE3FXDW@[D?OCHYZMR<7^_;C!C@AH9=T\ S2TYZ]4.8&Q>B3Y]$_18Y1G_NI
M?_U$\M$!.PD)V\R/1X62VP+$Q!EL7%JRX(Z*C$RHX%/-P:N@)1=K9^Z#8::$
MTH&QE;="(K#4]PZ.W R:HN4IN52ZB>TBN+_3=OD>L)F!0"Y$)[!/G&$\JJ@Q
M3,M+.VD6-\9'4-".;]:553C7=!WU!V3KT-QLD*G2.=-=F(AL3..18 7(T7R^
M@+M150B@,:JT@YS3N9*TT;#Q: >6=L:$N(8GYEOQ@'M5[%2T!_64W= *:H>.
MQDV ?Y?-<>_2OHPWJ/B=,A^7=CNRF4.GL"O-"KYJYJNB$X"Q1S@[K2JQ_B#X
M7);,;?[9 <<CNO$+%DKS>QL-6F5F#4R3X(YIPV>[EA^:5C=L93;MM"IPS?T#
MU/QW\SQGDFDJ=D7;WG_-67ZQXOC\7TEN_JOL"_9J;(_!URYR< @BDT,0>0 ]
M&:>O4F/8'HT[Y^^#T[>S!O"6DY&O\#8EMD&#Z9(+PV4[6_ \9_+1(6SI#9W:
ME^$'_'9]S@JZ%.:F S.R'7]A.5^6:;?J"A+1KMJ./\/VHJ1[Q;*QN,S9BN63
M=JKGTV88V(&-VE[@L(]<-I<?P7P<YD< P^)@"C ?YX7%^9_V,T3WXS!,V]"+
M#%&?(>KCO'S(I/E@<?P^J;W\.TW3.$X2+*.3B5?!!,M;DL#7SX9I P\L#D3Z
MLUSCU<8[Y.D^P&KZ5(=@.\4[$=LIGFM _'D#CS3U5QN+ QY8%;#>@?C^.-!3
M?I\XAJIBVK G&$?2%$.@%_T]FB1(=A+X^.N#/25QG*9^!#"_@CC&$'@:<013
M !HP)(Z;<W#O/ HWYU2X_85H_!M02P,$%     @ ?82N4I>*NQS     $P(
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M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ ?82N4AP1 2GA P  2@X  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( 'V$KE(Z=>;!%@@  /<A   8
M              " @24,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !]A*Y2DEOM:/8"  #]"0  &               @(%Q%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ?82N4B.ZROJ*!@
M$!H  !@              ("!G1<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( 'V$KE)W<6"6\ 8  $0N   8              " @5T>
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !]A*Y28]"\
MGP@'  !?'   &               @(&#)0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ ?82N4O%#TTOC"P  JA\  !@
M ("!P2P  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( 'V$
MKE(S[K*5#0L   $<   8              " @=HX  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !]A*Y2I0'3[DT6   N/P  &
M        @($=1   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ ?82N4O*Z(40Y P  F08  !D              ("!H%H  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !]A*Y2[?'YAQ@&   %#@
M&0              @($07@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( 'V$KE(RC)AO40,  -0&   9              " @5]D  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ?82N4I+3-/C\
M!@  M1(  !D              ("!YV<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !]A*Y2>:!/S+H&  !U$0  &0
M@($:;P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( 'V$
MKE*Q>MF8J@,  #\(   9              " @0MV  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ ?82N4H >@R6*!0  "0T  !D
M         ("!['D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !]A*Y2M)5?[FL#  #3"@  &0              @(&M?P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( 'V$KE*!'MYCNP4  & /
M   9              " @4^#  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ ?82N4GQ8KQQ.$   52D  !D              ("!08D
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !]A*Y2MJ9J
MSR@"  "K!   &0              @('&F0  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( 'V$KE*>%.#]Q!8  "Q$   9
M  " @26<  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M?82N4D)HJ>H7!0  : L  !D              ("!(+,  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !]A*Y2UR?=BO@"  !K!@  &0
M            @(%NN   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( 'V$KE)Z=0M(\ (   8&   9              " @9V[  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ?82N4D1XA$YI P
M)P@  !D              ("!Q+X  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !]A*Y2;5RI9 H#  !'!@  &0              @(%D
MP@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( 'V$KE(J
MO+<+@0,  /((   9              " @:7%  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ ?82N4OC\MQDI @  J 0  !D
M     ("!7<D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'V$KE*?UPG\H (  &(&   9              "
M@;S>  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ?82N
M4JC9!XDW P  T@@  !D              ("!D^$  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !]A*Y28+MP0$0#   >"P  &0
M        @($!Y0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( 'V$KE)?GDEDLP(  $<'   9              " @7SH  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ?82N4CI7<N4[ P  APD
M !D              ("!9NL  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !]A*Y2P^>-K.<"   2"0  &0              @('8[@
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( 'V$KE)U>SP<
MM (  /0&   9              " @?;Q  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ ?82N4@]5BPR3 @  7@<  !D
M ("!X?0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !]
MA*Y25&4+HIX"  "&!P  &0              @(&K]P  >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( 'V$KE)/$$W#2@,  !P*   9
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M970T-BYX;6Q02P$"% ,4    " !]A*Y2GWPO]@X#  "!"@  &0
M    @(%Z$@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M 'V$KE+U'U*8!P(  /($   9              " @;\5 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ ?82N4MI:V8;S 0  " 4  !D
M             ("!_1<! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !]A*Y26"2  W\#   =$0  &0              @($G&@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( 'V$KE)&*N?/H0(
M (4(   9              " @=T= 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ ?82N4LYR[=$C @  ^@0  !D              ("!
MM2 ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !]A*Y2
MA/_4]!$%  !.%@  &0              @($/(P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( 'V$KE*)J6IDTP(  & (   9
M      " @5<H 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ ?82N4M?+%31^ @  20@  !D              ("!82L! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !]A*Y2K<ZE9*L)  !8'@
M&0              @($6+@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( 'V$KE*TZ3!NO0(  +P&   9              " @?@W 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ?82N4C^)_FDP
M @  (04  !D              ("![#H! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !]A*Y2!'GUA04#  "O"   &0
M@(%3/0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( 'V$
MKE+W5%DJ) ,  "X2   -              "  8]  0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ ?82N4I>*NQS     $P(   L              ( !WD,!
M %]R96QS+RYR96QS4$L! A0#%     @ ?82N4N>K%^./!   82<   \
M         ( !QT0! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'V$KE)9
M=@'X]0$  #@C   :              "  8-) 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'V$KE(7R,P;VP$  -$B   3
M      "  ;!+ 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(
' +Q- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>170</ContextCount>
  <ElementCount>369</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Basis of Presentation and Going Concern Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition</Role>
      <ShortName>Basis of Presentation and Going Concern Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Equity Method Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestment</Role>
      <ShortName>Equity Method Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Accrued Liabilities and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables</Role>
      <ShortName>Accrued Liabilities and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Statutory Reserve</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/StatutoryReserve</Role>
      <ShortName>Statutory Reserve</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Restricted Net Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RestrictedNetAssets</Role>
      <ShortName>Restricted Net Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Concentrations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/Concentrations</Role>
      <ShortName>Concentrations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Organization and Nature of Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables</Role>
      <ShortName>Organization and Nature of Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/OrganizationandNatureofOperations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Equity Method Investment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</Role>
      <ShortName>Equity Method Investment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Accrued Liabilities and Other Payables (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables</Role>
      <ShortName>Accrued Liabilities and Other Payables (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Concentrations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConcentrationsTables</Role>
      <ShortName>Concentrations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/Concentrations</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Organization and Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsDetails</Role>
      <ShortName>Organization and Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofcompanyssubsidiariesconsolidatedfinancialstatementsTable</Role>
      <ShortName>Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/OrganizationandNatureofOperationsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Basis of Presentation and Going Concern Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernConditionDetails</Role>
      <ShortName>Basis of Presentation and Going Concern Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/BasisofPresentationandGoingConcernCondition</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of cash balances by geographic area</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofcashbalancesbygeographicareaTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of cash balances by geographic area</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of the effect of including these potential shares was antidilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleoftheeffectofincludingthesepotentialshareswasantidilutiveTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of the effect of including these potential shares was antidilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofprepaidexpensesandothercurrentassetsTable</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/PrepaidExpensesandOtherCurrentAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Equity Method Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityMethodInvestmentDetails</Role>
      <ShortName>Equity Method Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Equity Method Investment (Details) - Schedule of equity method investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofequitymethodinvestmentTable</Role>
      <ShortName>Equity Method Investment (Details) - Schedule of equity method investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Equity Method Investment (Details) - Schedule of financial information investee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleoffinancialinformationinvesteeTable</Role>
      <ShortName>Equity Method Investment (Details) - Schedule of financial information investee</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Equity Method Investment (Details) - Schedule of financial information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleoffinancialinformationTable</Role>
      <ShortName>Equity Method Investment (Details) - Schedule of financial information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofaccruedliabilitiesandotherpayablesTable</Role>
      <ShortName>Accrued Liabilities and Other Payables (Details) - Schedule of accrued liabilities and other payables</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/AccruedLiabilitiesandOtherPayablesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/RelatedPartyTransactions</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Equity (Details) - Schedule of stock options outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofstockoptionsoutstandingTable</Role>
      <ShortName>Equity (Details) - Schedule of stock options outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Equity (Details) - Schedule of stock option activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofstockoptionactivitiesTable</Role>
      <ShortName>Equity (Details) - Schedule of stock option activities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleoffairvalueoftheoptionsusingtheBlackScholesoptionpricingmodelTable</Role>
      <ShortName>Equity (Details) - Schedule of fair value of the options using the Black-Scholes option-pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/EquityMethodInvestmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Statutory Reserve (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/StatutoryReserveDetails</Role>
      <ShortName>Statutory Reserve (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/StatutoryReserve</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Restricted Net Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/RestrictedNetAssetsDetails</Role>
      <ShortName>Restricted Net Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/RestrictedNetAssets</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Concentrations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ConcentrationsDetails</Role>
      <ShortName>Concentrations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/ConcentrationsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Concentrations (Details) - Schedule of customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofcustomersTable</Role>
      <ShortName>Concentrations (Details) - Schedule of customers</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/ConcentrationsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Segment Information (Details) - Schedule of segment reporting information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofsegmentreportinginformationTable</Role>
      <ShortName>Segment Information (Details) - Schedule of segment reporting information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Segment Information (Details) - Schedule of real property operating</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofrealpropertyoperatingTable</Role>
      <ShortName>Segment Information (Details) - Schedule of real property operating</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Segment Information (Details) - Schedule of identifiable long-lived tangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofidentifiablelonglivedtangibleassetsTable</Role>
      <ShortName>Segment Information (Details) - Schedule of identifiable long-lived tangible assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/SegmentInformationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Commitments and Contingencies (Details) - Schedule of supplemental cash flow information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofsupplementalcashflowinformationTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of supplemental cash flow information</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Commitments and Contingencies (Details) - Schedule of lease term and discount rate for the Company???s operating lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofleasetermanddiscountratefortheCompanysoperatingleaseTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of lease term and discount rate for the Company???s operating lease</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="avco-20210331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Commitments and Contingencies (Details) - Schedule of maturity of lease liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avalonglobocare.com/role/ScheduleofmaturityofleaseliabilityTable</Role>
      <ShortName>Commitments and Contingencies (Details) - Schedule of maturity of lease liability</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avalonglobocare.com/role/CommitmentsandContingenciesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>avco-20210331.xml</File>
    <File>avco-20210331.xsd</File>
    <File>avco-20210331_cal.xml</File>
    <File>avco-20210331_def.xml</File>
    <File>avco-20210331_lab.xml</File>
    <File>avco-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001213900-21-026450-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-026450-xbrl.zip
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M? P?E)\\]QA^\+WVT;.T+\9<TUOP__?UWGN]J7V[/]<:]8;.7SGZZ?G!LS6
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M9:MH;TLGI^60+U8RI/>K .YE CB]7\8Y=[.>H%85P)7KG91$)CU!IBJ VUX
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MUUDTMTGLJ"=)L547E\7 VO#'_($2#=YQI]ENUA-@I"U6!E#YG?)>NY<T;#F
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MWC%SYH%4@]OA^E90"D8[]?I2,)-K)L/.S: L8/]"17(ADBYH?L$*G[M^.9C
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M80(97&)QN0A%P#6P%P\9VI[7LID37@/1LDP <2BM'C""-'L:2C+LS6<2EX@
M+![@,N7:]OS8?7( A?[LP;<&EN'!<D)7O+U#F1D;U@^JVKAGYMAQ;7<T!Y!
M9WP.!B<)T>:OR[<3BG8R <4  ((R',+Z[A,2@HO5$:#%GTTF(?4)+1Y[!/W
MM GS1B@C,2S!E@!^/Z8-!!<)D8UTGP2H)KB(=#Y' C(AWG43R#@BS3OU+$0<
M]SLR=?T-<Z<VBY/EEDUG#[9EXC/G8R!,'$$WM^=)'1&',%5?H,$&D&RM(8P%
M)Z8/7#PR1J1I-<0M,H/':XHT0J@=<+THX@64-Q-$VP6$^KM5*/=Q>3/ P%D.
M;N 8>'C$:AI0/L"_VR1*;$3(()-U9#.#]/TYLVWD2>W!<L$#>F2V.P4R#0@3
MB .TG8-'[ND3RMADZC[Q%++E..XCL-LCK$6,!<B9T-^146<.TQC%TX@R6 <)
M[AE3$!'V[/J 0((D""6BAIKH"1^$_YY?_WIU<:SW0V( VX\<"#4LTR<X^,?8
M#'\05RP0[+C:E&?V?* #;GL$[ 3[L'S7F]/K:/3<F6?&B,L!<K6A86(,@^:#
MMNP 9YF,1!]PC+KA'P8H[Q^UD><^@0+"AP3R4'/$-F)B/2@H2L"*PWS27^-(
M'^";(0TL9P T!@"!"[Z#KCOA -V//=*ON'RD:'!C,Q,#2ZX$(=CZ R)\26BA
M R0+ .."AZY03+LE(<)_+HC(,V!I0C1P B!O,.,*%@$$R\!LQD7I2#)9?,,)
MW0\^BP$B[(^):S3);9YK(X3T]-!B]H#T /+&S#8\SC2NX!+MK24S--KYV>WQ
M_;NO__HAQCHJ[VAOS\[O+_\M%8/>:*!OA<![; 2(]_BFXTRS4^D%_Q7BI1E2
MLM$DE=1-H%'58*2_A&'Y\.O5#V0XT.7\@-Z:/]9^M7!I[<JWN96F;Y!<((,
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M&N!Q[OSGW2KS6[IN*X\$+VB*J3)D<U[=A%5;F7A:-8GNE!^9:;%;(R]I73<
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M/.=</AM1YG@P(RV&\ 1C0)HV 4*/?6'<A!W2A1W2<IKZF!5.<<H-WY]-^+)
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MAYLU?JSD,9-94M/BK0:VF/7A^GIJS/$Q/_VYH\4'8]G+9-5"33EWYZ?H465
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MQ@_*G5/AM$PUN%A5ZV,+TP>JCD9K0>)!]QI N3#><99_+QRI&A;T[$DYV0U
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M*LMHP!_JC1$_6B UX(I3>SF:,6Q5Z#%C@/V3HJYBR?*(M]8).PG;LW!8%D#
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MS4=\T&1*(I?<?K>::DA@+=JJ>3 HEG$K'C*1\I,1@<LE*34R'(>N"E?X4&"
M'K\ G4P2=+7:M;M/V;E"<RVXH2JZ?VYY,.V&U'!KO!$-S(PQ(RZ1R0,:'F77
M.O) KS[YJF%1]BJ.W)?0H!E%9;/A>8[YN."<66@KOKA8)Y>DIFR23URM*$L
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M-OPNLJY499#O%ZXKYZH)&5?*OF9<59Q?U698M1E69;AN1EK)"NKD2O!F8NG
M4G<^J4IW"Y-G?MX&DO<Y$^T37,(UDS+61O*.LZ.*:CIM)M0FD?,&Y4'M6Q94
M7MB^[ID'Y3TFU78I"VZK[P?DL;$\-Z+:*17E![M@V8U8/?355U@'"R4\9:3S
M7A@>^VJ8#L46B[D(567S<+^2#/?O9'_%VC,7<$["DGSQR_\L3._MRG(]9T%Q
M3F%(Y-)@=LWZCB/_N5NIJ,YWZ?4WWC-S'IX-JTBTO#2M:K5E!^P*$17&HG-!
MXX:(#]K6B1QT_&J(?,V-5=YZ_/=*^6^U-)W;@:'R;1;J>;%]-4"O+IKX+M6
MY'R0*B*%.U4#1*Z5X2T\VWF[8RYS7DI&]^8Q!;UH].UOTLQPGDR+K%"I$U?B
M_[UP/7/R%K5SPQ#3S<.E-)2.XZK]TEA2>AV@W'8(EY\7V#ME:EHL?.7]P]G#
M;P\W=W\@3NXN[R_O?K\D6R V<C0,7LP#.'@,9;N;#^$\>S&FMB4!!5A/SX8I
M&=98^L+,?V/5TJ_,8C]LUYXQR9[#F7L,]F):$O!XZ?;N7): :B2'@0QP>(*Z
MPX\:@/Q)LB?XG.E(%O.DN6-/3$\R)AYS)-,:X2L]XP>\P072]2@%#5X![S9&
M@-4Q]HJ17DWOV5^+/E]8'H+E@-GD2D<(J<.>%E,Z _=$.IO#,G/'I'\C./A;
MUR?# +C'-_H"+X-AO4FF*Q'E2_ ;'TS',5^XKX).-@D 1<CA@KC2Q':DH\>%
M"]"[KD1Q-P# 9?P;9HR>I3=F.">U'O$#['9Y9S-X3'H$!,'QV).)9#P9)LAQ
MQ.L;;G8Q0\S"LU/;Q0VY\+Q!IY1$(.+-A.WB3@'"1P9[9Y(QA<O.CP)0/#/&
M+/-(4HX.""W]]'RPZ85BJ;$)^H?YN* ? ]V-S1=SS"PX'W@3,=EG>PKG"#2"
MN#!BBP%P 0GC^4X3,)*X\%=W\$@!&=V P)$$87F&/Q\9<],SIK@*O'49=OC0
MLKT07,I<$/<)-C+#5XX,]SG<  ?8QS1",C;'])*9\1?L!(\JB;KE=9$6"][S
M,:7%$D0>]@R69D"2STC:8]A@Z+DC6)!-TXO06L6K##]#>A@M'$0'7GQ!/'R3
M+M AZ8%N^H40W7@S)4>@/J8^!@(5(]^AD)TO'/:AJ+1)=B)4.AG0B&4B2;IW
M 06<<P(0CX",K B88'+DBJ7BR %@@<8PK^>:>6=P!IZ[/P)828SK+BN#0>P^
MW%V=/UQ><'J]OGR0SN[O+Q_N&RF)I;GM^"PLPF!#5 S_Y@I!3*5A*'V/X"S'
M"UX@]NS8BZ=GR?1<$ECNXM$UQZ;AF C0Z[,)5W=DP-NMZ9LT-]XB;-)>>*&\
M=IC@\\#.L75;$0F-V$T5D DA+87: WW%%0)B&\\&<G=@&?[W@BN364DL+)_3
MG2 <5P#B>&SB0Z!?%$*J+\$9!]B@^T+X!?S8?H,%@/WN^Q<?E8*93X!) CY'
MJ"3#0IRC VPHF."< 1[BAM8(3@'DW'0:?,-^C) 9 Z,%1=HU1AQ!'O+U^=0
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M;$T!&P?__""-V<B<&5/W'Q^NKK]^.-7^_DO!!4^K Z\3!4\)P5.6P%/7!2_
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M@"6]8OL5[,02]O=9NCO#OW%0\0R<%ZQT][45K2.-C3< 6MP5#O7,^(N1YB7
M%I+I8^^DUPO0(HJ,J'$ :CJH/0K?.) LW+H1E2 GE$;:PI-C<#\Z(H<^H>\,
M*Z)&D.E!FYV*-_GGY_<E\D(ED]J"I#96B?=(64D[<$X^]<0))[$0]6X &P?1
M@O(H_#8<%N@C9T$W@/?M@ -U1?<5B__:/^W9 H'&CDF< QTMYJB?1JYB</(^
MF=4KKZZL  -R_#:Y<^P8@VE(0!C;SE1:=W/'GCVG=D[BG[Z)VHND:V!N4UPP
MYS@=X)TYV,I/@^R<J%W3*A :RGM% 4M;[8XF:[AFEW9S'G %:G[Q9+K<;/3U
M,^ %J'-V,Q7TSLD@U#E1@TYJ>#Z^JOJ_4/V.\'M@IU.;S[!]6DR%!<!9MVAD
M%A4-<$EC3'R&+4/X?JAUAQ"ET6<B#+GR':5Q>$S\=!CN8\G=&'&GK'2CM+=R
M;V^EX;HFMJI!.0'"QV4>W<_%G$1E2N\^WG#GT1>.*/8#@I^C[N&Y4>GK5D[#
M9*Z1SB[\"4\V'**%JD(\/::EWG="O4B'/@$[;.0L3.Z">38=OW$=,#A!L$"C
MKFU9;-IRN_='+[SW7D OW'H8C<A%: >]UYY]IZ7%/-0QW)@)(3BFT-2%OX^(
MK')6%S5@8_W:BMFRF=:(OYWE](_V#AS\'5CFF8!OXXDL72"M7[%1VW?#6E#[
M-V*@MPYJC3CB_M.OWV]_QL9PO%T;;X>*+FFAZU9,_Z%=+)P8K8!_9\2:RK#'
MZ,E(>&C0-[(8\78F(D@2LNV_(:6F;*XEGN83C[0!]0AG98]\E10C@^=\1A?W
M=,M9SMVY09V$A9_SHR:<$P8V5JR8W05Q/RI^#T?:2A/& D]GU(/X:H=YQNAG
M]8'[1-V= &SA5_DXY%_\+-@T=?DA7V'2@UCMAO@2@8_ZI*S&O0O7Y&]42+E$
M%%'W]B.+.2II"WY7@J"(LSF^RU0V430E"GA%@6PHL82JSW_DL83U7C%-&0Z!
M'QQ/#*"GM\]Y>Z=G7?._+-GV9$DNQ89%+,-:*0F&8%P6CWJ$PFL>!VX+/6Y#
MNMTH>S:3> J1QV8/Q2#>&;B-H]?M0'.;HHYE2BUL)@R(=ID@'"FILOG)+$'R
M$&:*B-R@UV=FH0,GU/U/LK:?=N*UBI*TA)OE.<O8>3+4.G!.@R'Z[_GB.J)W
M4 0B6SO(2O)99BNX2#"T  <48&Q\W) LEF]X\I@I!L=N>I$TA&E34E-$[I](
MAAS&6ZO'$R&/D*NG[V<Y[2)SY[%$D] :BB[+-4/IHQJF'DS%ZT;\=;0<ZEN9
M*R8F):"+_5_,^N^S84O?%BG@8DMKY_])YJ>0>CV!.XV\)S)1AC=S<MC(H[;C
M4>AY>@C EL" 0>VPD_,\4#''M+^I;5@NKZX5K<JML9\$)C*TL($^U_D7<"7X
M#]*"AA3."*JL$!*_"7H0_EM8GCGE6I[O^:"F')CJ:"U=:IUOB:\(.("?T[0;
M,04'/Z%Q1[9%<@AU0B(8D<_CSTJ1C@(,?:-7C1WCU1+]/O")!,(>*774+S#$
M-OEH+%@69C50_RQXM/L3SVPS,%@9S!,D4(-0)!@4?)8)-9KF":FHY_I1E[%X
M%TY3P;R\>$+>,]E%/ <#]H0P2V,;X!8)?PG"1&@0&6+R21B*]-$03\M#,B'*
MBR\Z,S!QRZ.(E3WG$5E*T'RCG(M(JE\6]F3*B'G&24A (O WKL=Q^,;GL<P=
M$S5].VC'PF?KX-VS%Q[/AUW,\-= /,;4$X2=R0%$EJ0KC8"? &,"V<=>?$-N
MS";&8NJ=2%=\8 *1,'T=^5:R1T!58KJ#P NB N?#3)'*J'U_9.82I\A, A()
M1 N>1>63021BG25D/FJRUNG*JC[D*,'>,Y%ELQ9,ESGAW+SU!N&%PP>-EY']
MF>9C^9.9 JQ?,* ODR@D/CA/Z?'1>>K-R,,)4 ^VVA5_?CC=T32MI@S2:M <
MK6;,T&K,_*RF3,]:;WC6WW\I=B,3<S"I)Q!<_#L:QW$9#";)',N9/?PR.=84
MD!"RF=1U3J4-@=&CP'1"8)+30M<!AM!(*;(B0[8(7U,X7_MNO&$F-?"UH?CS
M3UX X.?_?R<=YL/IRN*>)A;V-+&JIUDE/0TIZ&E2+4]3RGB:5,6SHP(>(0[R
M^-AI>9:G<M[+]3=D>9KX\T]T(R7*,")\+Z/"I-'E)<TK+FE:;4E#ZDH:45+2
MO'J29I23-*:4I"F%) 7J2 KS\:CV^B_N?#L7OK= @1Y9;Q^2;%S[\\R]F11A
MWG&5&LR<#BG5*2N>%@%F69LO"<QQ]\/IH" PZPHY/4O(?3B-94]L.P6B 3D+
MR2R#=2@S9N7Y@TW! +L(=W)EW:(WV7574T@WR_PL3+A#02H%P3FM$/C>DKEZ
MP4;XYXZ 1\_@S40X(E="VN<7<0CF&@J4/Z._#$XYY2KV/IRJG4X"R.B/3Y/4
M$/WRJ_#[7PGW^ATHMA>4'"FZ.@<P@S+"EH ><"-<P(Q&^)K@JQ]..R>=;CKD
M><#%63 &$^[8B+V8;+P:U<-,BBX(-?HWM$Y7U8?B2D;7/HTA^Q[TD/%BBF\%
M!>'KU'Z-#F,-_;WN WJE Z]O40_0:77Y-^T$U7:"ZBY:DK>TT$Y071.%[035
M[=^4=H)J.T$UR =J)ZAN:3)#.T%U8Q2V$U3WO&GQ.GSY$/;; %'03E"MC#X/
M?()JZ(DIZ;F(.7\#2O)?<0M*Q%?;"3ZGO) JDE_4(4ANX8TIMNIIE6"N2(OY
MX7ZVS.D_/GC.@GWXY30-.Y5A :X$W(@D&L1V4P]FDYW%EQYT]4)+AW05I:<O
M/)9^CZ'T*RO('#AHKU@[^;;I(_<*B/1V\FT[^;:=?+M7DV_]Q-WR@F@IIA87
M>/Y)G/&#N/-O&'WY /=+B4LRE6)_$?EUJ_RA==2+4!E;]_VG:X!W(<@$PVNW
MS$%VO#+LEX0VH@?H%,[3!X."D*<LO1RN9&!=L_AKO@F/X]MW4;32Z@GMC. U
M_.R%W+_[J+ 4W'^J$=B(H5_MC&#23]H9P<75E79&<*-&AK4S@ML9P>V,X'=U
MY=L9P>V,X$WHIYT1O(>S!QMA+K0S@K=X=#M1!=H9P?5:X9MS[W9&<#LCN)T1
MW%@YG9;;4<*GOIY?_E98 !<+]@<SG(=7>U6.P8J( F86Z)V!TB\(_/+"I^6A
MIH**\G KBJ:7A1N77B[D*_J*,_2ZX'N^4K^*-7:PE*U2$H+R: ,S&ZSL]=$6
MS:SA!NG-A![VG[F+&*-^25EY,(^5#IAM(I18>+WT[*C8GDRVLJ8Q!WFZ KPF
M-0LG\OY(ZI-0OVZYY*XF!TD%14F $']]LF#/>D*UH<JU.T.0M$%17NS]"3X
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MZO&M_^MXY]^T$;H:[&K^UB"U/YJ\+&YZ=Z\(N4(WZ(DM1>Q/P%T[B??WKE"
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M\ J.SI#Z ]1-9;>OC%CSTN8G!VFOIR://4$7<3@5:LPR/Z M:O8B&]C3N9.
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MK-VW.CJ$6O"693 <Y\:P7I,D+(M\ER]GP3WV]Q?->L9U/^:L-.8!%\@EHL:
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M]EL+>7.K C9,,E6>#EQF7@T5ZXEUZHK>)#GI=#<S H))5FL0D<5<,],"DLT
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M&CD_J?;+X?=E0\ W -$==];9>,ZX+1,]\,-5X%[X6V[?XA3Q)Q]3MB*;@Q)
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M%^I*Z#3"YWQ.<^3+Q7YK/OMB9%#  N36\)*L22B./"RBR'?D_-[*1Y;B@X;
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M9H*V0V8XIZT8M]X3@\L'K2=DI8N'DI)6@_P5L$!2WFMIP62"-HK&;B*H$>E
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M/0D83*]&":KCMX,RT'5FV1K?NRH>Z>#[6)4#JWU4>V]I-8AVIN.:-Z(VY=K
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M5B+N4I6W/XY^@FBWCZ S>8&!M8,E'V7DUEK(NKG4*DTS[&3=/^]/50:S WW
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M372[4/-@1>1UKG/"2%HP[ZSX)322,W$"U\24!* /"8D<W&F-T//H(DJR*F6
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M]<%RW?1N8W_Z+U'5[ZB6QF]0/VD*TK9F'56F,BK:K\U,]::5Z.I?3U4,ZU<
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M2!1BNB096W'E:BB,67=Z%8Z3V;'*A%)PA+1G$'&YZ/$<KI77T9)/?C(%[5:
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M203G>03EKA;HY6C\WXGRW#C?$Z$$"+"!GU+X[+9XG1'8Z0/LIA&-'^IRBWV
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M\,)SK;G'3+S>^D^..)SPO-?-9/.T6:Y^!JO9>K;Z,#-[^M.@A,*!CFB:*@#
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M)P2F_IL+YBJ2=AR=G]$2!Q5TMI&JREVV]]";O?JA?\CIXL^@G1_;1$.K']O
M#.]U NC!N!<H=BM[L7FC$8%,4H'YHQ82\NG]\+1I*9)@BK4:Y=T86AN!?S"
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M,U3,C[7"_<1SR'\(P%XLESRY=0M#.T!'^>>Y&ZEHSX9K9(D7$<,=:/#+)O^
M>=<+C)"LL\F[3;(:RY-LI42AE/>6D+X]P3O,X8WER>T,&=U, :3 @P@1SQ;^
MG0W!'KH.0!YX7$U-YIOQY5[5>G5^2FJ^1P=$W]P+3P$1@Y22:YVT+@75T;G'
M)K095FG2SFB-#IZ<\]?>6;-2L_QWT(&!Y;IG.G7H4-*2[^:RNVH.\+&YX#V
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M&C>MJCR*RT>U_@C8GH*Y>E/*^&&4H5*3;8<, ;R#<Y!++U.NH7T*Z)G1PCK
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M\YU! DSW4\VA2_T,/X[$O(^[(\T%ZF;_F!=EY=P5HY?#^+DGF/@^E] 4PI+
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MK(T#D-Q34\O]*2+)<L$-.%(A:#$%W* Y3B5NIT,S:$< N,*T:\)A9?'$A5"
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M?OT)3VQHU\ K^"S"@:&EKM]KP,BT[_JM-^.<#((])SGN7V-+-[L1 T_,!+$
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M^F[%(K>,S7KIX=74+"7W(XM>3@?BR>]7&>8:?BK1URIS&JN$9V4MOGN\E1S
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M2CH\WLKTT%&M[PO?2E!:!5VC6,_WJF&9-QB6='TB99.<L,.Y5GV(!!T#".Q
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M? _[KKWG0;:)'D%5R? Z6A1;IIHF6OWKJ>5C]_H>5=8GGEN]M::/=J@=?]+
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M"0 1              "  0    !A=F-O+3(P,C$P,S,Q+GAM;%!+ 0(4 Q0
M   ( 'V$KE*4>Y<<71D  ,X< 0 1              "  </1  !A=F-O+3(P
M,C$P,S,Q+GAS9%!+ 0(4 Q0    ( 'V$KE*'SK56LPX  .BU   5
M      "  4_K  !A=F-O+3(P,C$P,S,Q7V-A;"YX;6Q02P$"% ,4    " !]
MA*Y2=L83Y8E"  #N P0 %0              @ $U^@  879C;RTR,#(Q,#,S
M,5]D968N>&UL4$L! A0#%     @ ?82N4IXNM6BHG@  >>\' !4
M     ( !\3P! &%V8V\M,C R,3 S,S%?;&%B+GAM;%!+ 0(4 Q0    ( 'V$
MKE+"#K]KY$(  *$P!  5              "  <S; 0!A=F-O+3(P,C$P,S,Q
>7W!R92YX;6Q02P4&      8 !@"* 0  XQX"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
